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Abstract 
Pharmaceutical compounding corresponds to the preparation of customised 
medicines in order to meet the specific needs of patients, which cannot be 
met by the proprietary medicines provided by the pharmaceutical industry. 
Historically, pharmaceutical compounding dates back to the very origins of 
pharmacy and, ever since, it has been an integral part of pharmacy practice. 
Nevertheless, little is known regarding current compounding practices in 
Europe and, therefore, the aim of this project was to identify and characterise 
the oral compounded medicines most frequently dispensed in European 
hospital pharmacies.  
The research method adopted was a large-scale, international (European) 
survey and the research instrument was a self-completion (country-specific) 
questionnaire. A total of 11 European countries were included in the 
research: Portugal, UK, Switzerland, Poland, Netherlands, Denmark, 
Slovenia, Finland, Spain, France and Germany. For most countries, a 
purposive sample of hospitals was contacted and invited to contribute data 
regarding the oral compounded medicines most frequently dispensed in their 
pharmacies. The pilot-study was launched in Portugal but fieldwork was 
undertaken in most countries. Information regarding legislation, professional 
organisations and information sources relevant to pharmaceutical 
compounding was also collected. 
The oral compounded medicines most frequently dispensed in hospital 
pharmacy varied considerably throughout Europe, from traditional cachets in 
Poland to complex tablets in the Netherlands and Denmark. A wide range of 
active substances, including NTI drugs, and dosage strengths were 
dispensed. Compounded medicines were prepared individually and also in 
batches of variable sizes. There is little consistency of compounding 
practices in Europe and there is a need for common legislation, professional 
organisations and information sources. This project corresponds to the 
largest and most complex research in pharmaceutical compounding across 
Europe and aims to contribute to the harmonisation of quality and safety of 
compounded medicines in Europe.   
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1. Introduction 
1.1 Pharmaceutical compounding 
Pharmaceutical compounding corresponds to the preparation of customised 
medicines in order to meet the specific needs of patients. The 
pharmaceutical industry provides patients with proprietary medicines based 
on a “one-size-fits-all” approach, but there are individual needs that require 
personalised therapy. In these situations, compounded medicines are an 
invaluable alternative that allows patients the benefit of a bespoke treatment. 
1.1.1 Historical context of compounding 
The origins of pharmacy date back to antiquity where primitive men mixed 
animal, vegetable and mineral substances for medicinal purposes. 
Archaeological research shows evidence of the preparation of medicines 
secundum artem1 by many early civilizations and throughout history. This 
practice is well documented in the Bible, and the apothecary2 is considered 
one of the earliest professions (Allen, 2003a; Marriott et al., 2010). The 
historic role of the apothecary as the individual involved in the preparation of 
medicines represents the heritage of pharmacy, and is symbolized by the 
traditional mortar and pestle (D’Angelo, 1997; Anderson, 2005; RPS, no 
date).  
The art (and later the science) of preparing medicines are at the very origins 
of pharmacy and, ever since, compounding has been an integral part of 
pharmacy practice (Allen, 2005a; Higby, 2005). Consequently, present and 
past definitions of pharmacy and pharmacists include the concept of 
compounding, or preparation of medicines (Allen, 2005a), as the following: 
• Pharmacy is the science or practice of preparing and dispensing medicinal 
drugs (OED, 2004); the making or compounding of medicines (Weiner and 
Simpson, 1989). 
 
                                            
1Secundum artem – according to art – in accordance with the rules of the art (OED, 1989). 
2Apothecary, the earlier name for one who prepared and sold drugs for medicinal purposes 
(OED, 1989). 
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• A pharmacist is a person who is professionally qualified to prepare and 
dispense medicinal drugs (OED, 2008); a person prepared to formulate, 
dispense and provide clinical information on drugs or medications to health 
professionals and patients (Myers, 2002). 
 
Although compounding involves other health care professionals, pharmacists 
possess unique skills and knowledge that are not duplicated by any other 
profession. Pharmacists, experts in pharmaceutical science, put together 
chemistry, physics, biology and mathematics into the practice of 
pharmaceutical compounding (Jenkins et al., 1957; Taylor and Harding, 
1999; Allen, 2005a). 
The prescription for a compounded medicine, an order written by a doctor (or 
other authorised health care professionals) directing the pharmacist to 
prepare a specific medicine for an individual patient, has also ancient roots 
and is traditionally hand-written, as shown in Figure 1.1 (Jenkins et al., 1957), 
though electronic prescriptions for compounded medicines are now more 
frequently encountered (Figure 1.2) (Joint Formulary Committee, 2008). 
    
Figure 1.1 (left) Example of a past prescription for dermatology compounding (adapted from 
Jenkins et al., 1957) and Figure 1.2 (right) Example of a contemporary prescription for 
paediatric compounding (courtesy of Farmácia Lordelo3). 
                                            
3Farmácia Lordelo is a community pharmacy in Vila Real, Portugal, specialised in 
pharmaceutical compounding (Farmácia Lordelo, 2009). 
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In the past, all prescriptions were for compounded medicines and it was not 
until the early 1900s, with the advent of industrialisation and drug 
manufacturing, that these prescriptions were gradually substituted by 
prescriptions for proprietary medicines4. In the USA (United States of 
America), by the 1930s about 75% of the prescriptions were for compounded 
medicines, whereas by the 1950s only 26%, by 1962 just 3-4% and by 1973 
about 1% of prescriptions were for compounded medicines. Over the years, 
the pharmaceutical industry took over the production of most medicines and 
the need for compounded medicines declined, with considerable impact on 
the practice of pharmacy (Allen, 2003a; 2005a; 2005b). The pharmacist’s 
traditional role of preparing compounded medicines gradually changed to that 
of dispensing proprietary medicines (Anderson, 2005). Despite the 
undeniable value of proprietary medicines, these are manufactured in only 
limited presentations (specific dosage forms and specific strengths) and in 
accordance with established windows of activity, which are adequate for the 
majority of patients but there are always individuals and health conditions 
that demand a personalised approach to treatment and, in these situations, 
the pharmaceutical industry is not able to meet their needs in a cost-effective 
manner (Allen, 2005a). Therefore, pharmaceutical compounding continues to 
be performed as an integral and fundamental part of contemporary pharmacy 
practice, providing alternative therapeutic options and meeting individualised 
patient needs. The flexibility of compounded medicines have become 
increasingly recognised as more attention has been given to patients as 
unique individuals (Allen, 2005c). In parallel, the practice of compounding 
has advanced beyond the traditional art, although at different rates in 
different countries (Anderson, 2005), and contemporary compounding is a 
highly technical and complex practice. These factors have contributed to the 
continued existence of pharmaceutical compounding and, along with the 
impetus to enhance quality standards, are responsible for the high quality 
compounded medicines that are prepared today (Allen, 2006a). 
                                            
4A proprietary medicinal product corresponds to any ready-prepared medicinal product 
placed on the market under a special name and in a special pack (European Parliament and 
the Council, 2001). Equivalent terms for proprietary medicinal products include the following: 
licensed, industrialised and commercial medicines. 
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1.1.2 Definition and practice of compounding 
In accordance with the US Pharmacopeial Convention (2005), 
pharmaceutical compounding “involves the preparation, mixing, assembling, 
packaging and labelling of a medicine (…) under an initiative based on the 
doctor-patient-pharmacist (triad) relationship in the course of professional 
practice”. The term “compounded medicines” stand for compounded drugs, 
compounded preparations and compounded formulations (US 
Pharmacopeial Convention, 2005). 
The US Food and Drug Administration (FDA) states that pharmaceutical 
compounding “is an age-old practice in which pharmacists combine, mix or 
alter ingredients to create unique medications that meet specific needs of 
individual patients”. This practice must not involve the preparation of 
medicines that are “essential copies” of available licensed medicines. In 
addition, compounding must not include substances that were removed from 
the market because of safety or efficacy issues, or substances that have not 
been approved for use in medicines (FDA, 2007). 
Compounding corresponds, then, to the preparation of unlicensed medicines 
(sterile and non-sterile) in order to meet specific patient needs, which are not 
met by the licensed medicines available. Compounded medicines are 
traditionally prepared extemporaneously in community and hospital 
pharmacies for individualised patients. Notwithstanding this, compounded 
medicines may also be prepared in advance (of a patient’s request), in other 
settings apart from a pharmacy and in batches (of variable sizes). 
1.1.2.1 Triad relationship: doctor-patient-pharmacist 
Pharmaceutical compounding is characterised by the traditional triad 
relationship doctor-patient-pharmacist, which is represented when a doctor 
prescribes a compounded medicine that is prepared by a pharmacist for a 
specific patient (Figure 1.3). This triad relationship is the foundation for 
pharmaceutical compounding (Allen, 2005a; McElhiney, 2006a). 
Pharmaceutical compounding is also characterised by the Rx symbol, which 
stands for recipe, take (RPS, 2005; Marriott et al., 2010) (Figure 1.3). 
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Figure 1.3 Triad relationship: doctor-patient-pharmacist. 
Pharmacists are an essential member of the health care team and play a 
crucial role in the triad relationship, as the intermediary between patients and 
their doctors (Williams, 2010). Other health care professionals and caregivers 
may also be included in this relationship as, for instance, the nurses who 
administer the medicines to hospitalised patients (McElhiney, 2009; Trissel, 
2009). A good interaction between all members of the triad relationship is 
crucial for taking medicines to best effect (Joint Formulary Committee, 2008). 
1.1.2.2 Therapeutic alternative to proprietary medicines 
Compounded medicines should be regarded as a therapeutic alternative 
only, and exclusively, when there are no suitable proprietary medicines on 
the market. Compounded medicines should not substitute for corresponding 
licensed medicines when these are commercially available, not even for 
economical reasons (Sundberg, 1997; Allen, 2005a) because of the risks 
associated with compounding (Section 1.1.3). 
In addition, if the medicines needed are actually available as licensed 
medicines in other countries, the importation of the respective licensed 
medicines should always be considered first. Notwithstanding this, there is 
usually a limited knowledge of the availability of licensed medicines in other 
countries, and importation is often very difficult (Nunn, 2003). Therefore, it is 
accepted that the time and bureaucracy required for the importation of 
medicines may compromise the patients’ health and, in these situations, 
pharmaceutical compounding represents the therapeutic alternative of 
choice. 
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1.1.2.3 Compounding vs manufacturing 
A medicinal product may be obtained either by manufacturing (majority) or by 
compounding / extemporaneous preparation (exception), two distinct 
methods that yield proprietary medicines and compounded medicines, 
respectively (Table 1.1).  
Proprietary medicines have a marketing authorisation, which is obtained 
either by a centralised authorisation procedure or by national authorisation 
procedures. The European Medicines Agency (EMA/EMEA), which protects 
and promotes public health through the evaluation and supervision of 
medicines for human use, is responsible for the centralised procedure. This 
procedure results in a single marketing authorisation, valid in all European 
Union countries (also in Iceland, Liechtenstein and Norway), and is 
compulsory for certain medicines (e.g. treatment of cancer). National 
medicines authorities, on the other hand, are responsible for the national 
authorisations and each EU Member State has its own procedures. For the 
simultaneous authorisation of medicines in several countries, there are also 
the decentralised and mutual-recognition procedures (EMA, 2012a). 
As opposed to proprietary medicines, compounded medicines are exempt of 
a marketing authorisation (Section 14.1). The criterion that best differentiates 
compounding from manufacturing is the existence of the triad relationship 
(Section 1.1.2.1) (McElhiney, 2006a) and the smaller scale of preparation5 in 
compounding (US Pharmacopeial Convention, 2005). Manufacturing is the 
more recent, common practice (Section 1.1.1) and the larger scale of 
production6 requires compliance with GMP (Good Manufacturing Practice). 
The safety and efficacy of compounded medicines is not assured and, 
therefore, compounding is a more risky practice (Section 1.1.3). 
Both proprietary medicines and raw materials in bulk are used in the 
preparation of compounded medicines, which are assigned a beyond-use-
                                            
5The term “preparation” should be used when referring to a compounded medicine (Allen, 
2007c). 
6The term “production” should be used when referring to a proprietary medicine (Allen, 
2007c). 
Chapter 1: INTRODUCTION | Pharmaceutical compounding | 22 
 
date7 (US Pharmacopeial Convention, 2005), whereas only raw materials in 
bulk are used in the production of proprietary medicines, which are assigned 
an expiry date (Table 1.1). Raw materials in bulk should preferably be used 
in the preparation of medicines, particularly when these are prepared on a 
large scale (i.e. production of proprietary medicines and preparation of 
compounded medicines in batches). The use of proprietary medicines in 
compounding is convenient as it is not always easy to acess the respective 
raw materials in bulk (and in reasonable small quantities). However, 
proprietary medicines not only include the required active substance(s) but 
also a number of excipients that may compromise the resulting compounded 
medicines. 
Table 1.1 Comparison of pharmaceutical compounding and manufacturing (adapted from 
McElhiney, 2006a). 
Main differences Compounding Manufacturing 
Output Compounded medicine Proprietary medicine 
Timescale 50 centuries 2 centuries 
Need Exception Majority 
Terminology Preparation Production 
Scale Smaller/Individual Larger 
GMP requirements No Yes  
Safety and efficacy Not assured Assured 
Risk Higher Lower 
Raw materials Proprietary medicines  or bulk Bulk 
Date assigned Beyond-use date (shorter) 
Expiry date 
(longer) 
 
                                            
7The beyond-use-date is the date after which a compounded preparation is not to be used 
and is determined from the date the preparation is compounded. Because compounded 
preparations are intended for administration immediately or following short-term storage, 
their beyond-use dates may be assigned based on criteria different from those applied to 
assigning expiry dates to manufactured drug product (US Pharmacopeial Convention, 2005). 
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For instance, in the preparation of a liquid dosage form from crushed tablets, 
insoluble excipients may compromise the medicine’s appeareance (e.g. 
coatings) whereas soluble excipients may compromise the medicine’s 
stability (e.g. pH); the filtration of insoluble excipients, although common 
practice, may remove signifcant ammounts of active substance(s), if 
extraction from tablets is not complete (Ahmed et al., 1987; Boulton et al., 
1994; Fawcett et al., 1995; Woods, no date). In addition, depending on the 
brand of the proprietary medicines used, the resulting compounded 
medicines may be considerably different. For instance, according to 
Ashworth (2011), a mercaptopurine oral suspension prepared with Mylan 
tablets results in a “creamy and smooth” suspension whereas with Roxanne 
tablets results in a “globby and gritty” suspension. 
1.1.2.4 Activities not included in compounding 
Not included in the definition and practice of compounding are: off-label use 
(of proprietary medicines), reconstitution and repackaging of medicines. 
None of these activities affect the integrity of medicines and therefore, the 
output is still the proprietary or compounded medicine and not an alternative 
(compounded) medicine. Also not included in the definition and practice of 
compounding is the handling of medicines that does not involve the 
preparation of an alternative (compounded) medicine. 
a. Off-label use 
The term off-label use refers to the use of a proprietary medicine outside the 
labelled (licensed) indications, as follows: therapeutic indications, age group, 
dosage and/or route of administration, for which the medicine is not licensed. 
The terms off-label use, off-label prescribing and off-label medicines are 
commonly used interchangeably and represent an unlicensed use of a 
licensed medicine. Off-label use must not be confused with unlicensed 
medicines since the later are exempt from the requirement of a marketing 
authorisation and, as a result, do not have any labelled (licensed) indications. 
In conclusion, the use of a medicine outside the labelled indications (off-label 
use) should only apply to proprietary medicines. The confusion of these 
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concepts is very common in the literature (Brion et al., 2003; Pandolfini and 
Bonati, 2005). 
The use of both unlicensed medicines and licensed medicines for unlicensed 
indications (off-label use) is often necessary, particularly in paediatric 
patients, since the licensed indications frequently do not cover the 
therapeutic needs of this age group (Joint Formulary Committee, 2008). It 
has been estimated that 50-70% of the prescriptions include an off-label use 
of a proprietary medicine (Allen, 2007a). Information sources such as the 
Micromedex and the BNFC (British National Formulary for Children, Section 
4.2.2) provide practical guidance on the off-label use of medicines (Standing 
and Tuleu, 2005; McElhiney, 2009). 
b. Reconstitution of medicines 
Pharmaceutical compounding does not include reconstitution of medicines 
(CSHP, 2010) but the definition of both is often confused (Lam, no date). 
Reconstitution of medicines involves the reconstitution of liquids or solids into 
a final liquid dosage form. According to the European Directorate for the 
Quality of Medicines & HealthCare (EDQM, 2007), a directorate of the 
Council of Europe, some preparations for oral use are prepared by dilution of 
concentrated liquid preparations (reconstitution of liquids); or from powders 
or granules for the preparation of oral solutions or suspensions, oral drops or 
syrups, using a suitable vehicle (reconstitution of solids). The final 
preparations must comply with the requirements for the respective dosage 
forms (EDQM, 2007). Reconstitution of medicines is an activity performed in 
accordance with the directions of the manufacturer as, for instance, the 
reconstitution of the oral antibiotic Augmentin 125/31 SF (Sugar Free) 
Suspension (eMC, 2010a) and the reconstitution of the antibiotic Augmentin 
500/100 Intravenous (IV) (eMC, 2010b). Oral antibiotics for reconstitution are 
presented as a powder in a multidose container with sufficient space for the 
addition of purified water (Edafiogho and Winfield, 2004), whereas IV 
antibiotics for reconstitution are usually presented as a sterile powder in a 
vial with sufficient space for the addition of water for injections or other sterile 
vehicle. The antibiotics presented as powders are commonly stable for up to 
2 years whereas, when reconstituted, the stability is considerably reduced 
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(normally 10-14 days for oral antibiotics and just a few hours for IV 
antibiotics) (Edafiogho and Winfield, 2004). No official guidelines for 
reconstitution exist as yet (Torniainen, 2007) apart from the risk assessment 
considered in the Resolution CM/ResAP(2011)1 (Council of Europe, 2011). 
Whenever directed, reconstitution is required for the intended use of 
medicines and, therefore, should be clearly distinguished from the practice of 
pharmaceutical compounding. 
c. Repackaging of medicines 
Repackaging is defined as the “act of removing a preparation from its original 
primary container and placing it into another primary container, usually of 
smaller size” (US Pharmacopeial Convention, 2005). 
This practice is often associated with parcelling oral solid dosage forms, such 
as tablets and capsules, into single-dose (often single-unit) containers but it 
also applies to liquid and semi-solid dosage forms as, for instance, 
repackaging a multidose oral liquid into unidose oral syringes and 
repackaging a multidose cream into unidose blister packs. In addition, 
repackaging is often associated with parcelling proprietary medicines but it 
also applies to parcelling compounded medicines. 
Repackaging is a common practice in the hospital setting, in which large 
packs are converted into “patient packs”. Although time consuming and 
labour intensive, it represents a very important aspect of pharmacy practice 
because it may not only significantly reduce waste of medicines but it may 
also reduce medication errors and, consequently, improve patient safety (US 
Pharmacopeial Convention, 2005; McElhiney, 2010). 
d. Handling of medicines 
Handling of medicines includes all manipulations of medicines by health care 
professionals and patients that aim to facilitate the intake of medicines, 
mainly: segmenting tablets and opening capsules. Segmenting tablets may 
also be performed to adjust dosage strengths and for economic reasons 
since, in general, different strengths of the same drug cost about the same 
(Sam, 2002; Allen, 2005d). 
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This practice is performed in a variety of settings, from the patients’ home to 
hospitals’ wards. In a study performed in a UK (United Kingdom of Great 
Britain and Northern Ireland) paediatric hospital, Tuleu et al. (2003) 
confirmed that cutting or grinding tablets on the wards was a very common 
practice for nurses. Notwithstanding, Tuleu et al. (2005) concluded that 
cutting nifedipine tablets did not provide accurate and reproducible dosing 
(even when using proprietary tablet cutters). Furthermore, there are tablets 
that cannot be segmented without affecting the appropriate release of the 
active substance(s), as in the case of some modified-release tablets (Marriott 
and Kirby, 2009). Segmenting tablets is occasionally considered in the 
literature as pharmaceutical compounding (Brion et al., 2003) but this 
practice should be clearly distinguished as a separate activity. Handling of 
medicines by health care professionals and patients should be avoided as 
much as possible and, when unavoidable, it should be performed with 
caution to prevent dosing deviations.  
Ideally, the handling of medicines (i.e. segmenting tablets and opening 
capsules) should be substituted by the preparation of compounded 
medicines (adapted to the individual patient needs) (Sam, 2002). 
Pharmaceutical compounding is a regulated practice performed in registered 
facilities, by registered professionals, as opposed to the unreliable 
manipulation of medicines, which can be performed in an uncontrolled 
manner. 
1.1.3 Risks associated with compounding 
The quality, safety and efficacy of compounded medicines is not guaranteed 
and these medicines are exempt from a marketing authorisation or product 
licence, unlike proprietary medicines. For these reasons, compounded 
medicines are considered by the authorities as unapproved (FDA, 2009) or 
unlicensed medicines (MHRA, 2008).  
Compounded medicines should only be dispensed when no suitable licensed 
alternative is available (Joint Formulary Committee, 2008) and it is suggested 
that patients should be aware that these medicines are not approved (FDA, 
2007; CompoundingToday, 2011a).  
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According to the FDA (2011a), “some compounded drugs may present risks 
to patients because compounded drugs have not been evaluated for safety 
and effectiveness”. The practice of pharmaceutical compounding carries 
significant risk but there are clinical needs that can only be met by 
unapproved or unlicensed medicines. Therefore, the risk-benefit balance of 
compounded medicines must be considered at all times and, as for 
proprietary medicines, the benefits of administering the medicine should be 
greater than the associated risks (Joint Formulary Committee, 2008).  
Compounded medicines have endangered public health in a few unfortunate 
events worldwide, some with devastating repercussions. A single error in 
compounding can easily result in a patient’s death. Examples of such 
unfortunate events will be described throughout the thesis. The FDA is aware 
of more than 200 adverse events involving 71 compounded medicines since 
1990 (Allen, 2003b; FDA, 2007). When pharmaceutical compounding is not 
performed properly, patients are exposed to potentially very serious health 
risks (FDA, 2011b). Compounding errors can be made at all stages of the 
preparation, from the selection of raw materials to the labelling of the final 
medicine. Standard operating procedures (SOP) should be put in place and 
no pharmacy should be involved in pharmaceutical compounding without an 
ongoing QC program (Allen, 2003b).  
All health care professionals play an important role in reducing compounding 
errors. Doctors and pharmacists have the responsibility to guarantee that 
patients take effective, safe and quality compounded medicines and the 
authorities have the responsibility to develop appropriate guidelines (EAHP, 
2008).  
1.1.4 Importance of compounding 
Compounding provides invaluable alternative medicines to the 
pharmaceutical industry as there are specific situations in which the 
proprietary medicines available do not meet particular patient needs, as 
follows: 
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1. Need for alternative dosage forms 
The acceptance ability of a dosage form to a particular patient depends on 
the patients and their health conditions. The majority of proprietary medicines 
are available in solid dosage forms (tablets and capsules), which usually 
represent a problem for the paediatric population; for patients with swallowing 
difficulties (dysphagia), commonly the geriatric population and also for 
patients for whom the oral route is compromised (e.g. in oral cancer) (Allen, 
2005b; McNulty, 2007; Barbosa, 2009). 
2. Need for particular dosages/strengths 
Proprietary medicines are available in standardised dosage strengths but 
there are specific situations in which patients need personalised strengths as, 
for instance, the paediatric population (depending on the age and body 
weight / surface area) and the geriatric population (considering concomitant 
diseases and organ failures) (Allen, 2005b; Barbosa, 2009). 
3. Need for alternative raw materials 
There are specific raw materials that are not well tolerated by particular 
patients, such as: colorants (hypersensitive patients), lactose (intolerant), 
parabens (allergic), phenylalanine (phenylketonuria) and sucrose (diabetic 
patients) (Allen, 2005e; Barbosa, 2009). 
4. Need for alternative organoleptic characteristics 
The flavour, colour and texture of medicines are determinant factors in 
patients’ compliance to therapy, particularly in the paediatric and geriatric 
populations. Personalisation of the organoleptic characteristics of medicines 
in order to meet the individual preferences is possible by means of 
pharmaceutical compounding (Allen, 1997a). For instance, unpleasant bitter 
substances, such as promethazine HCl and quinine sulfate, may be 
successfully masked with orange or raspberry syrup (Kloesel, 2001; 
CompoundingToday, 2005). 
 
Additionally, there are specific situations in which the necessary proprietary 
medicines are not available from the pharmaceutical industry, as follows: 
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1. Medicines’ shortages 
Occasionally, the pharmaceutical industry is not able to meet the demand for 
particular medicines, and proprietary medicines become temporarily 
unavailable. Limited production capability, manufacturing problems and lack 
of raw materials are some of the common causes for shortage of medicines. 
In these situations, pharmaceutical compounding is a valuable resource to 
“bridge the gap” until the proprietary medicines are once again commercially 
available (Allen, 2005b; Donyai, 2006).  
2. Discontinued medicines 
There is a long and growing list of important proprietary medicines that have 
been discontinued by the pharmaceutical industry, mainly for commercial 
reasons and which consequently are no longer available to patients. 
Pharmaceutical compounding offers these patients the possibility to continue 
their treatments by means of compounded medicines (Ashworth, 2002a; 
Allen, 2005b). 
Finally, there are situations in which necessary proprietary medicines have 
never been made available by the pharmaceutical industry: 
1. Special combinations 
There are patients who need several proprietary medicines, and these could 
be brought together in one single dosage form to ease the process of 
administration (i.e. polypharmacy) as, for instance, special combinations in 
oncology patients (Section 1.1.5) and dermatology patients (e.g. 
hydroquinone, retinoic acid and glycolic acid in hyperpigmentation disorders) 
(Allen, 2004; 2005e; Barbosa, 2009). 
2. Orphan medicines 
Orphan medicines are medicines for diagnosing, preventing or treating rare 
diseases8 which, under normal market conditions, have little interest for 
pharmaceutical industry because these are intended for a small number of 
patients only (EMA, no date). Compounded medicines for rare diseases are 
an invaluable resource for these patients and, in many cases, represent the 
                                            
8Rare diseases are life-threatening, or chronically debilitating conditions, that affect no more 
than 5 in 10,000 people in the EU (European Union) (EMA, no date). 
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only therapeutic option available. Examples of orphan medicines include 3,4-
diaminopyridine for Lambert-Eaton myasthenic syndrome and pyridoxal 
phosphate for neonatal epilepsy (Dooms, 2010).  
1.1.5 Specialties of compounding 
Pharmaceutical compounding is a valuable therapeutic option in all areas of 
medicine, with particular importance in the following specialties: 
1. Paediatric compounding (considered separately in Section 1.1.5.1) 
2. Geriatric compounding 
The aging population is growing and the elderly are faced with age-related 
conditions that often demand a personalised approach to treatment as, for 
example, polymedication, swallowing difficulties (dysphagia) and compliance 
issues. Compounded medicines add value to geriatric and hospice9 care by 
helping patients live in a more dignified manner (Allen, 2002a; 2009a). 
3. Dermatology compounding 
Dermatology conditions often require personalised therapy to adjust the 
treatment to the patients’ skin type and disorders (Barbosa, 2009). 
Furthermore, although there have been significant advances in the treatment 
of dermatology conditions, there are traditional compounded medicines that 
remain useful in current practice (Parish and Witkowski, 2000). Some of the 
dermatology conditions that benefit from pharmaceutical compounding are 
hyperpigmentation (Allen, 2004), psoriasis (Williams and Humphreys, 2011) 
and wounds (Allen, 2002b; Helmke, 2004a; 2004b). 
4. Gastroenterology compounding 
There are many gastrointestinal (GI) disorders and there is need for 
particular medicines, which are not commercially available, that can be 
made available through compounding (Allen, 2005f). Examples include: 
ranitidine HCl 15 mg/mL oral liquid and omeprazole 2 mg/mL oral liquid, both 
for the treatment of ulcers (e.g. gastric and duodenal) and other GI disorders 
(e.g. pathological hypersecretory conditions) (Allen, 2006b; 2007b). 
                                            
9Hospice is a concept of care designed for end-of-life patients and focus on the physical and 
emotional needs of patients in the final stages of life in order to ensure that these achieve 
the best quality of life in their remaining time (Kuntz, 2006a). 
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5. Dentistry compounding 
Dentists and dental patients benefit from pharmaceutical compounding as 
this practice allows a wide range of therapeutic alternatives. Mouthwashes, 
for instance, are one of the most frequently compounded dosage forms in 
dentistry, and may include specific combinations which are not commercially 
available because of the need for extended stability in proprietary medicines 
(Allen, 2002c; Fonseca, 2006). 
6. Oncology compounding 
The treatment of cancer often involves special combinations of active 
substances to ease the administration of medicines. Without pharmaceutical 
compounding, these active substances would have to be given individually 
and, therefore, compounded “cocktails” are a valuable alternative for cancer 
patients (Allen, 2005b). These treatments compromise the immune system 
of patients, who become more vulnerable to opportunistic infections, for 
instance, oral mucositis. Compounded mouthwashes for chemo-induced oral 
mucositis (CIOM) play a major role in the quality of life of cancer patients 
(Section 3.4.4) (McElhiney, 2008a). 
7. Ophthalmology compounding 
The preparation of sterile compounded medicines is an integral part of 
pharmaceutical compounding practice. Pharmacists are often requested to 
prepare ophthalmic compounded medicines to meet particular individual 
needs, for instance, medicines without preservatives; and to replace the 
increasing number of discontinued proprietary medicines, for example: 
epinephrine bitartrate ophthalmic solution and tetracycline HCl ophthalmic 
ointment (Ashworth, 2002b; Batistuzzo, 2010; Sautou, 2011). 
8. Veterinary compounding 
The preparation of compounded medicines for animals has always been part 
of veterinary medicine. A few decades ago, only a few proprietary medicines 
were approved for veterinary use and, although more veterinary medicines 
are nowadays available on the market, there are always situations in which 
animals require a personalised medicine adapted to their specific needs 
(Papich, 2005). Veterinary compounding is a complex practice since 
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different species of animals have different pathophysiology and, 
consequently, different response to medicines (Allen, 1997b; 2009b). In a 
regional survey conducted by the International Journal of Pharmaceutical 
Compounding (IJPC), it was concluded that the top 5 veterinary 
compounded medicines were the following: potassium bromide capsules; 
metronidazole suspension; methimazole oral liquid; diethylstilbestrol 
capsules; and potassium bromide solution (Davis, 1999). 
1.1.5.1 Paediatric compounding 
“Paediatrics does not deal with miniature men and women”: this renowned 
statement by Abraham Jacobi (1830-1919), father of American paediatrics, is 
still today the fundamental principal of paediatrics. The paediatric population 
is very different from adults and corresponds to a heterogeneous group, from 
preterm newborn infants to adolescents10, with a spectrum of different 
pathophysiologies associated with growth and development. There are 
substantial changes in body proportions and composition during growth and 
development, and this dynamic process of maturation is what makes the 
paediatric population so special and so different from adults (Kearns et al., 
2003; WHO, 2007). These age-related changes profoundly affect the 
absorption, distribution, metabolism and excretion (ADME) of medicines and, 
consequently, the response of the paediatric population to therapy. Issues to 
consider are, for instance, immaturity of the GI tract and consequent reduced 
gastric acid secretion and prolonged gastric emptying (impacting on 
absorption); immaturity of the blood-brain barrier and consequent facilitated 
penetration of medicines into the CNS (Central Nervous System) 
(distribution); immaturity of the hepatic and renal functions and consequent 
altered metabolizing and clearance capacities (metabolism and excretion).  
The paediatric population has, therefore, an increased sensibility or toxicity to 
medicines and these issues have to be considered when developing 
medicines for such a vulnerable group. In addition to different physiologies, 
there are also paediatric-specific pathologies that differentiate this population 
                                            
10The paediatric population may be categorised as follows: preterm newborn infants (<37 
weeks); term newborn infants (0–27 days); infants and toddlers (28 days – 23 months); 
children (2–11 years); and adolescents (12–16 or 18 years, depending on the country) 
(EMEA, 2001). 
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from adults, for instance respiratory distress syndrome and patent ductus 
arteriosus (EMEA, 2001; WHO, 2007; Paediatric Formulary Committee, 
2008; EMEA, 2009).  
As a result, the paediatric population requires age-appropriate formulations, 
but the development of such particular medicines represents, almost always, 
a major challenge to the pharmaceutical industry (EMEA, 2006). Not only is 
the paediatric population a heterogeneous and vulnerable group, but the 
corresponding clinical trials are also more difficult to conduct than for adults, 
take much longer, cost considerably more and raise several ethical questions 
(EMA, 2007), which together potentially delay the marketing of medicines. 
The paediatric population represents a relatively small market size11 and, 
consequently, paediatric indications are usually not profitable (or have a 
limited return on investment). For these reasons, the majority of proprietary 
medicines do not have paediatric indications and, as a result, 50% to 90% of 
the medicines used in paediatrics have not been studied in this population 
(EMA, 2007; Nahata and Allen, 2008). Paediatric patients have therefore 
been described as “therapeutic or pharmaceutical orphans” (Shirkey, 1963) 
since the medicines available are mainly proprietary medicines used “off-
label” (Section 1.1.2) or, alternatively, compounded medicines prepared 
extemporaneously. 
Pharmaceutical compounding assumes particularly high importance in the 
paediatric population, especially for tackling the need for particular strengths 
- based on body weight (mg/kg) or surface area (mg/m2) - and the need for 
alternative dosage forms (Section 1.1.4) (Nahata and Allen, 2008). 
Compounded medicines are, and will continue to be, a major means by 
which medicines are made available to paediatric patients (Standing and 
Tuleu, 2005). 
  
                                            
11Only 20% of the EU population (≈100 million) is aged less than 16 years (EMA, 2007). 
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1.2 Hospital pharmacy 
The supply of medicines in hospitals is provided by the hospital pharmacy, a 
specific department within the hospital in which medicines are made 
available to patients by a dedicated team of health care professionals, 
usually comprising pharmacists and pharmacy technicians. The art, practice 
and profession of choosing, preparing, storing, compounding and dispensing 
medicines and medical devices in the hospital setting are the responsibility of 
the hospital pharmacy (EAHP, 2009). In addition, hospital pharmacists play 
an active role in the pharmacotherapeutic care and treatment of patients by 
cooperating with doctors in the clinical decision-making and ensuring a safe, 
effective and rational use of quality medicines (Gala, 2004; Štefančič, 2007). 
Nowadays, the concept of clinical pharmacy has gained widespread 
acceptance and importance and hospital services are evolving from being 
product-oriented to becoming more patient-oriented (Scott et al., 2005). 
Pharmacists are an integral part of the hospital staff and their responsibilities 
have evolved in tandem with the advances in medicine and technology, and 
also with the expectations of today’s informed society (Scott et al., 2005). 
According to the European Association of Hospital Pharmacy (EAHP) 
(Section 14.2.1), hospital pharmacists are expected to ensure the “7 rights”, 
as follows: right patient, right dose, right route, right time, right drug with the 
right information and right documentation (EAHP, 2009).  
1.2.1 Compounding in hospital pharmacy 
The provision of sterile and non-sterile compounded medicines in hospitals is 
of great importance considering the particular, and often critical, health 
conditions of hospitalised patients. Proprietary medicines are not always the 
most appropriate therapeutic option to meet those particular needs and, in 
these situations, pharmaceutical compounding is an invaluable therapeutic 
alternative. The extent of this practice varies from hospital to hospital, in 
accordance with the hospital specialties and number of beds; the doctor’s 
prescribing habits; and the characteristics of the hospital pharmacy. 
Furthermore, hospitals which are engaged in clinical trials are likely to require 
additional compounded medicines for these particular studies (Allen, 2005b; 
Yska et al., 2009). As a result, hospital pharmacies may prepare from just a 
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few individualised compounded medicines to batches of those medicines 
which are routinely demanded, in anticipation of doctors’ prescriptions and 
standard hospital protocols (McElhiney, 2008b). Alternatively, hospital 
pharmacies may even outsource part (or all) of their compounding activities 
and dispense compounded medicines prepared by others (Allen, 2011). 
Hospitals operate under very tight budgetary constraints and, although the 
mortar and pestle are still fundamental in a compounding laboratory, there is 
also need for more sophisticated and technologically advanced equipment, 
particularly in batch compounding (Kuntz, 2006b; McElhiney, 2006b; 2006c), 
and not all hospitals are willing to make such an investment. Furthermore, 
hospital pharmacy staff should undergo specialist compounding education 
and training, and must also access up-to-date compounding information 
sources, which requires an additional investment for hospital pharmacy 
(McElhiney, 2006b; 2007). For these reasons, increasing numbers of 
hospitals are nowadays outsourcing their compounding activities and 
dispensing compounded medicines prepared by others (Allen, 2011). 
Hospitals operate 24 hours per day and 7 days per week to provide around-
the-clock patient care. Hospitalised patients may require medicines at 
anytime of the day or night and these have to be made available by the 
hospital pharmacy. Therefore, it is important that hospital pharmacies 
prepare (or outsource) compounded medicines in advance (McElhiney, 
2008b) so that patients have all routinely required (proprietary and 
compounded) medicines readily available.  
Hospitalised patients are not always conscious or able to actively participate 
in their treatment, which makes a significant difference when compared to the 
community pharmacy patients (McElhiney, 2006a) and increases the 
potential need for individualised therapy. In fact, hospital therapies including 
total parenteral nutrition (TPN) and IV admixtures are supplied predominantly 
as compounded medicines (Winckler, 2004; Allen, 2005b). Pharmaceutical 
compounding is a common and challenging practice in the hospital setting, 
but very little attention has been given to the preparation of non-sterile 
compounded medicines, as opposed to those which are sterile (McElhiney, 
2006a).  
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1.2.1.1 European context 
Only a few studies have been published addressing pharmaceutical 
compounding in Europe and, therefore, little is known regarding current 
compounding practices in European hospital pharmacies.  
Every 5 years, the EAHP undertakes a survey on the state-of-the-art of 
hospital pharmacy in Europe. In 2005 (latest available survey), 22 European 
countries participated in the survey and data from 825 hospitals were 
collected (24% response rate), but this included only limited information on 
hospital compounding practices (EAHP, 2005; 2010a). This information will 
be addressed for each European country in the corresponding chapters, 
following the methodology. 
In 1998, Conroy et al. (2000) determined the extent of use of both 
compounded medicines and proprietary medicines “off-label” in children, in a 
sample of 5 European hospitals (UK, Sweden, Germany, Italy and 
Netherlands) for a period of 4 weeks, and concluded that 46% of the 2,262 
prescriptions included either compounded medicines or proprietary 
medicines “off-label”. Out of these, only 164 (7.3%) prescriptions were for 
compounded medicines (the majority from the Netherlands) but no additional 
information was published regarding pharmaceutical compounding alone. 
This situation is common in the literature as the majority of studies consider 
the use of both unlicensed medicines and proprietary medicines “off-label” 
together (without differentiation) and no detailed information is usually 
published regarding the practice of pharmaceutical compounding (Cuzzolin et 
al., 2003; Pandolfini and Bonati, 2005; Cuzzolin et al., 2006; Giam and 
McLachlan, 2008). 
In 2000, Brion et al. (2003) conducted wide-ranging research on the 
extemporaneous preparation of oral compounded medicines for children in 
European hospitals. A questionnaire was developed and distributed to 41 
pharmacists, working or providing services to children’s hospitals, in 18 
European countries. The aims were to determine the most frequently 
prepared oral liquids, powders, capsules and segments (i.e. fragments of 
tablets), in a 6-month period, and to evaluate the respective “formulations” 
and stability. Only 21 (51%) questionnaires were returned, from a total of 16 
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European countries, but it was concluded that compounded medicines were 
prepared according to varying methods in Europe, and also that dosage 
forms were country-specific. Although the authors recognised that the sample 
of hospitals was too small to draw representative findings, this study was the 
first to address pharmaceutical compounding in a Europe-wide comparative 
analysis and the need for further research was highlighted (Conroy, 2003). 
Detailed results from Brion et al. (2003) will be addressed throughout this 
thesis, alongside the findings of the present research. 
The Europe-wide studies described have focused particularly on paediatric 
patients and no research has been published so far including other 
specialties of compounding. In fact, there is currently no knowledge regarding 
the diversity and extent of compounded medicines dispensed to all 
hospitalised patients in a variety of hospital settings (rather than just 
paediatric hospitals) in Europe.  
Furthermore, in Europe, there is lack of consensus with regards to 
compounding terminology and the words used to define and describe this 
practice are usually only correctly understood in context (Fenton-May, 2008). 
There is also a lack of consensus with regards to compounding standards of 
practice, and each European country has very different circumstances 
whether of facilities, equipment, staff training or expectations (Fenton-May, 
2007). In one survey, stakeholders from 5 European hospitals in Spain, 
Denmark, Ireland and Finland were invited to describe their practices and it 
was evident that there are conflicting understandings of compounding. It was 
also clear that compounding regulations and information sources vary 
considerably between countries and that there is a strong need for a better 
understanding of compounding practices in Europe (Fenton-May, 2008). 
  
INTRODUCTION | Aim and objectives | 38 
 
1.3 Aim and objectives 
The aim of this research was to identify and characterise the 
extemporaneously compounded oral medicines most frequently dispensed in 
European hospital pharmacies.  
The objectives, for each European country included in the project, were 
derived in a systematic manner utilising the views of external stakeholders, 
experts and country-specific representatives, and corresponded to the 
following: 
• To identify the official concept of compounded medicines, including types 
and definitions. 
• To determine the national regulations and legal requirements for the 
practice of compounding. 
• To recognise the most relevant professional organisations and information 
sources on compounding. 
• To demonstrate the most frequently dispensed oral dosage forms. 
• To identify the range of strengths and pack sizes associated with the 
different active substances. 
• To categorise the most frequently dispensed oral compounded medicines 
according to their therapeutic classification.  
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2. Methodology 
To identify and characterise the oral compounded medicines most frequently 
dispensed in European hospital pharmacies, the research adopted was a 
large-scale international survey and the method was a descriptive, cross-
sectional study.  
According to the literature, descriptive studies document or describe 
phenomena (i.e. the activities undertaken by pharmacists or other health care 
professionals). Descriptive studies provide important information with regards 
to pharmacy services and the use of medicines, and are essential for the 
improvement of services (Smith, 2005). Cross-sectional studies are often 
referred to as a type of a descriptive study, in which data are collected at one 
point in time. In these studies, the respondents are generally asked to report 
on events retrospectively (Bowling, 2002). For instance, a study of the 
compounded medicines dispensed in a UK paediatric hospital pharmacy 
retrieved data over a 12-month period (Tuleu et al., 2003); this was a 
descriptive and cross-sectional study in which retrospective data were 
reported. In the present research project, European hospital pharmacies 
were requested to provide data already in existence and relating to the most 
recent available year. Hence, in this study retrospective data were collected 
across Europe, ranging from the year 2006 to 2009, depending on the date 
study was initiated in a particular country and on the availability of data in 
each hospital pharmacy. According to Giam and McLachlan (2008), the most 
common study periods in this field range from 2 to 4 months, but it was 
suggested that 12 months would best characterise compounding practices 
Europe-wide.  
Survey research is viewed as a quantitative methodological approach in 
which data are collected from a sample in order to identify frequencies of 
events (Smith, 2002). Quantitative research is appropriate in situations where 
there is pre-existing knowledge of the phenomena of interest, which allows 
the use of standardised methods of data collection (Bowling, 2005). For 
example, in a retrospective survey conducted in New Zealand, the extent of 
extemporaneously compounded oral liquids prepared was determined and 
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quantitative data were obtained based on compounding logbooks and batch 
sheets (Kairuz et al., 2007). In another study, the information regarding oral 
compounded medicines dispensed to paediatric patients in Portuguese 
hospitals was gathered by reference to records held by the hospital 
pharmaceutical services (Barros and Almeida, 2008). Almost all hospital 
pharmacies keep a record of the compounded medicines dispensed 
(although to different extents) and quantitative data may be obtained to 
document the prevalence of this practice. Compounding records identify the 
compounded medicines dispensed more accurately than the respective 
prescriptions (Giam and McLachlan, 2008). In the present research project, 
quantitative data were gathered at the hospital by a member of the pharmacy 
staff (in most cases), familiar with the record keeping of their compounding 
practices. A self-completion questionnaire was designed as the research 
instrument so that the required data were systematically and accurately 
collected. This instrument was further developed in order to generate 
country-specific questionnaires adapted to the specificities of each European 
country.  
In summary, the international survey designed was therefore a descriptive 
and cross-sectional study that involved the collection of quantitative data 
across Europe by means of a country-specific questionnaire. 
2.1 International survey 
An international survey on pharmaceutical compounding in Europe is 
challenging. The continent of Europe is constituted by 49 countries (Figure 
2.1), including 27 member states of the EU (European Union) and 22 non-
member states (Europa, 2009). Considering only the member states of the 
EU, there are a total of 23 official languages (Europa, 2008), which 
represents a big challenge since different languages are often a strong 
limitation to clear and effective communication. It cannot be assumed that 
English is universally understood and language barriers have to be 
considered when planning a research project in Europe. A good interaction 
between researchers and all participants from different countries is absolutely 
crucial for success. Furthermore, access to relevant national literature may 
be limited as local information and publications are usually restricted to the 
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official language. Because of the potential impact of restricting literature 
reviews to only English language papers (Smith et al., 2008), literature 
sources in the national official language should also be considered. 
 
Figure 2.1 Map of Europe adapted from National Geographic Society (2009). 
Besides different languages, international research challenges may include 
cultural contexts and traditions, different perspectives and local views that 
influence the acceptability, feasibility and validity of the research (Smith et al., 
2008). Because questions may not be interpreted as intended and some 
terms may be used differently, or not at all, in some countries (Smith, 1997a), 
it is very important to have a deep understanding of the cultural differences 
and national contexts of any research so that it does not impact the 
applicability and outcomes of a study. 
Apart from these predictable challenges, common to all international settings, 
the study of pharmaceutical compounding brings even more complexity to 
the research. Pharmaceutical compounding is part of pharmacy practice 
worldwide, but the approach to preparing and dispensing compounded 
medicines varies considerably. In each country, several factors contribute to 
a unique approach to the practice of compounding, as follows: 
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• The tradition of pharmaceutical compounding as an integral part of 
pharmacy practice and its progress from the pre-industrialisation era until 
nowadays. 
• The triad relationship doctor-patient-pharmacist (Section 1.1.2.1) and local 
prescribing and dispensing habits. 
• The existence of a legal framework for pharmaceutical compounding. 
• The existence of professional organisations dedicated to this practice. 
• The availability of official and/or non-official specialist information sources. 
Altogether, these factors are responsible for different approaches to 
pharmaceutical compounding and, as a result, instead of a single approach 
worldwide, country-specific approaches have to be considered. It may be 
necessary to adopt different research strategies in each country so that these 
variable factors are considered, which dramatically increases the complexity 
of the research, but is also key to its success. 
2.1.1 Country-specific questionnaire 
The research instrument developed for this survey was a self-completion 
country-specific questionnaire. A questionnaire is the most commonly 
adopted instrument in survey research and is the instrument of choice for 
collecting factual information, in a relatively inexpensive way and in a short 
period of time, from large and widespread samples (Smith, 2005). The study 
of pharmaceutical compounding in Europe requires a research instrument 
that is both flexible and adaptable to the specific practices in each country, 
and a universal/standardised questionnaire would not be possible. Actually, 
experience suggests that many instruments that have been developed and 
validated in one country are not culturally sensitive and are thus 
inappropriate for use in another country; flexible research instruments are 
crucial in international collaborative studies (Rosser et al., 1997). Therefore, 
a country-specific questionnaire was developed for Portugal and it was 
subsequently customised to the majority of the European countries included 
in the research. The purpose of the customised differences within 
questionnaires was to ensure that comparable data were obtained for each 
country so that Europe-wide comparisons could be made. As a result, the 
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contents of the country-specific questionnaires varied slightly but the 
structure and layout were kept the same.  
All questionnaires were self-completion in design in order for the respondents 
to insert the required data in their own time. In addition, questionnaires were 
designed to be sent preferably by email as this is the most accessible and 
efficient means of contacting a large and widespread sample of European 
hospitals. All questionnaires were developed in Microsoft Excel since this is 
the most commonly used computer-based programme to keep records and 
organize data into lists (Frye, 2004). Another advantage of sending Excel 
spreadsheets by email is that respondents are more likely to enter data 
electronically, which can then be easily fed directly into the database that will 
be used for analysis (Smith et al., 2008). Further, for those who are not 
familiar with Microsoft Excel, questionnaires could be easily printed out and 
filled in by hand. In the development of the country-specific questionnaires, 
the goal was to enable the collection of the information as accurately and 
precisely as possible so that, if it the research were to be repeated, the 
results would be comparable country by country (Bowling, 2005).  
The country-specific questionnaires will be addressed in the respective 
chapters in detail, considering the specific approaches to the practice of 
compounding in each European country.  
2.1.2 European hospital pharmacies 
Compounded medicines are prepared in hospital and community pharmacies 
worldwide, and only are rarely prepared in other settings (i.e. pharmaceutical 
industry). In some countries, there is a clear predominance of pharmaceutical 
compounding in one particular setting. For instance, in the USA and Brazil, 
the practice of compounding occurs to such a great extent in the community 
setting that there are specialty (compounding) pharmacies almost only 
preparing and dispensing compounded medicines (Carvalho, 2005). On the 
other hand, in the UK, pharmaceutical compounding rarely occurs in the 
community setting. Actually, according to Rennison and Portlock (2003), the 
practice of compounding in UK community pharmacies is too low to ensure 
that pharmacists maintain their expertise and competence and, as a result, 
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the authors suggested that the preparation of compounded medicines in the 
community setting was no longer appropriate. Throughout Europe, there is 
evidence of compounded medicines being prepared and dispensed in 
community pharmacies to different extents, as in the following pharmacies: 
Farmácia Lordelo, in Portugal (Carvalho, 2005); Farmacia Marro, in Spain 
(Marro, 2008); and Faust Apoteke, in Germany (Zueck, 2008). As opposed to 
this wide variability of compounding in community pharmacies worldwide, 
pharmaceutical compounding in hospital pharmacies is universal. Unlike the 
community pharmacy patient, the hospital pharmacy patient usually requires 
around-the-clock care and individualised therapy is often demanded to meet 
the immediate needs of the critically ill (McElhiney, 2006a). For this reason, 
pharmaceutical compounding is an essential component of pharmacy 
practice in hospitals, and compounded medicines are dispensed in hospital 
pharmacies worldwide. Consequently, the focus of this international research 
was not the community setting but rather European hospital pharmacies.  
It is important to highlight that the international survey was specifically 
designed to collect data regarding the compounded medicines dispensed, 
and not just the compounded medicines prepared in hospital pharmacies. 
This distinction is crucial, particularly in a Europe-wide project, as not all 
compounded medicines dispensed in hospitals are necessarily prepared in 
the respective hospital pharmacies (i.e. these may be prepared in local 
community pharmacies). Therefore, so that the need for compounded 
medicines in the European hospital pharmacies can be accurately estimated, 
the questionnaires addressed the compounded medicines dispensed (to both 
inpatients and outpatients, when applicable) instead of the compounded 
medicines prepared in the hospital setting.  
2.1.3 Oral compounded medicines 
The practice of compounding can be broadly distinguished as sterile 
pharmaceutical compounding and non-sterile pharmaceutical compounding. 
Sterile compounded medicines require aseptic preparation and are subject to 
a test for sterility (US Pharmacopeial Convention, 2005). Because of the 
high-risks inherent to the preparation of sterile compounded medicines, this 
practice is quite well documented and regulated. On the other hand, the 
Chapter 2: METHODOLOGY | International survey | 45 
 
preparation of non-sterile compounded medicines is less acknowledged and 
usually less regulated. According to McElhiney (2006a), although hospital 
pharmacies in the USA are seriously addressing their sterile compounding 
operations, very little attention is being given to non-sterile compounding 
practices; this is likely to be the same in Europe. 
Non-sterile compounding includes the preparation of both oral and non-oral 
dosage forms but, due to the limited time and resources allocated to this 
international survey, it was decided not to include all non-sterile dosage 
forms in the research. Because of the increased risks inherent to the 
preparation of oral compounded medicines, all non-oral dosage forms were 
excluded from the focus of this research (e.g. liquid preparations for 
cutaneous application; rectal preparations) and only (non-sterile) oral dosage 
forms were considered for data collection and analysis.  
Oral compounded medicines may be distinguished as solid dosage forms 
and liquid dosage forms, as follows: 
a. Solid dosage forms 
Capsules are solid preparations with hard or soft shells of various shapes 
and capacities, usually containing a single dose of active substance(s). 
Several categories of capsules may be distinguished, namely: hard capsules, 
soft capsules, gastro-resistant capsules, modified-release capsules and 
cachets (EDQM, 2007). The most common are hard gelatin capsules, which 
consist of 2 sections (one slipping over the other) and are supplied in a 
variety of sizes (000-5). Hard gelatin capsules are easily administered and 
filled either extemporaneously or commercially in large quantities (Rudnic 
and Schwartz, 2005). Manual (or semi-automatic) capsule machines are 
used in hospital pharmacies for the preparation of 50-100 (maximum 300) 
units of capsules at a time. The classic manually operated bench-top 
equipment consists of a series of stacked plates with holes, in which the size 
and number of the holes determines the size and number of capsules to be 
prepared (Podczeck, 2004). Nevertheless, non-standardised quantities of 
capsules (i.e. <50 units) may also be prepared in this bench-top equipment 
provided that the pharmacy has a device to temporarily seal the additional 
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holes. Unless otherwise indicated, an estimate of 50 units of capsules, per 
pack dispensed, was adopted for the purposes of overall data comparison, 
as explained in Section 5.4.2.1.  
Powders (oral) are preparations consisting of solid, loose and dry particles of 
varying degrees of fineness, which contain 1 or more active substances (with 
or without excipients). Oral powders are usually administered in, or with, 
water or another suitable liquid, and may also by swallowed directly. Oral 
powders are presented as single-dose or multidose preparations; single-dose 
powders are enclosed in individual containers, such as sachets or vials 
(EDQM, 2007). Oral powders may also be dispensed in envelopes or pots; 
multidose powders require the provision of a measuring device capable of 
delivering the quantity prescribed (EDQM, 2007). Powders are one of the 
oldest dosage forms but have been largely replaced by capsules and tablets 
because, although stable and flexible, these are very time-consuming to 
prepare (O’Connor et al., 2005) and are difficult to administer without waste. 
Unless otherwise indicated, an estimate of 13 units of oral powders, per pack 
dispensed, was adopted for the purposes of overall data comparison, as 
explained in Section 3.4.2.  
Tablets are solid preparations, each containing a single dose of one or more 
active substances, and they are obtained by compressing uniform volumes of 
particles (or by another appropriate manufacturing technique). Some tablets 
are swallowed whole, others after chewed; some are dissolved or dispersed 
in water before being administered and others are retained in the mouth 
(where the active substance is liberated) (EDQM, 2007). Tablets are a 
popular dosage form because of the economy of preparation on a large 
scale, stability and ease of administration (Rudnic and Schwartz, 2005). The 
preparation of tablets requires specific tableting equipment and not all 
pharmacies can afford such an investment. 
 
b. Liquid dosage forms 
Liquid preparations for oral use are usually solutions, emulsions or 
suspensions containing 1 or more active substances in a suitable vehicle. 
Several categories of these preparations may be distinguished, including the 
following: oral solutions, emulsions and suspensions; powders and granules 
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for oral solutions and suspensions; oral drops; and syrups (EDQM, 2007). 
However, this distinction is not always straightforward (Section 4.4.3), 
particularly in relation to solutions, suspensions and syrups, as it depends on 
the characteristics of the respective oral liquids (e.g. solubility and 
consistency); and also in relation to oral drops, as it depends on the 
characteristics of the container / additional devices (e.g. dropper). 
Oral liquids may be supplied in single-dose or multidose containers and, for 
the purposes of overall data comparison, quantities <10 mL were taken to 
correspond to unidose whereas quantities >10 mL corresponded to multidose 
containers (Section 5.4.2.2), unless otherwise indicated. For quantities =10 
mL, data entries were considered individually and within the respective 
national databases. In addition, an estimate of 12 units of unidose oral 
liquids, per pack dispensed, was adopted for the purposes of overall data 
comparison, unless otherwise indicated, as explained in Section 5.4.2.2. 
Although oral liquids may be rapidly prepared, allow dosing flexibility (by 
variable volumes) and are easy to administer (particularly to paediatric and 
geriatric patients, Section 1.1.5), their formulation and stability are usually 
complex. Issues with solubility; uniformity; taste masking and physical, 
chemical and microbiological stability must be considered when preparing 
oral liquid compounded medicines (Woods, no date). Several categories of 
excipients are usually required to ensure optimal formulations (e.g. 
suspending agents, buffers and preservatives) and to enhance compliance 
(e.g. sweetening and flavouring agents). However, the choice of excipients 
must also consider the patients’ pathophysiology (e.g. ethanol is not 
recommended in paediatric patients and sucrose is not recommended in 
diabetic patients), which adds even more complexity to the extemporaneous 
preparation of oral liquid dosage forms. 
The preparation of compounded medicines in variable strengths is facilitated 
when oral solids (capsules and powders) are prepared, as opposed to liquid 
dosage forms that usually require more complicated dosing calculations. On 
the other hand, oral liquids allow dosing flexibility, which is not easily 
achieved with solid dosage forms. 
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Although the aim was to identify and characterise the extemporaneously 
compounded oral medicines, for the purposes of this research, 
extemporaneously does not mean a medicine prepared just before being 
dispensed/administered but, instead, refers to compounded medicines in 
general, including those prepared in advance. This terminology was adopted 
because it is closely associated with the concept of compounded medicines 
in the UK. 
2.2 Sampling methods 
The population of interest in this project was hospital pharmacies in Europe, 
which represented a very large and numerous sampling frame. It would be 
impractical and unnecessary to recruit all hospital pharmacies spread across 
Europe. By selecting a sample from the complete population, it is possible to 
conduct more detailed research within limited time, staff and resources. Also, 
better quality data may be achieved since there is more time for checking 
and analysing the information collected (Bowling, 2002; Smith et al., 2008). 
Due to the complexity of the Europe-wide research, sampling the hospital 
pharmacies was not straightforward and a multi-stage sampling procedure 
was adopted: 
• 1st stage: sample of European countries (primary sampling units). 
• 2nd stage: sample of hospital pharmacies (within each European country).  
2.2.1 Sample of European countries 
Identification of, and access to, the population of interest is one of the first 
considerations of any researcher (Smith, 1997b). When sampling the 
European countries, the first consideration to be made was the following: are 
all European countries equally relevant to the purpose of the research? 
Europe is a large and heterogeneous continent constituted by 49 countries 
(Figure 2.1), including 27 members of the EU and 22 non-members; the 
members of the EU cover most of the continent and more countries are 
expected to join the Union. The EU brings together the European countries 
committed to closer cooperation and, thanks to the Union, citizens of the 
member countries can travel, live and work anywhere in Europe. This 
fundamental right of the EU citizens to move cross-borders raises many 
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challenges; with regards to health care, patients and professionals have an 
easier access to health systems abroad within the EU and are more 
interconnected than ever (Europa, 2009). Therefore, the European countries 
are not all equally relevant to the purpose of this research. The most relevant 
countries are actually those with fewer frontiers and whose citizens share 
enhanced collaborations and expectations in Europe, i.e. the members of the 
EU and the non-members with close connections to the Union.  
To ensure that the relevant countries were represented in the sample, a 
stratification procedure was undertaken to divide the population of interest in 
groups and subgroups, prior to sample selection. According to Bowling 
(2002), dividing the population in strata and sampling from each stratum 
avoids under or over representation of certain groups of the population. 
Stratification assures the researcher that there will be sufficient numbers in 
each group to enable comparisons, avoiding inadequate representations of 
the population (Smith et al., 2008).  
The 49 European countries (population of interest) were initially divided in the 
classic 2 groups: members of the EU (group 1) and non-members of the EU 
(group 2). The members of the EU were ordered by population (Figure 2.2) 
and these were further divided in 3 subgroups, of 9 countries each, according 
to their population (Table 2.1). The population of interest is generally 
stratified according to the variables believed to be important to the study 
objectives (Smith et al., 2008). 
 
Figure 2.2 Population (in millions) per member state of the EU in 2007 (adapted from 
Europa, 2008). 
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Table 2.1 Members of the EU divided in 3 subgroups according to their population (the 
countries selected were underlined). 
 
Subgroup 1 Subgroup 2 Subgroup 3 
Germany Portugal Finland 
France Belgium Ireland 
UK Czech Republic Lithuania 
Italy Hungary Latvia 
Spain Sweden Slovenia 
Poland Austria Estonia 
Romania Bulgaria Cyprus 
Netherlands Denmark Luxembourg 
Greece Slovakia Malta 
 
In a study that aims to identify the most frequently dispensed oral 
compounded medicines in Europe, the determinant variable is the population 
and not the size of the country or its geographical location. For this reason, 
the stratification procedure was carried out considering the population per 
country. The resulting 3 subgroups reflect the diversity of the population 
within the EU, from the most populated to the least populated countries 
(Table 2.1). Stratification is particularly useful in ensuring that samples are 
representative (Smith, 2005). In order to get the best coverage of Europe, 
sampling was then carried out in each subgroup. A larger sample fraction 
was taken from subgroup 1 (more populated countries) to provide results that 
represent the majority of the EU population. Thereafter, two identical sample 
fractions were taken from subgroups 2 and 3, so that the different subgroups 
of the population were all represented in the sample. The method adopted at 
this stage was convenience sampling and a total of 10 members of the EU 
were selected, which are underlined in Table 2.1. 
At last, considering the non-members of the EU (group 2), one country was 
selected from this strata and the method adopted was an opportunistic 
sampling12 procedure.  
                                            
12Opportunistic samples share features of convenience samples in terms of the selection 
procedure but may also be representative of the population of interest (Smith, 2002). 
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In fact, Switzerland was not only the most convenient country from this group 
but also the one that shares more relations with the Union (ergo opportunistic 
sample). Over 900,000 EU citizens live and work in Switzerland, and many 
more cross the borders or transit the country on a regular basis (EEAS, 
2011). For these reasons, Switzerland was the non-member of the EU 
considered in this research. The stratification and sampling of European 
countries are shown in Figure 2.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Stratification and sampling of European countries. 
In summary, the international survey was undertaken on sample of 11 
European countries, namely: Germany, France, UK, Spain, Poland, 
Netherlands, Portugal, Denmark, Finland, Slovenia and Switzerland (Figure 
2.4). These include Eastern and Western, Mediterranean and Scandinavian 
European countries, in a total of 10 members and 1 non-member of the EU. 
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Figure 2.4 European countries included in the international survey. 
2.2.2 Sample of hospital pharmacies 
Sampling theory assumes a random sample and, in general, the 
representativeness of the study population is enhanced by the use of random 
sampling methods (Bowling, 2002). However, this is not always the case as, 
for instance, in studies that aim to select individuals or settings with a 
particular characteristic within the population of interest. In a study that aims 
to identify the most frequently dispensed oral compounded medicines in 
Europe, hospital pharmacies that dispense a few, or no oral compounded 
medicines at all, might be selected in a random sampling method, whilst 
hospital pharmacies that dispense the most might be omitted. This sampling 
method would negatively impact the outcome of the research. The procedure 
in which the researcher purposively identifies and selects the individuals or 
settings expected to present the study characteristic is called purposive 
sampling (Smith, 2005). Therefore, the method adopted to sample the 
hospital pharmacies in each European country was a purposive sampling 
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procedure, which is a deliberately non-random method of sampling that aims 
to sample a group of people or settings with a particular characteristic 
(Bowling, 2002). In this research, the hospital pharmacies that most 
frequently dispense oral compounded medicines are the ones that present 
the study characteristic. Consequently, the purposive sample in each 
European country corresponded to those hospital pharmacies that most 
frequently dispense oral compounded medicines in that country. Identifying 
the purposive samples was not straightforward and, for some countries, it 
involved seeking the expert opinion of several national stakeholders on 
pharmaceutical compounding.  
Sampling is always liable to be affected by errors, which cannot be 
eliminated but should be reduced to an acceptable level (Bowling, 2002). In 
order to minimise sampling error in this research, purposive samples were 
regularly checked and more hospital pharmacies were added to the initial 
lists, when appropriate. For every European country, the goal was to identify 
all relevant hospital pharmacies so that if the study were to be conducted by 
another researcher, the purposive samples would be equivalent. 
It is important to highlight that the size of the purposive samples varied 
considerably within the European countries since it corresponded to the 
number of hospital pharmacies that most frequently dispense oral 
compounded medicines in that country. This study characteristic is not 
necessarily proportional to the population in the country, nor its size, and it 
can only be estimated following a deep understanding of the compounding 
practices in each country. Additionally, it is not possible to anticipate if all 
paediatric hospitals across Europe would be relevant to this research and it 
should not be assumed that the majority of oral compounded medicines are 
dispensed in these specialist hospitals. In conclusion, the size and nature of 
the purposive samples are country-specific and these will be discussed in the 
respective chapters. 
In summary, a multi-stage sampling procedure was adopted to identify the 
hospital pharmacies that most frequently dispense oral compounded 
medicines, per country, as follows:  
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On a 1st stage, the European countries were stratified and a convenience 
sample of members of the EU was selected plus an opportunistic sample of 
non-members of the EU. On a 2nd stage, a purposive sample of hospital 
pharmacies was selected, per European country. Altogether, the sample 
selected may be described as a stratified purposive sample. 
The European countries included in the research will be described in 
chronological order, per individual chapter, followed by an overview and 
discussion of compounding in Europe. 
2.3 Data collection
A systematic process of data collection was undertaken, which included a 
structured literature review and a detailed register of the views of external 
stakeholders, experts and country-specific representatives. A wide-ranging 
and time-consuming process of data collection was performed for each 
European country, in order to meet the objectives of the study, as follows: 
• Identification and understanding of the official concept of compounded 
medicines (types and definitions); national regulations and legal requirements 
for the practice of compounding. 
• Identification of the most relevant professional organisations and 
information sources on compounding. 
• Identification of existing knowledge on the practice of compounding.  
The literature review was undertaken for each European country considered, 
including both national and international information sources, in English and 
in the following official languages: Danish, Dutch, Finnish, French, German, 
Portuguese, Polish, Slovenian and Spanish. The assistance of national 
stakeholders and the staff at the UCL (University College London) School of 
Pharmacy with selected translations was very helpful at this stage. The 
literature review included academic journals and databases; conference 
presentations and abstracts; professional journals, databases, newsletters 
and websites; legal and policy documents; pharmacopoeias; official and non-
official formularies and textbooks.  
As part of the process of data collection, selected external stakeholders, 
experts and country-specific representatives were contacted and their views 
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were registered in detail. For each European country, if relevant data on 
hospital compounding practices had recently been collected by other 
researchers or organisations, the need for conducting the national survey 
was revised at this stage. Relevant data were identified in the UK, France 
and Germany, which will be addressed in the respective chapters. 
So that information was easily accessed and updated, a robust data 
organisation system was developed for filling large quantities of data. 
Information was archived for each country and, within each, data from the 
hospital pharmacies was registered, in detail, in individual portfolios. 
Considerable effort was required to encourage the selected European 
hospitals to collaborate with data collection. For many hospital pharmacies, 
gathering the required data was an arduous and time consuming process 
and, therefore, data collection was not finalised until the very end of the 
research. For each European country, data collection procedures will be 
thoroughly addressed in the respective chapters. 
2.4 Data processing and analysis 
European hospitals were divided in 3 categories: participant, non-participant 
and non-respondent hospitals.  
Participant hospitals contributed the required data but to variable extents. 
The majority of hospitals provided quantitative datasets but some provided 
semi-quantitative and qualitative data, as well as incomplete datasets, which 
were processed and analysed accordingly. Data from hospital pharmacies 
were provided in variable formats, from completed questionnaires provided 
by the researcher to their own formats, either manually or electronically. 
Hospital pharmacies were frequently contacted to confirm the interpretation 
of the datasets, in particular with regards to the quantities of the different 
dosage forms dispensed. For each dataset, data entries were checked in 
detail and transcribed to a national database (in Microsoft Excel). Incomplete 
or not clearly identified data entries were checked with the hospital pharmacy 
staff. Non-valid data entries were excluded from the processed database 
(Section 2.4.1).  
Chapter 2: METHODOLOGY | Data processing and analysis | 56 
 
Non-participant hospitals did not contribute data and the reasons appointed 
for not participating were grouped together and assigned codes. The coding 
frame was developed considering the actual responses (Smith, 2005) as 
shown in Table 2.2. In code A, compounded medicines were not dispensed 
at all by the hospital pharmacy (A1) or, alternatively, compounded medicines 
were dispensed but none for oral administration (A2). In code B, 
compounded medicines were dispensed by the hospital pharmacy but data 
was not provided because of the following reasons: only few compounded 
medicines were dispensed (B1); only few oral compounded medicines were 
dispensed (B2); the required data was not readily accessible (B3); there were 
no compounding records at the hospital pharmacy (B4); or the required data 
was deemed confidential (B5). In code C, no reason was appointed by 
hospital pharmacies for not participating in the research. 
Table 2.2 The coding frame for the reasons appointed by hospital pharmacies for not 
participating in the research. 
A Not dispensed 
A1 Compounded medicines 
A2 Oral compounded medicines 
B Dispensed 
B1 Few compounded medicines 
B2 Few oral compounded medicines 
B3 No readily accessible data 
B4 No records 
B5 Confidential data 
C Non-participant No reason appointed 
 
Participant hospitals that did not contribute complete, quantitative datasets 
were also assigned a code (Table 2.2). The reasons for not contributing the 
required data were not always clear and hospital pharmacies were frequently 
contacted for confirmation of their reasons. This approach occasionally 
resulted in receiving the required data afterwards, increasing the number of 
participant hospitals contributing complete and quantitative datasets. 
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Following data processing, data entries were analysed to determine the 
therapeutic category of the corresponding compounded medicines.  
Initially, it was though that the BNF (British National Formulary, Section 4.2.2) 
would be the appropriate reference for categorising the compounded 
medicines dispensed Europe-wide. The BNF is divided in 15 chapters, each 
of which is related to a particular system of the body or to an aspect of 
medical care, and active substances are distributed per therapeutic 
indications (Joint Formulary Committee, 2008). The BNF was used for data 
analysis in Portugal, UK and Poland. However, it was then concluded that 
many active substances dispensed abroad were actually not included in the 
BNF.  
Therefore, in a second approach to data analysis, an international reference 
was selected to categorise the compounded medicines dispensed Europe-
wide. The anatomical therapeutic chemical (ATC) classification system was 
thought to be the appropriate reference since the WHO (World Health 
Organization) recommends it for international comparisons. In this system, 
substances are divided in groups according to the organ or system on which 
they act and their therapeutic, pharmacological and chemical properties 
(WHO Collaborating Centre for Drug Statistics Methodology, 2008). This 
system was used for data analysis in Portugal, UK, Poland and France. 
However, the ATC classification includes only substances for which an ATC 
code was requested (by manufacturers, regulatory agencies or researchers) 
and, in fact, several active substances dispensed in Europe did not have 
such a code. In addition, many active substances were included in more than 
one therapeutic group13, which added ambiguity to data analysis since it was 
not possible to determine the actual therapeutic indication for every 
compounded medicine dispensed. Therefore, at this stage, it was concluded 
that the ATC classification system was not the appropriate reference source 
to categorise the compounded medicines dispensed Europe-wide.  
                                            
13Dexamethasone, for instance, was attributed the following ATC codes (not all inclusive): 
A01AC02 (Alimentary tract and metabolism); C05AA09 (Cardiovascular system); D07AB19 
(Dermatologicals); M02AB02 (Systemic hormonal preparations) and R01AD03 (Respiratory 
system) (WHO Collaborating Centre for Drug Statistics Methodology, 2008). 
Chapter 2: METHODOLOGY | Data processing and analysis | 58 
 
In a third approach to data analysis, “Martindale: The Complete Drug 
Reference” (Martindale 35, 2007) was concluded to be the reference of 
choice since it is based on published information and includes substances 
and medicines currently in use throughout the world. It contains over 5,500 
monographs arranged in 54 chapters, which bring together substances and 
groups of substances that have similar uses or actions. Active substances 
are included in one therapeutic group (only) that reflects the uses of the 
substances being described (Martindale 35, 2007). For comparative 
purposes, this unambiguous classification of active substances is the ideal 
system. Nevertheless, as indicated previously, it was not possible to 
determine the actual therapeutic indication for any dispensed product in this 
study and, therefore, the therapeutic groups assigned to active substances 
are regarded as the best estimate of the therapeutic indications of the 
compounded medicines dispensed. Another important feature of Martindale 
35 (2007) is the information on proprietary medicines, which covers a wide 
range of countries, and proved to be very helpful as European hospitals also 
reported proprietary medicines being used in pharmaceutical compounding. 
Data entries reporting proprietary medicines used in the preparation of the 
compounded medicines were processed and transcribed to the 
corresponding active substances, which were then categorised according to 
Martindale 35 (2007). “Synonyms” was another helpful feature in Martindale 
as European hospitals frequently reported active substances using 
equivalent or shortened designations (e.g. butylscopolamine bromide instead 
of hyoscine butylbromide).  
Included in the data analysis was the identification of Narrow Therapeutic 
Index (NTI) drugs dispensed in European hospitals. NTI drugs may be 
broadly defined as critical-dose substances for which small changes in 
systemic concentration can lead to significant changes in pharmacodynamic 
response, resulting in potentially toxic effects or subtherapeutic effects 
(Burns, 1999; Pope, 2009). An official definition and list of NTI drugs has not 
yet been published in Europe and, as a result, the official list published in 
Brazil by the national agency of sanitary vigilance - Agência Nacional de 
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Vigilância Sanitária (ANVISA, 2007) - was adopted for data analysis in this 
research. This is shown in Appendix 1. 
2.4.1 Exclusion criteria 
Not included in the definition and practice of compounding were: off-label use 
(of proprietary medicines); reconstitution, repackaging and handling of 
medicines, as explained in Section 1.1.2.4. Consequently, these activities 
were excluded from the survey. Veterinary compounding was excluded as 
well and all hospitals considered were for human patients only.  
Also excluded from this research were: 
• Sterile compounded medicines. 
• Non-sterile, non-oral dosage forms (Section 2.1.3). 
• Data entries corresponding to vehicles, for instance, Simple Syrup BP 
(British Pharmacopoeia) (see compounding formulary in Appendix 2). 
• Data entries in which the name of the active substance(s) could not be 
clearly identified or checked with hospital pharmacy staff. 
• Data entries in which the number of times dispensed corresponded to “0”.  
For all data entries in which the respective dosage form or number of times 
dispensed could not be clearly identified or checked with the hospital 
pharmacy staff, these were included in the research as qualitative data 
entries.  
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3. Compounding in Portugal 
Portugal joined the EU in 1986 and its official language is Portuguese 
(Europa, 2009). Portugal is constituted by the mainland and the archipelagos 
of Madeira and Açores. The mainland is situated in the South-westernmost 
point of continental Europe and the archipelagos in the Atlantic Ocean (INE, 
2009). Portugal occupies an area of 91,900 Km2 and is the 10th most 
populated country in the EU, with a population of 10.6 million in 2007 (Figure 
2.2) (Europa, 2008). The distribution of the population across the country is 
not homogeneous, but is strongly concentrated on the coast, particularly 
between the cities of Viana do Castelo and Setúbal, with higher incidence in 
the metropolitan areas of Lisbon (capital) and Porto (second largest city) 
(INE, 2009). 
In 2005, there were 204 hospitals in Portugal (ratio of 1.93 hospitals per 
100,000 population) and, in 2006, there were a total of 36,563 hospital beds 
(ratio of 345.44 hospital beds per 100,000 population) (WHO Regional Office 
for Europe, 2010) (Appendix 3). 
In 2005, there were 10,320 pharmacists in Portugal (ratio of 97.83 
pharmacists per 100,000 population) (WHO Regional Office for Europe, 
2010) (Appendix 4) and, according to the Portuguese statistical data, there 
were 738 pharmacists working in the hospital sector in 2008 (OF, 2008). 
Considering the total of 198 Portuguese hospitals (INE, 2009), there was a 
ratio of 3.7 pharmacists per hospital. Nevertheless, in 2005 more than 20 
Portuguese hospitals had only 1 hospital pharmacist, which has been 
suggested to not be sufficient for the 24 hours a day support that is required 
in hospitals (Machado and Silva, 2005). 
In Portugal, hospital pharmacy (also known as pharmaceutical services) 
corresponds to a department within the hospital that has technical and 
scientific autonomy and is usually directed by a hospital pharmacist, who 
reports to the administration board of the hospital. Pharmaceutical 
compounding is one of the activities undertaken in the hospital pharmacy 
and, for the majority of hospitals, it is the pharmacy’s responsibility to prepare 
cytotoxics, parenteral nutrition fluids and other medicines for intravenous 
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administration, in aseptic preparation facilities that have greatly improved 
over recent years. For economic reasons, other compounded medicines are 
sometimes prepared in centralised hospital pharmacies (Feio, 2008). The 
preparation of quality compounded medicines is a big concern for 
Portuguese hospital pharmacists and QC groups have been set up in many 
hospitals to ensure that these medicines are prepared and dispensed in 
conformity with the standards (Machado and Silva, 2005). Nevertheless, in 
December 2009, six patients who were admitted for eye surgery in one of the 
largest hospitals in Portugal were left blind due to a compounding error. The 
eye preparations were compounded with the wrong active substance and the 
QC group did not identify the mistake (Mesquita, 2009).  
Pharmaceutical compounding in hospital and community pharmacy is 
currently a common practice in Portugal. Non-sterile compounding occurs in 
both settings, whereas sterile compounding is almost restricted to hospital 
pharmacy (Carvalho et al., 2008). Compounded medicines have always been 
prepared and dispensed in Portugal, and since the foundation of a national 
compounding information centre, in 1999, that pharmaceutical compounding 
has begun a process of reformation and modernisation (Section 3.2.1). More 
initiatives have occurred subsequently, which have contributed to the 
promotion of pharmaceutical compounding in Portugal as, for instance, the 
publication of a contemporary formulary and the approval of up-to-date 
legislation. Portuguese pharmacists no longer consider compounded 
medicines an activity of the past but, instead, an opportunity for the future 
(ANF, 2008a) and pharmaceutical compounding is now recognised as a 
valuable therapeutic option in Portugal. 
There are very few published studies regarding the practice of 
pharmaceutical compounding in Portugal. Barros and Almeida (2008) 
identified the oral compounded medicines dispensed to paediatric patients in 
a convenience sample of 6 hospital pharmacies in Lisbon. They reported a 
total of 52 different oral compounded medicines, dispensed during a 2-month 
period in 2004. The most frequently dispensed oral dosage form was sachets 
and the most frequent therapeutic group was cardiovascular drugs. The most 
common active substances were: folic acid, ursodeoxycholic acid and 
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phenobarbital (oral powders); chloral hydrate, trimethoprim and midazolam 
(oral liquids). Paediatric and university hospitals largely compounded oral 
powders whereas general hospitals mainly compounded oral liquids. Rosa et 
al. (2006), from the hospital pharmacy at Hospital de Dona Estefânia, a 
maternity and children’s Portuguese hospital in Lisbon, reported that there is 
a lack of appropriate formulations for paediatrics. According to the authors, 
pharmaceutical compounding is one of the solutions to this problem and it is 
common practice to prepare sachets and oral liquids, starting from the 
respective proprietary medicines, in order to obtain medicines adapted for the 
paediatric population. A particularly valuable contribution to pharmaceutical 
compounding in Portugal was the Masters’ project by Pinto (2006). The 
researcher developed a universal vehicle for the easy and rapid preparation 
of oral suspensions with assured quality and appropriate characteristics for 
oral administration. The monograph for this vehicle was included in the 
Formulário Galénico Português (FGP) (Section 3.2.2) - Portuguese galenic 
formulary - and it was the basis for the development of further monographs 
for oral suspensions, containing different active substances, which were also 
included in the FGP. 
3.1 Legislation 
The first legislation regarding pharmaceutical compounding was published in 
1991 and remained in force until 2004, despite the fact that it became 
obsolete over the intervening years (e.g. the price of compounded medicines 
was not updated), and was contributing to a generalised lack of interest in 
compounded medicines in Portugal. Eventually, legislation appropriate for 
current practices was published in 2004 and this has contributed to a 
boosting of pharmaceutical compounding throughout the country. This is the 
current legislation and comprises a large set of legal documents concerning 
the practice of pharmaceutical compounding in community and hospital 
pharmacies. 
In Portugal, compounded medicines correspond to Medicamentos 
Manipulados and include any Fórmula Magistral (magistral formula) or 
Preparado Oficinal (officinal preparation) prepared and dispensed under the 
responsibility of a pharmacist. Fórmula Magistral corresponds to a medicine 
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prepared in a hospital or community pharmacy according to a doctor’s 
prescription that specifies the patient for whom the medicine is intended. 
Preparado Oficinal corresponds to any medicine prepared according to the 
indications of a compendium, a pharmacopoeia or a formulary in a hospital or 
community pharmacy, and is intended to be directly dispensed to the patients 
assisted by that pharmacy (Ministério da Saúde, 2004a). All monographs 
included in the FGP correspond to Preparados Oficinais since the FGP has 
been recognised by the Autoridade Nacional do Medicamento e Produtos de 
Saúde (INFARMED), the national authority of medicines and health products 
(INFARMED, 2004a; CETMED, 2005). 
Compounded medicines in Portugal may technically be prepared in advance 
provided that these are multidose preparations (packaged in single-dose 
containers) and are part of a list that as yet has not been published 
(Ministério da Saúde, 2004a). Hence, in practice, the advanced preparation 
of compounded medicines is not allowed in Portugal. 
The price of compounded medicines is specified by law and it is determined 
in accordance with the cost of the staff’s salary, the cost of raw materials and 
the cost of packaging materials (Ministérios da Economia e da Saúde, 2004). 
Before this regulation the price of compounded medicines was low and 
pharmacists were discouraged to prepare these medicines. Nowadays, 
pharmaceutical compounding is cost-effective and more and more 
pharmacists are investing in new facilities and modern equipment for 
compounding (Carvalho, 2005). 
It was established by law (Ministério da Saúde, 2004b) that the government 
would subsidise 50% of the cost of the compounded medicines included in a 
list, proposed by INFARMED, but this list was published only towards the end 
of 2010. This fact was criticised by the president of the national association of 
pharmacies (ANF) (Section 3.2.1) at the launching of the FGP 3rd edition 
(edn.) (ANF, 2008a). Before the publication of this list, the compounded 
medicines subsidised were the ones included in the Portuguese 
Pharmacopoeia 9 and in the National Galenic Formulary (Section 3.2.2) 
(Gabinete da Secretária de Estado da Saúde, 2005). This recently published 
list includes almost 90 entries of one or more active substances, and the 
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respective dosage forms, and these medicines are reimbursed for 30% of 
their cost. Further compounded medicines may be included in this list 
provided that one of the following conditions is met: nonexistence of 
proprietary medicines with the same active substance and in the same 
dosage form; existence of a therapeutic need with regards to the proprietary 
medicines available; need for adjustments of strengths or dosage forms to 
the therapeutic needs of specific populations, as for paediatrics or geriatrics. 
Prescriptions including a reference to proprietary medicines or other products 
are not subsidised in Portugal (Ministério da Saúde, 2010). 
With regards to raw materials, all substances included in compounded 
medicines must be part of the Portuguese Pharmacopoeia, or another 
scientific compendium, and must not be included in the list of substances that 
cannot be used in the prescription and preparation of compounded medicines 
(Ministério da Saúde, 2004a). This negative list determines that the following 
substances cannot be used in pharmaceutical compounding: animal organ 
extracts; active substances (for internal use) in a dosage higher than that 
authorised for proprietary medicines; active substances included in 
medicines that were suspended or repealed; and finally, a set of active 
substances, including: clobenzorex (and other anorectics); levothyroxine (and 
similar substances); fluoxetine and other substances (INFARMED, 2004b). 
Anti-obesity drugs are included in this negative list in order to avoid their 
misuse by means of pharmaceutical compounding. Levothyroxine is also 
included in the list because of a compounding error in the past including this 
active substance. In addition, there is a specific regulation for the suppliers of 
raw materials that specifies the conditions that these must meet (INFARMED, 
2004c).
When preparing a compounded medicine, the pharmacist must assure the 
quality of the preparation by following good compounding practices (GCP) in 
community and hospital pharmacies – “Boas práticas a observar na 
preparação de medicamentos manipulados em farmácia de oficina e 
hospitalar” – established by law (Ministério da Saúde, 2004c). These 
guidelines are constituted by a set of 8 norms, as follows: personnel; facilities 
and equipment; documentation; raw-materials; packaging materials; 
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compounding; QC and labelling. In Portugal, QC must be performed for all 
compounded medicines prepared and the QC tests are specified by law. The 
verification of organoleptic characteristics, final weight/volume, pH 
(solutions), uniformity of weight (solids) are some of the tests specified in the 
Portuguese GCP. 
If a hospital does not meet the necessary conditions for the preparation of 
specific compounded medicines, these may be prepared by an authorised 
body provided that the medicines required are for the exclusive use of the 
hospital (INFARMED, 2004d).  
With regards to community pharmacies, although compounding-specialist 
pharmacies are not found in Portugal, every community pharmacy must have 
a compounding laboratory and its dimensions are specified by law 
(INFARMED, 2007; Carvalho et al., 2008). Moreover, there is a list of the 
minimum compounding equipment that is required in a pharmacy, for 
instance, glass and porcelain mortars; balance (capable of weighing 
milligram quantities); measuring cylinders and pipettes (INFARMED, 2004e). 
3.2 Professional organisations and information sources 
3.2.1 Portuguese professional organisations 
• Associação Nacional das Farmácias (ANF): is the national association of 
pharmacies, a non-governmental organisation that represents and supports 
97% of Portuguese community pharmacies. The ANF is constituted by 
several organisations, each focused on a particular pharmaceutical activity 
(ANF, 2008b). The two ANF organisations relevant on pharmaceutical 
compounding are described below.  
i. Centro Tecnológico do Medicamento (CETMED): was the pharmaceutical 
technology department of ANF, a department created in 1999 to promote and 
develop pharmaceutical compounding by community pharmacies (and also 
hospital pharmacies) in Portugal, directed by Carlos Maurício Barbosa 
(Associate Professor at the Faculty of Pharmacy, University of Porto). From 
1999 to 2003, CETMED provided 160 consultations on pharmaceutical 
compounding to a total of 45 Portuguese hospital pharmacies (Barbosa et al., 
2003). The practice of pharmaceutical compounding resurged in Portugal as 
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pharmacists were encouraged and supported by CETMED to prepare and 
dispense compounded medicines. CETMED was closed down by ANF in 
2005 and its services were integrated in the Laboratório de Estudos 
Farmacêuticos. 
ii. Laboratório de Estudos Farmacêuticos (LEF): is the laboratory of 
pharmaceutical studies, the organisation from ANF that incorporated 
CETMED in 2005. The LEF, amongst other services, provides a 
compounding information centre that offers technical and scientific 
information services to all health care professionals. The LEF also develops 
monographs for the FGP and offers training courses on pharmaceutical 
compounding (LEF, 2006), the same services that were initiated by 
CETMED. 
• Associação Portuguesa de Farmacêuticos Hospitalares (APFH): is the 
Portuguese association of hospital pharmacists, an organisation that 
represents and supports Portuguese hospital pharmacists. The mission of 
APFH is to assist hospital pharmacists enable people to use medicines better 
(APFH, 2010). APFH organises a congress every 3 years and an annual 
symposium between (Batista, 2008). Pharmaceutical compounding in 
hospital pharmacy is usually one of the subjects discussed at the APFH 
events; in 2004, at the 5th congress of the APFH, there was a workshop 
entirely dedicated to compounding (Gouveia, 2005). APFH is a full member 
of the EAHP (Batista, 2008). 
3.2.2 Portuguese information sources 
• Formulário Galénico Português (FGP): is the Portuguese galenic 
formulary, a national reference for pharmaceutical compounding initiated by 
CETMED. It was first published in 2001 aiming to contribute to the quality of 
the compounded medicines prepared and dispensed in the Portuguese 
pharmacies; and also to contribute to the standardisation of pharmaceutical 
compounding in Portugal (CETMED, 2001). The FGP was developed based 
on a comparative study of formularies from selected EU countries, 
Switzerland, Norway and also USA (Barbosa and Pinto, 2001). A second and 
much larger edition of the FGP was published in 2005, including a total of 
133 monographs for (liquid and semi-solid) compounded medicines, current 
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legislation relevant for pharmaceutical compounding, technical information 
and recommendations, and also standard operating procedures (CETMED, 
2005). Monographs for compounded medicines are very comprehensive, 
including a total of 15 different sections (for most medicines): formula, 
method of preparation (manual and mechanical), description of the medicine, 
packaging, labelling, QC, beyond-use-date and storage conditions, 
clarifications, therapeutic indications, administration and usual dosages, 
secondary effects, precautions and contra-indications, interactions, 
intoxication symptoms and treatment and, finally, bibliography. All 
monographs are complemented with the respective work sheets. An example 
of a monograph from the FGP 2005 - Phenobarbital 1% Oral Suspension - is 
shown in Appendix 5. The current 3rd edition of the FGP was published in 
2007 and is very different from the previous editions, as a result of the 
integration of CETMED in LEF. The current edition is focused on Paediatrics 
and includes a total of 98 monographs for compounded medicines, 
exclusively oral liquids (solutions and suspensions) (LEF, 2007; ANF, 
2008a).  
• Farmacopeia Portuguesa (FP): is the Portuguese Pharmacopoeia, which 
includes monographs for compounded medicines, though the number of 
monographs has been gradually reduced throughout the years (Barbosa and 
Pinto, 2001). The current edition is the FP 9 and includes only 5 monographs 
for compounded medicines, namely: unguentum picis mineralis cum zinci 
oxydi et amylum; unguentum picis mineralis; suppositoria glyceroli; tincture 
picis mineralis; and sirupus ipecacuanhae (Comissão da FP, 2008). Since 
the number of monographs for compounded medicines included in the FP 9 
is very limited, Portuguese pharmacists in community and hospital 
pharmacies frequently use the FP IV (1946), which includes around 350 
monographs for compounded medicines (Farmacopeia Portuguesa IV, 1946; 
Barbosa and Pinto, 2001).  
• Formulário Galénico Nacional (FGN): is the national galenic formulary, the 
Portuguese official formulary that is still in force today. It was published in 
1969 and has not been updated since (Comissão Permanente da FP, 1969; 
Barbosa and Pinto, 2001).  
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• Formulario Officinal e Magistral: although dating from 1915, the Formulário 
Veiga (after the author Joaquim Urbano da Veiga) is another formulary that is 
commonly used by Portuguese pharmacists (Veiga et al., 1915; Barbosa and 
Pinto, 2001). 
• Tecnologia Farmacêutica: are the Portuguese textbooks of reference in 
pharmaceutical technology, edited in 3 volumes, which provide the basics for 
the practice of pharmaceutical compounding. This set of books is currently 
used in academia and in pharmacy practice in Portugal (Prista et al., 1995; 
1996a; 1996b; Barbosa and Pinto, 2001). 
3.3 Methods 
Portugal was the first European country included in the research. It was the 
most convenient country to start with because of the practice and expertise of 
Maria Carvalho (MC) in the field of pharmaceutical compounding in her home 
country; the easy access and proximity of MC to Portuguese hospital 
pharmacies; and the common language shared with all professionals. 
The research project in this country was initiated in 2006 by consulting 
Portuguese stakeholders, namely: Carlos Maurício Barbosa (Director of 
CETMED and Associate Professor at the Faculty of Pharmacy, University of 
Porto) and Jorge Brochado (President of the APFH and chief hospital 
pharmacist at the Hospital de Santo António), who contributed with their 
knowledge and experience to planning the research. Their recommendations 
and advice were particularly important in the initial stages of the research, 
namely in the design of the template questionnaire (Section 3.3.1) and in 
identifying the purposive sample of Portuguese hospitals (Section 3.3.2).  
It was concluded that the template questionnaire should be piloted in 
selected hospitals pharmacies before being distributed to the purposive 
sample of hospitals. A convenience sample14 of 3 hospitals was then 
established in 3 regions of Portugal, in order to even out possible 
geographical idiosyncrasies in the practice of pharmaceutical compounding. 
The pilot study was initiated at the beginning of 2007 with a visit to the 
                                            
14Convenience samples are useful in preliminary fieldwork and pilot studies (Smith, 2005). 
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following hospitals: Hospital Geral de Santo António, in Porto; Hospital de 
São Pedro, in Vila Real; and Hospital de Santa Maria, in Lisbon.  
The contents of the template questionnaire were carefully evaluated during 
the hospital visits. Data from the compounding records of each hospital was 
inserted in the template questionnaire to test its adequacy and, at the same 
time, to initiate data collection in Portugal. As a result of the pilot study, the 
contents of the template questionnaire were further tailored to the current 
hospital compounding practices and, at last, a first version of the Portuguese 
questionnaire was obtained.  
3.3.1 Country-specific questionnaire  
Although the aim of the project was to identify and characterise the 
extemporaneously compounded oral medicines most frequently dispensed in 
European hospital pharmacies, it was initially decided to include only the oral 
liquid compounded medicines in the research. At that time, it was considered 
that collecting data regarding other dosage forms would unnecessarily 
increase the time and length of a Europe-wide project.  
The research instrument developed to collect information regarding oral liquid 
compounded medicines was a self-completion questionnaire, designed to 
include all oral liquids dispensed by the hospital pharmacy in 2006. In an 
Excel table, for each oral liquid dispensed, the questionnaire addressed the 
following information: name of the active substance; strength; dosage form; 
volume; and number of times dispensed per month, from January to 
December 2006. The units of strength and volume were also required. Under 
dosage form was “solution / emulsion / suspension” so that it was clear which 
dosage forms were considered oral liquids. The first entry on the Excel table 
was an example including “Captopril, 1 mg/mL, solution, 100 mL, 24 (total 
times dispensed)”. Directions were included above the table, as the following: 
“Please fill in the following table with only the ORAL LIQUID compounded 
medicines dispensed by the hospital pharmacy in the year 2006”. It was 
decided that the questionnaire should address the compounded medicines 
dispensed instead of the compounded medicines prepared by the hospital 
pharmacy. This distinction is crucial, particularly in a Europe-wide project, as 
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not all compounded medicines dispensed in hospitals are necessarily 
prepared in the respective hospital pharmacies (Section 2.1.2). The Excel 
table is shown in Appendix 6 and the main heading in Figure 3.1.  
In order to estimate the importance of oral liquids in comparison to other 
dosage forms dispensed by the hospital pharmacy, 2 closed questions15 
were added to the questionnaire: 
1 - “Which was the main DOSAGE FORM dispensed by the hospital 
pharmacy in the year 2006?” The range of responses was: “Sachets, 
Capsules, Suppositories, Ointments/Creams, Solutions/Suspensions”. 
2 - “Considering all dosage forms, what is the average TOTAL number of 
compounded medicines dispensed by the hospital pharmacy in the year 
2006?” The range of responses was: “[< 100] … [> 2000]”. 
It is common practice to allow comments towards the end of the 
questionnaire (Smith, 2005). Hence, a few lines were added under the 
heading “Comments”, immediately after the 2 questions. Altogether, 
questions and comments were included in the questionnaire as a separate 
Excel sheet (Appendix 7). 
So that information was complete, an initial sheet with a brief introduction to 
the research project was also added to the questionnaire (Appendix 8). As a 
result, the template questionnaire was made in the format of a 3-sheet Excel 
document, including the following: an initial sheet with a brief introduction, 1 
table and a final sheet with questions and comments. 
In the initial stages of data collection, it was concluded that relevant data on 
oral compounded medicines was being left out by limiting the request to oral 
liquids only. In fact, several Portuguese hospitals dispensed only a few oral 
liquids when compared to other oral dosage forms. This situation was 
considered likely to occur throughout Europe and, therefore, the aim of the 
project was revised at this stage. 
 
                                            
15Closed questions limit the range of responses and, therefore, are preferable in self-
completion questionnaires since these questions are easier and quicker to respond (Smith, 
2005). 
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Although the inclusion of all oral dosage forms in the research would 
considerably increase the time and length of the project, it was decided that it 
would definitely raise the challenge and impact of a Europe-wide comparative 
study on pharmaceutical compounding. 
It was also found that not all hospital pharmacies kept compounding records 
for each month but, instead, per year. Therefore, the table was modified in 
order to include just the (total) number of times each compounded medicine 
was dispensed over the 12-month period. Moreover, the request for all oral 
liquid compounded medicines was contributing to a generalised delay in the 
process of data collection, as pharmacists were required to go through all 
compounding records which, for many pharmacies, corresponded to 
hundreds of pages of information. In order to optimise this process and to 
enhance response rates, the request for all oral liquids was substituted by the 
request for the most frequently dispensed oral compounded medicines. In 
order to identify and characterise the most frequently dispensed oral 
compounded medicines per country, it was concluded that data regarding the 
top 40 (if applicable) oral compounded medicines dispensed should be 
collected, per selected hospital, as the following: name of the active 
substance; strength; dosage form; quantity; and number of times dispensed 
in 2006. Finally, 3 more examples were included in the table, so that other 
dosage forms were also highlighted (Figure 3.2). 
In order to facilitate the process of data collection, the quantities in the 
examples were now given in intervals and not individual quantities (which 
was time-consuming for most pharmacies to provide). In addition, a 
distinction was made with regards to the quantities of oral liquid and oral solid 
dosage forms. Oral liquids were expected to be reported by number of 
multidose containers whereas oral solids were expected to be reported by 
number of packs (of unidose containers) dispensed. For comparative 
purposes, 1 multidose oral liquid is not equivalent to 1 unidose oral solid and, 
therefore, it was decided to make this distinction clear. The Excel table 
(version 2) is shown in Appendix 9 and the main heading in Figure 3.2.  
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At this stage, it was acknowledged that both multidose oral liquids and packs 
of unidose oral solids do not necessarily correspond to the treatment for 1 
single patient. In fact, compounded medicines may be prepared at the 
hospital pharmacy for a group of patients or even for an entire ward.  
With the purpose of estimating the importance of the most frequently 
dispensed oral compounded medicines in comparison to all oral compounded 
medicines dispensed by the hospital pharmacy, the following question was 
added to the questionnaire: 1 - “Please estimate the TOTAL number of ORAL 
COMPOUNDED MEDICINES dispensed by the hospital pharmacy in 2006.” 
Moreover, it was concluded that it would be interesting to find out how many 
pharmacists and technicians were part of the hospital pharmacy in 2006, so 
that the size of the pharmacy staff would be compared to the compounding 
activity in the pharmacy. Therefore a second question was added to the 
questionnaire, as follows: 2 - “Please indicate the number of PHARMACISTS 
and the number of TECHNICIANS working in the hospital pharmacy in 2006.” 
These 2 questions substituted the previous 2 closed questions in the 
template questionnaire (version 1). The “Comments” were kept at the end of 
the research instrument, as shown in Appendix 10. In conclusion, the 
template questionnaire (version 2) corresponded to a 3-sheet Excel 
document, including the following: an initial sheet with a brief introduction, 
one table (optimised) and a final sheet with questions and comments 
(optimised). 
Later in the process of data collection it was considered that if the 
questionnaire was even more simplified, response rates would probably be 
maximised. For this reason, the initial sheet with a brief introduction was 
removed from the Excel document and converted into a separate portable 
document format (PDF). Consequently, the Portuguese questionnaire 
resulted in a 2-sheet Excel document, which was complemented with a 
separate PDF introduction. 
Further on the process of data collection (Section 3.3.3), the questionnaire 
was even more simplified so that non-respondents were encouraged to 
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collaborate by providing key data. Hence, email reminders were sent to the 
majority of the hospitals including just the table. 
At this stage, it was decided that the introduction was not essential since all 
hospital pharmacists had been explained the project by telephone. Moreover, 
although it would be interesting to estimate the size of the pharmacy staff, 
this information was not essential to the aim of the project and, therefore, it 
was excluded from the research. Finally, in the course of data collection, it 
was concluded that hospital pharmacies not always had the 2006 
(specifically) data available. 
Moreover, because data collection was undertaken for more than 1 year, it 
was decided that the questionnaire should address the previous year, instead 
of 2006, so that the latest available data were collected. Hospital pharmacists 
were then requested to provide data for the previous year or, alternatively, 
the latest available year at the pharmacy. For comparative purposes, it was 
concluded that it would be more relevant to compare the latest available data 
than data regarding one specific year, as there were no relevant changes in 
the practice of pharmaceutical compounding for the years included in the 
research. 
3.3.2 Purposive sample of hospitals 
The purposive sample of Portuguese hospitals was established considering 
the complete list of hospitals that had contacted CETMED from 1999 to 2005 
(Section 3.1.1). Therefore, it was postulated that the hospital pharmacies that 
prepared and dispensed compounded medicines in Portugal would have 
contacted CETMED for its consultancy services at least once during its 
period of activity (1999-2005). The complete list of hospitals was provided by 
Carlos Maurício Barbosa and included a total of 60 Portuguese hospitals, 
distributed throughout the mainland and archipelagos, including the cities of: 
Almada, Amadora, Barcelos, Barreiro, Beja, Braga, Bragança, Chaves, 
Coimbra, Faro, Figueira da Foz, Funchal, Guarda, Guimarães, Horta, 
Lamego, Leiria, Lisbon (capital), Oeiras, Ovar, Penafiel, Porto, Santarém, 
Santa Maria da Feira, Santo Tirso, São João da Madeira, Setúbal, Tomar, 
Torres Vedras, Trofa, Viana do Castelo, Vila Nova de Famalicão, Vila Nova 
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de Gaia, Vila Real and Viseu. A total of 14 hospitals were from Lisbon and 9 
hospitals from Porto. Figure 3.3 displays the purposive sample of hospitals in 
the mainland only as the 2 archipelagos are not included in the map. The 
purposive sample of hospitals was concentrated on the coast, including 
Lisbon and Porto, which reflects the heterogeneous distribution of the 
population across the country (INE, 2009). 
 
Figure 3.3 Map of Portugal (mainland) adapted from National Geographic Society (1998a); 
indicating the location of the purposive sample of hospitals (   ). 
3.3.3 Data collection
The purposive sample in Portugal was provided as a list of 60 hospitals 
including only the name of the hospitals. Because the contact details of the 
chief pharmacists were not available at the hospital’s websites and none of 
the pharmaceutical bodies in Portugal were willing to share any of their 
details (not even their names), the telephone number of each hospital was 
searched online and each hospital pharmacy was contacted by telephone by 
MC. The individual discussions with hospital pharmacists were important for 
a personalised explanation of the research project and encouragement for 
collaboration. If pharmacists were willing to collaborate with data, their email 
addresses were requested at this stage so that they would receive the 
questionnaire attached to a brief introductory email. Only 1 hospital 
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pharmacist requested the questionnaire to be sent by post instead of email. 
Non-respondents were sent periodical email reminders, which were 
interspersed with telephone reminders, throughout the years of 2007, 2008 
and beginning of 2009. Persistent non-respondents who seemed available 
for a visit were suggested that data collection would be undertaken by MC 
directly at their pharmacies. A total of 5 Portuguese hospitals accepted the 
suggestion and data were collected during the hospitals visits: 1 hospital was 
visited in 2008 and 3 hospitals were visited in 2009 (at the very last stage of 
data collection in Portugal). In total, the research project in Portugal included 
the visit to 8 hospitals across the country and throughout the years of 2007, 
2008 and 2009. The hospital visits and the persistent email and telephone 
reminders were essential for a good response rate from such a large 
purposive sample of hospitals.  
3.4 Results and discussion 
In Portugal, 60 hospitals were contacted to participate in the research project 
and a response rate of 93% was obtained. Out of the 56 respondents, 39 
hospitals contributed with data regarding the oral compounded medicines 
most frequently dispensed by their pharmacies and 17 hospitals were non-
participants (Figure 3.4). Out of the 39 participant hospitals, almost 80% 
provided quantitative and complete datasets. All other replies were 
distributed as follows: 3 hospitals provided quantitative but incomplete 
datasets; 2 hospitals provided semi-quantitative data; and, finally, 3 hospitals 
provided qualitative data only. The main reasons stated by these hospitals for 
not sharing complete datasets were that data was not readily accessible and 
that no records were kept with regards to specific data.  
Over 50% of the participant hospitals submitted data in the questionnaire 
provided. The majority of the questionnaires were received by email and only 
1 questionnaire was received by post and another one by fax; 3 additional 
hospitals provided the required data by telephone. The participant hospitals 
shared data regarding different years which, in most cases, corresponded to 
the latest available year at the pharmacy, namely: 2006 (53%); 2007 (31%); 
2008 (14%); 2006 and 2007 (2 hospitals); and, finally, 2005 (1 hospital). 
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      Figure 3.4 Purposive sample showing respondent, participant and visited hospitals. 
The reasons stated by hospital pharmacies for not providing data were: 47% 
(n=8) of the non-participants did not dispense oral compounded medicines, in 
particular; 3 hospitals did not keep records of the compounded medicines 
dispensed; 2 hospitals did not dispense any compounded medicines at all 
(oral/non-oral); 1 hospital dispensed only a few compounded medicines; 1 
hospital dispensed oral compounded medicines but data was not readily 
accessible; 1 hospital dispensed oral compounded medicines but data was 
considered confidential. Only 1 hospital did not provide any reason for not 
participating in the research. 
Contacting such a large purposive sample of hospitals was a complex and 
time-consuming process, particularly because hospital pharmacists in 
Portugal were not readily accessible even by telephone. In most cases, more 
than 1 telephone call to the hospital pharmacy was necessary to reach the 
chief pharmacist or the person responsible for the pharmaceutical 
compounding department. Moreover, several pharmacists required an 
authorisation from the board of directors of the hospital prior to sharing any 
data, which complicated the process of data collection even more. A total of 
189 telephone calls were made to Portuguese hospital pharmacies (mean >3 
telephone calls per hospital) and a total of 127 emails were sent with 
requests for collaboration. During the telephone discussions, 29% of 
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respondents stated that they requested compounded medicines from other 
hospitals and/or community pharmacies, mainly because their facilities did 
not meet the minimum requirements for the preparation of certain 
compounded medicines, and/or they did not have enough staff for a 
pharmaceutical compounding department. Only 1 hospital pharmacy stated 
that they prepared compounded medicines for other hospitals. An example of 
a prescription for a compounded medicine request to a community pharmacy 
by a Portuguese hospital is show in Figure 1.2. 
3.4.1 Active substances  
A complete list of the active substances most frequently dispensed as oral 
compounded medicines in Portugal is shown in Table 3.1. All active 
substances reported were included in Martindale 35 (2007) and these were 
grouped according to the respective therapeutic classification, giving a total 
of 175 different active substances and 33 therapeutic groups. Cardiovascular 
drugs was the group with the greatest number of different active substances 
(n=26), followed by nutritional agents and vitamins (n=24) and antibacterials 
(n=16). Although these active substances were all reported as oral 
compounded medicines, the title of some therapeutic groups suggested non-
oral (therapeutic) indications, namely: dermatological drugs and sunscreens 
(Appendix 11); disinfectants and preservatives (Appendix 12); paraffins and 
similar bases (Appendix 13); stabilising and suspending agents (Appendix 
14); and supplementary drugs and other substances (Appendix 15). The 
active substances included in these groups were described in the respective 
appendixes.  
With reference to the official list provided by ANVISA (2007) (Appendix 1), a 
total of 8 NTI drugs were reported and these are underlined in Table 3.1. 
The active substances dispensed by most hospitals were: captopril and 
trimethoprim (n>25); ranitidine (n=21-25); chloral hydrate, furosemide, 
nystatin and spironolactone (n=16-20); aspirin, caffeine citrate, folic acid, 
hydrochlorothiazide, hydrocortisone, iodine and potassium iodide (Lugol’s 
Solution, see below), magnesium sulfate, omeprazole, phenobarbital, 
propranolol HCl, pyrazinamide and ursodeoxycholic acid (n=10-15). 
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Table 3.1 Active substances most frequently dispensed as oral compounded medicines in 
Portugal (NTI drugs underlined). 
Analgesics, anti-inflammatory drugs 
and antipyretics 
Aminophenazone, aspirin, codeine, 
indometacin, methadone HCl, morphine, 
morphine HCl, morphine sulfate, sodium 
salicylate 
 
Antibacterials 
Amoxicillin, cefuroxime, chloramphenicol, 
ciprofloxacin, clindamycin, doxycycline, 
ethambutol HCl, isoniazid, neomycin, 
nitrofurantoin, pyrazinamide, rifampicin, 
spiramycin, sulfadiazine, trimethoprim, 
vancomycin 
 
Antidepressants 
Fluoxetine HCl 
 
Antiepileptics 
Gabapentin, lamotrigine, levetiracetam, 
phenobarbital, phenytoin, primidone, 
stiripentol, topiramate, vigabatrin 
 
Antifungals 
Amphotericin B, nystatin, terbinafine, 
voriconazole 
 
Antigout drugs 
Allopurinol 
 
Antimalarials 
Hydroxychloroquine sulfate, mefloquine 
HCl, pyrimethamine, quinine 
 
Antimyasthenics 
Pyridostigmine bromide 
 
Antiparkinsonian drugs 
Carbidopa, levodopa, selegiline HCl, 
trihexyphenidyl HCl 
 
Antiprotozoals 
Metronidazole, metronidazole benzoate 
 
Antivirals 
Aciclovir, didanosine, ganciclovir, 
tenofovir, valganciclovir HCl 
 
Anxiolytic, sedatives, hypnotics and 
antipsychotics 
Chloral hydrate, cyamemazine, 
midazolam, risperidone 
 
Bronchodilators and anti-asthma drugs 
Aminophylline, caffeine, caffeine citrate 
 
 
Cardiovascular drugs 
Acenocoumarol, amiloride HCl, 
amiodarone, amlodipine besilate, 
bosentan, captopril, clonidine, 
colestyramine, diazoxide, digoxin, 
dipyridamole, enalapril, flecainide acetate, 
furosemide, hydrochlorothiazide, losartan 
potassium, metolazone, metoprolol, 
minoxidil, nifedipine, pravastatin sodium, 
propranolol HCl, ramipril, simvastatin, 
spironolactone, warfarin sodium 
 
Contrast media 
Barium sulfate 
 
Corticosteroids 
Dexamethasone, fludrocortisone acetate, 
hydrocortisone, prednisolone 
 
Cough suppressants, expectorants, 
mucolytics and nasal decongestants 
Acetylcysteine 
 
Dermatological drugs and sunscreens 
Salicylic acid, urea 
 
Disinfectants and preservatives 
Chlorhexidine, sodium benzoate 
 
Electrolytes 
Calcium chloride, magnesium sulfate, 
potassium chloride, potassium sodium 
hydrogen citrate, sodium bicarbonate, 
sodium chloride, sodium citrate, sodium 
phosphate 
 
GI drugs 
Calcium carbonate, ispaghula, 
omeprazole, pantoprazole, ranitidine, 
senna, sodium sulfate, sucralfate, 
sulfasalazine 
 
General anaesthetics 
Ketamine HCl 
 
Immunosuppressants 
Tacrolimus 
 
Local anaesthetics 
Cocaine, lidocaine, tetracaine 
Miotics, mydriatics and antiglaucoma 
drugs 
Acetazolamide 
 
Muscle relaxants 
Baclofen 
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Nutritional agents and vitamins 
Arginine, arginine HCl, ascorbic acid, 
biotin, calcium folinate, folic acid, folinic 
acid, glucose, isoleucine, lactose, leucine, 
medium-chain triglycerides, pyridoxine 
HCl, riboflavin, sodium fluoride, sorbitol, 
sucrose, thiamine, tocopherol, valine, 
vitamin A, vitamin E, zinc acetate, zinc 
sulfate 
 
Paraffins and similar bases 
Cholesterol 
 
Prostaglandins 
Misoprostol 
 
Stabilising and suspending agents 
Carmellose, ceratonia, methylcellulose 
 
Supplementary drugs and other 
substances 
Betaine, borax, boric acid, citric acid, 
creatine, fluorescein, glycerol, indigo 
carmine, methacholine chloride, miglustat, 
pancreatin, strychnine nitrate, 
ubidecarenone, ursodeoxycholic acid, 
xylose 
 
Thyroid and antithyroid drugs 
Iodine, levothyroxine sodium, potassium 
iodide, potassium perchlorate, sodium 
perchlorate 
 
Urological drugs 
Oxybutynin, sildenafil citrate 
The compounded medicines reported included just 1 active substance 
(single-drug) in most cases, or a maximum of 2 active substances in 
combination (excluding the oromucosal preparations for CIOM, Section 
3.4.4). The active substances reported in combination (multi-drug) were the 
following:  
• Oral liquids: ceratonia and sorbitol; hydrochlorothiazide and 
spironolactone; iodine and potassium iodide (Lugol’s Solution, see below); 
levodopa and carbidopa; and sodium citrate and citric acid (Shohl’s Solution, 
see below). 
• Oral powders: hydrochlorothiazide and amiloride HCl; hydrochlorothiazide 
and spironolactone; and ispaghula and senna (Agiolax, see below). 
Apart from compounded medicines including active substances, 1 hospital 
also reported placebo capsules, in a total of 1,400 units. 
Compounded medicines were also reported by the given titles (non-
proprietary names) which they are commonly known for, as follows: Lugol’s 
Solution (10 hospitals); Shohl’s Solution (2 hospitals); and Poção de Todd (1 
hospital). These 3 compounded medicines correspond to oral liquids and 
were dispensed in a total of 585 multidose containers. A formulary for the 
compounded medicines reported by given title is shown in Appendix 16. 
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The compounded medicines dispensed were reported either by the 
respective active substance(s), their given titles or by the proprietary 
medicines used in their preparation. 
In total, 10 proprietary medicines were reported by 4 hospitals, namely: 
Fungizone (amphotericin B); Lasix (furosemide) and Mycostatin (nystatin), as 
almost 300 multidose oral liquids; Agiolax (ispaghula and senna), Aptamil 
(infant feed), Eoprotin (infant feed), Protifar (nutritional protein supplement), 
Renilon (preparation for enteral nutrition), Resical (cation-exchange resin) 
and Uralyt-U (potassium sodium hydrogen citrate), as over 2,000 unidose 
oral powders. Although Resical was reported by only 1 hospital, it is likely 
that more hospitals might have used this proprietary medicine since a total of 
3 hospitals reported “cation-exchange resin” as part of the oral compounded 
medicines dispensed. Furthermore, other proprietary medicines might have 
been used in the preparation of the compounded medicines reported. 
However, this information is rarely part of the registry details of the 
compounded medicines dispensed and, therefore, it is not readily accessible 
by the majority of the hospital pharmacies.  
In addition, 3 hospitals reported nutritional supplements as part of the oral 
compounded medicines most frequently dispensed by their pharmacies. 
Although the exact composition of the supplements was rarely detailed, the 
majority of these were either glucose or protein-based. All nutritional 
supplements were dispensed as sachets (oral powders), in a sum of almost 
4,000 units. Two active substances reported were not permitted legally in 
pharmaceutical compounding in Portugal, namely: levothyroxine sodium (2 
hospitals) and fluoxetine HCl (1 hospital). Although not allowed, there may be 
a therapeutic need for compounded medicines including the active 
substances considered in the Portuguese negative list (Section 3.1). As a 
result, it is not surprising that Portuguese pharmacists use “forbidden” active 
substances in pharmaceutical compounding since, in these situations, 
compounded medicines may be the only therapeutic option available.  
The active substances were dispensed as oral solid dosage forms, oral liquid 
dosage forms and/or oromucosal preparations. These are discussed 
separately below. 
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3.4.2 Oral solids 
Oral solid dosage forms were reported by 87% (n=34) of participant hospitals 
and included oral powders (33 hospitals) and capsules (8 hospitals). In total, 
29 hospitals shared complete information with regards to the oral solids 
dispensed, whereas 3 hospitals disclosed only qualitative information and 2 
hospitals were not able to provide any information since they did not keep 
the records of the oral solids dispensed; qualitative data was processed and 
analysed accordingly (Section 2.4). The quantities of oral solids were 
provided as the number of packs and/or the number of individual units 
dispensed, which are shown separately below (Figure 3.5). A total of 16 
hospitals provided both figures whereas 7 hospitals provided the number of 
packs and 6 hospitals provided the number of individual units only. 
Oral powders were dispensed in larger quantities than capsules both in 
number of packs and in number of units dispensed. A total of 3,900 packs 
(99.5%) and 50,917 units (72.9%) of oral powders were reported but these 
figures are not directly comparable as 5 hospitals did not provide the number 
of packs and 7 hospitals did not provide the number of units of oral powders 
dispensed. Hence, both figures are considered together for analysis.  
  
Figure 3.5 Oral solids dispensed per number of packs and number of individual units. 
A total of 19 packs and 18,887 units of capsules were reported but, again, 
these figures are not directly comparable as, although all hospitals provided 
the number of units dispensed, 4 hospitals did not provide the number of 
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packs dispensed. For this reason, the number of units of capsules dispensed 
is considered individually for analysis. 
Oral powders were reported mainly as sachets (Figure 3.6) and only a few 
were dispensed in envelopes and flasks. These 2 containers (envelopes and 
flasks) are usually reserved for larger quantities of powders.  
                           
Figure 3.6 Individual powders folded in sachets (adapted from RPS, 2002b). 
The top 15 active substances dispensed as oral powders are listed in Figure 
3.7. This list includes the top 10 active substances ranked by number of 
packs and also the top 10 active substances ranked by number of individual 
units. A total of 5 active substances are common to both rankings, namely: 
magnesium sulfate, sodium chloride, calcium carbonate, phenobarbital and 
folic acid. Magnesium sulfate (30 mg - 40 g) was dispensed as oral powders 
by 13 hospitals, in a sum of 343 packs and 4,893 units. The pack sizes 
varied from 1 to 53 sachets and the quantity dispensed by most hospitals 
was 30 g. Oral doses of 5 g to 10 g of magnesium sulfate in 250 mL of water 
are given for rapid bowel evacuation (Martindale 35, 2007) and, therefore, it 
is likely that the 30 g corresponded to powders for oral liquids16. 
Phenobarbital was the second most frequently dispensed active substance, 
by number of packs (n=276), and it was reported in 18 different strengths 
(1.25-50 mg) by a total of 10 hospitals. Sodium chloride, on the other hand, 
was dispensed by only 2 hospitals, in strengths of 1 g, 1.5 g, 3 g and 5 g, in 
a sum of 236 packs and 4,349 units. 
                                            
16Powders (and granules) for oral solutions and suspensions, which were abbreviated to 
powders for oral liquids, generally conform to the definition of oral powders (Section 2.1.3). 
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Figure 3.7 Top 15 active substances dispensed as oral powders per number of units/packs. 
The pack size of oral powders varied within hospitals and active substances 
but it is possible to estimate an average pack size by considering the 16 
hospitals that provided both number of packs and number of individual units. 
According to these data, an average of 13 oral powders (sachets) per pack 
were dispensed by the participant hospitals, which was adopted for the 
purposes of overall data comparison. This figure indicates that, in general, 
oral powders are prepared in Portuguese hospitals for individual patients, 
which also explains the wide range of strengths reported for the majority of 
the active substances dispensed as oral powders. The most frequent 
therapeutic groups were “electrolytes” and “nutritional agents and vitamins”. 
The therapeutic group represented by more active substances was 
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cardiovascular drugs, which included 23 active substances dispensed as oral 
powders. 
Capsules were dispensed in Portugal by only 21% (n=8) of the participant 
hospitals and only 10 different active substances were reported (Figure 3.8). 
Zinc sulfate was the most frequently dispensed active substance, reported in 
3 strengths (220 mg, 250 mg and 300 mg) by a total of 4 hospitals; 3 
hospitals provided the quantities dispensed by number of units only, whereas 
1 hospital provided both quantities, as follows: 5 packs of 300 capsules of 
zinc sulfate each, corresponding to a total of 1,500 units dispensed.  
 
Figure 3.8 Active substances dispensed as capsules, per number of units. 
The pack sizes varied greatly within hospitals and active substances. For 
instance, phenytoin was dispensed in one pack of 3,000 units whereas 
sodium chloride was dispensed in packs of 30 units (Figure 3.8). These 
figures indicate that capsules are prepared by hospital pharmacies in 
Portugal either as a batch (for stock or to be dispensed to the wards) or 
individually (to be dispensed directly to patients). 
Placebo was also reported as capsules (Section 3.3.1). The most frequent 
therapeutic group was nutritional agents and vitamins and included zinc 
sulfate and riboflavin. The therapeutic group represented by more active 
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substances was electrolytes and included sodium phosphate, sodium 
bicarbonate and sodium chloride. 
One of the hospitals visited stated that they prepared capsules instead of 
sachets because capsules were less time-consuming to prepare, considering 
that manual (or semi-automatic) capsule machines enable the preparation of 
50-100 (maximum 300) units of capsules at a time (Section 2.1.3). 
Nevertheless, capsules had to be opened before administration to paediatric 
patients and their contents added to liquids or food.  
3.4.3 Oral liquids 
Oral liquid dosage forms were reported by all participant hospitals and 
included solutions (54%), suspensions (31%) and syrups17 (9.3%). It is likely 
that the classification of some oral liquids by the hospital pharmacies was not 
accurate and, therefore, some solutions may have corresponded to 
suspensions/syrups (and vice-versa). Only 6% of the oral liquid dosage forms 
dispensed were classified simply as oral liquids (Figure 3.9). None of the 
hospitals reported unidose containers and it was assumed that all oral liquids 
dispensed were, indeed, multidose. The volumes dispensed ranged from 10 
mL to 5,100 mL, per individual container. All hospitals reported the volumes 
dispensed per container, with the exception of 1 hospital that reported total 
volumes instead. 
 
Figure 3.9 Oral liquid dosage forms dispensed, per dosage form. 
                                            
17Syrups are aqueous preparations characterised by a sweet taste and viscous consistency. 
These may contain sucrose at a concentration of at least 45% (m/m) but the sweet taste may 
also be obtained by using other polyols or sweetening agents (EDQM, 2007). 
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Almost 14,000 units of oral liquids were reported. Some may have 
corresponded, instead, to mouthwashes for radiotherapy and chemotherapy 
patients (Section 3.4.4). If these mouthwashes were excluded, the oral 
liquids dispensed were slightly greater than 11,000 units. All volumes 
dispensed over 2,000 mL corresponded to the mouthwashes for radiotherapy 
and chemotherapy patients. It may then be concluded that these 
mouthwashes were prepared in large scale to be dispensed to the wards and 
not directly to individual patients.  
Oral liquids, solutions and suspensions were dispensed in a sum of 10,080 
units (90.7%) (excluding the mouthwashes) (Figure 3.9) and by 92% of the 
hospitals. The top 10 active substances dispensed were: morphine, 
trimethoprim, captopril, ranitidine and chloral hydrate (shown in Table 3.2.); 
sucrose, codeine, furosemide, sodium bicarbonate and omeprazole.  
Morphine was the most frequently dispensed active substance and it was 
reported by 5 hospitals in a sum of 1,186 units of 50 mL to 2,000 mL. The 
wide range of volumes dispensed indicated that morphine was prepared both 
in large scale to be dispensed to the wards and also in small scale to be 
dispensed directly to individual patients. This active substance was reported 
as morphine and morphine HCl, in 6 different strengths, from 0.2 mg/mL to 
20 mg/mL. The most frequently dispensed strengths were 10 mg/mL and 20 
mg/mL. 
Table 3.2 Oral liquids most frequently dispensed in Portugal. 
Active 
substances 
Number of 
strengths 
(most frequent) 
Range of 
volumes 
Number 
of 
hospitals 
Number 
of units 
dispensed 
Morphine 6 (10 and 20 mg/mL)  50-2,000 mL 5 1,186 
Trimethoprim 3 (10 mg/mL) 10-250 mL 18 1,055 
Captopril 4 (1 mg/mL) 25-500 mL 24 622 
Ranitidine 5 (15 and 2.5 mg/mL)  10-360 mL 20 562 
Chloral hydrate 4 (50 and 100 mg/mL) 20-500 mL 10 498 
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The next most frequently dispensed active substances were: trimethoprim, 
captopril, ranitidine and chloral hydrate. All these active substances have a 
monograph for an oral liquid compounded medicine in the FGP, either the 
FGP 2005 (CETMED) or the FGP 2007 (LEF) (Section 3.2.2). The most 
standardised active substance was trimethoprim that, although reported by 
18 hospitals, was dispensed only in 3 different strengths and in the volumes 
of just 10 mL to 250 mL. An example of a Portuguese prescription for 
trimethoprim 1% is shown in Figure 1.2. The most frequent strength was 10 
mg/mL, which corresponds to the strength indicated in the FGP monograph. 
Captopril was the active substance dispensed by most hospitals and, 
although dispensed in 4 different strengths, the 1 mg/mL corresponded to 
99% of all strengths dispensed, which is also the strength indicated in the 
FGP monograph. As a whole, the most frequent strengths of the oral liquid 
compounded medicines dispensed were those indicated in the respective 
monographs of the FGP, which suggests that an official national formulary 
was a key contribute to the standardisation of pharmaceutical compounding 
nation-wide. 
The active substances dispensed as oral liquids, solutions and suspensions 
were classified with reference to Martindale 35 (2007) (Figure 3.10) and the 
most frequent therapeutic groups were: cardiovascular drugs, which included 
2 of the top 10 active substances (captopril and furosemide); analgesics, 
anti-inflammatory drugs and antipyretics, which also included 2 of the top 10 
active substances (morphine and codeine); and antibacterials, which 
included trimethoprim, the second most frequently dispensed active 
substance.  
The top 3 therapeutic groups represented 51% of all oral liquids, solutions 
and suspensions dispensed and the top 10 active substances accounted for 
almost 60% of these, which indicates the focused nature of pharmaceutical 
compounding in Portugal. 
Syrups corresponded to only 9.3% of all oral liquids dispensed (Figure 3.9) 
and were reported by a total of 20 hospitals. As mentioned before, it is likely 
that the classification of some oral liquids was not accurate and, therefore, 
part of the solutions/suspensions might have corresponded to syrups (and 
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vice-versa) (Section 2.1.3). In any case, syrups were dispensed in much 
lesser quantities than the solutions or suspensions, as shown in Figure 3.9. 
 
Figure 3.10 Oral liquids, solutions and suspensions, per number of units and by therapeutic 
groups. 
The top 10 active substances dispensed as syrups were: chloral hydrate, 
trimethoprim, caffeine citrate, furosemide, sucrose, captopril, spironolactone, 
omeprazole, propranolol HCl and ranitidine. When compared to the top 10 of 
oral liquids, solutions and suspensions (mentioned above), only the following 
3 active substances were not included: caffeine citrate, which was reported 
by 6 hospitals in the strengths of 2% and 1.5 mg/mL (30-100 mL); 
spironolactone, which was reported by only 2 hospitals, in the strengths of 
2.5 mg/mL and 0.2% (50 mL and 60 mL); and propranolol HCl, which was 
reported by only 1 hospital and in the single strength of 1 mg/mL (80-320 
mL).  
The most frequently dispensed syrups were chloral hydrate (40-200 mg/mL; 
9 hospitals; 392 units) and trimethoprim (10 mg/mL; 8 hospitals; 208 units), 
which accounted for 58% of all syrups dispensed by the participant hospitals. 
When the oral liquid dosage forms are considered altogether, the top 5 active 
substances were: trimethoprim (1,263 units), morphine (1,206 units), chloral 
hydrate (890 units), captopril (665 units) and ranitidine (585 units). 
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Considering just the oral compounded medicines, liquid dosage forms 
(syrups, solutions and suspensions, excluding the mouthwashes) were 
dispensed in a total sum of 11,111 multidose containers and solid dosage 
forms (oral powders and capsules) were dispensed in a total sum of 69,804 
individual units. However, the number of units dispensed for the oral powders 
is not complete since a total of 12 additional hospitals dispensed oral 
powders but did not share the number of individual units dispensed. 
Therefore, the total sum of oral powders dispensed is much higher than 
69,804 units. It is not possible to accurately determine the ratio of oral solid 
dosage forms vs (versus) oral liquid dosage forms but it is likely that oral 
solids were more frequently dispensed than oral liquids. Nevertheless, more 
hospitals reported dispensing oral liquid dosage forms (n=39) than solid 
dosage forms (n=34) and only 2 hospitals reported all dosage forms 
(oromucosal preparations, syrups, solutions, suspensions, oral powders and 
capsules). These findings are in accordance with Rosa et al. (2006) who 
stated that is common practice to prepare both sachets and oral liquids in 
hospital pharmacy. According to Barros and Almeida (2008), oral powders 
(sachets) were the most frequently dispensed dosage form in a sample of 6 
Portuguese hospitals. However, this study was undertaken in 2004, before 
the publication of the FGP 2005 (CETMED) / FGP 2007 (LEF), which 
contributed to a change of practices in pharmaceutical compounding in 
Portugal, as the conversion of many sachets into liquid dosage forms. The 
most frequently dispensed active substances identified by the authors - folic 
acid, ursodeoxycholic acid and phenobarbital (oral powders) - are included in 
the top 15 listed in Figure 3.7, and two of their most frequently dispensed oral 
liquids - trimethoprim and chloral hydrate - are also part of the top 10 listed 
above. Cardiovascular drugs, the most frequent therapeutic group identified 
by the authors, was also the most frequent group with regards to oral liquids, 
solutions and suspensions. Although the size of the studies is very different, 
this comparison shows that the oral compounded medicines dispensed in 
Portugal changed only slightly from 2004 to 2008. 
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3.4.4 Oromucosal preparations 
Although the aim of the research was to identify and characterise the most 
frequently dispensed oral compounded medicines, some hospital pharmacies 
also shared data regarding oromucosal preparations. These medicines were 
either specifically classified by the hospital pharmacies as oromucosal or, 
alternatively, the additional comments relating to their use clearly suggested 
that these were not oral compounded medicines per se but instead 
oromucosal preparations.  
Oromucosal preparations are solid, semi-solid or liquid preparations 
containing one or more active substances intended for administration to the 
oral cavity and/or the throat to obtain a local or systemic effect. Several 
categories of oromucosal preparations may be distinguished as, for example: 
mouthwashes; oromucosal solutions and oromucosal suspensions; semi-
solid oromucosal preparations (e.g. oromucosal gel, oromucosal paste); and 
gargles. For many oromucosal preparations, it is likely that some proportion 
of the active substance(s) is swallowed and absorbed in the GI tract (EDQM, 
2007). The distinction between oral and oromucosal compounded medicines 
is not always clear and, therefore, it was decided to include the oromucosal 
preparations reported by the hospital pharmacies for data processing and 
analysis. At this stage, oromucosal preparations were then removed from the 
exclusion criteria of the research (Section 2.4.1).  
A total of 11 hospitals reported oromucosal preparations as part of the oral 
compounded medicines most frequently dispensed by their pharmacies, 
which represented 28% of all participant hospitals. However, more 
Portuguese hospitals might have dispensed oromucosal preparations but 
excluded this information from the dataset since the request for data 
specifically referred oral compounded medicines only. The most frequently 
dispensed oromucosal preparation was a mouthwash18 for aphthous ulcers 
(mucositis) in patients undergoing radiotherapy and chemotherapy, 
commonly known as chemo-induced oral mucositis (CIOM) (Chan and 
Ignoffo, 2005; McElhiney, 2011). The composition of this mouthwash varied 
                                            
18Mouthwashes are aqueous solutions intended for use in contact with the mucous 
membrane of the oral cavity and are not meant to be swallowed (EDQM, 2007). 
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slightly within hospitals and it corresponded to a sodium bicarbonate solution 
(in most cases) including one or more of the following active substances: 
amphotericin B and nystatin (antifungals); aciclovir (antivirals); chlorhexidine 
(disinfectants and preservatives) and lidocaine (local anaesthetics). More 
than 16,000 multidose containers of this mouthwash were reported as 
oromucosal preparations, in volumes of 50 mL to 560 mL. Furthermore, 
similar combinations of the active substances identified above were reported 
as oral liquids by 10 additional Portuguese hospitals and it is likely that these 
oral liquids corresponded, instead, to the mouthwashes for CIOM. Altogether, 
the oromucosal preparations and oral liquids including the active substances 
mentioned above were dispensed in a sum of over 19,000 multidose 
containers. Apart from these mouthwashes, two additional oromucosal 
preparations were reported by the participant hospitals, namely: sodium 
fluoride gel19 (20 g) in a total of 156 units (1 hospital); and artificial saliva20 
(100-1,000 mL) in a total of 602 units (4 hospitals).  
Although oromucosal preparations were not part of the aim of the research, 
Portuguese hospitals reported more oromucosal preparations than oral 
compounded medicines. The most frequently dispensed compounded 
medicines were, indeed, mouthwashes for CIOM, which is consistent with the 
fact that cancer is one of the major causes of discharge from all Portuguese 
hospitals (including through death) (Figure 3.11). 
 
Figure 3.11 Number of patients per 100,000 population discharged from all hospitals 
(including through death) in Portugal during 2006 (latest available year), categorised by 
principal diagnosis (WHO Regional Office for Europe, 2008).
                                            
19Semi-solid oromucosal preparations are hydrophilic gels or pastes intended for 
administration to the oral cavity or to a specific part of the oral cavity (EDQM, 2007). 
20Oromucosal solutions and oromucosal suspensions are liquid preparations intended for 
administration to the oral cavity by means of a suitable applicator (EDQM, 2007). 
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3.5 Summary 
• The foundation of CETMED, the development of the FGP and the approval of up-to-date 
legislation contributed to the modernisation of compounding practices in Portugal.  
• A purposive sample of 60 hospitals was included in the research (8 hospitals were 
visited) and a response rate of 93% was obtained. A total of 175 different active substances 
(including 8 NTI drugs) were reported corresponding to 33 different therapeutic groups. The 
top 3 therapeutic groups were: cardiovascular drugs (n=26), nutritional agents and vitamins 
(n=24) and antibacterials (n=16). Placebo was dispensed in a total sum of 1,400 units of 
capsules (n=1).  
• Oral solid dosage forms were reported by 87% of all participant hospitals and included 
oral powders and capsules. Oral powders (mainly sachets) were dispensed in a total sum of 
3,900 packs (99.5%) and 50,917 units (72.9%) and the top 5 active substances common to 
both rankings were: magnesium sulfate, sodium chloride, calcium carbonate, phenobarbital 
and folic acid. Capsules were dispensed in a total sum of 19 packs and 18,887 units and the 
top 5 active substances were: zinc sulfate, riboflavin, phenytoin, sodium phosphate and 
potassium perchlorate.  
• Oral liquid dosage forms were reported by all participant hospitals and included solutions, 
suspensions and syrups. Oral liquids (excluding mouthwashes) were dispensed in a total 
sum of 11,111 containers and the top 5 active substances were: trimethoprim, morphine, 
chloral hydrate, captopril and ranitidine. Oral liquids, solutions and suspensions were 
dispensed in a total of 10,080 multidose containers (90.7%) whereas syrups were dispensed 
in a total of 1,031 multidose containers (9.3%). It is likely that oral solids were more 
frequently dispensed than oral liquids. 
• Oromucosal preparations were reported by 28% of hospitals but over 19,000 multidose 
containers were dispensed, particularly mouthwashes for CIOM, which represented the most 
frequently dispensed compounded medicines in Portugal.  
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4. Compounding in the UK 
The United Kingdom of Great Britain and Northern Ireland (UK) joined the EU 
in 1973 and its official language is English (Europa, 2009). The UK is an 
archipelago located in the North Atlantic Ocean that is linked to continental 
Europe by the channel tunnel. The UK comprises Great Britain (England, 
Scotland and Wales) and Northern Ireland (Carr, 2011). It is the third most 
populated country in the EU, with a population of 60.9 million in 2007 (Figure 
2.2), but is physically only the 8th largest EU country, occupying a surface 
area of 243,800 Km2 (Europa, 2008). 
In 2007, there were 2,312 hospitals in the UK (ratio of 3.79 hospitals per 
100,000 population) and a total of 167,019 hospital beds (ratio of 370 
hospital beds per 100,000 population) (HOPE, 2009). Since the European 
health for all database (HFA-DB) does not include up-to-date information 
regarding the UK (WHO Regional Office for Europe, 2010) (Appendixes 3 
and 4), this information was obtained from the European Hospital and 
Healthcare Federation (HOPE, 2009). 
In 2007, there were 47,962 pharmacists registered with the Royal 
Pharmaceutical Society of Great Britain (RPSGB) (Section 4.2.1). 
Considering the UK population in the same year, there was a ratio of 78.66 
pharmacists per 100,000 population (Seston et al., 2007; HOPE, 2009). The 
average number of pharmacists per UK hospital could not be obtained from 
the EAHP (2005) as, although the UK participated in the 2005 survey, the 
response rate (3%) was too low to be included in their results. Therefore, 
considering that 21.7% of the pharmacists registered with the RPSGB in 
2005 were working for the hospital sector, in a total of 10,068 pharmacists, 
the UK average is 4.4 pharmacists per hospital21, which is slightly lower than 
the European average of 4.7 pharmacists per European hospital (EAHP, 
2005; HOPE, 2009; Douglas, 2011). 
Pharmaceutical compounding in the UK corresponds to the extemporaneous 
preparation of medicines in community and hospital pharmacies and also to 
                                            
21A total of 2,312 UK hospitals (HOPE, 2009) were considered in determining the average of 
pharmacists per hospital in the UK. 
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the manufacture of specials by licensed hospital manufacturing units and 
pharmaceutical industries (Section 4.1). The extemporaneous preparation of 
medicines, in particular, is becoming less common in the UK (Marriott et al., 
2010) and it has been considerably replaced by the use of specials (Tuleu et 
al., 2003). A widely reported compounding mistake in a UK community 
pharmacy, which led to the death of an infant, contributed to the general 
decline of this practice (Anonymous, 2000a; Carvalho et al., 2008). Rennison 
and Portlock (2003) even suggested that the extemporaneous preparation of 
medicines was no longer appropriate in the community setting. Likewise, in 
the hospital setting, this practice is no longer common as the majority of 
pharmacy departments dispense specials instead of preparing 
extemporaneously compounded medicines (Horton, 2006; Jackson and 
Lowey, 2010). On average, less than 2 extemporaneously compounded 
medicines are prepared on a daily basis per paediatric hospital in England 
(Tuleu et al., 2003; Yeung et al., 2004). Extemporaneous preparations are 
still considered a necessary and important alternative to proprietary 
medicines, particularly for children (Nunn, 2003), and there are still 
circumstances in which such medicines are required (Jackson and Lowey, 
2010). For example, captopril and nifedipine are 2 cardiovascular drugs 
frequently used for children, but there is no licensed liquid dosage form 
available in the UK (Tuleu et al., 2005; Mulla et al., 2007; Joint Formulary 
Committee, 2008). Indeed, the majority of cardiovascular drugs used in 
children are unlicensed medicines (Standing and Tuleu, 2005). 
Pharmaceutical compounding is, therefore, the alternative of choice to treat 
children who are unable to swallow licensed solid dosage forms. The lack of 
licensed liquids in the UK has been confirmed by Yeung et al. (2004) who 
concluded that 76% of the non-sterile extemporaneously compounded 
medicines prepared in 7 paediatric hospitals in England (for 12 months) were 
liquid dosage forms. According to their results, a total of 3,728 
extemporaneous preparations were reported by the participant hospitals and 
the most frequently dispensed active substances were potassium chloride, 
midazolam and vancomycin. A complete list of the top 20 active substances 
dispensed is shown in Appendix 17. Tuleu et al. (2003) concluded that out of 
the 672 extemporaneously compounded medicines prepared in an English 
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paediatric hospital, 45% were oral liquids and 13% were powders for 
reconstitution into liquid dosage forms. In relation to the therapeutic 
indications, 30% of these extemporaneous preparations were for metabolic 
disorders; 19% for CNS disorders; 11% were antivirals; and 10% were 
indicated for electrolytes disorders (Tuleu et al., 2003). Turner et al. (1996) 
studied prospectively unlicensed drug use in another English paediatric 
hospital (for 4 months) and concluded that the most frequently dispensed oral 
unlicensed medicines (including “off-label” indications) were: chloral hydrate, 
sucralfate and amiloride (oral liquids). 
In the UK, the lack of standardisation in pharmaceutical compounding has 
been raised by Mulla et al. (2007) who highlighted the fact that captopril 
formulations vary considerably throughout the country. According to their 
findings, 4 hospitals dispensed captopril tablets (intended to be crushed and 
dissolved in water before administration) and 22 hospitals dispensed 9 
different oral liquids containing captopril. Nevertheless, despite the fact that 
different hospitals prepare different formulations, these are used 
interchangeably by patients without the assurance of therapeutic equivalence 
(Mulla et al., 2007). The need for improving the quality and formulation of 
unlicensed medicines in the UK was also recognised by the National 
Advisory Board for the Manufacture of Pharmaceuticals in the NHS (National 
Health Service) who funded a research project undertaken by the Pharmacy 
Department at the Leeds Teaching Hospitals NHS Trust. The aim of this 
project was to improve the quality of oral unlicensed medicines prepared in 
the NHS by developing standardised and validated formulations for the 50 
most frequently dispensed extemporaneous preparations (Lowey and 
Jackson, 2007). The authors (Lowey and Jackson, 2008) emailed a 
questionnaire to a convenience sample of NHS Trusts in the regions of 
Yorkshire, the North-East and London, in order to collect data regarding the 
top 20 oral liquid extemporaneous preparations dispensed over 12 months 
(2005-2006); 51 Trusts participated in the research and a total of 117 
different extemporaneous preparations were dispensed as oral liquids, 
corresponding to an average of 10.3 different extemporaneous preparations 
per individual Trust. The most frequently dispensed dosage forms were 
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suspensions (66.2%) and solutions (22.2%). Oral powders were occasionally 
dispensed (4.3%) and capsules were only rarely dispensed (0.2%). 
According to the authors, more capsules are now produced by specials 
manufacturers instead of being extemporaneously compounded in hospital 
pharmacies. The top 5 extemporaneously compounded medicines were: 
levothyroxine, clobazam, clozapine, sodium chloride and morphine sulfate. A 
complete list of the top 50 extemporaneous preparations dispensed is shown 
in Appendix 18. Lowey and Jackson (2008) consider the practice of 
extemporaneous preparation a “manufacturing burden” on NHS hospitals and 
predicted that the “unnecessary use” of these medicines will decrease with 
time in the UK since the development of the “Pro-File” database, which 
allows NHS staff to identify and outsource specials effectively (NHS, no 
date). 
4.1 Legislation 
In the UK, medicinal products must be granted a Marketing Authorisation 
(formerly known as Product Licence) to be placed on the market or to be 
distributed by way of wholesale dealing (unless in accordance with any 
exception or exemption) (DHSS, 1994). Pharmaceutical compounding is 
included in the exemptions for medicines licensing, and pharmacists are 
allowed to prepare and dispense “unlicensed medicinal products” to fill a 
special need (MHRA, 2008). This exemption is conferred to pharmacists 
under Section 10 of the Medicines Act 1968 (DHSS, 1986). 
According to the definition of unlicensed medicines stated in the respective 
BP general monograph (BP Commission, 2008a), an unlicensed medicine is 
“one which is prepared, at the request of an authorised health care 
professional, to address patient medical requirements, unmet by current 
licensed medicines”. Unlicensed medicines may be either manufactured 
under a manufacturing specials licence (known as specials) or prepared 
extemporaneously under the supervision of a pharmacist (known as 
extemporaneous preparations). In addition, specials are usually produced in 
batches whereas extemporaneous preparations are considered one-off 
preparations only. In the UK, compounded medicines correspond then to 
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“unlicensed medicinal products” and include both specials and 
extemporaneous preparations. 
A licensed specials manufacturer operates in accordance with GMP and is 
subject to regular inspections from the MHRA (Medicines and Healthcare 
products Regulatory Agency) (Jackson and Lowey, 2010). Therefore, 
specials are manufactured according to GMP, whereas extemporaneous 
preparations may be prepared in a hospital or community pharmacy in 
accordance with less strict standards. Although both unlicensed, specials are 
then regarded as a quality assured alternative to extemporaneous 
preparations. For this reason, over the last few years, specials have been 
increasingly used in place of extemporaneously prepared medicines in the 
UK (RPSGB, 2010a). Nevertheless, specials are almost never supported by 
bioavailability and stability data (Tuleu et al., 2003) and, therefore, their 
quality and safety is not always guaranteed. Only licensed medicinal 
products with a Marketing Authorisation have their quality, safety and efficacy 
assured. 
Hence, in the UK, a medicinal product that does not have a Marketing 
Authorisation may be produced by a specials manufacturer (hospital 
manufacturing unit or pharmaceutical industry); prepared extemporaneously 
in a community or hospital pharmacy; or, alternatively, obtained from abroad 
(imported) (Paediatric Formulary Committee, 2008). 
The first agreed and detailed guidelines for pharmaceutical compounding in 
the UK were edited by Fenton-May (2002) in the format of a “Guide to the 
preparation of non sterile extemporaneous products in NHS hospitals” 
(Jackson and Lowey, 2010). This guide was intended for use as a reference 
in community and hospital pharmacies, which were not licensed as specials 
manufacturers, and included important guidelines on risk management; 
personnel and training; documentation; raw materials; facilities, equipment 
and processes; cleaning, disinfection and hygiene; monitoring and audit; and 
formulation and stability (Fenton-May, 2002). This guide was recently 
updated by Jackson and Lowey (2010), in the format of a book - Handbook of 
Extemporaneous Preparation - that also includes a formulary with 50 
technical monographs (Jackson and Lowey, 2010).  
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4.2 Professional organisations and information sources 
4.2.1 English professional organisations 
• Royal Pharmaceutical Society of Great Britain (RPSGB)22: is the dedicated 
professional leadership body for pharmacists and pharmacy in England, 
Scotland and Wales. The mission of the RPSGB is to promote and represent 
the professional interests of its members. Pharmaceutical compounding is 
included in the Society’s support and development activities. Several events 
related with compounding have been organised by the RPSGB (2008; 2009) 
and several documents and information sheets have also been published by 
the Society (RPS, 2002a; 2002b; 2004). The “Medicines, Ethics & Practice: A 
guide for pharmacists and pharmacy technicians”, for example, sets 
professional standards and provides guidance applicable to all pharmacists; 
it was first published by the RPSGB in 1988 (RPSGB, 2010b). The principles 
included in Section 2 - “Code of Ethics for Pharmacists and Pharmacy 
Technicians” - (RPSGB, 2007) were further expanded on a document named 
“Professional Standards and Guidance for the Sale and Supply of Medicines” 
that included a list of standards for the “Extemporaneous Preparation or 
Compounding (4.)” (Donnelly et al., 2008) as, for example: “If you wish to be 
involved in extemporaneous preparation you must ensure that: 4.1 a product 
is extemporaneously prepared only when there is no product with a 
Marketing Authorisation available and where you are able to prepare the 
product in compliance with accepted standards...” (Anonymous, 2000b; 
RPSGB, no date). 
• The Association of Commercial Specials Manufacturers (ACSM): 
represent the specials manufacturers in the UK and, to date, includes a total 
of 14 member companies. The ACSM works closely with pharmacists, 
regulators and other governmental/professional bodies and aims to educate 
and ensure the standards and the future of specials in the UK. According to 
the ACSM, specials are made “individually or in very small batches” and 
represent less than 1% of all prescriptions in the UK (ACSM, 2010). 
                                            
22Currently corresponds to the Royal Pharmaceutical Society (RPS) (RPSGB, 2011). 
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• UK paediatric organisations: such as the Centre for Paediatric Pharmacy 
Research (CPPR) and the Neonatal and Paediatric Pharmacists Group 
(NPPG) are also involved in pharmaceutical compounding, to a certain 
extent, although their focus is paediatric pharmacy and care in general 
(NPPG, 2010; CPPR, 2011). 
4.2.2 English information sources 
• British Pharmacopoeia (BP): is the UK’s official and authoritative collection 
of standards for medicinal and pharmaceutical substances and also 
formulated preparations (finished dosage forms). Since 1864, the BP has 
made an important contribution to protecting public health by setting publicly 
available standards for the quality of medicines (Breckenridge, 2008). The 
BP is updated every year and, in 2008, an important step was given towards 
the quality of unlicensed medicines in the UK. The BP 2008 edition 
introduced a general monograph and 9 individual monographs for unlicensed 
formulations (Appendix 19) with which compliance is mandatory (BP 
Commission, 2008a). The individual monographs are intended for those 
formulations manufactured under a specials licence and also those prepared 
extemporaneously under the supervision of a pharmacist (BP Commission, 
2008b). Hence, all medicinal products sold or supplied in the UK must 
comply with the respective BP monographs (Lee, 2010). The BP 2008 also 
included a revised “Supplementary Chapter V”, which provides guidance on 
the legal requirements, ethical considerations, labelling and standards for the 
preparation and manufacture of unlicensed medicines (BP Commission, 
2008c). The following BP editions (2009, 2010 and 2011) introduced further 
individual monographs for unlicensed medicines, which gives a total of 36 
monographs published since 2008 (Appendix 19) (Lee, 2010). An example of 
a BP monograph (Paediatric Phenobarbital Oral Solution) is shown in 
Appendix 20. 
• British Pharmaceutical Codex (BPC): was first published in 1907 by the 
Pharmaceutical Society of Great Britain in order to fulfil the need for an 
official reference that included information about commonly used medicines 
that were not part of the BP (Marriott et al., 2010). Subsequent revisions of 
the BPC were published throughout the years until 1973 (10th edition) and 
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1976 (Supplement to the BPC 1973). Part 6 of BPC 1973 includes a 
formulary with monographs for compounded medicines, from aerosol 
inhalations to waters aromatic, in a total of 55 different dosage forms / 
(traditional) pharmaceutical preparations (Council of the Pharmaceutical 
Society of Great Britain, 1973; 1976).  
• British National Formulary (BNF): is a therapeutic formulary that is 
published twice a year by the British Medical Association and the RPSGB. It 
includes important and up-to-date information regarding the selection, 
prescribing, dispensing and administration of medicines in the UK. Although 
pharmaceutical compounding is not the focus of the BNF, this formulary 
includes compounded medicines described in the BP and BPC (e.g. Liquid 
Paraffin Oral Emulsion, BP). It also includes important information regarding 
the availability of specials (e.g. spironolactone is available from Rosemont as 
“special order”) and labelling (cautionary and advisory labels for dispensed 
medicines are in respective appendixes) (Joint Formulary Committee, 2008). 
• BNF for children (BNFC): is also a therapeutic formulary, corresponding to 
the BNF but for paediatric patients, that is published once a year by the 
British Medical Association, the RPSGB, the Royal College of Paediatrics 
and Child Health, and the NPPG. The BNFC includes important advice 
regarding the use of unlicensed medicines and the “off-label” use of licensed 
medicines in children (Paediatric Formulary Committee, 2008). 
• UCLH (University College London Hospitals) Formulary: is an example of 
a hospital formulary that includes information regarding the availability of 
compounded medicines for different therapeutic indications. These 
therapeutic formularies aim to ensure a safe, effective and economic use of 
medicines within the Trusts (Beresford, 2002). 
• Pharmaceutical Compounding and Dispensing: is a reference in the UK for 
pharmacy students and practitioners involved in the practice of compounding. 
It includes an historical perspective of pharmacy and compounding; tutorials 
on the skills and techniques necessary for compounding the majority of the 
dosage forms; and a wide range of formulae for compounded medicines. 
This book was first published in 2006 and it is now on the 2nd edition (Marriott 
et al., 2010).  
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• Handbook of Extemporaneous Preparation: this book consists on an 
update of the “Guide to the Preparation of Non Sterile Extemporaneous 
Products in NHS hospitals” (Fenton-May, 2002) and also includes a 
formulary with 50 monographs of extemporaneous preparations. It was 
written to be implemented as the standard for the extemporaneous 
preparation of medicines in the NHS hospitals across UK (Jackson and 
Lowey, 2010). 
4.3 Methods 
The UK was the second European country included in the research. It was 
the most convenient country, after Portugal, since the research project was 
based at the UCL School of Pharmacy, in London. The easy access and 
proximity of MC to UK hospitals allowed the first visits to be taken in 2006, to 
Great Ormond Street Hospital for Children (NHS Trust) and University 
College Hospital (UCLH NHS Foundation Trust). The discussions with the 
stakeholders in both hospitals, Ann Horton23 and Tony Murphy24, were very 
important at this initial stage for a clear insight on the practice of 
extemporaneous preparations in the UK. Also in 2006, 2 further visits were 
undertaken in Leeds, namely:  
• Rosemont, a licensed specials manufacturer, for a better understanding of 
the concept of specials in the UK. 
• Leeds Teaching Hospitals NHS Trust, for a meeting with Andrew Lowey25, 
who contributed important guidance and advice to the set up of the research, 
based on his involvement in the project: The Quality and Formulation of 
Unlicensed, Non-Sterile, Oral Medicines Prepared in the NHS (Section 4) 
(Lowey and Jackson, 2007). 
At a second visit to UCLH, Tony Murphy contributed with his expert opinion 
on the layout and wording of the UK questionnaire. His guidance and advice 
were decisive in the achievement of a clear and straightforward 
questionnaire, adapted to the compounding practices in the UK.  
                                            
23Dispensary manager (2006), Great Ormond Street Hospital for Children NHS Trust. 
24Pharmacy manufacturing (2006), UCLH NHS Foundation Trust. 
25QA / research pharmacist (2006), Leeds Teaching Hospitals NHS Trust. 
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The fieldwork in this country was complete after the visit to 2 additional 
London hospitals, namely: “St Thomas’ Hospital (Guy’s and St Thomas’ NHS 
Foundation Trust)” (2007) and “St Bartholomew’s Hospital (Barts and The 
London NHS Trust)” (2008). In total, the research project in the UK included 
the visit to 5 hospitals and 1 licensed specials manufacturer (2006-2008). 
At the start of the project, Lowey and Jackson (2007) had already completed 
their research on “The Quality and Formulation of Unlicensed, Non-Sterile, 
Oral Medicines Prepared in the NHS” but, since their data collection referred 
to oral liquid extemporaneous preparations only (all other oral dosage forms 
and specials were excluded) and hospitals were selected by convenience, 
the project in the UK was designed to build on their results and discussion. 
4.3.1 Country-specific questionnaire  
The research instrument developed to collect information regarding oral 
compounded medicines most frequently dispensed in UK hospital 
pharmacies was a self-completion questionnaire, based on the template 
established for Portugal (version 2, Section 3.3.1) and adapted to the 
practice of pharmaceutical compounding in the UK. The fieldwork and 
discussions with stakeholders contributed to the design of a UK-specific 
questionnaire, similar to the Portuguese template, but including all necessary 
adjustments to avoid misunderstandings. For instance, in Portugal, the 
concept of compounded medicines refers to extemporaneous preparations 
only whereas, in the UK, compounded medicines correspond to unlicensed 
medicines and include both extemporaneous preparations and specials. As a 
result, the UK questionnaire was initially formatted as a 4-sheet Excel 
document, including: an initial sheet with a brief introduction (Appendix 21) 
and a final sheet with 2 questions (Appendix 22), like the Portuguese 
template. However, instead of 1 individual table for unlicensed medicines, the 
UK questionnaire included 1 table for extemporaneous preparations and a 
second table for specials. The main headings of both tables are shown in 
Figure 4.1 and Figure 4.2.  
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Figure 4.1 C
ountry-specific questionnaire (U
K
): Table 1 (extem
poraneous preparations). 
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Figure 4.2 C
ountry-specific questionnaire (U
K
): Table 2 (specials). 
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In table 1, extemporaneous preparations were defined as “unlicensed 
medicines prepared by the hospital pharmacy (under the Section 10 
exemption)” whereas, in table 2, specials were defined as “unlicensed 
medicines prepared by a hospital manufacturing unit or commercial 
manufacturer (holding a “Specials” Manufacturing Licence)”. Both definitions 
were adapted from the BP official definitions (Section 4.1). Since data 
collection in the UK was undertaken during 2007, the questionnaire 
addressed information relating to 2006. Furthermore, in the final sheet with 
questions, instead of a request for the overall total number of unlicensed 
medicines, pharmacists were requested the overall total number of both oral 
extemporaneous preparations and oral specials (Appendix 22). So that the 
UK questionnaire was not too extensive, the initial introductory sheet was 
also removed from the Excel document and converted into a separate PDF. 
Consequently, the UK questionnaire resulted in a 3-sheet Excel document, 
which was complemented with a separate PDF introduction. 
4.3.2 Purposive sample of hospitals 
In the UK, specials are usually produced in batches whereas 
extemporaneous preparations are considered one-off preparations only. The 
purposive sample of hospitals included the complete list of licensed hospital 
manufacturing units described in the BNF 52 (Joint Formulary Committee, 
2006), which was further updated with 8 additional hospitals from the BNFC 
2007 (Paediatric Formulary Committee, 2007) (Appendix 23).  
In relation to extemporaneous preparations, it was considered likely that the 
paediatric hospitals were the hospitals that dispensed the largest quantities 
of extemporaneous preparations in the UK, due to the importance of 
pharmaceutical compounding to this patient population (Section 1.1.5.1). For 
this reason, the purposive sample of hospitals in the UK also included the 
complete list of paediatric hospitals provided by Yeung et al. (2004) 
(Appendix 24). Furthermore, 4 additional hospitals were added to the list, as 
a result of professional contacts established in the course of the project, 
which gave a purposive sample of 36 hospitals. 
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4.3.3 Data collection 
All hospitals in the purposive sample were contacted by email during 2007 in 
order to collect data regarding both extemporaneous preparations and 
specials most frequently dispensed in 2006. The email was sent to hospital 
pharmacists including the UK questionnaire attached, together with a 
separate PDF introduction. Non-respondents were sent periodical email 
reminders, up to a maximum of 5 email reminders per hospital. A few hospital 
pharmacists were also contacted by MC in person and by telephone. 
4.4 Results and discussion 
In the UK, 36 hospitals were contacted to participate in the research project, 
including 7 paediatric hospitals, 25 licensed specials manufacturers plus 4 
additional hospitals. In total, 20 hospitals responded to the request for 
collaboration (56% response rate) and 16 hospitals were non-respondents. 
The 20 respondent hospitals were located across England and Wales, as 
follows: Birmingham (n=1), Cardiff (n=1), Colchester (n=1), Huddersfield 
(n=1), London (n=8), Newcastle upon Tyne (n=3), Preston (n=1), Sheffield 
(n=1), Stockport (n=1), Stoke-on-Trent (n=1) and Surrey (n=1) (Figure 4.3).  
 
Figure 4.3 Map of the UK adapted from National Geographic Society (1998b); indicating the 
location of the respondent hospitals (   ). 
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From the 20 respondents, 15 hospitals contributed data regarding oral 
unlicensed medicines most frequently dispensed in 2006 and 5 hospitals 
were non-participants (Figure 4.4).  
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Purposive sample distributed by respondent and participant hospitals. 
All participant hospitals shared complete datasets, including the oral 
extemporaneous preparations and/or specials dispensed. In total, 8 hospitals 
contributed data regarding both extemporaneous preparations and specials; 
6 hospitals contributed data on extemporaneous preparations and 1 hospital 
on specials only.  
With reference to the coding frame in Table 2.2, the 5 non-participant 
hospitals did not contribute data for the following reasons: 3 hospitals 
dispensed oral unlicensed medicines but data were not readily accessible 
and 2 hospitals dispensed oral unlicensed medicines but data were classified 
as confidential. The disclosure of information regarding specials, in particular, 
represented a problem for some hospitals, either because data were not 
readily accessible: “we cannot pull off the information from our current 
antiquated computer system (paediatric hospital, in West Midlands); 
unfortunately I was unable to get any information about the oral specials” 
(licensed hospital manufacturing unit, in London); or, alternatively, because 
data were classified as confidential (particularly in the case of licensed 
specials manufacturers): “I have been told the Trust does not favour sharing 
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this information; as a commercially focused manufacturer I cannot release 
confidential information regarding quantities we produce” (licensed hospital 
manufacturing units, in London). The oral specials reported by the UK 
hospitals were prepared in their own manufacturing units and/or bought from 
other specials manufacturers. In total, 18 different specials manufacturers 
were reported by the participant hospitals. 
A total of 4 UK hospitals were visited by MC with the purpose of collecting 
data and visiting the preparation/manufacturing areas (Section 4.3). Although 
all 4 hospitals contributed to the research project, none of these provided 
data during the visit but provided it later. The hospital visits were undertaken 
between 2006 and 2008 but all datasets referred specifically to 2006, for 
comparative purposes. All UK hospitals sent the required data by email; 10 
hospitals supplied data in the questionnaire provided and 5 hospitals in their 
own formats. A total of 7 hospitals provided datasets including non-oral 
unlicensed medicines (e.g. enemas, nasal drops and topical solutions), which 
were excluded accordingly (Section 2.4.1). After data processing, the UK 
database included a total of 489 data entries, corresponding to the datasets 
of 15 hospitals. 
4.4.1 Active substances  
A complete list of the active substances most frequently dispensed as oral 
unlicensed medicines in the UK is shown in Table 4.1. Active substances 
were grouped according to the respective therapeutic classification 
(Martindale 35, 2007), giving a total of 159 different active substances and 36 
therapeutic groups. Cardiovascular drugs was the group with the greatest 
number of different active substances (n=21), followed by antibacterials 
(n=15) and electrolytes (n=14). Although these active substances were all 
reported as oral unlicensed medicines, the title of some therapeutic groups 
suggested non-oral (therapeutic) indications, namely: dermatological drugs 
and sunscreens (Appendix 11); disinfectants and preservatives (Appendix 
12); paraffins and similar bases (Appendix 13); and supplementary drugs and 
other substances (Appendix 15). The active substances included in these 
groups are described in the respective appendixes. 
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Table 4.1 Active substances most frequently dispensed as oral unlicensed medicines in the 
UK (NTI drugs underlined). 
Analgesics, anti-inflammatory drugs 
and antipyretics 
Diclofenac, indometacin, methadone HCl, 
morphine, morphine HCl, morphine 
sulfate, naproxen, paracetamol 
 
Antibacterials 
Benzylpenicillin, clindamycin, clindamycin 
HCl, colistin sulfate, ethambutol HCl, 
gentamicin sulfate, isoniazid, neomycin, 
oxytetracycline, pyrazinamide, rifabutin, 
sulfadiazine, tetracycline, vancomycin, 
vancomycin HCl 
 
Antidepressants 
Amitriptyline, dosulepin HCl, imipramine 
 
Antidiabetics 
Gliclazide, metformin HCl 
 
Antiepileptics 
Clobazam, clonazepam, gabapentin, 
phenobarbital, phenobarbital sodium, 
primidone 
 
Antifungals 
Amphotericin B, griseofulvin 
 
Antigout drugs 
Allopurinol, probenecid 
 
Antihistamines 
Cyclizine 
 
Antimalarials 
Hydroxychloroquine sulfate, primaquine 
phosphate, quinine dihydrochloride, 
quinine sulfate 
 
Antimyasthenics 
Pyridostigmine bromide 
 
Antineoplastics 
Aminolevulinic acid HCl, busulfan, 
cyclophosphamide, hydroxycarbamide, 
mercaptopurine, methotrexate, tioguanine 
 
 
Antiparkinsonian drugs 
Carbidopa, levodopa, trihexyphenidyl HCl 
 
 
Antivirals 
Didanosine, valaciclovir HCl 
 
 
 
Anxiolytic, sedatives, hypnotics and 
antipsychotics 
Chlordiazepoxide, chloral hydrate, 
clozapine, levomepromazine, lorazepam, 
midazolam, midazolam maleate, 
secobarbital, zuclopenthixol 
 
Blood products, plasma expanders and 
haemostatics 
Tranexamic acid 
 
Bronchodilators and anti-asthma drugs 
Caffeine, caffeine citrate 
 
Cardiovascular drugs 
Amiodarone, amlodipine besilate, 
captopril, chlorothiazide, clonidine, 
diazoxide, diltiazem HCl, doxazosin 
mesilate, enalapril, flecainide acetate, 
furosemide, hydralazine HCl, labetalol 
HCl, lisinopril, metoprolol, metoprolol 
tartrate, prazosin HCl, propranolol HCl, 
spironolactone, verapamil HCl, warfarin 
sodium 
 
Chelators, antidotes and antagonists 
Calcium polystyrene sulfonate, mesna 
(sodium 2-mercaptoethanesulphonate), 
methionine, naltrexone 
 
Contrast media 
Meglumine amidotrizoate, sodium 
amidotrizoate 
 
Corticosteroids 
Dexamethasone, fludrocortisone acetate, 
hydrocortisone, prednisolone 
 
Cough suppressants, expectorants, 
mucolytics and nasal decongestants 
Acetylcysteine, ammonium chloride 
 
Dermatological drugs and sunscreens 
Acitretin 
 
Disinfectants and preservatives 
Sodium benzoate, sodium metabisulfite 
 
Electrolytes 
Calcium gluconate, magnesium chloride, 
magnesium glycerophosphate, 
magnesium sulfate, monobasic potassium 
phosphate, monobasic sodium 
phosphate, phosphate, potassium 
chloride, potassium citrate, potassium 
phosphate, sodium bicarbonate, sodium 
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chloride, sodium citrate, sodium 
phosphate 
 
GI drugs 
Calcium carbonate, hyoscine 
butylbromide, hyoscine hydrobromide, 
loperamide HCl, omeprazole, 
propantheline bromide 
 
General anaesthetics 
Chloroform, ketamine HCl 
 
Hypothalamic and pituitary hormones 
Desmopressin 
 
Immunosuppressants 
Azathioprine, tacrolimus 
 
 
Miotics, mydriatics and antiglaucoma 
drugs 
Acetazolamide 
 
 
Muscle relaxants 
Dantrolene sodium, tizanidine HCl 
 
Nutritional agents and vitamins 
Arginine, calcium folinate, citrulline, 
ergocalciferol, folinic acid, glucose, 
glycine, lactose, menadiol sodium 
phosphate, pyridoxine HCl, thiamine, 
vitamin D 
 
Paraffins and similar bases 
Cholesterol 
 
Stimulants and anorectics 
Methylphenidate HCl 
 
Supplementary drugs and other 
substances 
Citric acid, glycerol, glycopyrronium 
bromide, macrogols, manuka, 
monosodium glutamate, sodium 
phenylbutyrate, tetrabenazine, xylose 
 
Thyroid and antithyroid drugs 
Levothyroxine sodium, potassium iodide, 
potassium perchlorate 
 
Urological drugs 
Sildenafil citrate 
With reference to the official list provided by ANVISA (2007) (Appendix 1), a 
total of 7 NTI drugs were dispensed as oral compounded medicines 
(underlined in Table 4.1). 
The active substances dispensed by most hospitals were: ethambutol HCl 
(n=10); clobazam and sodium chloride (n=9); pyrazinamide and pyridoxine 
HCl (n=7). 
All active substances reported were included in Martindale 35 (2007), with 
the exception of nickel sulfate that was dispensed by 1 hospital as 11.2 mg 
capsules (Appendix 26). Since nickel sulfate is the most common cause of 
contact allergy, it is likely that it was indicated for oral hyposensitization 
therapy or allergy testing (Tammaro et al., 2009). 
Almost all compounded medicines included just 1 active substance (single-
drug) in their composition. In fact, only 4 compounded medicines included 
more than 1 active substance, namely: aminoacids in combination (named as 
aminoacid formula B); co-careldopa (carbidopa and levodopa); Gastrografin 
(meglumine amidotrizoate and sodium amidotrizoate) and tricitrate oral 
 Chapter 4: COMPOUNDING IN THE UK | Results and discussion | 113 
 
solution (sodium citrate, potassium citrate and citric acid monohydrate). Apart 
from compounded medicines including active substances, 2 hospitals also 
reported compounded medicines including placebo, which was dispensed 
both as capsules and oral powders, in a total of 392 units of oral solids.  
UK hospitals reported a number of compounded medicines by their given 
titles as, for instance: Albright’s Solution (2 hospitals), Joulie’s Solution (2 
hospitals), Knox Mouthwash (1 hospital), Peppermint Water (3 hospitals), 
Simple Linctus Paediatric26 (1 hospital) and St Mark’s Powders (1 hospital). 
These compounded medicines were added to the given titles formulary 
(Appendix 16). Peppermint Water (Concentrated) and Simple Linctus 
Paediatric are official formulae since these are included in official texts, 
namely the BP and BPC (Marriott et al., 2010).  
Almost all compounded medicines were reported by active substances and 
only 2 were reported by the respective proprietary names, as follows: 
Calcium Resonium (calcium polystyrene sulfonate) and Gastrografin 
(meglumine amidotrizoate and sodium amidotrizoate). These were reported 
by only 1 hospital and, although named as the proprietary medicines that 
were likely used in their preparation, both were reported specifically as 
specials and not as one-off extemporaneous preparations. Because specials 
are usually prepared in large scale, these should preferably include raw 
materials in bulk instead (Section 1.1.2.2). Finally, 2 hospitals reported 
capsules including “radio-opaque pellets”. These pellets27 are used as faecal 
markers for faecal fat estimation in the diagnosis and control of 
malabsorption (Simpson et al., 1979). 
The UK participant hospitals reported both oral (liquids and solids) and 
oromucosal unlicensed medicines, which are discussed separately below. 
The most frequently dispensed dosage forms were oral liquids. A total of 
50,571 unidose and multidose oral liquids were reported, which represented 
                                            
26Although linctuses are not an official PhEur dosage form, these are subject of an individual 
monograph in the BP (Oral Liquids of the BP) and correspond to viscous oral liquids 
containing 1 or more active substances dissolved in a vehicle that usually contains a high 
proportion of sucrose, other sugars or a suitable polyhydric alcohol or alcohols. Linctuses are 
intended for use in the treatment or relief of cough (BP Commission, 2008a). 
27Pellets correspond to small cylinders (about 3.2 mm in diameter by 8 mm in length) of an 
active substance (Rudnic and Schwartz, 2005). 
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over 95% of all unlicensed medicines dispensed (both extemporaneous 
preparations and specials). Only 4% of the medicines dispensed 
corresponded to oral solids. Oromucosal preparations accounted for less 
than 1% of the unlicensed medicines reported, as shown in Figure 4.5.  
4.4.2 Oral solids 
Oral solid dosage forms were dispensed by 10 hospitals (67% of all 
participants) and included both oral powders and capsules. In total, 2,256 
packs of oral solids were reported, which represented only 4.3% of all 
unlicensed medicines dispensed (Figure 4.5). 
 
Figure 4.5 Oral and oromucosal unlicensed medicines dispensed per number of units/packs. 
The most frequently dispensed oral solid dosage forms were oral powders, 
which were dispensed by a total of 5 hospitals, in a sum of 2,120 packs, 
representing 94% of all oral solids. Out of the 2,120 packs of oral powders, 
91% were specials and only 9% were extemporaneous preparations. 
Specials were dispensed by only 1 hospital, which suggests that this is a 
particular “type” of hospital. A total of 3 different active substances were 
dispensed as specials, namely: glucose, dispensed both as specials and 
extemporaneous preparations, in packs of 14.6 g and 75 g (n=934); manuka 
dispensed as specials only, in packs of 80 g (n=800); and calcium 
polystyrene sulfonate, dispensed as specials only, in packs of 15 g (n=200). 
The top 5 active substances dispensed as extemporaneous preparations 
were: lactose (n=70); glucose, sodium citrate and sodium chloride (St Mark’s 
50,571 
2,256 189 
Oral liquids Oral solids Oromucosal preparations 
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Powders) (n=23); and xylose (n=18). Placebo was also reported as 
extemporaneous preparations, in a total of 10 packs of oral powders and 
dispensed by only 1 hospital. In general, specials were dispensed in much 
larger quantities than extemporaneous preparations. 
Capsules were so dispensed by 7 hospitals, in a sum of 136 packs, which 
represented only 6% of all oral solids. Although capsules were reported by 
more hospitals, in comparison with extemporaneous preparations, capsules 
were dispensed in much lesser quantity probably because these were not 
dispensed as specials but only as extemporaneous preparations. The most 
frequently dispensed capsules were radio-opaque pellets (2 hospitals), 
followed by potassium iodide (65 mg; 1 hospital) and potassium perchlorate 
(200 mg; 1 hospital). Placebo capsules were also reported by 1 hospital. 
4.4.3 Oral liquids 
Oral liquid dosage forms were dispensed by all participant hospitals and 
included solutions, suspensions, mixtures28 and syrups. Oral liquids 
represented 95.4% of all unlicensed medicines dispensed (Figure 4.5). 
The strengths of oral liquids were frequently reported per dosing unit (e.g. 
100 mg/5 mL and 3 mg/10 mL) and not just per mL. In order to avoid 
administration errors, the pharmacist when labelling a compounded medicine 
must carefully decide whether to indicate the strength of an oral liquid per 
dosing unit or just per mL, as this interchange is likely to confuse patients 
(Jackson and Lowey, 2010). The volumes reported ranged from 4 mL to 
1,000 mL. Although none of the hospitals distinguished unidose from 
multidose containers, it was assumed that quantities <10 mL corresponded 
to unidose whereas quantities ≥10 mL corresponded to multidose containers 
(Section 2.1.3). On this basis only 2 hospitals dispensed unidose oral liquids 
and, in total, only 3 active substances were dispensed as unidose, namely: 
midazolam (10 mg/mL), midazolam maleate (12.5 mg/5 mL) and mesna (100 
mg/mL). The 3 unidose oral liquids were dispensed as unlicensed solutions, 
                                            
28Although mixtures are not an official PhEur dosage form, these are subject of an individual 
monograph in the BP (Oral Liquids of the BP) and correspond to an oral liquid containing 1 
or more active substances dissolved, suspended or dispersed in a suitable vehicle (BP 
Commission, 2008a). 
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in a total of 371 units; midazolam and midazolam maleate were dispensed as 
oral specials.  
Multidose containers were dispensed in much larger quantities; 50,200 
multidose oral liquids. The quantities of multidose oral liquids, per dosage 
form, were reported as follows: solutions and suspensions (n=49,578), 
mixtures (n=142) and syrups (n=88). In addition, a total of 316 multidose oral 
liquids were not classified with regards to the dosage form and 76 were 
classified generally as oral liquids.   
Solutions and suspensions were specifically reported by all participant 
hospitals, in a sum of 49,578 multidose units, which corresponded to almost 
99% of all multidose oral liquids dispensed. The majority of the solutions and 
suspensions reported were described as specials (n=44,137), which 
represented 89% of all multidose solutions and suspensions dispensed. The 
top 5 active substances are shown in Table 4.2.  
Paracetamol was the most frequently dispensed active substance. It was 
reported as an oral special by only 1 hospital, a licensed specials 
manufacturer, in the single strength of 1g/10 mL and in a sum of 14,500 
multidose units. Batch sizes varied from 500 to 2,500 multidose units of 200 
mL each. 
Table 4.2 Oral unlicensed medicines most frequently dispensed as multidose solutions and 
suspensions. 
Active 
substances Strengths Volumes 
Number 
of 
hospitals 
Number of  
units dispensed 
Extemporaneous 
preparations Specials 
Paracetamol 1 g/10 mL 200 mL 1 _____ 14,500 
Sodium 
bicarbonate 
1 mmol/mL 
(8.4%) 50-200 mL 4 28 5,348 
Peppermint Water 100 mL  200 mL 4 23 3,009 
Phenobarbital 
sodium 50 mg/5 mL 15-200 mL 2 14 2,492 
Diclofenac 50 mg/5 mL 150 mL 1 _____ 2,040 
 
Paracetamol oral liquid is licensed in the UK both as an oral suspension of 
120 mg/5 mL and another of 250 mg/5 mL which corresponds to 240 mg/10 
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mL and 500 mg/10 mL, respectively (Joint Formulary Committee, 2008). The 
special dispensed by the UK hospital is twice the strength of the highest 
strength licensed suspension, which indicates that there is a need for a 
licensed paracetamol oral liquid for adults. Nevertheless, specials are 
unlicensed medicines and, therefore, these should only be prescribed in 
exceptional situations. Paracetamol 1 g/10 mL (14,500 multidose units) 
represented 29% of all multidose solutions and suspensions dispensed by 
the UK hospitals, which is not consistent with the concept of compounded 
medicines (Section 1.1.4) nor with the “individual or small batch production” 
claimed by specials manufacturers (Section 4.2.1). Sodium bicarbonate was 
the next most frequently dispensed active substance, which was dispensed 
both as extemporaneous preparations (n=28) and specials (n=5,348) by a 
total of 4 hospitals and in the single strength of 1 mmol/mL (equivalent to 
8.4%). As stated in the BNF 56: “Oral solutions of sodium bicarbonate are 
required occasionally; these need to be obtained on special order and the 
strength of sodium bicarbonate should be stated on the prescription” (Joint 
Formulary Committee, 2008). The next most frequently dispensed active 
substances were, in decreasing order, Peppermint Water, phenobarbital 
sodium and diclofenac (Table 4.2). For the top 5 active substances reported 
and, in general, specials were dispensed in much larger quantities than 
extemporaneous preparations. In fact, out of the 50,200 multidose oral 
liquids, 88% corresponded to specials and only 12% to extemporaneous 
preparations. Although extemporaneous preparations are associated with 
more risks than specials, the evident large scale production of specials is of 
concern since these medicines are unlicensed and, therefore, their quality, 
safety and efficacy has not been accessed by the MHRA. 
The active substances dispensed as multidose solutions and suspensions 
were classified with reference to Martindale 35 (2007) and the most frequent 
therapeutic groups were: analgesics, anti-inflammatory drugs and 
antipyretics, which represented 36% of all therapeutic groups and included 
paracetamol and diclofenac; electrolytes (20%), which included sodium 
bicarbonate; and gastrointestinal drugs (7%), which included Peppermint 
Water (Figure 4.6). Whereas the leading therapeutic group with regards to 
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unlicensed medicines dispensed in hospitals was analgesics, anti-
inflammatory drugs and antipyretics, the leading therapeutic group in terms of 
prescription items dispensed in the community in England (2006-2007) was 
cardiovascular drugs (NHS, 2008).  
 
Figure 4.6 Solutions and suspensions (multidose) dispensed by number of units and 
classified by therapeutic groups. 
As part of the multidose oral liquids, mixtures were reported by 4 hospitals in 
a sum of 142 (0.3%) units. Only 7 active substances were reported as 
mixtures and these were (in decreasing order): magnesium chloride, chloral 
hydrate, magnesium sulfate, caffeine citrate, phosphate, sodium benzoate 
and hydralazine HCl. Only caffeine citrate was reported as a special.  
Also part of the multidose oral liquids, syrups were reported by 3 hospitals, in 
a sum of 88 (0.2%) units. The most frequently dispensed syrup was chloral 
hydrate (500 mg/5 mL), which was reported as a special only. Chloral 
hydrate and glycerol were the only active substances reported as syrups. 
Nevertheless, it is likely that more active substances were dispensed as 
syrups but these might have been classified by the hospital pharmacies as 
solutions, suspensions or even mixtures. The ambiguity of the dosage forms 
classification is well represented in the chloral hydrate that was reported as a 
syrup, mixture and solution. In the UK, the BPC (Section 4.2.2) describes a 
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Chloral Hydrate Mixture that contains 20% of syrup and a Chloral Hydrate 
Elixir Paediatric29, in which syrup is the main vehicle (Council of the 
Pharmaceutical Society of Great Britain, 1973) (Appendix 2). Yet, both 
mixture and elixir described in the BPC are classified in the BNF 56 as an 
oral solution (Joint Formulary Committee, 2008). Moreover, chloral hydrate in 
syrup is classified in the international literature as an oral liquid (in general) 
(Appendix 2) (Allen, 2006c). In practice, pharmacists face the ambiguity of 
the dosage forms classification on a daily basis and, in case of uncertainty, 
oral liquid compounded medicines should be classified as liquid preparations 
for oral use (EDQM, 2011). 
The multidose oral liquids (solutions, suspensions, mixtures and syrups), 
both specials and extemporaneous preparations, were dispensed in a variety 
of strengths. The active substances dispensed in the greatest range of 
strengths are shown in Table 4.3. In general, extemporaneous preparations 
were dispensed in a greater range of strengths than specials. This was 
expected since specials are produced in batches and, therefore, in order to 
optimise costs, specials manufacturers are interested in producing selected 
strengths only. Nevertheless, the purpose of pharmaceutical compounding is 
to offer a customised therapeutic alternative to patients and the 
standardisation of strengths is not consistent with individualised therapy. 
Table 4.3 Active substances dispensed in the greatest range of strengths. 
Active  
substances 
Number of strengths 
Total  
(range) 
Extemporaneous 
preparations Specials 
Levothyroxine 
sodium 8 (25-200 µg/5 mL) 8 3 
Clonidine 6 (25 µg-50 mg/5 mL) 5 2 
Ethambutol HCL  6 (100-600 mg/5 mL) 5 3 
 
Although it may be argued that the standardisation of strengths leads to 
fewer compounding errors, nowadays, with the computerisation and a 
                                            
29Although elixirs are not an official PhEur dosage form, these are subject of an individual 
monograph in the BP (Oral Liquids of the BP) and correspond to clear and flavoured oral 
liquids containing 1 or more active substances dissolved in a vehicle that usually contains a 
high proportion of sucrose, or a suitable polyhydric alcohol or alcohols, and may also contain 
ethanol (96% or diluted) (BP Commission, 2008a). 
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QA/QC (quality assurance / quality control) system in hospitals and 
community pharmacies, the quality of compounded medicines may be 
assured. 
The top 10 active substances dispensed as extemporaneous preparations is 
shown in Table 4.4. Whereas the top 3 unlicensed medicines dispensed were 
specials and corresponded to paracetamol (n=14,500), sodium bicarbonate 
(n=5,348) and Peppermint Water (n=3,009); the top 3 extemporaneous 
preparations were dispensed in much lesser quantities and corresponded to 
clozapine (n=701), midazolam (n=632) and Albright’s Solution (n=444).  
Table 4.4 Top 10 active substances dispensed as extemporaneous preparations, per 
number of units. 
 
Active substances Units dispensed 
1. Clozapine      701 
2. Midazolam      632 
3. Albright’s Solution    444 
4. Joulie’s Solution    420 
5. Glycopyrronium bromide  309 
6. Levothyroxine sodium   253 
7. Morphine sulfate    238 
8. Clonidine      213 
9. Omeprazole     193 
10. Sodium chloride      84 
 
Considering both oral solids and liquids, the top 10 extemporaneous 
preparations dispensed by the UK hospitals corresponded to oral liquids only, 
which is in accordance with Brion et al. (2003), Tuleu et al. (2003) and Yeung 
et al. (2004), who concluded that the most frequently dispensed dosage 
forms in the UK were oral liquid dosage forms. With reference to the top 20 
active substances described by Yeung et al. (2004) (Appendix 17), only 
midazolam, clonidine and sodium chloride were included in their list. On the 
other hand, the top 50 extemporaneous preparations dispensed by a 
convenience sample30 of NHS hospitals (Lowey and Jackson, 2008) 
                                            
30Convenience samples are those in which the researcher selects the individuals that are 
more readily accessible and willing to participate in the research, despite the fact that these 
may not be representative (Smith, 2005). 
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(Appendix 18) included the majority of the active substances described in 
Table 4.4. In fact, only Albright’s Solution and glycopyrronium bromide were 
not included in their list. In comparison, clozapine was dispensed in very 
similar quantities whereas midazolam, Joulie’s Solution and omeprazole 
were reported in much larger quantities than the NHS sample by Lowey and 
Jackson (2008).  
4.4.4 Oromucosal preparations  
In the UK, oromucosal preparations were reported by 6 hospitals (40% of all 
participant hospitals) and only 5 different active substances were dispensed, 
as follows:  
• Tranexamic acid: is an antifibrinolytic agent that is used in the prophylaxis 
and treatment of haemorrhage associated with excessive fibrinolysis. 
Tranexamic acid solutions have been widely used as mouthwashes, 
particularly in the NHS (Martindale 35, 2007; Lowey and Jackson, 2008). 
This active substance was reported by 5 hospitals in the single strength of 50 
mg/mL and in a sum of 104 multidose units (100-500 mL).  
• Knox Mouthwash: according to Jackson and Lowey (2010) there are 
several formulae for this mouthwash, including different active substances 
and in different strengths. Typically, it includes triamcinolone acetonide (500 
µg/mL = 2.5 mg/5 mL) and erythromycin ethyl succinate (47.5 mg/mL = 237.5 
mg/5 mL) (Appendix 16) (Jackson and Lowey, 2010). Knox Mouthwash was 
the only special reported by the participant hospitals; it was dispensed in a 
sum of 83 multidose units (100-300 mL) and by only 1 hospital. The strengths 
reported for the active substances were 2.5 mg/5 mL and 250 mg/5 mL, 
which are very similar to the formula mentioned above.  
• Folinic acid: is the active form of folic acid and it is given as calcium or 
sodium folinate (Martindale 35, 2007). It was dispensed as an oromucosal 
preparation in the strength of 3 mg/10 mL (200 mL) and by only 1 hospital. 
• Tetracycline: is an antibacterial with a wide spectrum of activity 
(Martindale 35, 2007). It was dispensed as an oromucosal preparation in the 
strength of 5% (200 mL), by only 1 hospital. 
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A total sum of 189 multidose units of oromucosal preparations were reported, 
which accounted for less than 1% of all unlicensed medicines dispensed 
(Figure 4.5). Out of the 189 oromucosal preparations, 56% (n=106) were 
extemporaneous preparations and 44% (n=83) were specials. 
4.5 Summary  
• Compounded medicines in the UK correspond to unlicensed medicinal products and 
include both specials and extemporaneous preparations. Specials are manufactured 
according to GMP in licensed hospital manufacturing units or pharmaceutical industries.  
• To date, there is no professional organisation specifically dedicated to pharmaceutical 
compounding, nor an official and up-to-date compounding formulary in the UK. The BP 
includes a general monograph and also individual monographs for unlicensed medicines. 
• A purposive sample of 36 hospitals was included in the research (5 hospitals and 1 
licensed specials manufacturer were visited) and a response rate of 56% was obtained. A 
total of 159 different active substances (including 7 NTI drugs) were reported corresponding 
to 36 different therapeutic groups. The top 3 therapeutic groups were cardiovascular drugs 
(n=21), antibacterials (n=15) and electrolytes (n=14). Placebo was dispensed as capsules 
and oral powders in a sum of 392 units (n=2). 
• Oral solid dosage forms were reported by 67% of all participant hospitals and included 
oral powders and capsules. Oral powders were dispensed in a sum of 2,120 packs and the 
top 3 active substances were: glucose, manuka and calcium polystyrene sulfonate. Capsules 
were dispensed in a sum of 136 packs and the top 3 active substances were: radio-opaque 
pellets, potassium iodide and potassium perchlorate. 
• Oral liquid dosage forms were reported by all participant hospitals and included solutions, 
suspensions, mixtures and syrups; the respective strengths were frequently reported per 
dosing unit. Oral liquids were dispensed in a total sum of 50,571 containers and the top 5 
active substances were: paracetamol, sodium bicarbonate, Peppermint Water, phenobarbital 
sodium and diclofenac. Solutions and suspensions were dispensed in a total of 49,578 
multidose containers (98.8%) whereas mixtures and syrups were dispensed in a total of 142 
and 88 multidose containers (0.5%). Oral liquids were more frequently dispensed than oral 
solids. In general, specials were dispensed in much larger quantities than extemporaneous 
preparations but these were reported in a greater range of strengths. 
• Oromucosal preparations were reported by 40% of hospitals, in a sum of 189 multidose 
containers, and the active substances dispensed were: tranexamic acid, Knox Mouthwash, 
folinic acid and tetracycline.  
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5. Compounding in Switzerland 
Switzerland was the only non-member of the EU that was included in the 
international survey. It is considered the non-member with the greatest 
relations with the EU and was included in the research because of these 
close interconnections (Section 2.2.1). Switzerland is centrally located in 
Europe, bordering France in the West, Germany in the North, Austria and the 
principality of Liechtenstein in the East, and Italy in the South (Switzerland 
Tourism, 2010a). Switzerland occupies an area of 41,290 Km2 and has a 
population of 7.6 million (Europa, 2009). The largest Swiss cities are (in 
decreasing order): Zurich, Geneva, Basel, Bern and Lucerne. This country is 
administratively divided into 26 cantons and has 4 official languages 
(traditionally spoken in different regions of the country), as follows: Swiss 
(German) (64%), French (20%), Italian (7%) and Rumantsch (1%) 
(Switzerland Tourism, 2010a; 2010b).  
In 2005, there were 337 hospitals in Switzerland (ratio of 4.53 hospitals per 
100,000 population) and a total of 41,196 hospital beds (ratio of 553.92 
hospital beds per 100,000 population) (WHO Regional Office for Europe, 
2010) (Appendix 3).  
In 2006, there were 4,269 pharmacists in Switzerland (ratio of 57.04 
pharmacists per 100,000 population) (WHO Regional Office for Europe, 
2010) (Appendix 4). According to the EAHP survey, the average number of 
pharmacists in Swiss hospitals is 4.1, compared to the European average of 
4.7 pharmacists per European hospital. Nevertheless, Swiss hospitals have 
an average of 6.7 qualified pharmacy technicians/assistants per hospital, 
compared to the European average of 6. Switzerland also has an average of 
2.2 non-qualified pharmacy assistants per hospital (EAHP, 2005; Hartmann, 
2010). 
Hospital pharmacists in Switzerland are reported to make an important 
contribution to the safe, correct and economic use of medicines (Grünig, 
2006) and, according to Zelger31 (2006), the practice of pharmaceutical 
compounding is considered to reinforce the presence and importance of 
                                            
31Georges Zelger is the president of the GSASA (Section 5.2.1). 
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hospital pharmacists in Switzerland. Postgraduate education in hospital 
pharmacy has been officially recognised and Swiss pharmacists now have 
the opportunity of being awarded the professional qualification of “Hospital 
Pharmacist FPH (Foederatio Pharmaceutica Helvetiae - Swiss 
Pharmaceutical Federation)”. This specialisation includes 5 areas of 
expertise and pharmaceutical manufacture is one of these areas (Grünig, 
2006; Zelger, 2006). 
Because Switzerland is not a member of the EU, the movement of goods 
across borders is limited and, in the case of urgent need, it may be difficult to 
get medicines from other countries. In addition, Switzerland is a small country 
with a limited market for medicines and, therefore, important pharmaceutical 
formulations (e.g. isoniazid, quinine, hydromorphone and hydrocodone for 
injection) have been removed from the market by pharmaceutical industries 
for purely economic reasons (Martinelli, 2006). As a result, pharmaceutical 
compounding plays an increasingly important role in this country.  
In Switzerland, compounded medicines may be prepared individually or in 
batches of small quantities. The practice of pharmaceutical compounding is 
subject to many legal constraints and, therefore, only a limited number of 
Swiss hospitals are able to prepare and dispense compounded medicines 
(Surber et al., 2006). The preparation of compounded medicines in small 
quantities must comply with the Swiss “GMP for the production of 
compounded medicines in small quantities”, which is particularly intended for 
non-sterile compounding (Martinelli, 2006) (Section 5.1). However, there is 
not yet a definition for “small quantity” and, according to Zelger (2006), this 
will have a huge impact on hospital compounding once it is established. In 
addition, the preparation of compounded medicines in small quantities is 
restricted to the formulas included in officially recognised references. In 
Switzerland, the only authorised reference is the Swiss Pharmacopoeia 
(PhHelv, Section 5.2.2) which, according to Martinelli (2006), does not 
include many essential pharmaceutical formulations. This situation reduces 
the flexibility of the hospitals in meeting patients’ needs and, ultimately, the 
patient health may suffer (Martinelli, 2006). 
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In a study by Di Paolo et al. (2006), conducted prospectively in a Swiss 
paediatric university hospital, the use of unlicensed and off-label medicines in 
children was a common practice. Of the 483 prescriptions analysed over 6 
months (2001/2002), 24% were for unlicensed medicines and the majority of 
these were prepared by the hospital pharmacy “in-house” either as batch 
preparations (e.g. chloral hydrate, caffeine citrate and morphine solutions) or 
as individualised preparations (e.g. captopril, furosemide, hydrochlorothiazide 
and spironolactone capsules, solutions and suspensions). The oral 
unlicensed medicines included in the top 10 (unlicensed and off-label) were: 
spironolactone oral suspension 5 mg/mL, hydrochlorothiazide oral 
suspension 5 mg/mL and captopril oral capsules (Di Paolo et al., 2006). 
As the country is administratively divided in 26 cantons, the Swiss health 
care system does not operate on a national level. Instead, every canton has 
its own health care services and laws (Zelger, 2006). For this reason, there 
are differences in pharmaceutical compounding practices and regulations 
throughout Switzerland. 
5.1 Legislation 
According to Swiss legislation, medicines must be authorised by Swissmedic 
(Section 5.2.1) to be placed on the market. Compounded medicines are 
included in the exemptions to this authorisation and are classified into 3 
categories, as follows: 
1. Formule Magistrale (magistral formulae): correspond to the medicines 
prepared according to a medical prescription in a community pharmacy or 
hospital pharmacy or, by request of these, in a establishment which is a 
holder of a manufacturing authorisation, and which are intended for use by 
one person or a specific group of people (L’Assemblée Fédérale de la 
Confédération Suisse, 2000). 
2. Formule Officinale (officinal formulae): correspond to the medicines 
prepared in small quantities in a community pharmacy, hospital pharmacy, 
drugstore or in another establishment which is a holder of a manufacturing 
authorisation, and in accordance with a special monograph of the PhHelv 
(Section 5.2.2), another pharmacopoeia, or a formulary recognised by 
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Swissmedic (Section 5.2.1), and which are intended to be dispensed to the 
customers of that establishment (L’Assemblée Fédérale de la Confédération 
Suisse, 2000). So far, Swissmedic (Section 5.2.1) has not recognised any 
national or international formularies (Gosdschan, 2008). Thus, only the 
monographs included in the pharmacopoeias belong to this category of 
officinal formulae. 
3. Formule Propre (own formulae): correspond to the medicines prepared in 
small quantities in a community pharmacy, hospital pharmacy, drugstore or in 
another establishment which is a holder a manufacturing authorisation, in 
accordance with a formula of that particular establishment (L’Assemblée 
Fédérale de la Confédération Suisse, 2000). A hospital’s individual formulae 
belong to this category of own formulae (Gosdschan, 2008). 
In Switzerland, compounded medicines prepared in small quantities are 
subject to GMP - Règles de Bonnes Pratiques de Fabrication de 
Médicaments en Petites Quantités - which are part of the PhHelv (Section 
5.2.2) (Swissmedic, 2006a; Zelger, 2006). These guidelines encompass a set 
of 9 norms, namely: quality management; personnel; facilities and 
equipment; documents; production; QC; outsourcing production; claims and 
product withdrawals; and autoinspection. These GMP requirements are part 
of a QA system, which guarantees that compounded medicines are 
consistently prepared with appropriate quality. 
5.2 Professional organisations and information sources 
5.2.1 Swiss professional organisations 
• Swiss Agency for Therapeutic Products (Swissmedic): is the Swiss agency 
for the authorisation and supervision of therapeutic products and aims to 
ensure that authorised therapeutic products are of high quality, effective and 
safe; it is responsible for the PhHelv (Section 5.2.2). Companies that 
manufacture or distribute medicinal products in Switzerland require a licence 
granted by Swissmedic (Swissmedic, 2009; 2010). Swissmedic is an 
independent body responsible for developing and enforcing medicines 
legislation and regulations (Zelger, 2006). 
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• Société Suisse des Pharmaciens (pharmaSuisse): is the Swiss society of 
pharmacists, which has departments of “Politics and Economy”, “Science, 
Education and Quality” and “Communication and Marketing”. In 2009, there 
were 1,353 (78.2%) pharmacies and 5,528 individual members of 
pharmaSuisse (no date). The pharmaSuisse is the entity responsible for the 
Formularium Helveticum, a non-official Swiss formulary (Section 5.2.2) 
(Riedl, 2008). 
• Swiss Society of Public Health Administration and Hospital Pharmacists 
(GSASA): is a small professional group, comprising mainly hospital 
pharmacists, that has an important and active role in the Swiss health care 
system. The GSASA has several departments, linked to specific working 
groups, including the departments of drug manufacturing, risk management 
and quality. The GSASA created its own professional quality referencing 
system: Quality Referential for Swiss Hospital Pharmacies (QRHP) (Zelger, 
2006; GSASA, 2010; Weidemeier et al., no date). In 1999, GSASA 
introduced the postgraduate education in Swiss hospital pharmacy (Grünig, 
2006). 
5.2.2 Swiss information sources 
Switzerland has not published an official formulary for pharmaceutical 
compounding. Instead, there are 2 non-official formularies that have not been 
updated recently and are considered largely obsolete: Formularium 
Helveticum, published in 1991 by pharmaSuisse; and Formularium Clinicum, 
published in 1996 by GSASA (Barbosa and Pinto, 2001). According to 
Martinelli (2006), no professional organisation has been appointed so far for 
financing and/or developing an officially recognised formulary. As a result, 
the only official reference source in Switzerland with monographs for 
compounded medicines is the PhHelv. 
• Pharmacopoea Helvetica (PhHelv): is the Swiss Pharmacopoeia that, in 
association with the PhEur, constitutes the official pharmacopoeia in 
Switzerland. The PhHelv 10, published in 2006, includes 134 (official) 
monographs, almost half of which are for pharmaceutical preparations. The 
10th edition introduced, among others, GMP for cytotoxic medicines (in small 
quantities) and also an (official) monograph for Methadone HCl 10 mg/mL 
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Oral Solution (Appendix 2). A monograph for methadone oral solution was 
already included in the Formularium Helveticum but it was a non-official 
formula. The monographs for pharmaceutical preparations included in the 
PhHelv correspond to standardised quality preparations (Swissmedic, 2006a; 
2006b; 2009). However, the PhHelv does not include all pharmaceutical 
preparations and there is a general lack of official monographs for 
compounded medicines in Switzerland (Martinelli, 2006). Swissmedic does 
not have sufficient resources to include all the necessary pharmaceutical 
preparations in the PhHelv and, therefore, there is a gap between the 
officinal formulae that are needed and the official monographs that are 
published in Switzerland (Gosdschan, 2008). 
• E-Drug Compounding: is a website that contains compounding information 
collected by a medium sized Swiss hospital pharmacy for over 30 years and 
which aims to support the practice of pharmaceutical compounding, 
particularly in developing countries (E-Drug Compounding, 2011a). It 
includes a long list of free downloadable monographs for ophthalmic 
preparations; oral dosage forms (27 compounded medicines and 6 vehicles); 
parenteral forms; suppositories; topical preparations; other pharmaceutical 
preparations; and cosmetic preparations (E-Drug Compounding, 2011b). 
5.3 Methods 
Switzerland was the first European country included in the research in which 
information regarding the practice of pharmaceutical compounding was not 
readily accessible and, therefore, there was a need for an international 
collaboration with Swiss stakeholders. Hans Stötter (clinical reviewer and 
head of the working group on paediatrics at Swissmedic, Section 5.2.1) was 
contacted in July 2007 and the Swiss questionnaire was discussed at this 
stage. The questionnaire was developed in English and comprised a detailed 
introduction, as suggested by the stakeholder, 1 Excel table and 2 additional 
questions, as the Portuguese and UK questionnaires. 
In January 2008, it was decided that Bettina Gasser (Masters’ student at 
Swissmedic) would contribute to the research as part of her thesis on “Drug 
safety in Paediatrics” (Gasser, 2008). Therefore, MC visited Swissmedic to 
set up the research but, in the meantime, the Masters’ student had already 
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contacted part of the Swiss hospital pharmacies, by telephone and email, 
with the request for oral compounded medicines most frequently dispensed 
to paediatrics (only). The Swiss questionnaire (main heading in Figure 5.1) 
was sent to hospital pharmacies, despite the fact that it was incomplete (i.e. 
the definition of compounded medicines corresponded to the UK definition of 
extemporaneous preparations - Section 4.3.1). 
However, since the Masters’ student explained the purpose of the research 
to each participant, the questionnaire was regarded by hospital pharmacies 
just as a table for data collection. Furthermore, the questionnaire was 
initiated in 2007 and, therefore, it addressed information relating to 2006, 
despite the fact that data collection was undertaken in 2008. For these 
reasons, data collected in Switzerland referred to oral compounded 
medicines dispensed to paediatrics (only) and in the year 2006.  
The purposive sample of hospitals was established by the stakeholder and 
the Masters’ student; and it included 33 hospitals (1 per city), distributed 
throughout the country. The hospital in Bern was visited by MC and, although 
only 1 hospital was included in fieldwork, several discussions with national 
stakeholders took place in Bern, which contributed to a better understanding 
of the practice of pharmaceutical compounding in Switzerland. 
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5.4 Results and discussion 
Following the visit to Swissmedic, a total of 15 datasets were returned to MC 
by email, which corresponded to the oral compounded medicines most 
frequently dispensed to paediatric patients in 15 Swiss hospital pharmacies 
(45% response rate of 33 pharmacies). The participant hospitals were 
located across the country, in the cities of: Basel, Bern (capital), Biel, Chur, 
Fribourg, Geneva, La Chaux de Fonds, Lausanne, Lugano, Lucern, 
Munsterlingen, Neuchatel, Sion, Winterthur and Zurich (Figure 5.2), 
corresponding to a total of 12 cantons and including the largest Swiss cities. 
 
Figure 5.2 Map of Switzerland adapted from National Geographic Society (1998c); indicating 
the location of the participant hospitals (   ). 
The majority of non-participant hospitals stated that they had not dispensed 
any compounded medicines to paediatric patients, which does not 
necessarily mean that they had not dispensed any compounded medicines at 
all. If all oral compounded medicines had been requested (instead of for 
paediatrics only), more hospitals may have contributed with data to the 
research. 
A total of 12 hospital pharmacies shared data in the questionnaire provided 
and 3 (20%) hospitals shared data in their own format. A total of 5 hospitals 
provided datasets including non-oral compounded medicines (e.g. IV and eye 
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preparations; topical and rectal compounded medicines), which were 
excluded accordingly (Section 2.4.1). After data processing, the Swiss 
database included a total of 469 data entries, corresponding to the datasets 
of 15 hospitals. 
5.4.1 Active substances  
A complete list of the active substances most frequently dispensed as oral 
compounded medicines in Switzerland (for paediatric patients) is shown in 
Table 5.1. Active substances were grouped according to the respective 
therapeutic classification (Martindale 35, 2007), giving a total of 142 different 
active substances and 31 therapeutic groups. Cardiovascular drugs was the 
group with the greatest number of different active substances (n=29), 
followed by electrolytes (n=14) and antibacterials (n=12). Although these 
active substances were all reported as oral compounded medicines, the title 
of some therapeutic groups suggested non-oral (therapeutic) indications, 
namely: disinfectants and preservatives (Appendix 12); and paraffins and 
similar bases (Appendix 13). The active substances included in these groups 
are described in the respective appendixes. 
With reference to the official list provided by ANVISA (2007) (Appendix 1), a 
total of 3 NTI drugs were dispensed as oral compounded medicines 
(underlined in Table 5.1) 
The active substances dispensed by most hospitals were: spironolactone 
(n=12), phenobarbital (n=11) and captopril (n=10). 
All active substances reported were included in Martindale 35 (2007) with the 
exception of cystamine dihydrochloride, which was dispensed by 1 hospital 
as 150 mg capsules (Appendix 26). Cystamine is considered a potential 
candidate for the treatment of the neurodegenerative disorder Huntington 
disease (Borrell-Pagès et al., 2006). 
The majority (93%) of compounded medicines dispensed included just 1 
active substance and only 7% included 2 or more active substances. 
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Table 5.1 Active substances most frequently dispensed as oral compounded medicines in 
Switzerland (for paediatric patients) (NTI drugs underlined). 
Analgesics, anti-inflammatory drugs 
and antipyretics  
Aspirin, codeine, codeine phosphate, 
hydromorphone HCl, indometacin, 
methadone HCl, morphine, morphine HCl, 
opium 
 
Anthelmintics 
Levamisole 
 
Antibacterials  
Dapsone, flucloxacillin sodium, isoniazid, 
neomycin, neomycin sulfate, polymyxin B 
sulfate, pyrazinamide, rifabutin, rifampicin, 
sulfadoxine, spiramycin, trimethoprim 
 
Antidepressants 
Fluoxetine HCl, oxitriptan 
 
Antiepileptics  
Clobazam, ethosuximide, mesuximide, 
phenobarbital, phenytoin, primidone, 
topiramate, vigabatrin 
 
Antimalarials  
Primaquine phosphate, pyrimethamine 
 
Antineoplastics 
Busulfan, etoposide, hydroxycarbamide, 
mercaptopurine 
 
Antiparkinsonian drugs  
Levodopa, carbidopa 
 
Antiprotozoals  
Metronidazole 
 
Antivirals 
Ganciclovir, nevirapine, valganciclovir HCl 
 
Anxiolytic, sedatives, hypnotics and 
antipsychotics 
Chloral hydrate, diazepam, midazolam 
 
Bronchodilators and anti-asthma drugs 
Caffeine, caffeine citrate 
 
Cardiovascular drugs 
Acenocoumarol, amiodarone, amiodarone 
HCl, amlodipine besilate, atropine sulfate, 
captopril, carvedilol, clonidine HCl, 
diazoxide, dihydralazine sulfate, 
dipyridamole, enalapril, enalapril maleate, 
flecainide acetate, fluvastatin sodium, 
furosemide, hydrochlorothiazide, labetalol 
HCl, losartan potassium, metoprolol, 
metoprolol tartrate, nifedipine, 
phenoxybenzamine HCl, phenprocoumon, 
propafenone HCl, propranolol HCl, sotalol 
HCl, spironolactone, valsartan 
 
Chelators, antidotes and antagonists 
Activated charcoal, deferiprone 
 
Corticosteroids 
Dexamethasone, fludrocortisone acetate, 
hydrocortisone, prednisone 
 
Cough suppressants, expectorants, 
mucolytics and nasal decongestants 
Ipecacuanha, naphazoline 
 
Disinfectants and preservatives 
Chlorhexidine, sodium benzoate 
 
Electrolytes 
Calcium glycerophosphate, calcium 
hydrogen phosphate, calcium phosphate, 
dibasic potassium phosphate, dibasic 
sodium phosphate, magnesium 
gluconate, magnesium sulfate, monobasic 
potassium phosphate, potassium chloride, 
potassium citrate, potassium gluconate, 
sodium bicarbonate, sodium chloride, 
sodium citrate 
 
GI drugs 
Calcium carbonate, cisapride, hyoscine 
butylbromide, mesalazine, omeprazole,  
ranitidine, ranitidine HCl 
 
General anaesthetics 
Ketamine HCl 
 
Immunosuppressants 
Azathioprine, mycophenolate mofetil, 
tacrolimus 
 
Local anaesthetics 
Oxybuprocaine HCl 
 
Miotics, mydriatics and antiglaucoma 
drugs 
Acetazolamide 
 
Muscle relaxants 
Baclofen, tizanidine HCl 
 
Nutritional agents and vitamins 
Arginine HCl, calcium folinate, folic acid, 
glucose, isoleucine, pyridoxine HCl, 
sucrose, valine, zinc acetate, zinc sulfate 
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Paraffins and similar bases 
Cholesterol, liquid paraffin 
 
 
Prostaglandins 
Misoprostol 
 
 
Sex hormones 
Ethinylestradiol 
 
 
 
Supplementary drugs and other 
substances 
Ammonia, macrogol 4000, melatonin, 
strychnine nitrate, thalidomide, 
ursodeoxycholic acid 
 
Thyroid and antithyroid drugs 
Iodine, levothyroxine sodium, potassium 
iodide, sodium perchlorate 
 
Urological drugs 
Sildenafil citrate
In total, 8 different compounded medicines were dispensed as multi-drugs, 
as follows: dibasic potassium phosphate and monobasic potassium 
phosphate; iodine and potassium iodide (Lugol's Solution, see below); 
levodopa and carbidopa; monobasic potassium phosphate and dibasic 
sodium phosphate; oxybuprocaine HCl and naphazoline; polymyxin B sulfate 
and neomycin; sodium chloride, sodium citrate, potassium chloride and 
glucose (WHO Oral Rehydration Salts - ORS - see below); and sulfadoxine 
and pyrimethamine.  
Two compounded medicines were reported by the given titles which they are 
commonly known for, as follows:  
• Lugol’s Solution (5%): it was dispensed by 1 hospital in a total of 37 
containers of 20 mL (Appendix 16). 
• WHO ORS (27.9 g): it was dispensed by 1 hospital in a total of 30 packs of 
oral solids of 20 sachets each (to be dissolved in 1 L of water). The WHO 
ORS corresponds to a balanced glucose-electrolyte mixture, recommended 
by WHO/UNICEF, for the treatment of clinical dehydration throughout the 
world; and it has substantially contributed to the global reduction in mortality 
from diarrhoea. The standard solution (311 mOsm/L) was improved to a 
hypo-osmolar solution (245 mOsm/L), by reducing the glucose and sodium 
chloride concentrations, to avoid possible adverse effects of hypertonicity on 
net fluid absorption (WHO and UNICEF, 2006). The Swiss hospital 
dispensed the WHO ORS standard; both standard and hypo-osmolar 
solutions are shown in Appendix 16. 
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The majority of compounded medicines were reported by active substances 
and only 9% by the respective proprietary medicines as, for instance: Adalat 
(nifedipine), Prograf (tacrolimus) and Viagra (sildenafil citrate). Proprietary 
medicines were reported by a total of 8 hospitals and these were used in the 
preparation of both oral solid and oral liquid dosage forms. 
5.4.2 Oral compounded medicines 
In Switzerland, the most frequently dispensed oral compounded medicines 
were liquid dosage forms. A total of 33,328 packs/units (74.1%) of oral liquids 
were reported, whereas 11,556 packs (25.7%) of oral solids and 80 units 
(0.2%) of oromucosal preparations were reported by the participant hospitals 
(Figure 5.3). This is not in accordance with Brion et al. (2003), who 
concluded that capsules were the most frequently dispensed oral dosage 
forms for children in Switzerland but their findings were based on only 2 
Swiss hospitals. 
 
Figure 5.3 Number of packs/units of oral (and oromucosal) compounded medicines 
dispensed in Switzerland, per dosage forms.  
The most frequently dispensed active substance was morphine (Figure 5.4). 
Morphine was dispensed as oral liquids (solutions), both as morphine and 
morphine HCl, in a total of 20,313 packs/units, which represented 42% of all 
active substances dispensed. It was reported by 6 hospitals, in 6 different 
strengths (0.01-4%), either in packs of single-dose units (2-10 mL) or 
individual multidose units (20-200 mL). 
25.7% 
74.1% 
0.2% 
Oral solids Oral liquid dosage forms Oromucosal preparations 
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The next most frequently dispensed active substances were neomycin (6%), 
sodium citrate (5%) and omeprazole (4%), as shown in Figure 5.4. Neomycin 
was dispensed as oral solids (capsules) and oral liquids (solutions and 
syrups) by 2 hospitals only; it was reported as neomycin sulfate and 
neomycin in combination with polymyxin B sulfate.  
Sodium citrate was dispensed as oral solids (capsules and sachets) and oral 
liquids (solutions) by a total of 6 hospitals; it was reported as single-drug as 
well as part of the WHO ORS (Appendix 16). 
Omeprazole was dispensed as oral liquids (solutions and suspensions) and 
in the single strength of 2 mg/mL; it was reported by 4 hospitals as multidose 
units of 50 mL, 60 mL and 100 mL. 
 
Figure 5.4 Overall top 20 active substances per number of packs/units dispensed. 
The top 20 active substances included captopril, spironolactone and 
hydrochlorothiazide, which corresponded to the oral unlicensed medicines 
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included in the top 10 (unlicensed and off-label) dispensed in a Swiss 
paediatric hospital (Di Paolo et al., 2006). 
In Switzerland, oral compounded medicines were reported in a wide range of 
strengths, particularly with regards to oral solids. The active substances 
dispensed in the greatest range of strengths were:  
• Captopril: 19 (0.01-7.5 mg) oral solids and 1 (1 mg/mL) oral liquid. 
• Phenobarbital: 14 (0.05-30 mg) oral solids and 3 (1-5 mg/mL) liquids. 
• Carvedilol: 13 (0.1-5 mg) oral solids. 
• Propranolol HCl: 10 (1-8 mg) oral solids and 1 (2 mg/mL) oral liquid. 
• Spironolactone: 8 (0.25-7.25 mg) oral solids and 3 (2-10 mg/mL) liquids. 
• Hydrochlorothiazide: 9 (1-8 mg) oral solids and 1 (5 mg/mL) oral liquid. 
• Propafenone HCl: 9 (5-70 mg) oral solids. 
• Sildenafil citrate: 9 (0.5-20 mg) oral solids. 
Oral solids were reported in a wider range of strengths that oral liquid dosage 
forms, which is expected considering that oral liquids allow dosing flexibility 
by variable volumes, which is not easily achieved with solid dosage forms 
(Section 2.1.3). The strength of compounded medicines dispensed to 
paediatric patients is based on the age and body weight (mg/kg) / surface 
area (mg/m2) of patients (Section 1.1.5.1) and, therefore, variable strengths 
may be required in this population. The wide range of strengths encountered 
in Switzerland reinforces the importance of compounding in meeting the 
needs for particular strengths in the paediatric population (Section 1.1.4). 
The overall top 10 therapeutic groups are displayed in Figure 5.5. The most 
frequent therapeutic group was analgesics, anti-inflammatory drugs and 
antipyretics, which corresponded to almost 50% of all therapeutic groups 
(mainly because of the large quantities reported of morphine). The next most 
frequent therapeutic groups were electrolytes (11%) and cardiovascular 
drugs (10.5%). A total of 9 hospital pharmacies reported active substances 
from the top 2 groups; whilst cardiovascular drugs were reported by all 
participant hospitals. 
In 2005, the number of patients discharged from all hospitals (including 
through death) in Switzerland was highest for diseases of the 
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musculoskeletal system (2,145 patients / 100,000 population); injury and 
poisoning; and diseases of the circulatory system (Figure 5.6) (WHO 
Regional Office for Europe, 2008). Thus, it was to be expected then that 
“analgesics, anti-inflammatory drugs and antipyretics” and “cardiovascular 
drugs” were part of the top therapeutic groups in Switzerland (Figure 5.5). 
 
Figure 5.5 Overall top 10 therapeutic groups ranked by number of packs/units dispensed. 
 
Figure 5.6 Number of patients per 100,000 population discharged from all hospitals 
(including through death) in Switzerland during 2005 (latest available year), categorised by 
principal diagnosis (WHO Regional Office for Europe, 2008). 
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5.4.2.1 Oral solids 
Oral solid dosage forms corresponded to 25.7% of all compounded 
medicines (Figure 5.3) and were dispensed by all participant hospitals, with 
the exception of 1 hospital that reported oral liquids only (93%). The oral 
solids dispensed included capsules, oral powders and tablets.  
Capsules accounted for 85% of oral solids (Figure 5.7) and were reported by 
all participant hospitals that dispensed oral solids. Considering that data in 
Switzerland referred to paediatric patients only, it is likely that the capsules 
reported were commonly opened before administration and their contents 
added to liquids or food. The top 3 active substances dispensed as capsules 
(and ranked by number of individual units) corresponded to the top 3 
dispensed as oral solids, as follows: potassium citrate (39,200 units, 2 
hospitals), captopril (37,916 units, 8 hospitals) and cystamine dihydrochloride 
(33,000 units, 1 hospital). Captopril (capsules) was also identified by Di Paolo 
et al. (2006) as a frequently dispensed oral compounded medicine in a Swiss 
paediatric hospital. One hospital stated that their capsules included mannitol 
(as a main excipient), which represents a good alternative for lactose 
intolerant patients. Capsules were dispensed in variable pack sizes, from 1 
unit to 1,000 individual units of capsules. The most frequently dispensed 
pack sizes were 50 units (37.2%), followed by 100 units (14.8%), 60 units 
(13.3%) and 30 units (11.8%). Therefore, an estimate of 50 units of capsules, 
per pack dispensed, was adopted for the purposes of overall data 
comparison. 
         
Figure 5.7 Oral solid dosage forms dispensed per number of packs. 
1,505 
9,823 
228 
Oral powders Capsules Tablets 
 Chapter 5: COMPOUNDING IN SWITZERLAND | Results and discussion | 140 
 
Oral powders corresponded to 13% of oral solids (Figure 5.7) and were 
reported by 5 hospitals only. The top 3 active substances so dispensed (and 
ranked by number of individual units) were: calcium carbonate (996 units, 1 
hospital); macrogol 4000 (801 units, 1 hospital); and the WHO ORS (Section 
5.4.1). 
Tablets comprised only 2% of all oral solids (Figure 5.7) and were reported 
by only 1 hospital. The preparation of tablets requires specialist tableting 
equipment and not all hospitals can afford such an investment (Section 
2.1.3). A total of only 4 active substances were reported as tablets: isoniazid 
100 mg (packs of 100); deferiprone 500 mg (packs of 500); arginine HCl 500 
mg (packs of 100); and levamisole 50 mg (packs of 50).  
The top 3 therapeutic groups (for oral solids only) were: cardiovascular drugs 
(98,888 units of capsules), electrolytes (92,477 units of capsules and oral 
powders) and supplementary drugs and other substances (938,261 units of 
capsules and oral powders). Cardiovascular drugs and electrolytes were in 
the overall top 3 therapeutic groups (Figure 5.5). 
5.4.2.2 Oral liquids 
Oral liquid dosage forms corresponded to 74.1% of all compounded 
medicines (Figure 5.3) and were dispensed by all participant hospitals, with 
the exception of 1 hospital that reported oral solids only (93%). The dosage 
forms dispensed32 included solutions, suspensions, syrups and oral drops33. 
Oral liquids allow dosing flexibility and are easy to administer (in particular to 
paediatric patients) (Section 2.1.3) and, hence, it was expected that these 
were the most frequently dispensed dosage forms to paediatric patients in 
Switzerland. 
The volumes reported ranged from 2 mL to 500 mL, which included both 
unidose and multidose containers. Unidose containers were reported by 
number of packs (e.g. 12x2.5 mL) and included volumes from 2 mL up to 10 
mL. The most frequently dispensed pack size was 12 individual units, which 
                                            
32There was evidence of a tincture (opium) dispensed by 1 hospital but it was classified as 
an oral solution and, therefore, it was not considered a tincture. 
33Oral drops are solutions, emulsions or suspensions that are administered in small volumes 
such as drops by means of a suitable device (EDQM, 2007). 
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was adopted for the purposes of overall data comparison. The active 
substances reported as unidose were morphine HCl (0.1% and 1%) and 
caffeine citrate (10 mg/mL), which were dispensed as unidose solutions, in a 
total of 19,079 packs (228,689 units), by 2 hospitals. These 2 active 
substances were identified by Di Paolo et al. (2006) as part of the 
compounded medicines prepared as batches in a Swiss paediatric hospital. 
Multidose containers, on the other hand, were reported by number of 
individual containers and included volumes from 10 mL up to 500 mL. For 
volumes of 10 mL, oral liquids were considered multidose, with the exception 
of those reported by number of packs. 
Solutions and suspensions corresponded to 92.9% (30,971 multidose 
containers / unidose packs) of all oral liquids and were reported by 14 
hospitals. The top 3 active substances dispensed as solutions and 
suspensions were: morphine, sodium citrate and omeprazole (Section 5.4.2), 
which were all part of the top 5 overall active substances (Figure 5.4). One 
hospital pharmacy stated that their suspensions were prepared with the 
proprietary suspending vehicles Ora-Sweet and Ora-Plus. 
Syrups corresponded to 7% (2,343 multidose containers; 15-250 mL) of all 
oral liquids and were reported by 8 hospitals. Nevertheless, it is likely that the 
classification of some oral liquids by the hospital pharmacies was not 
accurate and, therefore, part of the solutions/suspensions might have 
corresponded to syrups (and vice-versa) (Section 2.1.3). A total of 14 active 
substances were dispensed as syrups and the top 3 were as follows: 
neomycin in combination with polymyxin B sulfate (41.6%), potassium 
chloride (26.3%) and codeine / codeine phosphate (21.2%). 
Oral drops were reported by only 1 hospital and only 1 compounded 
medicine was dispensed, namely: morphine solution 2% (50 mL), which 
corresponded to less than 0.1% (14 multidose containers) of all oral liquids. 
Likewise, the classification of some oral liquids by the hospital pharmacies 
may not have been accurate and, therefore, part of the solutions/suspensions 
might have corresponded to oral drops (and vice-versa) (Section 2.1.3). 
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5.4.2.3 Oromucosal preparations 
In Switzerland, only 1 oromucosal preparation was dispensed, namely: 
chlorhexidine 0.05% solution (Appendix 12) by only 1 hospital (7%). A total of 
80 multidose containers of 250 mL were reported, which corresponded to 
0.2% of all compounded medicines reported (Figure 5.3). 
5.5 Summary 
• Switzerland was the only non-member of the EU included in the international survey but it 
is considered the non-member with the greatest relations with the EU. 
• Compounded medicines in Switzerland correspond to magistral, officinal and own 
formulae, which may be prepared individually or in batches of small quantities. Batch 
preparation must comply with the respective GMP and the compounded medicines prepared 
in small quantities are restricted to the formulas included in the PhHelv. 
• Data collection in Switzerland was undertaken by a Masters’ student at Swissmedic and 
referred to oral compounded medicines dispensed to paediatric patients (only). 
• A purposive sample of 33 hospitals was included in the research and a response rate of 
45% was obtained. A total of 142 different active substances (including 3 NTI drugs) were 
reported corresponding to 31 different therapeutic groups. The top 3 therapeutic groups were 
cardiovascular drugs (n=29), electrolytes (n=14) and antibacterials (n=12).  
• Oral solid dosage forms were reported by 93% of all participant hospitals and included 
capsules, oral powders and tablets. Capsules were dispensed in a sum of 9,823 packs and 
the top 3 active substances were: potassium citrate, captopril and cystamine dihydrochloride. 
Oral powders were dispensed in a total of 1,505 packs and the top 3 active substances 
were: calcium carbonate, macrogol 4000 and the WHO ORS. Tablets were dispensed in a 
total of 228 packs and only 4 active substances were reported, namely: isoniazid, 
deferiprone, arginine HCl and levamisole. 
• Oral liquid dosage forms were reported by 93% of all participant hospitals and included 
solutions, suspensions, syrups and oral drops. Oral liquids were dispensed in a total sum of 
33,328 multidose containers / unidose packs and the top 3 active substances were: 
morphine, sodium citrate and omeprazole. Solutions and suspensions were dispensed in a 
total of 30,971 (92.9%) multidose containers / unidose packs whereas syrups were 
dispensed in a total of 2,343 (7%) and oral drops in a total of 14 (<0.1%) multidose 
containers.  
• Oral liquids (74.1%) were more frequently dispensed than oral solids (25.7%).  
• Oromucosal preparations were dispensed by only 1 hospital (7%) and corresponded to 
chlorhexidine 0.05% solution, in a sum of 80 multidose containers (0.2%) of 250 mL. 
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6. Compounding in Poland 
Poland is an Eastern European country that joined the EU in 2004 and its 
official language is Polish (Europa, 2009). Poland occupies an area of 
312,700 Km2, from the Baltic Sea in the North to Slovakia in the South, and is 
the 6th most populated country in the EU, with a population of 38.2 million in 
2007 (Figure 2.2) (Europa, 2008). Poland is administratively divided in 16 
districts (Informator turystyczny, 2012). 
In 2006, there were 792 hospitals in Poland (ratio of 2.08 hospitals per 
100,000 population) and a total of 196,828 hospital beds (ratio of 516.17 
hospital beds per 100,000 population) (WHO Regional Office for Europe, 
2010) (Appendix 3).  
In 2006, there were 22,442 pharmacists in Poland (ratio of 58.85 pharmacists 
per 100,000 population) (WHO Regional Office for Europe, 2010) (Appendix 
4), of which 9% were hospital pharmacists (Pawłowska34, 2006a). According 
to the EAHP survey, the average number of pharmacists in Polish hospitals 
is 3.4, compared to the European average of 4.7. Moreover, Polish hospitals 
have an average of 3.8 qualified pharmacy technicians/assistants per 
hospital (European average is 6). Poland also has an average of 2.0 non-
qualified pharmacy assistants per hospital (EAHP, 2005; Hartmann, 2010). In 
the opinion of Kozaczuk (2007), hospital pharmacies need to employ enough 
pharmacists/technicians for an adequate provision of services but 
pharmaceutical legislation in Poland lacks regulations on the ratio of 
pharmacists/technicians per number of beds/services.  
The preparation of compounded medicines occurs in both hospital and 
community pharmacies throughout Poland. Sterile and non-sterile 
compounded medicines are prepared in the hospital setting but not all 
hospitals have an aseptic preparation area (Pawłowska, 2010). Hospital 
pharmacy is one of the pharmaceutical specialisations in Poland and 
specialised hospital pharmacists are expected to be familiar with formulation 
improvement and compounding procedures, particularly in relation to sterile 
                                            
34Janina Pawłowska is the director of the department of hospital pharmacy affairs of the 
Polish pharmaceutical chamber (Section 6.2.1).  
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compounding (Kozaczuk, 2006). As pharmaceutical compounding allows 
pharmacists the adjustment of dosage forms and strengths to individual 
patient needs, it is considered an important pharmaceutical service carried 
out at Polish hospitals (Kozaczuk, 2006; 2007; Grześkowiak, 2010; 
Pawłowska, 2010). For instance, the adjustment of strengths of omeprazole 
for paediatric use is common practice in Poland and the preparation of 
capsules containing a customised number of enteric-coated pellets (Section 
4.4.1) was recommended by Gajewska et al. (2007). However, hard (gelatin) 
capsules (Section 2.1.3) are not common in Poland and the most frequently 
dispensed (solid) compounded medicines are, instead, starch capsules or 
cachets (Section 6.4.2). In fact, Polish hospitals prepare large quantities of 
starch capsules by weighing each dose of the powder into individual 
capsules, which is an arduous and time-consuming manual process (Płaczek 
and Sznitowska, 2006). As a consequence, the preparation of hard gelatin 
capsules (in capsule machines) was recommend by Płaczek and Sznitowska 
(2006) as an alternative. 
6.1 Legislation 
In Poland, pharmacy services include the preparation of compounded 
medicines (Kozaczuk, 2007). Two types of compounded medicines may be 
distinguished: Lekiem Aptecznym and Lekiem Recepturowym, which 
correspond to the officinal and magistral formulae considered in the 
European legislation (Section 14.1). Lekiem Aptecznym is, therefore, a 
medicine prepared in a pharmacy, according to the Polish Pharmacopoeia or 
pharmacopoeias recognised in EU member states, and dispensed directly by 
the pharmacy (officinal formula). Lekiem Recepturowym is a medicine 
prepared in a pharmacy according to a doctor's prescription (magistral 
formula) (Ministerstwo Zdrowia, 2001; Janicki et al., 2003). In practice, no 
distinction is made with regards to the type of compounded medicines 
prepared and dispensed by Polish pharmacies, but almost all compounded 
medicines correspond to magistral formulae (Lekiem Recepturowym). 
The Główny Inspektorat Farmaceutyczny (main pharmaceutical inspectorate) 
for the Polish district of Pomorskie was visited by MC and, in an interview 
with the pharmaceutical inspector Weronika Żebrowska, the Polish legislation 
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for pharmaceutical compounding was discussed in detail (Główny Inspektorat 
Farmaceutyczny, 2008; 2010; Żebrowska, 2008). In Poland, the advance 
preparation of compounded medicines is not permitted and, therefore, batch 
preparation is only possible if several requests for the same compounded 
medicine are placed at the same time (Główny Inspektorat Farmaceutyczny, 
2008). In addition, the preparation of compounded medicines for other 
pharmacies (third-party compounding) is not permitted and, as a result, 
compounded medicines have to be prepared and dispensed by the pharmacy 
receiving the order (EAHP, 2005; Główny Inspektorat Farmaceutyczny, 
2008). 
Polish legislation does not restrict the use of any active substances in 
pharmaceutical compounding, provided that these are included in the Polish 
Pharmacopoeia. In addition, Polish legislation does not specify any QA/QC 
requirements for pharmaceutical compounding, apart from acknowledging 
that it is the pharmacist’s responsibility to assure the quality of the 
compounded medicines dispensed (Główny Inspektorat Farmaceutyczny, 
2008).  
With regards to record keeping, each request has to be given a reference 
code and 3 dates (date of prescription, preparation and dispensing) have to 
be recorded. Records have to be kept for a minimum of 5 years. Thus, it is 
not required to keep detailed documentation of the compounded medicines 
prepared, which makes it arduous and time-consuming to track down the 
medicines dispensed at a given time. The price of compounded medicines is 
established by law and depends on the dosage form and number of units 
dispensed (Ministerstwo Zdrowia, 2008). Therefore, the cost of compounded 
medicines should be the same throughout the country (Główny Inspektorat 
Farmaceutyczny, 2008). 
6.2 Professional organisations and information sources 
6.2.1 Polish professional organisations 
In Poland, there is not currently a specific professional organisation for 
pharmaceutical compounding. Instead, there are organisations dedicated to 
pharmacy and pharmacists, including: 
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• Naczelna Izba Aptekarska: is the Polish pharmaceutical chamber, a self-
governing professional body for pharmacists that represents their 
professional, social and economic interests. Membership is compulsory for all 
pharmacists who perform professional services (Naczelna Izba Aptekarska, 
2012). This chamber comprises several national pharmaceutical 
departments, including the department of hospital pharmacy affairs that deals 
with the problems and challenges within hospital pharmacy in Poland 
(Pawłowska, 2006b). 
• Polskie Towarzystwo Farmaceutyczne (PTFarm): is the Polish 
pharmaceutical society, an organisation established for more than 60 years 
that supports pharmacists and ensures the overall development of pharmacy 
in Poland. The PTFarm is responsible for several publications, including the 
Polish Pharmacopoeia (PTFarm, 2012). 
6.2.2 Polish information sources 
In Poland, there are 2 official pharmacopoeias in force, as follows: 
• Farmakopea Polska VIII (PTFarm, 2008): is a translation of the PhEur and, 
hence, does not include monographs for compounded medicines. 
• Farmakopea Polska VI (PTFarm, 2002): is the traditional Polish 
Pharmacopoeia, which has greater use among pharmacists than the 
Farmakopea Polska VIII. This pharmacopoeia includes a chapter on galenic 
preparations, with monographs containing the formula and method of 
preparation for selected topical and herbal preparations. 
There is no official national formulary for pharmaceutical compounding. 
Instead, there are several textbooks which address the preparation of 
compounded medicines, including: Receptariusz (Stanisław et al., 1992); 
Ćwiczenia z Receptury (Krówczyński and Jachowicz, 2000); Zbiór Recept 
(Janicki et al., 2003); and Receptura Apteczna (Jachowicz, 2005). 
6.3 Methods 
Małgorzata Sznitowska, Vice-Rector for research and Director of the 
department of pharmaceutical technology at the Faculty of Pharmacy from 
the Gdański Uniwersytet Medyczny (Medical University of Gdańsk), was 
contacted as a stakeholder for collaboration. The Medical University of 
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Gdańsk is the largest medical academic institution in northern Poland and 
one of the 2 that specialise in hospital pharmacy (Kozaczuk, 2006; Medical 
University of Gdańsk, 2010). Małgorzata Sznitowska agreed to collaborate 
and was assisted by the researcher Monika Gajewska and the Masters’ 
student Aleksandra Neubauer-Vasquez.  
In April 2008, MC visited the Medical University of Gdańsk to discuss and 
initiate the research project, to gain a better understanding of the current 
compounding practices in Poland and to start data collection (Section 6.3.2). 
6.3.1 Purposive sample of hospitals 
The purposive sample of hospitals was established following consultation 
with Małgorzata Sznitowska and included 13 hospitals in northern and central 
Poland, as follows: Bydgoszcz (3 hospitals), Gdańsk (4 hospitals), Poznań (4 
hospitals), Warszawa (1 hospitals) and Wejherowo (1 hospital) (Figure 6.1). 
These hospitals were likely to dispense the largest quantities of compounded 
medicines in northern and central Poland; 10 hospitals were classified as 
general hospitals and 3 as paediatric hospitals. 
 
Figure 6.1 Map of Poland adapted from National Geographic Society (1998d); indicating the 
location of the purposive sample of hospitals pharmacies (   ). 
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6.3.2 Data collection 
Data collection in Poland was initiated during a 5-day visit to the Medical 
University of Gdańsk and included a visit to 2 hospitals and 1 community 
pharmacy. The fieldwork was organised by the stakeholder and was 
undertaken by MC, the Masters’ student and other researchers.  
It was acknowledged during fieldwork that the pharmacy staff did not speak 
English and, therefore, the visits were undertaken in Polish but were 
simultaneously translated by the Masters’ student and/or the researchers. At 
this stage, it was evident that language was a strong limitation to clear and 
effective communication between MC and the Polish pharmacy staff (Section 
2.1). Therefore, it was decided that the Masters’ student would contact the 
purposive sample of hospitals in Polish, by telephone and email, instead of 
MC in English.  
Another important finding during fieldwork was that Polish pharmacies kept 
manual records of the compounded medicines dispensed and, therefore, 
retrieving the required data was an arduous and time-consuming process. In 
fact, computing systems for drug information were very modest in Poland 
(EAHP, 2005). In addition, for those pharmacies that only recorded a 
reference code and 3 dates per compounding request (Section 6.1), 
retrieving the required data was even more arduous and time-consuming 
since it was necessary to track down and analyse each compounding request 
individually (Figure 6.2). Therefore, it was decided that the purposive sample 
of hospitals would be encouraged to contribute data in the most convenient 
format, instead of filling out a country-specific questionnaire (which was 
unlikely to elicit any responders), including the following information: active 
substance, strength, dosage form, pack size and number of times dispensed 
for the oral compounded medicines most frequently dispensed in 2007. 
Because of the difficulties in retrieving the required data from manual 
records, the majority of hospital pharmacies were not willing to participate in 
the research. For this reason, the Masters’ student visited 5 additional 
hospitals (total of 7 participant hospitals visited) with the purpose of collecting 
data on site by consulting the manual records and the corresponding 
compounding requests (Figure 6.3).  
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Figure 6.2 (left) Compounding request for 5 different oral solid compounded medicines: 
aspirin 10-100 mg (n=4) and 1 placebo (n=1) (patient and pharmacy details omitted).  
Figure 6.3 (right) Compounded medicines prepared in a Polish hospital pharmacy and the 
corresponding compounding requests and manual records. 
6.4 Results and discussion 
Of the 13 hospitals contacted, 12 hospital pharmacies responded to the 
request for collaboration (response rate of 92%) (Figure 6.4). All 12 hospitals 
participated in the research and contributed data regarding the oral 
compounded medicines most frequently dispensed by their pharmacies in 
2007. In total, 10 hospitals provided complete datasets and 2 hospitals 
supplied only qualitative/semi-quantitative information because of the 
difficulties associated with data collection (Section 6.3.3). 
 
Figure 6.4 Purposive sample distributed by respondent, participant and visited hospitals. 
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A total of 7 participant hospitals were visited by MC and/or the Masters’ 
student (Figure 6.4) and the respective datasets were collected during the 
visits. All other hospitals shared the required data directly with the Masters’ 
student by telephone/email. The fact that 54% of the hospitals were visited 
was probably one of the major reasons for the high response rate achieved. 
6.4.1 Active substances  
A list of the active substances most frequently dispensed as oral 
compounded medicines is shown in Table 6.1. All active substances reported 
were included in Martindale 35 (2007) and these were grouped according to 
the respective therapeutic classification, giving a total of 149 different active 
substances and 31 therapeutic groups. Cardiovascular drugs was the group 
with the greatest number of different active substances (n=28), followed by 
antibacterials (n=15) and analgesics, anti-inflammatory drugs and 
antipyretics / electrolytes / supplementary drugs and other substances 
(n=10). 
Although these active substances were all reported as oral compounded 
medicines, the title of 2 therapeutic groups suggested non-oral (therapeutic) 
indications, namely: disinfectants and preservatives (Appendix 12) and 
supplementary drugs and other substances (Appendix 15). The active 
substances included in these groups are described in the respective 
appendixes. 
With reference to the official list provided by ANVISA (2007) (Appendix 1), a 
total of 6 NTI drugs were dispensed as oral compounded medicines 
(underlined in Table 6.1). NTI drugs were reported by the majority (67%) of 
participant hospitals. 
The active substances dispensed by most hospitals were: furazidin, 
phenobarbital and ursodeoxycholic acid (n=11), spironolactone (n=9) and 
midazolam (n=8). 
Compounded medicines were also reported by the given titles which they are 
commonly known for in Poland as, for instance, Sol. Sal. Erlenmayeri and 
Mixture Nervinae (Section 6.4.3). 
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Table 6.1 Active substances most frequently dispensed as oral compounded medicines in 
Poland (NTI drugs underlined). 
Analgesics, anti-inflammatory drugs 
and antipyretics 
Aminophenazone, aspirin, codeine 
phosphate, dipyrone, ethylmorphine HCl, 
ibuprofen, morphine, morphine HCl, 
paracetamol, sodium salicylate 
Antibacterials 
Azithromycin, ciprofloxacin HCl, 
ciprofloxacin lactate, clindamycin, colistin 
sulfate, co-trimoxazole, doxycycline, 
furazidin, gentamicin sulfate, isoniazid, 
neomycin, rifampicin, spiramycin, 
sulfadiazine, vancomycin 
Antidementia drugs 
Piracetam 
Antidepressants 
Doxepin HCl, fluoxetine HCl, mianserin 
HCl 
Antiepileptics 
Carbamazepine, clonazepam, 
lamotrigine, phenobarbital, phenytoin, 
topiramate, valproic acid, vigabatrin 
Antifungals 
Fluconazole, ketoconazole, nystatin, 
voriconazole 
Antihistamines 
Cetirizine HCl, hydroxyzine HCl 
Antimalarials 
Pyrimethamine 
Antineoplastics 
Cyclophosphamide, mercaptopurine, 
methotrexate, tioguanine 
Antiparkinsonian drugs 
Benserazide, levodopa, selegiline HCl 
Antiprotozoals 
Metronidazole 
Antivirals 
Aciclovir, inosine pranobex 
Anxiolytic, sedatives, hypnotics and 
antipsychotics 
Allobarbital, diazepam, midazolam, 
nitrazepam 
 
Blood products, plasma expanders and 
haemostatics 
Aminocaproic acid, tranexamic acid 
Bronchodilators and anti-asthma drugs 
Aminophylline, caffeine, theophylline 
Cardiovascular drugs 
Acebutolol, acenocoumarol, amiloride 
HCl, amiodarone, amlodipine besilate, 
atenolol, bisoprolol fumarate, captopril, 
carvedilol, colestyramine, diltiazem HCl, 
doxazosin mesilate, enalapril, flecainide 
acetate, furosemide, hydrochlorothiazide, 
losartan potassium, metildigoxin, 
metoprolol, nifedipine, nitrendipine, 
potassium canrenoate, propranolol HCl, 
ramipril, sotalol HCl, spironolactone, 
trimetazidine HCl, verapamil HCl 
Chelators, antidotes and antagonists 
Methylthioninium chloride, sodium 
polystyrene sulfonate 
Corticosteroids 
Fludrocortisone acetate, hydrocortisone, 
methylprednisolone, prednisone 
Cough suppressants, expectorants, 
mucolytics and nasal decongestants 
Acetylcysteine, ephedrine HCl 
Disinfectants and preservatives 
Sodium benzoate 
Electrolytes 
Calcium chloride, calcium gluconate, 
calcium lactate, dibasic sodium 
phosphate, magnesium, monobasic 
sodium phosphate, potassium chloride, 
sodium bicarbonate, sodium chloride, 
sodium citrate 
GI drugs 
Calcium carbonate, cisapride, magnesium 
carbonate, metoclopramide, omeprazole, 
oxyphenonium bromide, ranitidine HCl, 
sulfasalazine 
Hypothalamic and pituitary hormones 
Desmopressin acetate 
Immunosuppressants 
Mycophenolate mofetil, tacrolimus 
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Miotics, mydriatics and antiglaucoma 
drugs 
Acetazolamide 
Muscle relaxants 
Baclofen, tolperisone HCl 
Nutritional agents and vitamins 
Arginine HCl, calcium folinate, carnitine, 
folic acid, ornithine aspartate, pyridoxine 
HCl, thiamine, vitamin A, vitamin D 
Sex hormones 
Megestrol acetate 
Supplementary drugs and other 
substances 
Ammonium bromide, citric acid, 
crataegus, drotaverine, pancreatin, 
potassium bromide, sodium bromide, 
thyme, ursodeoxycholic acid, valerian 
Thyroid and antithyroid drugs 
Levothyroxine sodium, potassium iodide 
Urological drugs 
Oxybutynin HCl, papaverine HCl, 
sildenafil citrate
The majority of compounded medicines were recorded at the hospital 
pharmacies according to the respective proprietary medicines. This finding 
suggests that proprietary medicines are frequently used in the preparation of 
compounded medicines, instead of raw materials in bulk (Section 1.1.2.2). In 
fact, it was acknowledged during fieldwork (Section 6.3.2) that, in Poland, it is 
not always easy to acess raw materials in bulk (and in small quantities). 
When compounded medicines were recorded by the respective active 
substances, these were frequently recorded in Latin, which facilitated data 
processing and analysis by MC. 
6.4.2 Oral solids 
The dosage forms reported included cachets (12 hospitals) and hard (gelatin) 
capsules (1 hospital), which correspond to 2 different categories of capsules 
(Section 2.1.3) (Figure 6.5). Cachets consist of a hard shell made of 
unleavened bread (usually from rice flour), divided in 2 cylindrical sections, 
which enclose a single dose of 1 or more active substances (EDQM, 2007) 
(Figure 6.6). Cachets are also known as starch capsules (Płaczek and 
Sznitowska, 2006). When moistened with water, cachets become soft, elastic 
and slippery (Rudnic and Schwartz, 2005). Therefore, before administration, 
cachets are usually immersed in water for a few seconds, placed on the 
tongue and swallowed with a draught of water (EDQM, 2007). Due to their 
large size (Figure 6.5), patients are likely to experience difficulties when 
swallowing cachets, particularly the paediatric population. For this reason, 
cachets are commonly opened just before administration and their contents 
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added to liquids or food (Figure 6.6) (Płaczek and Sznitowska, 2006; 
Gajewska et al., 2007). 
 
 
Figure 6.5 (above) Capsules: hard (gelatin) capsules and cachets (courtesy of Sznitowska 
and Gajewska, 2009). 
Figure 6.6 (below) Cachets and corresponding contents (courtesy of Sznitowska and 
Gajewska, 2009). 
Cachets are commonly prepared by weighing each dose of the powder into 
each unit, which is an arduous and time-consuming manual process that may 
be substituted by the preparation of hard (gelatin) capsules (in capsule 
machines) (Płaczek and Sznitowska, 2006). Therefore, cachets are often 
considered an obsolete dosage form that was formerly used in pharmacy but 
is very rarely used in practice today (RPS, 2002b; Winfield and Kennedy, 
2004; Rudnic and Schwartz, 2005; Marriott et al., 2010). However, according 
to Płaczek and Sznitowska (2006), cachets are prepared in large quantities in 
Poland, which was confirmed with the fact that out of the 213,021 units of 
oral solids dispensed by the participant hospitals, 191,060 units (89.7%) were 
cachets and only 21,961 units (10.3%) were hard (gelatin) capsules. This 
finding suggests that compounding practices in Poland are still very 
traditional, which is supported by the fact that some compounding 
Hard capsules Cachets 
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laboratories still store raw materials in amber recipients (Figure 6.7), instead 
of the suppliers’ GMP-conditioned original containers, as observed during 
fieldwork. 
 
Figure 6.7 Storage of raw materials in a Polish compounding laboratory. 
The top 5 active substances dispensed as oral solids are listed in Table 6.2. 
Although cisapride was the most frequently dispensed active substance, its 
use in pharmaceutical compounding should be restricted because it is likely 
to cause cardiac arrhythmias. In fact, cisapride has already been withdrawn 
completely in the UK (Martindale 35, 2007). Furthermore, aminophenazone 
has also been considered unsuitable for use because of the risk of 
agranulocytosis, which may be sudden and unpredictable (Martindale 35, 
2007). Aminophenazone (and papaverine) was frequently dispensed in 
combination with other active substances such as, for example: 
aminophenazone, sodium salicylate, caffeine, sodium benzoate, dipyrone 
and phenobarbital. This particular combination was named “neurological” 
cachets and was dispensed by 1 hospital.  
Table 6.2 Top 5 active substances dispensed as oral solids. 
Active 
substances 
Number  
of strengths 
Number  
of hospitals 
Number 
of units 
Cisapride 28 6 17,513 
Calcium 
Carbonate 9 6 13,710 
Aminophenazone  
(in combination) 2 4 12,950 
Captopril 23 6 12,941 
Papaverine  
(in combination)  6  4 11,513 
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Although the majority of oral solids (78%) comprised 1 active substance only, 
combinations of up to 6 different active substances (in the same unit) were 
also dispensed by the participant hospitals. These combinations are 
commonly known as polypharmacy35 and their rational was, in most cases, to 
minimise the intake of several medicines. As a result, not all combinations 
were therapeutically coherent and, therefore, the safety and efficacy of the 
compounded medicines dispensed was likely to be affected. An example of 
such combinations is shown in Appendix 2.  
In polypharmacy, attention should be paid to the compatibility and possible 
interactions between the different active substances so that the stability of 
the compounded medicine is consistent with the beyond-use date assigned 
(Allen, 2008). In addition, when active substances are combined in the same 
dosage form, they are administered at the same time, which raises 
pharmacokinetics issues as the ADME of the compounded medicine is likely 
to be affected. For these reasons, despite the convenience of polypharmacy 
(particularly in the hospital setting), the combination of different active 
substances should be supported by adequate literature. Nevertheless, in 
most cases, there is insufficient data to support multiple combinations and, 
therefore, the practice of polypharmacy should be generally avoided. 
The top 5 active substances (Table 6.2) were dispensed by 4 to 6 participant 
hospitals and, in general, in several different strengths. However, the active 
substance dispensed in the greatest number of strengths was 
ursodeoxycholic acid: 29 strengths (0.1 mg to 250 mg). When used for 
dissolution of cholesterol-rich gallstones, the licensed dose of 
ursodeoxycholic acid (Appendix 15) is 6-12 mg/kg daily; for primary biliary 
cirrhosis, the licensed dose is 10-15 mg/kg daily (Martindale 35, 2007). 
Therefore, the low strengths of 0.1 mg and 0.6 mg, reported by only 1 
hospital, were likely a mistake and only the strengths from 5 mg onwards 
were considered. Ursodeoxycholic acid is commercially available in Poland 
as solid dosage forms (capsules and tablets) only and in just 3 strengths (150 
mg, 250 mg and 300 mg). Therefore, there is a need for alternative dosage 
                                            
35Combination of several drugs in one dose; synonym: “shotgun” therapy (Worthen, 2004). 
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forms and strengths (Section 1.1.4), in particular for the paediatric population, 
which are made available by the preparation of compounded medicines. The 
next active substances dispensed in the greatest range of strengths were 
cisapride (28 strengths, 0.2-10 mg) and mercaptopurine (27 strengths, 6-59 
mg). The usual dose of cisapride (where still licensed) is 5-10 mg (three to 
four times daily) and of mercaptopurine (as initial antineoplastic dose) is 2.5 
mg/kg daily (Martindale 35, 2007), which are in accordance with the 
strengths reported (considering also the paediatric population). 
The top therapeutic groups (oral solids only) were: cardiovascular drugs 
(30%), GI drugs (20.1%), multiple combinations of active substances from 
different groups (19.4%) and supplementary drugs and other substances 
(8.5%). Cardiovascular drugs and GI drugs represented over 50% of all oral 
solids dispensed, which is consistent with the fact that diseases of the 
circulatory system and digestive system are the major causes of discharge 
from all Polish hospitals, as shown in Figure 6.8. 
 
Figure 6.8 Number of patients per 100,000 population discharged from all hospitals 
(including through death) in Poland during 2004 (latest available year), categorised by 
principal diagnosis (WHO Regional Office for Europe, 2008). 
6.4.3 Oral liquids 
Oral liquid dosage forms were dispensed by 92% of all participant hospitals 
(only 1 hospital did not report oral liquids) and included solutions and 
suspensions (n=10), mixtures (n=5) and syrups (n=5). In total, 9 hospitals 
shared quantitative datasets with regards to the oral liquids dispensed, 
whereas 1 hospital disclosed only qualitative data and another hospital only 
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semi-quantitative data, which was processed and analysed accordingly 
(Section 2.4).  
A total of 5,797 units of oral liquids were reported and, considering that 
volumes were not always clear, these were all assumed to be multidose. The 
majority of oral liquids were reported as solutions (71.5%) (Figure 6.9) but it 
is likely that the classification of some oral liquids was not accurate and, 
therefore, a proportion of the solutions may have corresponded to 
suspensions or mixtures/syrups (and vice-versa) (Section 2.1.3). Altogether, 
solutions and suspensions represented 81.3% of all oral liquids dispensed.  
 
 
Figure 6.9 Oral liquid dosage forms dispensed per number of (multidose) units. 
The most frequently dispensed oral liquids were Sol. Sal. Erlenmayeri and 
Mixture Nervinae (Appendix 16), which were dispensed by 3 hospitals and 
represented 41.1% of all oral liquids. These compounded medicines 
correspond to bromide oral liquids including ammonium, potassium and 
sodium bromide, in variable strengths; such preparations are described as 
triple bromides (Hollister, 1983). Bromides depress the CNS and have been 
used as sedatives, anti-epileptics and anticonvulsants. However, potassium 
and sodium bromide are considered toxic and have generally been replaced 
by more effective, less toxic drugs (Martindale 35, 2007) as, for instance, the 
benzodiazepines for sedative-hypnotic effects. Bromides have a long shelf 
life and, therefore, tend to accumulate with repeated doses. The most 
common manifestation of bromides toxicity is a confusional state with marked 
delirium (Hollister, 1983). In conclusion, the most frequently dispensed oral 
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liquids in Poland are potentially toxic and, therefore, the risk-benefit balance 
(Section 1.1.3) of these compounded medicines should be considered. 
The next most frequently dispensed oral liquids included midazolam, which 
was reported as solutions, suspensions, mixtures and syrups, by a total of 8 
hospitals. The most frequent strengths reported were 2 mg/mL and 2.5 
mg/mL. Sol. Sal. Erlenmayeri, Mixture Nervinae and midazolam oral liquids 
represented almost 52% of all oral liquids dispensed in Poland. 
Mixtures corresponded to 10.9% of all oral liquids (Figure 6.9) and were 
reported by 5 hospitals. The most frequently dispensed mixture was Mixture 
Nervinae (Appendix 16), which corresponded to almost 50% of all mixtures 
reported. Syrups, on the other hand, corresponded to 7.8% of all oral liquids 
(Figure 6.9) and were reported by 5 hospitals. In total, only 5 active 
substances were dispensed as syrups, as follows (in decreasing order): 
midazolam, phenobarbital, vancomycin, codeine and ephedrine. 
The top 3 therapeutic groups (oral liquids only) were: supplementary drugs 
and other substances, which included the bromide oral liquids, followed by 
electrolytes and “anxiolytic, sedatives, hypnotics and antipsychotics”, which 
included the midazolam oral liquids. These 3 therapeutic groups represented 
over 70% of all oral liquids dispensed, which suggests that there is a need for 
licensed oral liquid dosage forms in Poland particularly from these 3 groups. 
The multidose oral liquids may be quantitatively compared to the oral solids 
dispensed (in packs). Considering that cachets are comparable to oral 
powders, in relation to the method of preparation (hence no oral powders 
were reported in Poland), an estimation of 13 units of cachets were 
dispensed per pack (Section 2.1.3). As a result, the 191,060 individual units 
of cachets corresponded to approximately 14,697 packs (of 13 units each). In 
addition, considering that capsules were dispensed in packs of 50 units 
(Section 2.1.3), the 21,961 individual units of capsules corresponded 
approximately to 439 packs (of 50 units each). Therefore, when the 5,797 
units of (multidose) oral liquids are compared to the estimation of 15,136 
packs of oral solids, it is concluded that oral solids were dispensed in larger 
quantities than oral liquids. 
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6.4.4 Oromucosal preparations 
In Poland, oromucosal preparations were not reported by any participant 
hospital. 
6.5 Summary 
• Compounded medicines in Poland may be identified in officinal and magistral formulae. 
Batch preparation (in advance) and third-party compounding are not permitted; QA/QC 
requirements are not specified by law; a reference code and 3 dates are the only 
requirements for record keeping.  
• A professional organisation and a formulary for pharmaceutical compounding are not 
currently in existence. Compounding practices in Poland are still very traditional. 
• A purposive sample of 13 hospitals was included in the research and a response rate of 
92% was obtained. A total of 143 different active substances (including 6 NTI drugs) were 
reported corresponding to 31 different therapeutic groups. The top 3 therapeutic groups were 
cardiovascular drugs (n=28), antibacterials (n=15) and analgesics, anti-inflammatory drugs 
and antipyretics / electrolytes / supplementary drugs and other substances (n=10). 
• Oral solid dosage forms were reported by all participant hospitals and included cachets 
and hard (gelatin) capsules only. A total of 213,021 individual units of oral solids were 
reported, with the majority (89.7%) being cachets, which were dispensed by all participant 
hospitals, whereas hard capsules (10.3%) were dispensed by only 1 hospital. The top 5 
active substances dispensed as oral solids were: cisapride, calcium carbonate, 
aminophenazone (in combination), captopril and papaverine (in combination). 
• Oral liquid dosage forms were reported by 92% of all participant hospitals and included 
solutions, suspensions, mixtures and syrups, in a total sum of 5,797 multidose (estimated) 
units. The most frequently dispensed oral liquids were: Sol. Sal. Erlenmayeri and Mixture 
Nervinae, which are potentially toxic, followed by oral liquids including midazolam. 
• Mixtures were dispensed in a total sum of 634 units (10.9% of all oral liquids) and the 
most frequently dispensed was Mixture Nervinae. Syrups accounted for 7.8% of all oral 
liquids and only 5 active substances were dispensed: midazolam, phenobarbital, 
vancomycin, codeine and ephedrine. 
• Oral solids were dispensed in larger quantities than oral liquids. 
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7. Compounding in the Netherlands 
The Netherlands is one of the 6 founding member states of the EU and its 
official language is Dutch (Europa, 2009), although English is spoken by 
almost everyone (NBTC, 2010). The Netherlands, in Western Europe36, 
occupies an area of 33,800 Km2 between Belgium and Germany, and is the 
8th most populated country in the EU, with a population of 16.3 million in 2007 
(Figure 2.2) (Europa, 2008). 
In 2007, there were 190 hospitals in the Netherlands (ratio of 1.16 hospitals 
per 100,000 population) and a total of 78,764 hospital beds (ratio of 480.8 
hospital beds per 100,000 population) (WHO Regional Office for Europe, 
2010) (Appendix 3). 
In 2007, there were 2,871 pharmacists in the Netherlands (ratio of 17.53 
pharmacists per 100,000 population) (WHO Regional Office for Europe, 
2010) (Appendix 4). According to the EAHP survey, there are on average 5.2 
pharmacists per hospital, which is higher than the European average of 4.7. 
Moreover, Dutch hospitals have an average of 28.3 qualified pharmacy 
technicians/assistants per hospital, also higher than the European average of 
6. Regarding non-qualified pharmacy assistants, the Netherlands has an 
average of 4.8 (EAHP, 2005; Hartmann, 2010).  
The Netherlands has a long history of preparing compounded medicines, 
both individually and for stock, and this remains an important activity of Dutch 
hospital pharmacists (Simons-Sanders, 2005; Le Brun, 2007a). In the past, 
pharmacists used to prepare compounded medicines that were commercially 
available, however, current policy in most Dutch hospitals is that the 
compounded medicines prepared must not be commercially available 
(Simons-Sanders, 2005; Le Brun, 2007b). Actually, according to the Dutch 
GMP in Hospital Pharmacy (GMP-H, Section 7.1), the preparation of 
medicinal products in hospital pharmacy aims at enabling every accepted 
pharmacotherapy, if the prescribed medicine is not commercially available 
(Berg et al., 1998). With the increasing quality standards in hospital 
pharmacy, pharmaceutical compounding is less profitable and Dutch hospital 
                                            
36The Netherlands Antilles and Aruba (NBTC, 2010) were not considered in the research. 
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pharmacists have to choose whether to invest in meeting the standards or to 
outsource the compounded medicines dispensed (Le Brun, 2007a). Hence, 
the majority of Dutch hospitals (74%) prepare compounded medicines for 
other hospitals and community pharmacies (EAHP, 2005). The requirements 
for outsourcing compounded medicines are the following: only non-
commercially available medicines may be outsourced; a formal agreement 
must be established between the preparation and dispensing pharmacies; 
the dispensing pharmacy must be GMP-H approved and a product dossier 
must be developed for every compounded medicine outsourced (Le Brun, 
2007a; 2011). 
Jong et al. (2001) conducted a 5-week prospective study on the use of off-
label and unlicensed medicines prescribed at a Dutch academic children’s 
hospital. According to their findings, 237 patients from 4 hospital units 
received a total of 2,139 prescriptions, out of which 760 (36%) were 
compounded medicines (of which 9% were prepared from proprietary 
medicines). Compounded medicines were prescribed to paediatric patients in 
all hospital units, with a particularly high incidence in the neonatal intensive 
care unit. The top 5 active substances prescribed as off-label and unlicensed 
medicines were cisapride, caffeine, tobramycin, spironolactone and 
furosemide (Jong et al., 2001). 
With regards to the community setting, Buurma et al. (2003) conducted a 2-
week prospective study on the frequency, nature and determinants of 
prescriptions for compounded medicines in 79 Dutch community pharmacies. 
Compounded medicines corresponded to 3.4% of all prescriptions in the 
community setting, but with 2.3% actually prepared at the dispensing 
pharmacy. Although the majority of compounded medicines (66.3%) were 
prepared at the dispensing pharmacy, 28.4% were prepared by compounding 
companies and a minority by hospitals. Dermatological products were the 
most frequent dosage forms and therapeutic groups (Buurma et al., 2003). 
Apart from compounded medicines prepared by Dutch hospital and 
community pharmacies, there is evidence of compounded medicines being 
prepared by “compounding companies” in the Netherlands. According to 
Buurma et al. (2003), the considerable proportion of compounded medicines 
 Chapter 7: COMPOUNDING IN THE NETHERLANDS | Legislation | 162 
 
from these companies is of concern since the legality of this practice is 
controversial. Compounding companies usually prepare and sell 
compounded medicines that are more broadly needed and, until now, have 
been able to avoid any formal medicine approval (Buurma et al., 2003). 
Examples include potassium chloride 75 mg/mL oral liquid FNA (Formularium 
der Nederlandse Apothekers, Section 7.2.2) and Hoestdrank FNA (Appendix 
16) (Fagron, 2012). 
7.1 Legislation 
In the Netherlands, it was acknowledged that the preparation of compounded 
medicines in hospital pharmacy required more than methods of preparation 
and QC and, in the 1970s, the GMP philosophy was gradually introduced 
(Berg et al., 1998). In 1996, the first guide to GMP in hospital pharmacy 
(GMP-Z) was published by the Dutch association of hospital pharmacists 
(NVZA) and the Royal Dutch association for the advancement of pharmacy 
(KNMP) (Section 7.2.1), in cooperation with the Netherlands public health 
inspectorate and other experts (Le Brun, 2007b; Kirchdorfer, 2011). In 1998, 
the official English version of the GMP-Z was published, which is generally 
abbreviated to GMP-H (Berg et al., 1998). The structure of GMP-H is similar 
to the industrial (European) GMP (Section 14.1) but comprises 4 additional 
chapters specifically applicable to hospital pharmacy, as follows: H1. Quality 
of design of the formulation and preparation method; H2. Extemporaneous 
compounding; H3. Aseptic dispensing, and H4. Dispensing of hazardous 
materials and products (Berg et al., 1998; Simons-Sanders, 2005). Industrial 
GMP does not apply to pharmaceutical compounding and, therefore, the 
GMP-H (in particular the 4 additional chapters) enables Dutch hospital 
pharmacies to prepare compounded medicines in accordance with GMP 
(Berg et al., 1998; Le Brun, 2011). The NVZA set up a steering committee to 
coordinate the implementation of GMP-H (Simons-Sanders, 2005), an 
expensive and time-consuming process but, at present, the majority of Dutch 
hospital pharmacies are GMP-H approved (Le Brun, 2011).  
GMP-H has been the quality standard for manufacturing in Dutch hospital 
pharmacies (Simons-Sanders, 2005) and, as a result, the Netherlands is 
considered one of the European countries with the most rigorous GMP 
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regulations and QC requirements (EAHP, 2005). According to the latest 
EAHP survey, SOP (for compounding) are used in more than 90% of Dutch 
hospital pharmacies (EAHP, 2005). 
The GMP-H distinguishes 2 types of compounded medicines, as follows: 
• Standardised preparations, “performed in the pharmacy on a regular 
basis, as stock preparation or extemporaneous compounding, and for which 
sufficient guarantees are available to assure the quality of both formulation 
and method of preparation”. Examples of standardised preparations are the 
FNA compounded medicines (Section 7.2.2). Standardised preparations may 
be prepared individually (extemporaneous compounding) or for stock (Berg 
et al., 1998).  
• Non-standardised preparations, “for which no well-investigated formulation 
and/or no well-investigated (and validated) preparation method are 
available”. As stated in the GMP-H, the risks of limited “quality of design” 
data in non-standardised preparations should be weighed against the risk of 
not supplying the requested medicine to the patient. Non-standardised 
preparations may only be prepared individually (Berg et al., 1998).  
Documentation for both standardised and non-standardised preparations 
should be compiled in product files. The preparation of compounded 
medicines for stock must follow validated instructions, from the preparation to 
the respective QC, which should be included in the respective product files. 
Because of the facilitated QC of batches, stock preparation should always be 
preferable to individual preparation (Berg et al., 1998; Simons-Sanders, 
2005). It is expected that pharmaceutical compounding will increase in the 
Netherlands (Vree, 2007) and, in the near future, that stock preparation will 
be centralised in teaching hospitals and a few large regional hospitals, 
whereas all other hospitals will be restricted to individual preparations (Le 
Brun, 2007a). 
7.2 Professional organisations and information sources 
7.2.1 Dutch professional organisations 
• Koninklijke Nederlandse Maatschappij ter Bevordering der Pharmacie 
(KNMP): is the Royal Dutch association for the advancement of pharmacy, 
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an organisation that supports hospital and community pharmacy in the 
Netherlands by offering a range of products and services, including the Dutch 
official formulary (FNA, Section 7.2.2) and the Laboratorium der Nederlandse 
Apothekers (LNA) - the laboratory of Dutch pharmacists. The LNA is focused 
on pharmaceutical compounding and supports the preparation and control of 
compounded medicines by the pharmacy members (KNMP, 2012a). Some of 
the items provided by LNA include 400 batch preparation records and 150 
SOP for “general preparation operations” (LNA procedures) (Bouwman, 
2007). The Wetenschappelijk Instituut Nederlandse Apothekers (WINAp) is 
the scientific institute for Dutch pharmacists, which is part of KNMP. Over 
90% of all pharmacists in the Netherlands are members of KNMP (2012b). 
• Nederlandse Vereniging van Ziekenhuisapothekers (NVZA): is the Dutch 
association of hospital pharmacists, a professional organisation that 
represents and supports pharmacists in the hospital setting. The NVZA and 
KNMP, in cooperation with the Netherlands public health inspectorate and 
other experts, are responsible for the development and implementation of the 
GMP-H (Section 7.1) (Hoeven, 2008; NVZA, 2012). The NVZA includes a 
Paediatrics Special Interest Group (SIG), which conducted a survey on 
paediatric hospitals and concluded that there were many different (non-
standardised) compounded medicines in Dutch hospitals. According to Liem 
(2008), this situation is problematic especially when patients are discharged 
from hospitals and compounded medicines are then supplied by community 
pharmacies. The SIG, in cooperation with the WINAp, are developing 
monographs for standardised oral liquids including active substances 
frequently prescribed to paediatric patients (e.g. furosemide 2 mg/mL, 
enalapril 1 mg/mL and hydrochlorothiazide 0.5 mg/mL) (Liem, 2008).  
7.2.2 Dutch information sources 
• Formularium der Nederlandse Apothekers (FNA): is the Dutch official 
formulary for pharmaceutical compounding (Barbosa and Pinto, 2001), edited 
by the WINAp and commissioned by the KNMP. The FNA was first published 
in 1967 and is regularly updated: every 5 years (print version) and every 
month (web version). This formulary currently comprises 200 standardised 
monographs for compounded medicines and is divided in 11 chapters, from 
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dermatologicals to parenterals. For each monograph, more than 1 strength 
may be described as, for example: morphine HCl (oral liquid) 1, 5 and 20 
mg/mL; and dithranol (cream) 0.05, 0.1, 0.2, 0.3, 0.4, 0.6, 0.8, 1, 2 and 3% 
(WINAp, 2004; Bouwman, 2007), which supports the importance of 
pharmaceutical compounding in meeting the individual needs of patients for 
particular strengths (Section 1.1.4). The monographs included in the FNA do 
not have any corresponding proprietary medicines across the EU and are 
regularly revised and updated by the LNA (Postma, 2011). There is evidence 
of compounding companies preparing and selling FNA compounded 
medicines (e.g. potassium chloride 75 mg/mL oral liquid FNA; Hoestdrank 
FNA, Appendix 16) to Dutch hospital and community pharmacies (Fagron, 
2012) but the legality of this activity is unclear (Section 7.1). There is 
cooperation between the Dutch formulary and the German formulary (NRF, 
Section 13.2.2) in relation to formulations, procedures and guidelines, which 
is gradually developing into harmonisation of both (Bouwman, 2007). 
• Recepteerkunde: Productzorg en Bereiding van Geneesmiddelen: is a 
textbook by Bouwman-Boer et al. (2009), recommended in the GMP-H (Berg 
et al., 1998), that includes practical information regarding the design and 
preparation of medicines in the pharmacy setting. According to Le Brun 
(2011), this textbook contains modern formulations, figures and pictures; an 
international edition is under discussion with the EAHP. 
7.3 Methods 
The research project in the Netherlands was set up in collaboration with Frits 
Boom (hospital pharmacist at the Zaans Medisch Centrum) who provided 
invaluable guidance at all stages of the research, from the development of 
the customised questionnaire to the data collection stage. The stakeholder 
also planned and scheduled visits to 4 hospital pharmacies, and other 
institutions, in the Netherlands (Section 7.3.3). The purposive sample of 
hospitals was completed by Yvonne Bouwman (pharmacist at LNA), who 
suggested a list of 13 additional hospitals likely to dispense the largest 
quantities of compounded medicines in the Netherlands (Section 7.3.2). 
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7.3.1 Country-specific questionnaire  
The research instrument developed to collect information regarding oral 
compounded medicines most frequently dispensed in Dutch hospital 
pharmacies was a self-completion questionnaire (main heading in Figure 
7.1), which was based on the template established for Portugal (Section 
3.3.1) and adapted to the practice of pharmaceutical compounding in the 
Netherlands.  
So that the Dutch questionnaire was not too extensive, the separate PDF 
introduction (Appendixes 8 / Portugal and 21 / UK) was substituted by a brief 
introduction in the body of the email and the final sheet with questions and 
comments (Appendixes 10 / Portugal and 22 / UK) was eliminated from the 
questionnaire. Considering the questions, although the overall total number 
of compounded medicines dispensed and the number of pharmacists / 
technicians would provide relevant information, these questions were 
considered non-essential for the aim of the research. With regards to 
comments, it was expected that pharmacists would add their comments 
directly in the data, or in the body of the email, where applicable, as seen in 
previous countries. As a result, the Dutch questionnaire comprised 1 table 
only, in order to simplify the request for information and to enhance the 
response rate.  
The Dutch questionnaire was developed in English, following 
recommendations of the stakeholder who asserted that translating was 
unnecessary since the Dutch population was generally fluent in English. This 
was confirmed from other sources such as the Netherlands Board of Tourism 
& Conventions (NBTC, 2010). Data collection in the Netherlands was 
undertaken mainly in 2009 and, therefore, the questionnaire addressed 
information relating to 2008. 
Compounded medicines were defined in the Dutch questionnaire as 
“standardised and/or non-standardised formulations prepared by a 
pharmacy”, which is in accordance with the concept of compounded 
medicines in the Netherlands (Section 7.1). 
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An extra column “Manufacturer” was added to the questionnaire so that the 
compounded medicines prepared in other hospital/community pharmacies 
would be identified. To avoid duplication of data, it is important to identify the 
“manufacturer” of the compounded medicines dispensed and, if applicable, to 
exclude the repeated data entries from the hospital’s datasets.  
7.3.2 Purposive sample of hospitals 
A total of 17 hospitals were selected across the Netherlands, from the cities 
of: Amersfoort, Amsterdam (capital), Arnhem, Dordrecht, Eindhoven, 
Groningen, Haarlem, Heerlen, Hengelo, Hertogenbosch, Nijmegen, 
Rotterdam, The Hague, Utrecht, Zaandam and Zwolle (Figure 7.2). Each city 
corresponded to 1 hospital, with the exception of Amsterdam (2 hospitals). 
These hospitals were identified by the stakeholders as the ones in which the 
largest quantities of compounded medicines were likely dispensed in the 
Netherlands. 
 
Figure 7.2 Map of the Netherlands adapted from National Geographic Society (1998e); 
indicating the location of the purposive sample of hospitals (   ). 
7.3.3 Data collection 
Data collection in the Netherlands was initiated during 10 days of fieldwork 
planned and scheduled by Frits Boom. The purpose of this fieldwork was to 
allow a better understanding of the current compounding practices in the 
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Netherlands and to start data collection. Fieldwork was undertaken by MC in 
September 2008, and consisted in visits to selected hospital pharmacies and 
other institutions, as follows: 4 hospitals in Zaandam, Haarlem, Groningen 
and Utrecht; 2 community pharmacies in Breda; the LNA in The Hague; and 
the Health Care Inspectorate in Hertogenbosch. Data regarding oral 
compounded medicines most frequently dispensed in 2007 was collected by 
MC in 1 hospital; another hospital shared the required data during the visit; 
and the 2 other hospitals after the visit, by email. 
The list of 13 additional hospitals suggested by Yvonne Bouwman was 
provided including the address of each hospital and the name of the key 
contact person in the respective pharmacy. The telephone number of each 
hospital was then searched online and all 13 hospitals were contacted by 
telephone by MC. However, only 3 hospital pharmacists were available by 
telephone and, after a brief explanation of the research project, they all 
accepted to contribute data by email. The majority of hospital pharmacists 
were not available by telephone (even after several calls, for some hospitals) 
and the email address of the key contact persons were provided by the 
hospital pharmacy staff.  
The customised questionnaire was attached to a brief introductory email, as 
well as an electronic copy of the article published in the IJPC by Carvalho et 
al. (2008) and the power-point slides for an oral presentation by MC at the 1st 
Conference of the EuPFI (European Paediatric Formulation Initiative) 
(Carvalho, 2009). The IJPC article introduced the design and purpose of the 
research and the EuPFI presentation described preliminary findings. Non-
respondents were sent periodical email reminders, up to a maximum of 5 
emails per hospital pharmacy (excluding the EuPFI presentation to avoid an 
overload of information).  
At the EDQM Expert Workshop on “Promoting standards for the quality and 
safety assurance of pharmacy-prepared medicinal products for the needs of 
patients”, in November 2009, Frits Boom offered to contact all non-
respondents with the request to contribute data. This invaluable support 
resulted in a considerable increase in the response rate at the final stage of 
data collection. 
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7.4 Results and discussion 
Of the 17 hospitals contacted, 13 hospital pharmacies responded to the 
request for collaboration and 4 were non-respondents, resulting in a 
response rate of 76%. Of the 13 respondents, 12 contributed data regarding 
the oral compounded medicines most frequently dispensed by their 
pharmacies and only 1 hospital was non-participant (Figure 7.3); this hospital 
dispensed oral compounded medicines, but data were not readily accessible 
and the staff at the pharmacy did not have the resources, at that time, to 
gather the required information. All participant hospitals shared complete 
datasets and no partial data were provided in the Netherlands. 
A total of 4 participant hospitals were visited by MC (Figure 7.3) in 
September 2008 (Section 7.3.3) and, therefore, data was shared regarding 
2007. Notwithstanding, 1 hospital did not provide the required information 
soon after the visit but, instead, in 2009 and data was shared regarding both 
2007 and 2008. All other hospitals shared data in 2009 and the respective 
datasets related to 2008. As a result, the Dutch database included datasets 
regarding both 2007 (3 hospitals) and 2008 (9 hospitals). 
 
            
Figure 7.3 Purposive sample of hospitals in the Netherlands. 
All participant hospitals provided datasets in electronic formats: 5 hospital 
pharmacies in the questionnaire provided and 7 hospital pharmacies in their 
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own formats, which (in general) were very complete, extensive and detailed. 
For instance, the strength and pack size of the compounded medicines 
dispensed were almost always stated. Compounded medicines that were 
included in the FNA were often reported. Active substances were commonly 
described in full, including the respective salts and hydration states. Dosage 
forms were usually described in detail, including the description of the final 
container. Moreover, some participant hospitals even distinguished 
standardised from non-standardised preparations (Section 7.1). According to 
the EAHP survey, between 2000 and 2005, computerisation for 
pharmaceutical compounding increased by more than 20% in the 
Netherlands (EAHP, 2005). 
Although the questionnaire provided included the column “Manufacturer” 
(Section 7.3.1), so that the compounded medicines prepared in other 
hospital/community pharmacies would be identified, none of the participant 
hospitals stated that they had dispensed medicines prepared by others. 
Because the hospitals contacted were deemed to be the ones that dispensed 
the largest quantities of compounded medicines in the Netherlands, and also 
because the information provided was (in general) very complete and 
detailed, it is likely that all medicines dispensed were, in fact, prepared in the 
respective pharmacies.  
Non-oral compounded medicines (i.e. vaginal, rectal and topical) were 
reported by 3 hospitals and the reconstitution of proprietary antibiotics (i.e. 
Floxapen 25 mg/mL, 100 mL) by another hospital, which were all excluded 
from the hospital’s datasets (Section 2.4.1). After data processing, the Dutch 
database included a total of 1,208 data entries, corresponding to the datasets 
of 12 hospitals. 
7.4.1 Active substances  
A list of the active substances most frequently dispensed as oral 
compounded medicines in the Netherlands is shown in Table 7.1. Active 
substances were grouped according to the respective therapeutic 
classification (Martindale 35, 2007), giving a total of 226 different active 
substances and 38 therapeutic groups. 
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Table 7.1 Active substances most frequently dispensed as oral compounded medicines in 
the Netherlands (NTI drugs underlined). 
Analgesics, anti-inflammatory drugs 
and antipyretics  
Aspirin, carbasalate calcium, codeine, 
codeine phosphate, diclofenac, etoricoxib, 
ibuprofen, methadone HCl, morphine, 
morphine HCl, naproxen, opium, 
paracetamol, propyphenazone, tramadol 
HCl 
 
Anthelmintics  
Diethylcarbamazine citrate 
 
Antibacterials  
Aztreonam, clindamycin, clioquinol, 
colistin sulfate, demeclocycline,  
ethambutol HCl, isoniazid, neomycin, 
neomycin sulfate, nitrofurantoin, 
norfloxacin, sulfadiazine, 
sulfamethoxazole, thioacetazone, 
tobramycin, trimethoprim, vancomycin 
 
Antidepressants 
Imipramine HCl, lithium carbonate 
 
Antidiabetics 
Tolbutamide 
 
Antiepileptics  
Clobazam, phenobarbital, phenytoin, 
phenytoin sodium, pregabalin, primidone, 
topiramate, vigabatrin 
 
Antifungals 
Amphotericin B, nystatin 
 
Antigout drugs 
Allopurinol, colchicine, probenecid 
 
Antihistamines  
Alimemazine tartrate, deptropine citrate, 
fexofenadine HCl, promethazine, 
tripelennamine citrate 
 
Antimalarials  
Chloroquine, primaquine, primaquine 
phosphate 
 
Antimyasthenics  
3,4-diaminopyridine, fampridine 
 
Antineoplastics 
Busulfan, cyclophosphamide, lomustine, 
mercaptopurine, methotrexate 
 
Antiparkinsonian drugs  
Amantadine, carbidopa, levodopa, 
trihexyphenidyl HCl 
Antivirals 
Valaciclovir HCl, valganciclovir HCl 
 
Anxiolytic, sedatives, hypnotics and 
antipsychotics 
Chloral hydrate, clozapine, diazepam, 
haloperidol, levomepromazine, 
lorazepam, midazolam, midazolam HCl, 
nitrazepam, oxazepam, pericyazine, 
perphenazine, quetiapine fumarate, 
temazepam, zuclopenthixol decanoate 
 
Blood products, plasma expanders and 
haemostatics 
Tranexamic acid 
 
Bronchodilators and anti-asthma drugs 
Caffeine, theophylline 
 
Cardiovascular drugs 
Acenocoumarol, adrenaline, amiloride 
HCl, amlodipine besilate, atenolol, 
atropine, atropine sulfate, bosentan,  
captopril, carvedilol, clonidine HCl, 
clopidogrel bisulfate, colestyramine, 
diazoxide, enalapril, enalapril maleate, 
furosemide, hydrochlorothiazide, 
isosorbide, labetalol HCl, mannitol, 
metoprolol tartrate, nifedipine, 
phenprocoumon, propranolol HCl, sotalol 
HCl, spironolactone, triamterene, warfarin 
sodium; 
 
Chelators, antidotes and antagonists 
Methionine, methylthioninium chloride, 
penicillamine, prussian blue, sodium 
polystyrene sulfonate, trientine 
dihydrochloride 
 
Contrast media 
Barium sulfate, meglumine amidotrizoate, 
meglumine ioxitalamate, sodium 
amidotrizoate, sodium ioxitalamate 
 
Corticosteroids 
Dexamethasone, dexamethasone sodium 
phosphate, fludrocortisone acetate, 
hydrocortisone, prednisolone 
 
Cough suppressants, expectorants, 
mucolytics and nasal decongestants 
Ammonium chloride, ephedrine HCl 
 
Disinfectants and preservatives 
Cetrimide, chlorhexidine HCl, povidone-
iodine, sodium benzoate, sodium 
metabisulfite 
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Electrolytes 
Calcium, calcium acetate, calcium 
gluconate, magnesium gluconate, 
magnesium sulfate, monobasic potassium 
phosphate, phosphate, potassium 
chloride, potassium citrate, potassium 
phosphate, sodium chloride, sodium 
citrate 
 
GI drugs 
Calcium carbonate, lactulose, liquorice, 
metoclopramide, ranitidine, ranitidine HCl, 
senna, sennosides, sodium sulfate, 
sulfasalazine 
 
Hypothalamic and pituitary hormones 
Desmopressin acetate 
 
Immunosuppressants 
Azathioprine, tacrolimus 
 
Local anaesthetics 
Cocaine HCl, lidocaine, lidocaine HCl 
 
Miotics, mydriatics and antiglaucoma 
drugs 
Acetazolamide, carbachol 
 
Muscle relaxants 
Baclofen, dantrolene sodium 
 
Nutritional agents and vitamins 
Alpha tocopherol, arginine HCl, ascorbic 
acid, citrulline, colecalciferol, ferrous 
fumarate, folic acid, folinic acid, fructose, 
glucose, glucose monohydrate, lactose, 
nicotinamide, phytomenadione, pyridoxine 
HCl, riboflavin, sodium fluoride, sucrose, 
thiamine, tocopherol, vitamin A, vitamin D, 
vitamin E, vitamin K, zinc sulfate 
 
Organic solvents 
Dimethyl sulfoxide 
 
Sex hormones 
Oxandrolone, oxymetholone, prasterone 
 
Stabilising and suspending agents 
Cellulose, methylcellulose 
 
Stimulants and anorectics 
Amfetamine, dexamfetamine sulfate, 
methylphenidate HCl 
 
Supplementary drugs and other 
substances 
Cannabis, citric acid, glycerol, 
glycopyrronium bromide, hydrochloric 
acid, macrogols, melatonin, monosodium 
glutamate, pancreatin, sodium carbonate, 
sodium phenylbutyrate, tetrabenazine, 
trypsin, ursodeoxycholic acid 
 
Thyroid and antithyroid drugs 
Iodine, levothyroxine sodium, potassium 
iodide, potassium perchlorate, sodium 
perchlorate 
 
Urological drugs 
Sildenafil citrate 
 
Cardiovascular drugs was the group with the greatest number of different 
active substances (n=29), followed by nutritional agents and vitamins (n=25) 
and antibacterials (n=17).  
Although these active substances were all reported as oral compounded 
medicines, the title of some therapeutic groups suggested non-oral 
(therapeutic) indications, namely: disinfectants and preservatives (Appendix 
12); organic solvents (Appendix 25); stabilising and suspending agents 
(Appendix 14); and supplementary drugs and other substances (Appendix 
15). The active substances included in these groups are described in the 
respective appendixes. 
With reference to the official list provided by ANVISA (2007) (Appendix 1), a 
total of 9 NTI drugs were dispensed as oral compounded medicines 
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(underlined in Table 7.1). NTI drugs were reported by the majority (83%) of 
participant hospitals. 
The active substances dispensed by most hospitals were: furosemide and 
phenobarbital (n=11), hydrochlorothiazide (n=10) and spironolactone (n=9).  
All active substances reported were included in Martindale 35 (2007), with 
the exception of the following:  
• Ammonia spirit aniseed: was reported by 2 hospitals as part of an anti-
cough preparation, named Hoestdrank FNA or Mixtura resolvens, which is 
included in the Dutch official formulary (FNA, Section 7.2.2) and is shown in 
the given titles formulary (Appendix 16). Ammonia spirit aniseed (Appendix 
26) is commercially available in the Netherlands for the preparation of 
compounded medicines. 
• Heptobarbital: was reported by 2 hospitals as capsules of heptobarbital 
200 mg and heptobarbital 60 mg combined with phenobarbital. Heptobarbital 
is described in the literature as a barbiturate (Louis et al., 2009). 
The majority of compounded medicines dispensed included 1 active 
substance only. Nevertheless, combinations of up to 3 active substances 
were also dispensed, in a total of 17 compounded medicines, as follows:  
• 3 active substances: Hoestdrank FNA (mentioned above); mannitol, 
lactulose and sucrose. 
• 2 active substances: ammonium chloride and liquorice (similar to 
Hoestdrank FNA); amphetamine and phenobarbital; atropine sulfate and 
diazepam; citric acid and glycerol; colistin sulfate and norfloxacin; 
Gastrografin (meglumine amidotrizoate and sodium amidotrizoate); 
heptobarbital and phenobarbital; methadone HCl and metoclopramide; 
Movicolon (macrogols and electrolytes); sodium ioxitalamate and meglumine 
ioxitalamate; sodium phosphate and potassium phosphate; spironolactone 
and hydrochlorothiazide; tobramycin and colistin sulfate; triamterene and 
hydrochlorothiazide; tripelennamine citrate and codeine. 
Apart from compounded medicines including active substances, 3 hospitals 
also reported compounded medicines including placebo, namely tablets and 
capsules, in a total of 130,652 units. 
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In addition, 8 proprietary medicines were reported as part of the oral 
compounded medicines dispensed, both as solid and liquid dosage forms 
and by 7 hospitals, as follows: Capoten (captopril), Cyklokapron (tranexamic 
acid), Gastrografin (meglumine amidotrizoate and sodium amidotrizoate), 
Movicolon (macrogols and electrolytes), Mysoline (primidone), Prunasine 
(senna), Resonium (sodium polystyrene sulfonate) and Telebrix (sodium 
ioxitalamate).  
7.4.2 Oral solids 
Oral solid dosage forms were reported by 92% of all participant hospitals and 
included capsules (n=11), oral powders (n=8), powders for oral liquids (n=3) 
and tablets (n=2). In total, 3,281,601 individual units of oral solids were 
reported but the majority (79.8%) corresponded to tablets (Figure 7.4). 
 
Figure 7.4 Oral solid dosage forms dispensed per number of units. 
Tablets were dispensed in a total of 2,619,800 units (Figure 7.4) but only by 2 
participant hospitals, which supplied other hospital pharmacies. The 
preparation of tablets requires specific tableting equipment and not all 
hospitals can afford such an investment (Section 2.1.3). Therefore, it is not 
unexpected that not all hospitals reported this dosage form. The top 5 active 
substances (and respective strengths) dispensed as tablets were: oxazepam 
(5-50 mg), furosemide (20-40 mg), haloperidol (0.5-5 mg), ferrous fumarate 
(200 mg) and dexamethasone (0.5-20 mg) (Table 7.2). These 5 active 
substances represented 57% of all tablets and were dispensed in packs of 50 
units. Despite the fact that tablets are commonly prepared in large scale 
(because of the characteristics of the tableting equipment) and, therefore, it 
2,619,800 
633,355 
9,767 
18,679 
28,446 
Tablets Capsules Oral powders Powders for oral liquids 
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would be expected that active substances were prepared in limited strengths, 
the majority of active substances were reported by Dutch hospitals in a wide 
range of strengths. 
Capsules corresponded to 19.3% of all oral solids (Figure 7.4) and were 
reported by all participant hospitals. The top 5 active substances (and 
respective strengths) dispensed as capsules were: captopril (0.5-6.25 mg, 7 
strengths), dexamethasone (1-40 mg, 6 strengths), spironolactone (0.1-20 
mg, 11 strengths), atropine sulfate (0.5 mg) and hydrocortisone (0.25-5 mg, 6 
strengths) (Table 7.3). 
Dexamethasone was the only active substances common to both top 5 active 
substances dispensed as tablets and as capsules, and was reported by a 
total of 7 hospitals. The overall top 5 active substances dispensed as oral 
solids (and respective number of hospitals) were, in decreasing order: 
oxazepam (n=1), captopril (n=6), furosemide (n=5), haloperidol (n=1) and 
ferrous fumarate (n=1) (Tables 7.2 and 7.3).  
Table 7.2 Top 5 active substances 
dispensed as tablets. 
Table 7.3 Top 5 active substances 
dispensed as capsules. 
Active substances Number of units 
Oxazepam 600,000 
Furosemide 300,000 
Haloperidol 220,000 
Ferrous fumarate 215,000 
Dexamethasone 160,000 
Active substances Number of units 
Captopril 387,260 
Dexamethasone 41,222 
Spironolactone 21,280 
Atropine sulfate 19,000 
Hydrocortisone 15,571 
 
Furosemide (Table 7.2) and spironolactone (Table 7.3) were also part of the 
active substances dispensed by most hospitals (Section 7.4.1). Furthermore, 
these 2 active substances were also included in the top 5 active substances 
prescribed as off-label and unlicensed medicines at a Dutch children’s 
hospital (Jong et al., 2001). The other active substances identified by Jong et 
al. (2001) were cisapride, caffeine and tobramycin but, since unlicensed 
medicines corresponded to only 36% of the prescriptions analysed and only 
1 hospital was included in their research, it was expected that only a few 
results would be directly comparable. 
 Chapter 7: COMPOUNDING IN THE NETHERLANDS | Results and discussion | 177 
 
Powders for oral liquids and oral powders represented only 0.9% of all oral 
solids (Figure 7.4). Powders for oral liquids (0.6%) were dispensed by 3 
hospitals, for a total of 10 active substances. Tobramycin (640 mg) and 
colistin sulfate (800 mg), in combination, were the most frequently dispensed 
active substances. Oral powders (0.3%) were dispensed by 8 hospitals, with 
a total of 26 active substances. Sodium polystyrene sulfonate (15 g) and 
magnesium sulfate (15-30 g) were the most frequently dispensed active 
substances. The top therapeutic groups (oral solids only) were: “anxiolytic, 
sedatives, hypnotics and antipsychotics” and “cardiovascular drugs”, which 
represented 58% of all oral solids dispensed (Figure 7.5). The active 
substances most frequently dispensed from these groups were oxazepam 
and haloperidol (anxiolytic, sedatives, hypnotics and antipsychotics), 
captopril and furosemide (cardiovascular drugs), as displayed in Tables 7.2 
and 7.3. 
 
 
Figure 7.5 Top 10 therapeutic groups (oral solids) ranked by number of units dispensed. 
231,689 
16,551 
18,747 
23,935 
24,164 
88,983 
145,000 
354,166 
470,386 
914,024 
993,956 
0 400,000 800,000 1,200,000 
Others 
Chelators antidotes and antagonists 
Antigout drugs 
Antiparkinsonian drugs 
Antibacterials 
Muscle relaxants 
Antidiabetics 
Corticosteroids 
Nutritional agents and vitamins 
Cardiovascular drugs 
Anxiolytic sedatives hypnotics and 
antipsychotics 
Number of units dispensed 
 Chapter 7: COMPOUNDING IN THE NETHERLANDS | Results and discussion | 178 
 
7.4.3 Oral liquids 
Oral liquid dosage forms were reported by all participant hospitals and 
included both multidose and unidose containers (Figure 7.6), as follows: 
• Multidose: solutions and suspensions (n=12), oral drops (n=8) and syrups 
(n=3). 
• Unidose: oral syringes (n=5). 
Only 1 hospital distinguished the oral liquids dispensed as (unidose) oral 
syringes37 but it was assumed that quantities <10 mL corresponded to 
unidose whereas quantities ≥10 mL corresponded to multidose containers 
(Section 2.1.3). As a result, it was concluded that 5 hospitals dispensed 
unidose oral liquids in the Netherlands, as displayed in Figure 7.6.  
 
Figure 7.6 Number of units of oral liquids (unidose and multidose) dispensed per hospital. 
Eight active substances were dispensed as unidose (n=3,178 units), in 
limited strengths and in volumes of 0.5 mL to 8 mL. The top 5 compounded 
medicines dispensed as unidose oral liquids are displayed in Table 7.4. 
                                            
37An oral syringe is used for accurate measurement and controlled administration of an oral 
liquid medicine. Oral syringes should be clearly labelled “Oral” or “Enteral” and should not be 
compatible with IV or other parenteral devices, to avoid inadvertent IV administration of oral 
liquid medicines (Paediatric Formulary Committee, 2008). 
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Table 7.4 Top 5 compounded medicines dispensed as unidose oral liquids. 
Active substances Strengths Volumes Number  of units 
Mercaptopurine 10 mg/mL 1.4-6 mL 2,020 
Azathioprine 10 mg/mL 2.5-8 mL 369 
Phytomenadione 10 mg/mL 5 mL 315 
Amphotericin B 100 mg/mL 0.5 and 1 mL 269 
Methotrexate 5-7.2 mg/mL 2-5 mL 108 
 
Multidose oral liquids were dispensed in larger quantities than unidose oral 
liquids (82,104 multidose units vs 3,178 unidose units) and were reported by 
all hospitals with 180 to 18,594 units per hospital (Figure 7.6). Multidose oral 
liquids were reported as solutions, suspensions and oral liquids (92%), oral 
drops (6%) and syrups (2%) (Figure 7.7). 
 
Figure 7.7 Multidose oral liquid dosage forms dispensed per number of units. 
Solutions, suspensions and oral liquids (in general) were reported by all 
participant hospitals, in a total sum of 75,650 units (from 10 mL to 2,000 mL). 
The majority were reported as oral liquids (75%), followed by solutions (17%) 
and suspensions (8%) but it is likely that the classification of some oral 
liquids was not accurate and, therefore, part of the solutions/suspensions 
may have corresponded to other liquid dosage forms (and vice-versa) 
(Section 2.1.3). The top 5 active substances were: sodium ioxitalamate and 
meglumine ioxitalamate (3 hospitals); this is contrast media commonly given 
in combination by mouth for imaging the GI tract (Martindale 35, 2007); 
potassium chloride (7 hospitals), magnesium sulfate (5 hospitals) and 
mercaptopurine (3 hospitals). These active substances represented 59% of 
all solutions, suspensions and oral liquids dispensed. 
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Oral drops corresponded to 6% of all oral liquids (Figure 7.7) and were 
reported by 8 hospitals. In total, 13 active substances were reported as oral 
drops and the top 5 (in decreasing order) corresponded to: temazepam, 
adrenaline, vitamin K, potassium iodide and iodine. Potassium iodide and 
iodine were almost always dispensed as Sterke Waterige Jooddruppels, an 
oral solution equivalent to the Lugol's Solution 5% (Appendix 16). These oral 
drops are included in the FNA (Section 7.2.2), at the section Vervallen, which 
comprises compounded medicines that are no longer commonly used in the 
Netherlands (WINAp, 2004).  
Syrups comprised only 2% of all oral liquids (Figure 7.7) and were reported 
by just 3 hospitals. The most frequently dispensed syrup was named “cough 
syrup” (300 mL) and was reported by only 1 hospital. The other syrups 
included a total of 5 different active substances and were dispensed in 
containers of 10 mL to 300 mL. 
The top therapeutic groups (oral liquids only) were: contrast media and 
electrolytes, which represented 57% of all oral liquids dispensed (Figure 7.8). 
The active substances most frequently dispensed from these groups were 
sodium ioxitalamate and meglumine ioxitalamate (contrast media); potassium 
chloride and magnesium sulfate (electrolytes), which corresponded to the 
most frequently dispensed active substances as solutions, suspensions and 
oral liquids (above). 
The multidose oral liquids may be quantitatively compared to the oral solids 
dispensed (in packs). Since almost all tablets were dispensed in packs of 50 
units (Section 7.4.2), the 2,619,800 units of tablets corresponded to 52,396 
packs of tablets (of 50 units each). In addition, considering that capsules 
were dispensed in packs of 50 units (estimated; Section 2.1.3), the 633,355 
individual units of capsules corresponded approximately to 12,667 packs of 
oral capsules (of 50 units each). As a result, a total of approximately 65,063 
packs of oral solids were dispensed in the Netherlands. Therefore, when the 
82,104 units of multidose oral liquids are compared to the estimation of 
65,063 packs of oral solids, it is concluded that oral liquids were dispensed in 
larger quantities than oral solids, though similar within an order of magnitude. 
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Figure 7.8 Top 10 therapeutic groups (oral liquids) ranked by number of units dispensed. 
When further comparing oral solids and oral liquids, there were 3 therapeutic 
groups common to the top 5 groups for oral solids and oral liquids. This 
finding suggests that the respective active substances are dispensed both as 
solid and liquid dosage forms. The common therapeutic groups were: 
“nutritional agents and vitamins”, “cardiovascular drugs” and “anxiolytic, 
sedatives, hypnotics and antipsychotics“, which is consistent with the fact 
that diseases of the circulatory system and digestive system corresponded to 
the major causes of discharge from all Dutch hospitals, as shown in Figure 
7.9. 
 
Figure 7.9 Number of patients per 100,000 population discharged from all hospitals 
(including through death) in the Netherlands during 2006 (latest available year), categorised 
by principal diagnosis (WHO Regional Office for Europe, 2008). 
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7.4.4 Oromucosal preparations 
In the Netherlands, oromucosal preparations were reported by 4 hospitals 
(33% of all participant hospitals) and, in total, 8 different compounded 
medicines were dispensed, in a sum of 1,838 multidose containers, namely: 
amphotericin B 2% paste (5 g); cetrimide 0.1% mouthwash (300 mL); 
chlorhexidine HCl 2% ointment; colistin sulfate 1 mg/mL mouthwash (100 
mL); povidone-iodine 1% mouthwash (100 mL); sodium fluoride 1% 
mouthwash and gel (100 mL); and tacrolimus 1mg/g paste (30 g). 
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7.5 Summary 
• Compounded medicines in the Netherlands may be distinguished in standardised 
preparations (individual or for stock) and non-standardised preparations (individual only). 
• GMP-H is the quality standard for pharmaceutical compounding in Dutch hospital 
pharmacies. The LNA (WINAp/KNMP) is a Dutch laboratory focused on pharmaceutical 
compounding and the FNA is the official national compounding formulary.  
• A purposive sample of 17 hospitals was included in the research and a response rate of 
76% was obtained. A total of 227 different active substances (including 9 NTI drugs) were 
reported corresponding to 38 different therapeutic groups. The top 3 therapeutic groups were 
cardiovascular drugs (n=29), nutritional agents and vitamins (n=25) and antibacterials 
(n=17). Placebo was dispensed in a total sum of 130,652 units of capsules and tablets (n=3). 
• Oral solid dosage forms were reported by 92% of all participant hospitals and included 
tablets, capsules, powders for oral liquids and oral powders. Tablets were dispensed in a 
total sum of 2,619,800 units (79.8% of all oral solids) and the top 5 active substances were: 
oxazepam, furosemide, haloperidol, ferrous fumarate and dexamethasone. Capsules were 
dispensed in a total of 633,355 units (19.3% of all oral solids) and the top 5 active 
substances were: captopril, dexamethasone, spironolactone, atropine sulfate and 
hydrocortisone. Powders for oral liquids and oral powders represented only 0.9% of all oral 
solids. 
• Oral liquid dosage forms were reported by all participant hospitals and included solutions 
and suspensions, oral drops and syrups (multidose) and oral syringes (unidose). Multidose 
oral liquids were dispensed in larger quantities than unidose oral liquids (82,104 multidose 
units vs 3,178 unidose units). Solutions and suspensions (and oral liquids in general) were 
dispensed in a total sum of 75,650 multidose containers (92% of all multidose oral liquids) 
and the top 5 active substances were: sodium ioxitalamate and meglumine ioxitalamate, 
potassium chloride, magnesium sulfate and mercaptopurine. Oral drops were dispensed in a 
total of 4,966 containers (6% of all multidose oral liquids) and the top 5 active substances 
were: temazepam, adrenaline, vitamin K, potassium iodide and iodine. Syrups accounted for 
only 2% of all multidose oral liquids dispensed. Unidose oral liquids were dispensed in a total 
of 3,178 unidose units and the top 5 active substances were: mercaptopurine, azathioprine, 
phytomenadione, amphotericin B and methotrexate.  
• Oral liquids were dispensed in larger quantities than oral solids, though similar within an 
order of magnitude. 
• Oromucosal preparations were reported by 33% of hospitals and included 7 different 
active substances (amphotericin B, cetrimide, chlorhexidine HCl, colistin sulfate, povidone-
iodine, sodium fluoride and tacrolimus), in a total of just 1,838 multidose containers. 
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8. Compounding in Denmark 
Denmark is a Scandinavian country, bordered by the North Sea and 
Germany, that joined the EU in 1973 and its official language is Danish 
(Europa, 2009; Ministry of Foreign Affairs of Denmark, 2010). Denmark is 
small, with a surface area of 43,100 km2, that consists of the peninsula of 
Jylland and some 400 named islands, the largest being Fyn and Sjælland 
(Europa, 2008; 2009). Denmark is divided into 5 regions: Capital Region of 
Denmark, Zealand Region, Region of Southern Denmark, Central Denmark 
Region and North Denmark Region (Danish Regions, 2008). The hospital 
sector is the responsibility of the 5 regions and each region must provide free 
treatment to the residents of the region (Ministry of Health and Prevention, 
2008). Denmark is the 17th most populated country in the EU, with a 
population of 5.4 million in 2007 (Figure 2.2) (Europa, 2008). The most 
populated cities are Copenhagen (capital), followed by Ǻrhus, Odense and 
Ǻlborg (Ministry of Foreign Affairs of Denmark, 2010). 
In 2005, there were 59 hospitals in Denmark (ratio of 1.09 hospitals per 
100,000 population) and, in 2007, there were a total of 19,086 hospital beds 
(ratio of 349.48 hospital beds per 100,000 population) (WHO Regional Office 
for Europe, 2010) (Appendix 3). 
In 2006, there were 3,723 pharmacists in Denmark (ratio of 68.51 
pharmacists per 100,000 population) (WHO Regional Office for Europe, 
2010) (Appendix 4), and about 4% worked in hospital pharmacy (EAHP and 
HOPE, 2002). According to the EAHP survey, the average number of 
pharmacists in Danish hospitals is 10.3, which is more than twice the 
European average of 4.7 pharmacists per European hospital. In addition, 
Danish hospitals have an average of 28.2 qualified pharmacy 
technicians/assistants per hospital (36% increase in relation to the year 
2000), which is much higher than the European average of 6. Denmark also 
has an average of 3.8 non-qualified pharmacy assistants per hospital (EAHP, 
2005; Hartmann, 2010). 
In Denmark, compounded medicines are prepared both in community and 
hospital pharmacies. Danish hospital pharmacies also manufacture licensed 
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medicines, previously authorised by the Danish Medicines Agency (DMA, 
Section 8.2.1). These licensed medicines are not supplied by the 
pharmaceutical industry and have a Marketing Authorisation that belongs to a 
company named Amgros. Amgros I/S is owned by the 5 Danish regions and 
is the holder of the Marketing Authorisation for all medicines manufactured by 
the Danish public hospital pharmacies (AMGROS, no date). Amgros is 
responsible for handling all aspects of medicines supply to public hospitals by 
hospital pharmacies, including the manufacture and purchase of medicines. 
As the holder of the Marketing Authorisation, Amgros is also responsible for 
ensuring that the manufacture of medicines in hospital pharmacies is 
performed in accordance with GMP standards (Kart and Teilmann, 2008). 
According to the EAHP survey, Denmark is one of the European countries 
with the most rigorous GMP regulations and QC requirements (EAHP, 2005). 
All Danish hospital pharmacies that participated in the EAHP survey used 
written SOP and tested finished batches. Between 2000 and 2005, hospital 
pharmacies increased the testing of raw materials, packaging materials and 
finished batches by 17% (EAHP, 2005). 
In Denmark, the preparation of compounded medicines and the manufacture 
of licensed medicines are centralised and only selected hospitals and 
community pharmacies perform these activities. According to Bent Hansen, 
head of Amgros’ Executive Committee, the medicines prepared in hospital 
pharmacies must be “coordinated and optimised on a national scale” (Kart 
and Teilmann, 2008). Hence, the majority of Danish hospitals (60%) prepare 
compounded medicines for other hospitals and community pharmacies 
(EAHP, 2005). With regards to the community setting, pharmaceutical 
compounding is performed in very few pharmacies. In 2007, it was reported 
that compounding was centralised in 3 community pharmacies only (Herborg 
et al., 2007). 
Amgros and the Danish hospital pharmacies are computerised and access 
an intranet service to share information and databases on medicines (Kart 
and Teilmann, 2008). All hospital pharmacies included in the EAHP survey 
used computer systems for drug information and, between 2000 and 2005, 
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computerisation for pharmaceutical compounding increased by more than 
20% (EAHP, 2005). 
The Odense University Hospital is the regional hospital for southern Denmark 
(1 of the 5 Danish regions) and one of Denmark’s largest public hospitals. 
The hospital pharmacy, Sygehusapotek Fyn, is responsible for distributing 
the medicines throughout the hospital, including compounded medicines and 
the few manufactured licensed medicines. According to Lisbeth Muurholm 
(hospital pharmacy manager), the production department is the largest in the 
pharmacy with 52 employees distributed in 4 sectors: cytotoxic preparation, 
extemporaneous preparation, licensed medicines manufacture and technical 
assistance. The department of quality (QA/QC) has 17 employees who 
perform chemical and microbiological analyses and oversee the overall 
quality of medicines from the department of production (Muurholm, 2008). 
8.1 Legislation 
The Ministry of the Interior and Health was established in February 2010 and 
is responsible for the pharmacy sector in Denmark (Ministry of the Interior 
and Health, 2010). Under this Ministry, the DMA regulates medicinal products 
and pharmacies (DMA, 2010a). Relevant Danish legislation comprises 3 
main acts: Danish Medicines Act, Danish Pharmacy Act and Danish Health 
Act.  
The Danish Medicines Act establishes the definition of medicinal products 
and states that a medicinal product may only be marketed or dispensed in 
Denmark when a Marketing Authorisation has been granted. Nevertheless, 
there are exceptions that do not need a Marketing Authorisation; 
compounded medicines are one of these exceptions and are defined in the 
Danish Medicines Act as “medicinal products prepared in a pharmacy for an 
individual patient or animal in accordance with a prescription from a doctor or 
a veterinarian (the magistral formula)” (Ministry of the Interior and Health, 
2005). 
The Danish Pharmacy Act states the tasks that a pharmacy is responsible for 
carrying out, which includes pharmaceutical compounding. This Act states 
that pharmacists may only prepare and dispense compounded medicines 
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which are different to commercially available medicines (Ministry of the 
Interior and Health, 2008). 
According to Danish legislation, pharmacies may only prepare batches of 
compounded medicines (in advance) upon previous authorisation by the 
DMA. The community pharmacies authorised to prepare batches of 
compounded medicines are: Glostrup Apotek, Skanderborg Apotek, Lemvig 
Apotek, Hillerød Frederiksborg Apotek and Løgstør Apotek. In Denmark, 
community pharmacies are allowed to prepare and dispense compounded 
medicines to other community pharmacies and also to hospital pharmacies. 
On the other hand, hospital pharmacies are only allowed to prepare and 
dispense compounded medicines to other hospitals. Exceptionally, hospital 
pharmacies may prepare and dispense compounded medicines to 
community pharmacies provided that several conditions are met, including 
the fact that no Danish community pharmacy is able to prepare the 
compounded medicines required for the continuation of a patient’s treatment 
(DMA, 1996). 
Danish legislation establishes in detail the cost of any compounded medicine 
prepared. This mainly depends on the dosage form, raw materials and the 
quantity prepared (DMA, 2010b). 
8.2 Professional organisations and information sources 
8.2.1 Danish professional organisations 
• Danish Medicines Agency (DMA): is the regulatory agency in Denmark 
that aims to ensure the availability of effective and safe medicinal products, 
medical devices and new therapies; and to promote the proper use of such 
health care products (DMA, 2010a). The authorisation for hospital 
pharmacies to manufacture licensed medicines is issued by the DMA. 
• Amgros I/S: is a company that belongs to the 5 Danish regions that is 
responsible for the manufacture of licensed medicines in public hospitals and 
own the respective Marketing Authorisations. 
• Association of Danish Pharmacies: is the employer and professional 
organisation of the Danish community pharmacies. A total of 252 proprietary 
pharmacists belong to this organisation (Apotek, 2008) but, as mentioned 
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above, only a few prepare compounded medicines at their pharmacies 
(Section 8). 
8.2.2 Danish information sources 
Denmark has not published an official formulary for pharmaceutical 
compounding. The references used include the PhEur and the following 
information sources (EAHP and HOPE, 2002): 
• Danske Lægemiddelstandarder (DLS): are the Danish drug standards, 
published by the DMA (2012), which include a chapter on the quality of 
compounded medicines (Magistrelle Lægemidlers Kvalitet) based on the 
PhEur and industrial (European) GMP (Section 14.1) (Handlos, 2007). 
8.3 Methods 
Denmark was included in the research following the interest of Daniel Bar-
Shalom (University of Copenhagen, Faculty of Pharmaceutical Sciences) in 
collaborating to the Europe-wide project, presented at the 1st Conference of 
the EuPFI (Carvalho, 2009). The stakeholder provided invaluable guidance in 
the identification of the purposive sample and development of the customised 
questionnaire. Stakeholders from hospital pharmacy also contributed to the 
identification of the purposive sample, namely: Trine Schnor (Region 
Hovedstadens Apotek) and Line Poulsen (Sygehusapoteket). Because 
pharmaceutical compounding is centralised in a few hospital and community 
pharmacies, which prepare compounded medicines not only for their own 
patients but also for other pharmacies across the country, stakeholders 
suggested a purposive sample comprising both hospital and community 
pharmacies (Section 8.3.2). 
8.3.1 Country-specific questionnaire  
The research instrument developed to collect information regarding oral 
compounded medicines most frequently dispensed in Danish hospital and 
community pharmacies was a self-completion questionnaire (main heading in 
Figure 8.1), which was based on the template established for Portugal 
(Section 3.3.1) and adapted to the practice of pharmaceutical compounding 
in Denmark. 
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This customised questionnaire comprised 1 table only (to simplify the request 
for information and enhance response rates) and was developed in English, 
following recommendations of a stakeholder who asserted that translating 
was unnecessary since the Danish population was generally fluent in 
English. Data collection in Denmark was undertaken in 2009 and, therefore, 
the questionnaire addressed information relating to 2008 (or 2007), 
depending on the latest available data. 
Compounded medicines were defined in the Danish questionnaire as 
“medicines prepared by the pharmacy, in small scale, in order to meet 
individualised needs of patients”, which is in accordance with the official 
definition stated in the Danish Medicines Act (Section 8.1). The definition 
adopted, in comparison to the official definition, excluded the reference to 
veterinary since only human compounded medicines were being studied. 
Moreover, “in small scale” was added to the definition to ensure that 
“licensed” compounded medicines were excluded. Finally, “individual patient” 
was substituted for “in order to meet individualised needs of patients” for a 
better understanding of the concept of the medicines being studied. 
8.3.2 Purposive sample of pharmacies 
A total of 5 hospitals and 2 community pharmacies were selected across 
Denmark, from the cities of: Ǻlborg, Ǻrhus, Hillerød, Holbæk and Odense; 
Glostrup and Skanderborg, respectively (Figure 8.2), covering the 5 Danish 
regions and including the most populated cities. These pharmacies were 
identified by the stakeholders as the ones in which the largest quantities of 
compounded medicines were likely to be dispensed. The 2 community 
pharmacies selected were part of the list of pharmacies authorised by the 
DMA to prepare and dispense batches of compounded medicines (in 
advance) (DMA, 1996). According to the stakeholders, out of the 5 
community pharmacies identified in Danish legislation (Section 8.1), only the 
2 pharmacies identified prepared and dispensed compounded medicines in 
Denmark. The 2 community pharmacies were known to prepare both sterile 
and non-sterile compounded medicines for Danish hospitals and, therefore, 
research on pharmaceutical compounding in Denmark must acknowledge the 
compounded medicines prepared in these 2 pharmacies. According to 
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Handlos (2009), such a complete research has been tried in the past but it 
was unsuccessful because of the low response rate, in particular from the 
community setting. 
 
Figure 8.2 Map of Denmark adapted from National Geographic Society (1998f); indicating 
the location of the purposive sample of hospitals and community pharmacies (   ). 
8.3.3 Data collection 
The purposive sample was provided by the stakeholders including the name 
and email address of the key contact person in each hospital and community 
pharmacy. All 7 pharmacies were initially contacted by MC by email with the 
request to share data regarding the oral compounded medicines most 
frequently dispensed in 2008 (or 2007). The customised questionnaire was 
attached to a brief introductory email, together with an electronic copy of the 
IJPC article (Carvalho et al., 2008). Non-respondents were sent periodical 
email reminders and, ultimately, these were contacted by telephone by MC. 
Persistent non-respondents were sent up to 8 email reminders and received 
up to 4 telephone calls. 
It was considered that a visit to 1 community pharmacy and 2 hospital 
pharmacies was the necessary fieldwork for a better understanding of the 
practice of pharmaceutical compounding in Denmark.  
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At this stage, non-respondents were contacted again but with the purpose of 
scheduling a visit to the pharmacy / compounding laboratory. Because only 2 
non-respondents accepted a visit to the pharmacy, one of the participant 
hospitals, which had already provided the required data, was contacted again 
with the request for a visit. Fieldwork was then undertaken in June 2009 and 
a total of 3 pharmacies were visited by MC: 1 community pharmacy and 2 
hospital pharmacies (Figure 8.3). 
 
 
 
 
 
 
 
 
Figure 8.3 Purposive sample and pharmacies visited in Denmark. 
8.4 Results and discussion 
All 7 hospital and community pharmacies responded to the request for 
collaboration (100% response rate) and provided complete datasets for 2008. 
All pharmacies provided datasets in electronic formats by email, including the 
pharmacies visited by MC, with the exception of 1 pharmacy that sent the 
required data by post. A total of 5 pharmacies shared data in the 
questionnaire provided (Section 8.3.1) and 2 pharmacies in their own 
formats.  
The fact that all pharmacists contacted were fluent in English and were 
willing to contribute data is likely to have contributed to the 100% response 
rate achieved. Also, the electronic copy of the IJPC article (Carvalho et al., 
2008), attached to the brief introductory email, might have encouraged 
pharmacists to participate in the ongoing Europe-wide research. Danish 
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hospital pharmacies are computerised (Kart and Teilmann, 2008) and it is 
likely that the pharmacies contacted kept electronic records of the 
compounded medicines dispensed, which will have contributed to the ease of 
retrieving the requested information.  
One participant hospital stated that the compounded medicines dispensed 
were prepared either at their pharmacy or bought from other 
hospital/community pharmacies across the country. The hospital’s dataset 
was provided including the name of the “manufacturer”, in the column 
“Number of times dispensed in 2008” (Section 8.3.1), per compounded 
medicine dispensed. The “manufacturer” corresponded to the respective 
pharmacy and a total of 5 additional hospital/community pharmacies. This 
additional information was very important since 1 hospital and 2 community 
pharmacies were already included in the research and, therefore, the 
corresponding data was repeated. As a result, compounded medicines 
dispensed by this hospital that had already been reported by other participant 
pharmacies were excluded from the hospital’s dataset. This finding indicates 
that pharmaceutical compounding is centralised in Denmark (Section 8) and 
reinforces the importance of having included the 2 community pharmacies in 
the research, since these are the “manufacturers” of some of the 
compounded medicines dispensed in Danish hospital pharmacies (Section 
8.3.2).  
Non-oral compounded medicines, rectal and topical dosage forms, were 
reported by 2 pharmacies and were all excluded from the pharmacies’ 
datasets (Section 2.4.1).  
8.4.1 Active substances  
A complete list of the active substances most frequently dispensed as oral 
compounded medicines in Denmark is shown in Table 8.1. Active substances 
were grouped according to the respective therapeutic classification 
(Martindale 35, 2007), giving a total of 87 different active substances and 24 
therapeutic groups. Nutritional agents and vitamins was the group with the 
greatest number of different active substances (n=11), followed by 
electrolytes (n=10) and antibacterials (n=9).  
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Table 8.1 Active substances most frequently dispensed as oral compounded medicines in 
Denmark (NTI drugs underlined). 
Analgesics, anti-inflammatory drugs 
and antipyretics  
Capsaicin, codeine, indometacin, 
methadone HCl, morphine, opium 
 
Antibacterials  
Dapsone, ethambutol HCl, isoniazid, 
nitrofurantoin, pyrazinamide, sulfadiazine, 
sulfamethizole, sulfamethoxazole, 
trimethoprim 
 
Antiepileptics  
Clobazam, phenobarbital, phenytoin, 
topiramate 
 
Antigout drugs  
Allopurinol, colchicine 
 
Antimalarials  
Quinine HCl 
 
Antineoplastics 
Tegafur 
 
Antiparkinsonian drugs  
Amantadine, biperiden 
 
Anxiolytic, sedatives, hypnotics and 
antipsychotics 
Chloral hydrate, clozapine, 
levomepromazine, midazolam, 
nitrazepam, pentobarbital 
 
Blood products, plasma expanders and 
haemostatics 
Tranexamic acid 
 
Bronchodilators and anti-asthma drugs 
Caffeine, caffeine citrate 
 
Cardiovascular drugs 
Amlodipine besilate, atropine, captopril, 
carvedilol, metoprolol, nifedipine, 
propranolol HCl, spironolactone 
 
Chelators, antidotes and antagonists 
Methionine, naloxone HCl 
 
 
Corticosteroids 
Cortisone acetate, dexamethasone, 
fludrocortisone acetate, hydrocortisone, 
prednisolone 
 
Disinfectants and preservatives 
Chlorhexidine 
 
Electrolytes 
Dibasic sodium phosphate, dibasic 
potassium phosphate, magnesium 
chloride, magnesium sulfate, potassium 
chloride, potassium citrate, potassium 
phosphate, sodium bicarbonate, sodium 
chloride, sodium citrate 
 
GI drugs 
Bismuth salicylate, calcium carbonate 
 
Local anaesthetics 
Lidocaine 
 
Muscle relaxants 
Dantrolene sodium 
 
Nutritional agents and vitamins 
Alpha tocoferil acetate, carnitine, 
ergocalciferol, folic acid, glucose, lactose, 
levocarnitine, pyridoxine HCl, riboflavin, 
sucrose, zinc sulfate 
 
Prostaglandins 
Misoprostol 
 
Stimulants and anorectics 
Amfetamine sulfate, dexamfetamine 
sulfate 
 
Supplementary drugs and other 
substances 
Citric acid, disulfiram, glycerol, melatonin, 
potassium bromide 
 
Thyroid and antithyroid drugs 
Potassium iodide, potassium perchlorate, 
propylthiouracil, sodium iodide 
 
Urological drugs 
Sildenafil citrate
 
Although these active substances were all reported as oral compounded 
medicines, the title of 2 therapeutic groups suggested non-oral (therapeutic) 
indications, namely: disinfectants and preservatives (Appendix 12) and 
supplementary drugs and other substances (Appendix 15). The active 
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substances included in these groups are described in the respective 
appendixes. 
With reference to the official list provided by ANVISA (2007) (Appendix 1), a 
total of 3 NTI drugs were dispensed as oral compounded medicines 
(underlined in Table 8.1).  
The active substances dispensed by most pharmacies were: glucose and 
morphine (n=5), captopril and spironolactone (n=4). 
All active substances reported were included in Martindale 35 (2007), with 
the exception of uracil (Appendix 26), which was dispensed in combination 
with tegafur, by 1 pharmacy, as capsules prepared from the proprietary 
medicine Uftoral. Tegafur with uracil is indicated in the management of 
metastatic colorectal cancer (Joint Formulary Committee, 2008).  
The majority of compounded medicines included just 1 active substance and 
only the following combinations of active substances were reported: isoniazid 
and pyridoxine HCl; trimethoprim and sulfamethizole; trimethoprim and 
sulfamethoxazole; combination of phosphates; and combination of vitamins. 
Only a few compounded medicines were reported by the proprietary 
medicines used in their preparation, namely: Co-trimoxazole (tablets), Uftoral 
(capsules) and Viagra (oral liquid), which were dispensed by 2 pharmacies. 
8.4.2 Oral compounded medicines 
In Denmark, the most frequently dispensed oral compounded medicines 
were solid dosage forms. A total of 48,195 packs (62%) of oral solids were 
reported, whereas only 26,870 multidose units (34%) of oral liquids and 
3,000 multidose units (4%) of oromucosal preparations were reported by the 
Danish pharmacies (Figure 8.4). This fact is not in accordance with Brion et 
al. (2003), who concluded that oral liquids were the most frequently 
dispensed oral dosage forms in Denmark but their findings resulted from only 
1 Danish hospital.  
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Figure 8.4 Number of packs/units of oral (and oromucosal) compounded medicines 
dispensed in Denmark, per dosage forms. 
The majority of compounded medicines were dispensed in the 2 community 
pharmacies (54,885 packs/units) and only 30% (23,180 units) were 
dispensed in the 5 hospital pharmacies. In conclusion, community 
pharmacies dispensed a considerably larger quantity of compounded 
medicines when compared to the hospital setting, which reinforces the 
importance of having included the 2 community pharmacies in the research. 
A total of 75,065 packs/units of oral solid and oral liquid compounded 
medicines were dispensed and the most frequent active substances were:  
• Glucose (16%): a monosaccharide commonly used in the treatment of 
carbohydrate and fluid depletion, and also in the treatment of hypoglycaemia; 
the doses vary in accordance with the individual patient needs (Martindale 
35, 2007) and, therefore, it is not unexpected that this was the most 
frequently dispensed active substance in Denmark. Glucose was dispensed 
as oral powders and oral liquids. 
• Hydrocortisone (11%) and melatonin (10%), both dispensed as tablets.  
The top 20 active substances are shown in Figure 8.5. and the top 5 
corresponded to 51% of all active substances dispensed, which indicates the 
repetitive nature of pharmaceutical compounding in Denmark. In addition, the 
majority of active substances were dispensed in a limited number of 
strengths, which suggests that, to a certain extent, compounded medicines 
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are standardised in this country. The active substances dispensed in the 
greatest range of strengths were: glucose, 2 strengths (oral powders) and 4 
strengths (oral liquids); sodium chloride, 1 strength (tablets) and 5 strengths 
(oral liquids); isoniazid, 1 strength (tablets) and 3 strengths (oral liquids); 
propranolol HCl, 4 strengths oral liquids (1-4 mg/mL) and sildenafil citrate, 4 
strengths oral liquids (1-3 mg/mL). Oral liquids were associated with a 
greater range of strengths that oral solid dosage forms. 
 
Figure 8.5 Overall top 20 active substances per number of packs/units dispensed. 
Glucose and hydrocortisone are included in “nutritional agents and vitamins” 
and “corticosteroids”, respectively, which correspond to the top therapeutic 
groups and represent almost 50% of all therapeutic groups dispensed (Figure 
8.6). All Danish pharmacies dispensed oral compounded medicines 
corresponding to “nutritional agents and vitamins” and “electrolytes”.  
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Figure 8.6 Overall top 10 therapeutic groups per number of packs/units dispensed. 
In 2005, the number of patients discharged from all hospitals (including 
through death) in Denmark was highest for diseases of the circulatory system 
(2,559 patients / 100,000 population) (Figure 8.7) (WHO Regional Office for 
Europe, 2008). It was to be expected then that cardiovascular drugs were 
part of the top 10 therapeutic groups in Denmark (Figure 8.6). 
 
Figure 8.7 Number of patients per 100,000 population discharged from all hospitals 
(including through death) in Denmark during 2005 (latest available year), categorised by 
principal diagnosis (WHO Regional Office for Europe, 2008). 
4,632 
2,213 
2,327 
2,916 
3,532 
4,371 
4,389 
7,724 
7,860 (10%) 
16,671 (22%) 
18,430 (25%) 
0 2 4 6 8 10 12 14 16 18 20 
Others 
Stimulants and anorectics 
Antibacterials 
Analgesics anti-inflammatory drugs and 
antipyretics 
Antiparkinsonian drugs 
Cardiovascular drugs 
Antigout drugs 
Supplementary drugs and other substances 
Electrolytes 
Corticosteroids 
Nutritional agents and vitamins 
Number of packs/units dispensed 
Thousands 
1,112 
1,621 
1,766 
1,893 
1,920 
2,559 
0 500 1,000 1,500 2,000 2,500 3,000 
Musculoskeletal system 
Digestive system 
Respiratory system 
Cancer 
Injury and poisoning 
Circulatory system 
Per 100,000 population 
 Chapter 8: COMPOUNDING IN DENMARK | Results and discussion | 199 
 
8.4.2.1 Oral solids 
Oral solid dosage forms corresponded to 62% of all compounded medicines 
(Figure 8.4) but were dispensed by only 3 pharmacies (43%). The oral solids 
dispensed included, in decreasing order, tablets, oral powders and capsules 
(Figure 8.8). 
 
Figure 8.8 Oral solid dosage forms dispensed per number of packs. 
Tablets corresponded to 84% of all oral solids (Figure 8.8) and were reported 
by 2 pharmacies. The preparation of tablets requires specific tableting 
equipment and not all pharmacies can afford such an investment (Section 
2.1.3). The top 5 active substances (and respective strengths) dispensed as 
tablets were: hydrocortisone (1 mg and 5 mg), melatonin (3 mg), 
prednisolone (50 mg) and colchicine (500 µg), which were all part of the 
overall top 5 active substances (Figure 8.5), and amantadine (50 mg and 100 
mg). Tablets are commonly prepared in large scale because of the 
characteristics of the tableting equipment and, therefore, it is not unexpected 
that active substances were prepared in only 1 or 2 different strengths. 
Tablets were dispensed as packs of 100 units (89%), 50 units (10.7%) and 
10 units (0.3%).  
Oral powders corresponded to 15% of all oral solids (Figure 8.8) and were 
also reported by only 2 pharmacies. The only 3 active substances (and 
respective strengths) dispensed as oral powders were: glucose (75 g and 
82.5 g), which was the overall most frequently dispensed active substance 
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(Figure 8.5), lactose (200 g) and methionine (2.5 g). Oral powders were 
dispensed as sachets and envelopes (Section 2.1.3). 
Capsules corresponded to just 1% of all oral solids (Figure 8.8) and were 
reported by only 1 pharmacy. The only 2 active substances dispensed as 
capsules were: misoprostol (25 µg) and tegafur with uracil (500 mg).  
The top 3 therapeutic groups (oral solids only) were: corticosteroids (16,238 
packs of tablets), nutritional agents and vitamins (8,907 packs of oral 
powders and tablets) and supplementary drugs and other substances (7,240 
packs of tablets). “Nutritional agents and vitamins” and “corticosteroids” were 
also in the overall top 3 therapeutic groups (Figure 8.6). 
8.4.2.2 Oral liquids 
Oral liquid dosage forms corresponded to 34% of all compounded medicines 
(Figure 8.4) and were dispensed by all pharmacies. The oral liquids 
dispensed included solutions, suspensions, mixtures and oral drops. The 
majority of oral liquids were reported as solutions (76%) but it is likely that the 
classification of some oral liquids was not accurate and, therefore, part of the 
solutions might have corresponded to other liquid dosage forms (and vice-
versa) (Section 2.1.3); as, for instance, to syrups, which were not specified 
by any Danish pharmacy. Suspensions (10.4%) were the next most 
frequently dispensed dosage form, followed by oral drops (10.1%) and 
mixtures (0.2%). Again, it is likely that some interchange might have occurred 
in categorisation, in particular with regards to the suspensions/mixtures. 
Finally, a total of 3.3% were generally classified as oral liquids or were not 
classified with regards to the specific dosage form. 
The volumes reported ranged from 10 mL to 1,000 mL but the majority of oral 
liquids were in volumes of 100 mL and 500 mL. Oral syringes were not 
reported in Denmark and it was assumed that all oral liquids were multidose. 
Solutions and suspensions were specifically reported by 5 pharmacies, in a 
total of 23,217 multidose containers, which corresponded to 86.4% of all oral 
liquids reported. The active substances most frequently dispensed as 
solutions/suspensions were glucose, which was the overall most frequently 
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dispensed active substance (Figure 8.5), sodium citrate, tranexamic acid, 
phosphate and captopril.  
Mixtures represented only 0.2% of all oral liquids and were reported by only 1 
pharmacy, in a total of 59 multidose units. The only 2 active substances (and 
respective strengths) dispensed as mixtures were: potassium chloride (75 
mg/mL) and nitrazepam (0.5 mg/mL). 
Oral drops corresponded to 10.1% of all oral liquids and were reported by 
only 1 pharmacy, in a total of 2,721 multidose units. The only 2 active 
substances (and the respective volumes) reported as oral drops were: 
ergocalciferol (10 mL) and morphine (30 mL).  
The top 3 therapeutic groups (oral liquids only) were: nutritional agents and 
vitamins (9,523 units), electrolytes (5,993 units) and analgesics, anti-
inflammatory drugs and antipyretics (2,916 units). “Nutritional agents and 
vitamins” and “electrolytes” were in the overall top 3 therapeutic groups 
(Figure 8.6). 
8.4.2.3 Oromucosal preparations 
In Denmark, oromucosal preparations were reported by 1 pharmacy and, in 
total, only 2 different compounded medicines were reported, as follows: 
• Chlorhexidine mouthwash 0.12% (300 mL): chlorhexidine is an antiseptic 
and disinfectant that is formulated as a mouthwash for mouth infections, 
including candidiasis, and to reduce dental plaque accumulation (Martindale 
35, 2007). 
• Lidocaine gel 20% (100 mL): lidocaine may be used in local anaesthesia, 
and gels are commonly used for anaesthesia of the urinary tract in 
concentrations of 1-2%. Lidocaine ointments are used for anaesthesia of skin 
and mucous membranes in a maximum of 20 g daily of lidocaine ointment 
5% (Martindale 35, 2007). The pharmacy dispensed lidocaine gel 20%, a 
much higher concentration than what is described in the literature. 
A total sum of 3,000 multidose units of oromucosal preparations were 
dispensed but the majority corresponded to the chlorhexidine mouthwash. 
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8.5 Summary 
• In Denmark, pharmaceutical compounding is centralised in a few community and hospital 
pharmacies. Hospital pharmacies also manufacture licensed medicines, which are not 
supplied by the pharmaceutical industry. Amgros is the company responsible for the 
manufacture of licensed medicines in public hospitals and own the respective marketing 
authorisations. 
• A purposive sample of 7 hospital and community pharmacies was included in the 
research and a response rate of 100% was obtained. A total of 87 different active 
substances (including 3 NTI drugs) were reported corresponding to 24 different therapeutic 
groups. The top 3 therapeutic groups were nutritional agents and vitamins (n=11), 
electrolytes (n=10) and antibacterials (n=9). 
• Oral solid dosage forms were reported by 43% of pharmacies and included tablets, oral 
powders and capsules. Tablets were dispensed in a total sum of 40,448 packs (84% of all 
oral solids) and the top 5 active substances were: hydrocortisone, melatonin, prednisolone, 
colchicine and amantadine. Oral powders were dispensed in a total sum of 7,451 packs 
(15% of all oral solids) and the only active substances dispensed were glucose, lactose and 
methionine. Capsules were dispensed in a total sum of 296 packs (1% of all oral solids) and 
the only active substances dispensed were misoprostol and tegafur with uracil. 
• Oral liquid dosage forms were reported by all participant pharmacies and included 
solutions and suspensions, mixtures and oral drops (multidose). Solutions and suspensions 
were dispensed in a total sum of 23,217 units (86.4% of all oral liquids) and the top 5 active 
substances were: glucose, sodium citrate, tranexamic acid, phosphate and captopril. 
Mixtures and oral drops were dispensed in a total sum of 59 (0.2%) and 2,721 (10.1%) units, 
respectively. The only active substances dispensed were: potassium chloride and 
nitrazepam (mixtures); ergocalciferol and morphine (oral drops). 
• Oral solids were dispensed in larger quantities than oral liquids. 
• Oromucosal preparations were reported by only 1 pharmacy, in a total of 3,000 multidose 
units, as follows: chlorhexidine mouthwash 0.12% and lidocaine gel 20%. 
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9. Compounding in Slovenia 
Slovenia is a Mediterranean country, located between Croatia and Italy, that 
became independent from Yugoslavia in 1991 and joined the EU in 2004. 
Slovenian is the country’s official language (Europa, 2009). Slovenia is one of 
the smallest EU countries, occupying an area of 20,100 Km2, and is also one 
of the least populated EU countries, with a population of 2.0 million in 2007 
(Figure 2.2) (Europa, 2008). 
In 2007, there were 29 hospitals in Slovenia (ratio of 1.44 hospitals per 
100,000 population) and a total of 9,414 hospital beds (ratio of 466.18 
hospital beds per 100,000 population) (WHO Regional Office for Europe, 
2010) (Appendix 3). 
In 2006, there were 944 pharmacists in Slovenia (ratio of 47 pharmacists per 
100,000 population) (WHO Regional Office for Europe, 2010) (Appendix 4). 
According to the EAHP survey, the average number of pharmacists in 
Slovenian hospitals is 2.7, which is lower than the European average of 4.7 
pharmacists per European hospital. In fact, there has been a decrease in the 
number of hospital pharmacists in Slovenian hospitals which, according to 
Tajda Miharija Gala38, is affecting the efficiency and influence of pharmacists 
in hospitals (Gala, 2004). Slovenian hospitals have an average of 4.9 
qualified pharmacy technicians/assistants per hospital, which is also lower 
than the European average of 6, and an average of 0.9 non-qualified 
pharmacy assistants per hospital (EAHP, 2005; Hartmann, 2010). 
In Slovenia, all hospital pharmacies may prepare and dispense (sterile and 
non-sterile) compounded medicines and no specific licences are required for 
the practice of compounding (EAHP, 2005). It is assumed that all Slovenian 
hospitals have some sort of compounding capability (Čufar, 2009) but, 
according to Morgan (2009), community pharmacies have the most important 
role in compounding throughout the country. 
The largest hospital in Slovenia is the Ljubljana University Medical Centre, 
which employs more than 100 staff members at the pharmacy, including 29 
                                            
38Tajda Miharija Gala is the president of the section of hospital pharmacists of the Slovenian 
Pharmaceutical Society (Section 9.2.1) (Gala, 2011). 
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with pharmacy degrees (Štefančič, 2007; Gala, 2009). This hospital 
pharmacy is equipped with several compounding units for the preparation of 
sterile and non-sterile compounded medicines (Gala, 2009). The second 
largest hospital is the University Medical Centre Maribor, which employs 28 
staff members in the pharmacy, including 7 pharmacy graduates and 10 
pharmacy technicians. This hospital prepares compounded medicines, both 
sterile and non sterile, either individually or in small batches (Koder, 2011). 
According to Silvo Koder (head of hospital pharmacy), QC is performed on 
raw materials and final products (Koder, 2011). 
In 2003, a Department of Quality established by the Ministry of Health 
conducted a national survey in which all Slovenian hospitals were asked to 
complete a questionnaire. The “preparation and administration of drugs” was 
1 of the 10 major topics addressed and, despite the fact that only 50% of all 
Slovenian hospitals returned the complete questionnaire, it was concluded 
that there was a need for “improved drug preparation in validated working 
environments” (Gala, 2006). 
9.1 Legislation 
In Slovenia, compounded medicines may be either magistral preparations or 
galenic preparations, which are defined in the Slovenian Medicines Act 
(Ministrstvo za Zdravje, 2006), as follows:  
Magistral preparations for human use are medicines prepared in a pharmacy 
according to a prescription and intended for a specified patient. 
Galenic preparations for human use are medicines prepared in a (pharmacy) 
galenic laboratory according to the pharmacopoeia in force and intended for 
being dispensed at the pharmacy. These medicines may be prepared for 
individual patients or in batches, provided that the pharmacy has a certified 
(galenic) laboratory (Section 9.3.1). 
A proposal for a new Slovenian Medicines Act is being prepared, which will 
be compliant with the European Resolution CM/ResAP(2011)1 (Section 14.1) 
that came into force in January 2011 (Gala, 2011). 
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9.2 Professional organisations and information sources 
9.2.1 Slovenian professional organisations 
In Slovenia, there are 2 main professional organisations, namely: the 
Slovenian Chamber of Pharmacy and the Slovenian Pharmaceutical Society.  
The Slovenian Chamber of Pharmacy is an independent organisation, 
comprising all community and hospital pharmacies in Slovenia, which was 
established in 1992 to protect professional honour. By law, every Slovenian 
pharmacy must be a member of this chamber (Lekarniška zbornica Slovenije, 
2010). The Slovenian Chamber of Pharmacy and the Slovenian 
Pharmaceutical Society (Slovensko Farmacevtsko Društvo, 2010) perform 
various activities together in support of the professional and economical 
interests of its members (Gala, 2004). The Slovenian Chamber of Pharmacy 
is also responsible for planning and monitoring the specialisations for 
pharmacists, and “formulation of drugs” is one of the 5 specialisation 
programmes available (Čufar, 2007). 
Both professional organisations have a section specifically dedicated to 
hospital pharmacy. The hospital pharmacy section in the Slovenian 
Pharmaceutical Society has proposed that all hospital pharmacies would 
perform the following compounding activities by 2011: “preparation of 
cytotoxics, radiopharmaceuticals, TPN and all sterile medicines for high-risk 
wards” (Štefančič, 2007). 
9.2.2 Slovenian information sources 
The Slovenian Medicines Act (article 20, number 1) establishes that 
medicinal products must be manufactured in accordance with the PhEur and 
the Slovenian national supplement to the PhEur (Ministrstvo za Zdravje, 
2006), named Formularium Slovenicum (FS) and issued by the Javna 
Agencija Republike Slovenije za Zdravila in Medicinske Pripomočke (JAZMP) 
(Glover, 2011). The FS has been published since 1998 and is now in its 3rd 
edition (FS 3.0), which is available online by subscription and includes 
selected contents of the PhEur 7.0 (and respective supplements 7.1 and 
7.2.), as well as specific national content (JAZMP, 2011a). The FS enables 
the implementation of the PhEur in Slovenia, taking into consideration 
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national requirements (Cvelbar et al., 2003). In Chapter VI, national 
monographs include monographs for pharmaceutical preparations, for 
instance: Simple Syrup and Zinc Ointment, in a total of 14 different 
compounded medicines (JAZMP, 2011b). 
The Kodeks Galenskih Izdelkov (codex of galenic products), published in 
2009, includes a total of 103 monographs for both adult and paediatric 
compounded medicines (Obreza and Gašperlin, 2009). This codex is not 
legally binding and formulae have not been validated, which is considered a 
major deficiency by the working party of the codex (Glover, 2012). 
9.3 Methods 
The research project was initiated in 2007 with the help of Spela Godec 
(SG)39 who, in the initial stages, put MC in contact with Slovenian 
stakeholders and, in a later stage, provided invaluable support with 
translations (Section 9.3.3). The research project in Slovenia was then set up 
considering the expertise and advice of Slovenian pharmacists from 
academia, hospital pharmacy and the Slovenian Chamber of Pharmacy 
(Section 9.2.1).  
Tomi Laptoš (University Medical Centre Ljubljana) and Jure Bračun (Splošna 
Bolnišnica Celje), both pharmacists at Slovenian hospitals, contributed with 
important information regarding the concept of compounded medicines in 
Slovenia, and the respective compounding legislation. Jure Bračun also 
contacted selected Slovenian hospitals on behalf of MC (Section 9.3.3). 
Andreja Čufar (president of the Slovenian Chamber of Pharmacy) and Brigita 
Najdenov (Splošna Bolnišnica Jesenice) provided the complete list of 
Slovenian hospitals, including the classification of each hospital and the 
contact details for each hospital pharmacy. Although the Ministry of Health 
stated 26 hospitals in the official website (Ministry of Health, 2010), a total of 
29 hospitals were described in the literature and identified by the 
stakeholders, as follows: university hospitals (2); general hospitals (10); 
specialist hospitals (14); and 3 extra hospitals for diagnostic/surgical 
                                            
39SG was, at that time, an Erasmus student from the University of Ljubljana, Faculty of 
Pharmacy, at the CPPR (UCL School of Pharmacy, University of London). 
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procedures. With reference to the specialist hospitals, these were further 
divided in: gynecological (2), oncology (1), orthopedic (1), psychiatric (5), 
pulmonary (3) and rehabilitation (2) (Najdenov, 2009; Čižman, 2011).  
It was decided that no fieldwork would be undertaken in Slovenia (budgetary 
constraints) and, hence, all research was undertaken by MC at distance, 
which lengthened the timelines for the project in this country; data collection 
was initiated in 2009. 
9.3.1 Country-specific questionnaire 
The research instrument developed to collect information regarding oral 
compounded medicines most frequently dispensed in Slovenian hospital 
pharmacies was a self-completion questionnaire, based on the template 
established for Portugal (Section 3.3.1) and adapted to the practice of 
pharmaceutical compounding in Slovenia.  
This customised questionnaire comprised 1 table only and was developed in 
English to ease the direct communication with MC (avoiding the need for 
translators). Data collection in Slovenia was initiated in the year 2009 and, 
therefore, the questionnaire addressed information relating to 2008 (or 2007), 
depending on the latest available data. Compounded medicines were defined 
in the questionnaire as “medicines prepared by the pharmacy, in small scale, 
in order to meet individualised needs of patients”. The official terminology 
(Section 9.1) was not adopted since, according to Slovenian stakeholders, a 
brief explanation would be preferable to the request for magistral and galenic 
preparations. In Slovenia, magistral preparations commonly comprise for 
individual compounded medicines whereas galenic preparations commonly 
comprise for compounded medicines prepared in batches. Since batch 
preparation (of galenic preparations) is only allowed in pharmacies with a 
certified (galenic) laboratory, the official terminology could be confusing and, 
therefore, a brief and general definition of compounded medicines was 
adopted instead. 
In a later stage, the customised questionnaire and introductory email were 
translated into Slovenian by SG (Section 9.3.3) and, because the majority of 
translated emails were sent in January 2010, the translated questionnaire 
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addressed data from 2008 (and also 2009). The main heading of the 
translated Slovenian questionnaire is shown in Figure 9.1. 
9.3.2 Purposive sample of hospitals 
According to Čufar (2009), there were 3 specific hospitals that prepared the 
majority of compounded medicines in Slovenia but, in general, all Slovenian 
hospitals undertook some sort of compounding. A purposive sample 
constituted by 3 hospitals was considered too limited, and it was likely that 
more hospitals would also frequently dispense compounded medicines in 
Slovenia. For these reasons, instead of a purposive sample, all 29 hospitals 
in Slovenia (Section 9.3) were contacted and invited to participate in the 
study.  
9.3.3 Data collection 
The complete list of Slovenian hospitals was provided by 2 stakeholders 
including the contact details for each hospital pharmacy (Section 9.3). All 29 
hospitals were contacted by MC by email (in English) with the request to 
share data regarding the oral compounded medicines most frequently 
dispensed in 2008 (or the latest available year). A brief introductory email 
was then sent to each hospital pharmacy, with the questionnaire attached as 
well as an electronic copy of the IJPC article (Carvalho et al., 2008). After 1 
month, only 4 hospitals had replied to the request for collaboration.  
Because there was a possibility that some of the email addresses provided 
by the stakeholders were no longer in use, alternative email addresses were 
searched in the hospital’s websites (Ministry of Health, 2010). Email 
reminders were then sent periodically to all non-respondents, to a maximum 
of 5 email reminders per hospital. Jure Bračun (Section 9.3) also contacted 
selected non-respondents on behalf of MC.  
After a long period of time, only a few more hospital pharmacies had replied 
to the request for collaboration. It was suggested that the staff at the 
hospitals did not use email regularly. For this reason, all non-respondents 
were contacted by telephone by MC. It was very difficult to communicate with 
the receptionists at the hospitals, for language reasons, and also with the 
staff at the pharmacies. 
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In a last attempt to increase the number of participant hospitals, the 
questionnaire and introductory email were translated to Slovenian by SG and 
these were sent to all non-respondents.  
9.4 Results and discussion 
Out of the 29 hospitals contacted, 17 hospital pharmacies responded to the 
request for collaboration and 12 were non-respondents, resulting in a 
response rate of 59%. Furthermore, out of the 17 respondents, 9 contributed 
data regarding the oral compounded medicines most frequently dispensed by 
their pharmacies and 8 hospitals were non-participants (Figure 9.2).  
 
Figure 9.2 Purposive sample distributed by respondent and participant hospitals. 
With reference to the coding frame in Table 2.2, the reasons given by 
hospital pharmacies for not participating in the research may be summarised 
as follows: 4 hospitals did not dispense oral compounded medicines; 2 
hospitals dispensed oral compounded medicines but data was not readily 
accessible; 1 hospital dispensed very few oral compounded medicines; and 1 
hospital did not provide any reason for not collaborating. Because all 
hospitals in Slovenia were included in the research, it was expected that 
those hospitals that dispensed few (or none) compounded medicines would 
be least likely to participate. In addition, the English language was a barrier to 
effective communication between MC and the staff at the hospitals, which 
might have discouraged participation. If a purposive sample of hospitals had 
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been contacted (instead of all hospitals in Slovenia), and if a Slovenian 
collaborator had been appointed to contact these hospitals, the response rate 
would likely had been higher. Nevertheless, the response rate achieved was 
still higher than the 50% achieved in the national survey conducted by the 
Department of Quality (Section 9). In total, 8 hospitals provided complete 
datasets and only 1 hospital supplied qualitative information. All 8 hospitals 
provided datasets in electronic formats and also in the questionnaire 
provided (Section 9.3.1). All hospitals provided data regarding 2008, with the 
exception of 1 hospital that provided data regarding 2009.  
The participant hospitals were located across the country, in the cities of 
Celje, Golnik, Izola, Jesenice, Ljubljana (capital), Maribor, Novo Mesto, Ptuj 
and Sežana (Figure 9.3), which included the largest Slovenian cities, namely: 
Ljubljana (capital) and Maribor (Slovenia-Tourist-Guide, no date). 
 
Figure 9.3 Map of Slovenia adapted from National Geographic Society (2003); indicating the 
location of the participant hospitals (   ). 
9.4.1 Active substances  
A complete list of the active substances most frequently dispensed as oral 
compounded medicines in Slovenia is shown in Table 9.1. Active substances 
were grouped according to their therapeutic classification (Martindale 35, 
2007), giving a total of 68 different active substances and 19 therapeutic 
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groups. Antibacterials was the therapeutic group with the greatest number of 
different active substances (n=11), followed by cardiovascular drugs (n=10) 
and electrolytes (n=7). 
The title of all therapeutic groups suggest the respective oral indications, with 
the exception of supplementary drugs and other substances; the active 
substances included in this group were described in Appendix 15. 
With reference to the official list provided by ANVISA (2007) (Appendix 1), a 
total of 3 NTI drugs were dispensed as oral compounded medicines 
(underlined in Table 9.1). 
Table 9.1 Active substances most frequently dispensed as oral compounded medicines in 
Slovenia (NTI drugs underlined). 
Analgesics, anti-inflammatory drugs 
and antipyretics  
Indometacin, morphine, naproxen 
 
Antibacterials  
Amoxicillin, clavulanic acid, cloxacillin, 
isoniazid, nitrofurantoin, 
phenoxymethylpenicillin, pyrazinamide, 
rifampicin, roxithromycin, spiramycin, 
trimethoprim 
 
Antiepileptics  
Oxcarbazepine, phenobarbital, topiramate 
 
Antimalarials  
Pyrimethamine 
 
Antineoplastics 
Idarubicin HCl, lomustine, 
mercaptopurine, procarbazine HCl, 
tioguanine, trofosfamide 
 
Antiprotozoals  
Metronidazole 
 
Antivirals 
Oseltamivir phosphate, valganciclovir HCl 
 
Anxiolytic, sedatives, hypnotics and 
antipsychotics 
Chloral hydrate, midazolam, nitrazepam 
 
Bronchodilators and anti-asthma drugs 
Caffeine, theophylline 
 
Cardiovascular drugs 
Amiodarone, bisoprolol fumarate, 
captopril, clonidine, enalapril, furosemide, 
metoprolol, propafenone HCl, propranolol 
HCl, spironolactone 
 
Electrolytes 
Dibasic sodium phosphate, magnesium 
sulfate, monobasic sodium phosphate, 
potassium chloride, sodium bicarbonate, 
sodium chloride, sodium citrate 
 
GI drugs 
Calcium carbonate, pantoprazole, 
ranitidine, sodium sulfate 
 
Immunosuppressants 
Azathioprine, tacrolimus 
 
Local anaesthetics 
Benzocaine 
 
Miotics, mydriatics and antiglaucoma 
drugs 
Acetazolamide 
 
Nutritional agents and vitamins 
Glucose, lactose, riboflavin, tocoferil 
acetate, tocopherol, zinc 
 
Supplementary drugs and other 
substances 
Amylase, citric acid, macrogols 
 
Thyroid and antithyroid drugs 
Levothyroxine sodium 
 
 
Urological drugs 
Sildenafil citrate 
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The active substances dispensed by most hospitals were: sodium 
bicarbonate (n=7), midazolam (n=6), ranitidine and theophylline (n=5). 
All active substances reported were included in Martindale 35 (2007), with 
exception of lipase and protease (Appendix 26) that were dispensed by only 
1 hospital as oral powders (in combination with amylase). The source of 
these 3 pancreatic enzymes was a proprietary medicine (Panaze). Lipase, 
protease and amylase are constituents of pancreatin, or pancreas powder, a 
substance prepared from pancreases of mammals that is given orally in 
conditions of pancreatic exocrine deficiency (Martindale 35, 2007) (Appendix 
15).  
The majority of compounded medicines dispensed included 1 active 
substance only. In fact, only a few combinations of active substances were 
reported, as follows: 
• Amoxicillin and clavulanic acid: a common antibacterial combination that is 
commercially available as, for example, in Co-amoxiclav (Joint Formulary 
Committee, 2008). 
• Rifampicin and isoniazid: a common antituberculosis combination that is 
also commercially available as, for example, in Rifinah 150 (Joint Formulary 
Committee, 2008). 
• Lipase, protease and amylase (mentioned above). 
• Multiple combinations of electrolytes; electrolytes, glucose and macrogols; 
and also electrolytes, sodium sulfate and macrogols. 
The majority of compounded medicines were reported by the respective 
active substances and only 2 compounded medicines were reported by the 
proprietary medicines used in their preparation: Imuran (azathioprine) and 
Panaze (lipase, protease and amylase), which were dispensed by 2 
hospitals. It is likely that more compounded medicines were prepared from 
the respective proprietary medicines, in particular the commercially available 
combinations mentioned above. 
9.4.2 Oral solids 
Oral solid dosage forms were reported by all participant hospitals and 
included capsules (n=7), oral powders (n=6) and powders for oral liquids 
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(n=1). In total, 8 hospitals shared quantitative datasets, whereas 1 hospital 
disclosed only qualitative data with regards to the capsules dispensed, which 
was processed and analysed accordingly (Section 2.4). 
The quantities of oral solids were provided as the number of individual units 
and/or the number of packs dispensed, which are shown separately below 
(Figure 9.4). A total of 2 hospitals provided the number of units (only) 
whereas 6 hospitals provided the number of packs; pack sizes were 
commonly reported as an interval (e.g. 30-50 units of capsules) and, 
therefore, the corresponding number of units could not be accurately 
estimated. In total, 40,838 units and 1,717 packs of oral solids were reported. 
 
Figure 9.4 Oral solid dosage forms dispensed by number of units/packs. 
The top 10 active substances dispensed as oral solids by number of packs 
and by number of units are listed in Figures 9.5 and 9.6, respectively. A total 
of 3 active substances were common to both rankings, namely: sodium 
bicarbonate, furosemide and ranitidine. Sodium bicarbonate was the most 
frequently dispensed active substance in both rankings and represented 
33% and 32%, respectively, of all active substances dispensed as oral 
solids. Sodium bicarbonate is an alkalinising agent commonly indicated in 
the correction of metabolic acidosis, management of hyperkalaemia, 
alkalinisation of the urine and as an antacid. The treatment of acidotic states 
depends on the patient’s acid-base balance and electrolyte status and, 
therefore, it requires customised doses of bicarbonate (Martindale 35, 2007). 
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Sodium bicarbonate was dispensed as capsules by 7 hospitals (500-2,000 
mg, 5 strengths); one hospital reported capsules of 500 g but it was likely a 
mistake since the usual doses for the alkalinisation of the urine, for instance, 
correspond to a maximum of 10 g per day (in divided doses) and such a 
large amount of powder would not fit in an oral gelatin capsule (for human 
use).  
  
Figure 9.5 Top 10 active substances 
dispensed as oral solids by number of 
packs. 
Figure 9.6 Top 10 active substances 
dispensed as oral solids by number of 
units. 
Electrolytes 1 (Figure 9.6) stands for the combination of potassium chloride, 
sodium bicarbonate and sodium chloride, which corresponded to the majority 
(84%) of all oral powders dispensed (by number of units). This combination 
was named “laxative salts” and was reported by 2 hospitals. Electrolytes 2 
(Figure 9.6) represents the same combination of potassium chloride, sodium 
bicarbonate and sodium chloride, with the addition of sodium sulfate and 
macrogols. This combination was reported both as oral powders and 
powders for oral liquids, by a total of 2 hospitals. It was named “laxative salts” 
and also “Golytely”, which corresponds to a proprietary medicine for bowel 
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evacuation constituted by macrogols and electrolytes (Martindale 35, 2007). 
Golytely is supplied in powdered form for oral administration as a solution, 
following reconstitution (Braintree Laboratories, 2001) and its composition is 
equivalent to the compounded medicines reported (Appendix 2). Therefore, 
the oral powders reported as Golytely were likely powders for oral liquids. 
Capsules were the most frequently dispensed dosage form, both by number 
of units (75.5%) and by number of packs (55.5%) (Figure 9.4), and were 
reported by 78% of hospitals, for a total of 34 different active substances. 
The top 5 active substances (and respective strengths) were: sodium 
bicarbonate (800-2,000 mg), lactose, glucose, potassium chloride (3,000 mg) 
and caffeine (4-100 mg) (by number of packs); sodium bicarbonate (500 mg), 
theophylline (3-10 mg), alpha tocopherol (5 mg and 10 mg), phenobarbital (3-
10 mg) and sildenafil citrate (0.3-4 mg) (by number of units). These active 
substances were all included in the top 10 listed in Figures 9.5 and 9.6, with 
the exception of caffeine. 
Oral powders represented 23.8% and 44.5% of all oral solids dispensed by 
number of units and by number of packs, respectively. Oral powders were 
reported by 67% of hospitals, in a total of 29 different active substances. The 
top 5 active substances (by number of packs) and respective strengths were: 
riboflavin (25-200 mg), sodium bicarbonate (1,000 mg), furosemide (3-5 mg), 
amoxicillin (25-200 mg) and tocoferil acetate (5-200 mg), which were all 
included in the overall top 10 active substances dispensed as oral solids 
(Figure 9.5). 
Powders for oral liquids represented only 0.7% of all oral solids (by number 
of units) (Figure 9.4) and were reported by only 1 hospital. However, as 
identified above, it is likely that the oral powders reported as Golytely, in fact, 
corresponded to powders for oral liquids. 
The top 5 therapeutic groups, ranked by number of packs and by number of 
units of the corresponding oral solids, included the following 3 groups in 
common: electrolytes; nutritional agents and vitamins; and cardiovascular 
drugs. These 3 groups represented 67% and 63% of all oral solids dispensed 
by number of packs and by number of units, respectively. 
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9.4.3 Oral liquids 
Oral liquid dosage forms were reported by 89% of the participant hospitals 
and included solutions (n=7), suspensions (n=3) and syrups (n=1). The 
majority of oral liquids were reported as solutions (79%) (Figure 9.7) but it is 
likely that the classification of some oral liquids was not accurate and, 
therefore, part of the solutions might have corresponded to suspensions or 
syrups (and vice-versa) (Section 2.1.3). Altogether, solutions and 
suspensions represented 99% of all oral liquids dispensed. The volumes 
reported ranged from 20 mL to 3,000 mL and, therefore, it was assumed that 
all 3,279 units of oral liquids dispensed were multidose. 
                 
Figure 9.7 Oral liquid dosage forms dispensed by number of units. 
A total of 32 different active substances were dispensed as oral liquids and 
the top 10 active substances are shown in Figure 9.8.  
Golytely (Appendix 2) was one of the most frequently dispensed oral liquids 
(Figure 9.8) and was reported as a solution (1,000 mL) by 2 hospitals. 
Chloral hydrate (40 mg/mL and 50 mg/mL) and midazolam (1.5-2 mg/mL, 4 
strengths), both “anxiolytic, sedatives, hypnotics and antipsychotics”, were 
reported by 78% of hospitals and represented 43% of all oral liquids (Figure 
9.8). Phenobarbital was the only active substance common to the top 10 
dispensed as oral solids (Figure 9.6), which suggests that active substances 
are preferably dispensed either as solid or liquid dosage forms. 
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Figure 9.8 Top 10 active substances dispensed as oral liquids, ranked by number of units. 
Syrups corresponded to just 1% of all oral liquids (Figure 9.7) and were 
reported by only 1 hospital. The only 2 active substances (and respective 
volumes) dispensed as syrups were: levothyroxine sodium (40 mL) and 
valganciclovir HCl (82 mL).  
The top 3 therapeutic groups (oral liquids only) were: anxiolytic, sedatives, 
hypnotics and antipsychotics (chloral hydrate, midazolam and nitrazepam), 
which represented 43% of all oral liquids; followed by the combined 
electrolytes and gastrointestinal drugs (Golytely) and cardiovascular drugs (7 
active substances).  
The multidose oral liquids may be quantitatively compared to the oral solids 
dispensed (in packs). Estimating that capsules were dispensed in packs of 
50 units (Section 2.1.3), the 30,852 individual units of capsules corresponded 
approximately to 617 packs of capsules (of 50 units each). In addition, 
considering that oral powders were dispensed in packs of 13 units (Section 
2.1.3), the 9,718 individual units of oral powders corresponded approximately 
to 748 packs of oral powders (of 13 units each). As a result, a total of 
approximately 3,082 packs of oral solids were dispensed in Slovenia. 
Therefore, when the 3,279 units of multidose oral liquids are compared to the 
estimation of 3,082 packs of oral solids, it is concluded that oral liquids and 
oral solids were dispensed in approximately equal quantities. One hospital 
commented that they were substituting capsules for solutions/suspensions 
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and that is why they were currently preparing more oral liquids than oral 
solids. If other hospitals adopt this practice, oral liquids will become the most 
frequently dispensed dosage form in Slovenia. 
9.4.4 Oromucosal preparations 
In Slovenia, oromucosal preparations were not reported by any participant 
hospital. 
9.5 Summary 
• Compounded medicines in Slovenia may be categorised into magistral preparations and 
galenic preparations. Batch preparation (of galenic preparations) is only allowed in 
pharmacies with a certified (galenic) laboratory. 
• Formularium Slovenicum is the Slovenian national supplement to the PhEur, which 
enables the implementation of the PhEur in Slovenia, taking into consideration national 
requirements, and includes monographs for compounded medicines. 
• All 29 hospitals in Slovenia were included in the research and a response rate of 59% 
was obtained. A total of 68 different active substances (including 3 NTI drugs) were reported 
corresponding to 19 different therapeutic groups. The top 3 therapeutic groups were 
antibacterials (n=11), cardiovascular drugs (n=10) and electrolytes (n=7). 
• Oral solid dosage forms were reported by all participant hospitals and included capsules, 
oral powders and powders for oral liquids. Capsules were dispensed in a total sum of 30,852 
units (75.5% of all oral solids) and 953 packs (55.5%). The top 5 active substances were: 
sodium bicarbonate, lactose, glucose, potassium chloride and caffeine (by number of packs); 
sodium bicarbonate, theophylline, alpha tocopherol, phenobarbital and sildenafil citrate (by 
number of units). Oral powders were dispensed in a total sum of 9,718 units (23.8% of all 
oral solids) and 764 packs (44.5%). The top active substances dispensed were: riboflavin, 
sodium bicarbonate, furosemide, amoxicillin and tocoferil acetate (by number of packs); 
potassium chloride, sodium bicarbonate and sodium chloride (in combination) (by number of 
units). Powders for oral liquids were dispensed in a total of 268 units (0.7% of all oral solids). 
• Oral liquid dosage forms were reported by 89% of all participant hospitals and included 
solutions, suspensions and syrups, dispensed in a total sum of 3,279 units. The top active 
substances dispensed were: chloral hydrate, Golytely (potassium chloride, sodium 
bicarbonate, sodium chloride, sodium sulfate and macrogols) and midazolam. Solutions and 
suspensions represented 99% of all oral liquids whereas syrups represented 1%. The only 
active substances dispensed as syrups were levothyroxine sodium and valganciclovir HCl. 
• Oral liquids were dispensed in comparable quantities to oral solids. 
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10. Compounding in Finland 
Finland is a Northern country, bordered by the Baltic Sea in the South and 
Sweden in the West, that joined the EU in 1995. Its official languages are 
Finnish and Swedish (Europa, 2009). Although the 6th largest European 
country, with a surface area of 304,500 Km2, it is the 19th most populated 
(Figure 2.2), with a population of 5.3 million in 2007 (Europa, 2008). 
In 2007, there were 341 hospitals in Finland (ratio of 6.45 hospitals per 
100,000 population) (WHO Regional Office for Europe, 2010) (Appendix 3), 
including 21 central hospitals - 5 of which university hospitals (Pharmine, 
2010). In Finland, there is regional organisation of hospitals into districts, with 
each district having a central hospital supervised by a university hospital. 
University hospitals are the largest hospitals, and central hospitals are the 
most central, large hospitals in a particular district. Specialised medical care 
is provided in the 5 university hospitals, which are associated with a faculty of 
medicine and are located in the largest cities: Helsinki, Tampere, Turku, Oulu 
and Kuopio (Ovaskainen et al., 2005; Atkinson and Hirvonen, 2010). 
In 2007, there were a total of 36,095 hospital beds (ratio of 682.49 hospital 
beds per 100,000 population) (WHO Regional Office for Europe, 2010) 
(Appendix 3), which was slightly lower than in 2006 (ratio of 696.11 hospital 
beds per 100,000 population) (Pharmine, 2010). The number of hospital beds 
has decreased faster in Finland (and in the Northern countries) than in the 
rest of the EU (Koskinen et al., 2006). Nevertheless, the ratio of hospital beds 
in Finland is still fairly high when considering all the countries included in the 
research (Appendix 3).  
In 2007, there were 5,655 pharmacists in Finland (ratio of 107.11 
pharmacists per 100,000 population) (WHO Regional Office for Europe, 
2011) (Appendix 4) but there were only 545 hospital pharmacists (470 
Bachelors and 75 Masters of Science) (Atkinson and Hirvonen, 2010). 
The preparation of compounded medicines occurs in community and hospital 
pharmacies throughout Finland. All community pharmacies are required to 
have a laboratory for pharmaceutical compounding and a total of 0.5% of all 
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medicines dispensed in the community setting are compounded medicines 
(Bell et al., 2007). 
In Finnish hospital pharmacies, pharmaceutical compounding is one of the 
major activities (Ovaskainen et al., 2005) and is an essential function of 
hospital pharmacists (Koskinen and Kela, 2009). Compounded medicines are 
prepared and dispensed only when an alternative proprietary medicine is not 
available. These medicines are normally prepared on an individual basis and 
are usually distributed within the hospital in which the preparation takes place 
(Torniainen, 2007). A large number of compounded medicines are prepared 
in Finland, particularly oral powders for paediatric patients (Eronen et al., 
2005; Koskinen and Kela, 2009); intensive care and dermatology are two 
other areas that frequently require compounded medicines (Torniainen, 
2007). Both sterile and non-sterile compounded medicines are prepared in 
Finnish hospitals, but the university hospitals supply the largest variety of 
medicines, including a wide range of sterile products (Eronen et al., 2005; 
Puumalainen, 2009). Larger hospitals have validated procedures in place 
and several hospital pharmacies have invested in facilities to meet GMP 
standards (Eronen et al., 2005; Koskinen and Kela, 2009). According to the 
EAHP survey, SOP are used in more than 80% of Finnish hospital 
pharmacies (EAHP, 2005). In Finland, hospitals pharmacists are aware of the 
importance of preparing compounded medicines in accordance with 
standards of quality and, in February 2007, 50 hospital pharmacists 
(approximately) attended a course in Helsinki on the topic “Preparation of 
medicinal products in hospital pharmacies - GMP in focus” (Torniainen, 
2007).  
Inka Puumalainen (2009), president of the Finnish Hospital Pharmacists’ 
Association (Section 10.2), when asked about the future role of hospital 
pharmacy in the area of pharmaceutical compounding answered that “… 
medicines will be more patient-tailored and administration will vary. Hospital 
pharmacists will require specialised skills to produce these medicines.” 
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10.1 Legislation 
The National Agency for Medicines (NAM) is the entity responsible for 
monitoring the overall medicinal field in Finland, including the regulation of 
pharmacies and pharmaceutical products (Bell et al., 2007; NAM, no date). 
The NAM, working on behalf of the Ministry of Social Affairs and Health, 
supervises the activities of hospital pharmacists and has the authority to 
suspend permission for a pharmacy to operate, if activities do not comply 
with the laws and regulations in effect (Eronen et al., 2005; Bell et al., 2007). 
In Finland, compounded medicines (Ex tempore - Lääkevalmiste) are defined 
as medicinal products prepared on request, or in accordance with a 
prescription, for the immediate use by patients (NAM, 2006a). Pharmacies’ 
own medicinal (compounded) products (Omat Lääkevalmisteet) are also 
allowed in Finland, provided that the NAM is notified (Barbosa and Pinto, 
2001; NAM, 2006a; 2006b).  
In accordance with the Finnish Medicines Act (NAM, 2006b), “preparation 
other than industrial manufacture” may occur in community pharmacies (or in 
subsidiary pharmacies belonging to these) and also in hospital pharmacies. 
Pharmacies are allowed to dispense compounded medicines prepared in 
other pharmacies (contract manufacture), provided that the NAM is notified. 
A prerequisite for the preparation of compounded medicines is that “the 
personnel are sufficiently familiar with the preparation of medicinal products 
and that there are appropriate production facilities and equipment for such 
preparation” (NAM, 2006b). According to this legislation, the manufacture of 
medicinal products must comply with GMP. However, uncertainty exists 
regarding the interpretation of GMP in pharmaceutical compounding 
(Torniainen, 2007) and criteria may vary within Finnish hospital pharmacies. 
10.2 Professional organisations and information sources 
10.2.1 Finnish professional organisations 
In Finland, a specific professional organisation for pharmaceutical 
compounding is not currently in existence. There are however several 
organisations dedicated to pharmacy and pharmacists, including: 
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• Finnish Pharmacists’ Association: is a trade and professional body for 
individuals in the field of pharmacy (Farmasialiitto, 2012).  
• Association of Finnish Pharmacies (AFP): is a professional organisation of 
proprietary pharmacists (AFP, 2008). AFP is the editor organisation of the 
Finnish national formulary (Section 10.2.2). 
• Finnish Hospital Pharmacists’ Association (Satefa): is both the trade union 
and professional association for hospital pharmacists; it was originally part of 
the Finnish Pharmacists’ Association but it is now a separate entity 
(Leskinen, 2005). 
10.2.2 Finnish information sources 
• Dispensatorium Fennicum: is the Finnish national formulary, edited by the 
AFP (Section 10.2.1) (Suomen Apteekkariliitto, 2004), which corresponds to 
the official reference for pharmaceutical compounding in Finland. It was first 
published in 1971 and the 3rd edition (1993) includes 108 monographs for the 
compounded medicines suggested in an enquiry to Finnish pharmacies 
(Barbosa and Pinto, 2001). 
• International informational sources, such as the IJPC and the “Trissel’s 
stability of compounded formulations” (Section 14.2.2), are also commonly 
used in Finnish hospital pharmacies (Helin-Tanninen, 2010). 
10.3 Methods 
The research project was initiated in 2007, by consulting Finnish 
stakeholders in pharmacy and pharmaceutical compounding, but that data 
collection was not initiated until 2009 due to difficulties in identifying the 
purposive sample of hospitals. 
Experts from academia, hospital pharmacy and the NAM - Anne Juppo 
(University of Helsinki, Faculty of Pharmacy); Hanna Tolonen (Hospital 
District of Helsinki and Uusimaa) and Kristine Salminen (NAM, Enforcement 
& Inspection) - contributed with their expertise and advice towards the 
development of the Finnish questionnaire (Section 10.3.1) and identification 
of the purposive sample of hospitals (Section 10.3.2). It was decided that no 
fieldwork would be undertaken in Finland (budgetary constraints) and, hence, 
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all research was undertaken by MC at distance, which contributed to the 
length of the project in this country. 
10.3.1 Country-specific questionnaire  
The research instrument developed to collect information about oral 
compounded medicines most frequently dispensed in Finnish hospital 
pharmacies was a self-completion questionnaire (main heading in Figure 
10.1), which was based on the template established for Portugal (Section 
3.3.1) and adapted to the practice of pharmaceutical compounding in 
Finland. This customised questionnaire comprised 1 table only and was 
developed in English, as recommended by the stakeholders (Section 10.3), 
who asserted that translating was unnecessary since the Finnish population 
is generally fluent in English. Data collection in Finland was undertaken in the 
year 2009 and, therefore, the questionnaire addressed information relating to 
2008. Compounded medicines were defined as “extemporaneous 
formulations prepared by a pharmacy” because, according to the Finnish 
legislation, these correspond to Ex tempore - Lääkevalmiste and their 
preparation may occur in community pharmacies (or in subsidiary 
pharmacies belonging to these) and also in hospital pharmacies (Section 
10.1). Although compounded medicines are mainly dispensed in the hospital 
where the preparation takes place (Torniainen, 2007), an extra column was 
added to the questionnaire, namely “Manufacturer”, so that the compounded 
medicines prepared in other hospital/community pharmacies would be 
identified (Section 7.3.1). 
10.3.2 Purposive sample of hospitals 
A total of 8 hospitals were selected across Finland, including the 5 university 
hospitals and 3 central hospitals, from the following cities: Helsinki (capital), 
Tampere, Turku, Kuopio, Oulu, Jyvaskyla, Kotka and Lahti (Figure 10.2). 
University hospital pharmacies prepare the largest variety of compounded 
medicines (Puumalainen, 2009) and were identified by the stakeholders as 
the ones in which the largest quantities of compounded medicines were likely 
dispensed in Finland; for these reasons, all Finnish university hospitals were 
included in the research.  
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Figure 10.1 C
ountry-specific questionnaire (Finland).
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Figure 10.2 Map of Finland adapted from National Geographic Society (1998g); indicating 
the location of the purposive sample of hospitals (   ).  
It was concluded that it would be important to include non-university hospitals 
in the purposive sample so that data did not reflect the compounding 
practices of university hospitals only. As a result, the purposive sample 
included 3 additional central hospitals, which were also identified by the 
stakeholders as the ones in which the largest quantities of compounded 
medicines were likely dispensed in Finland. 
10.3.3 Data collection 
The purposive sample was provided by the Finnish stakeholders (Section 
10.3) including the name and email address of the key contact person in 
each hospital pharmacy. All 8 hospital pharmacies were initially contacted by 
MC by email with the request to share data regarding the oral compounded 
medicines most frequently dispensed in 2008 (or the latest available year). 
The customised questionnaire was attached to a brief introductory email, 
together with an electronic copy of the IJPC article (Carvalho et al., 2008) 
and the EuPFI presentation (Carvalho, 2009). Non-respondents were sent 
periodical email reminders, up to a maximum of 3 emails per hospital 
pharmacy (excluding the IJPC article and the EuPFI presentation to avoid an 
overload of information), after which non-respondents were contacted by 
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telephone. Persistent non-respondents, after being contacted by telephone 
and accepted to participate, were sent up to 4 additional email reminders. 
Data were collected by the hospital pharmacy’s staff and none of the Finnish 
hospitals were visited by MC. 
10.4 Results and discussion 
In total, 7 hospitals responded to the request for collaboration (88% response 
rate) and 1 hospital was non-respondent. All respondents contributed data 
regarding the oral compounded medicines most frequently dispensed in 2008 
(0 non-participant hospitals) (Figure 10.3). 
                
Figure 10.3 Purposive sample distributed by respondent and participant hospitals.  
A total of 6 hospitals provided complete datasets, whereas 1 hospital 
provided quantitative information for oral liquids but only semi-quantitative 
information for oral solids (Section 10.4.2). All Finnish hospitals sent the 
required data (in electronic formats) by email and the majority (57%) 
following the first email; only 4 hospitals were sent email reminders and only 
1 hospital was contacted by telephone. The fact that all contacted 
pharmacists were fluent in English and were willing to contribute data, was 
deemed to be one of the major reasons for the high response rate obtained. 
All Finnish hospital pharmacies are computerised and information technology 
plays an important role in pharmaceutical compounding (Eronen et al., 2005). 
Therefore, it is likely that all participant hospitals had electronic records of the 
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compounded medicines dispensed, which certainly contributed to the ease of 
retrieving the required information. In total, 5 (71%) hospitals supplied data in 
the questionnaire provided and 2 (29%) hospitals in their own formats. 
Although the Finnish questionnaire included the column “Manufacturer” 
(Figure 10.1), so that the compounded medicines prepared in other 
hospital/community pharmacies would be identified, none of the participant 
hospitals indicated that they had dispensed medicines prepared by others 
(contract manufacturing, Section 10.1). It was thus considered that all 
compounded medicines dispensed in the participant hospitals were prepared 
in the respective pharmacies. All participant hospitals provided datasets 
including oral compounded medicines only (non-orals were excluded). After 
data processing, the Finnish database included a total of 186 data entries, 
corresponding to the datasets of 7 hospitals. 
10.4.1 Active substances  
A complete list of the active substances most frequently dispensed as oral 
compounded medicines in Finland is shown in Table 10.1. All active 
substances reported were included in Martindale 35 (2007) and these were 
grouped according to the respective therapeutic classification, giving a total 
of 85 different active substances and 25 therapeutic groups. Cardiovascular 
drugs was the group with the greatest number of different active substances 
(n=19), followed by nutritional agents and vitamins (n=10) and antiepileptics 
(n=8). 
Although these active substances were all reported as oral compounded 
medicines, the title of some therapeutic groups suggested non-oral 
(therapeutic) indications, namely: dermatological drugs and sunscreens 
(Appendix 11); disinfectants and preservatives (Appendix 12); stabilising and 
suspending agents (Appendix 14); and supplementary drugs and other 
substances (Appendix 15). The active substances included in these groups 
were described in the respective appendixes. 
With reference to the official list provided by ANVISA (2007) (Appendix 1), a 
total of 4 NTI drugs were dispensed as oral compounded medicines 
(underlined in Table 10.1). 
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Table 10.1 Active substances most frequently dispensed as oral compounded medicines in 
Finland (NTI drugs underlined). 
Analgesics, anti-inflammatory drugs 
and antipyretics 
Aspirin, ethylmorphine HCl, indometacin, 
methadone HCl, morphine, morphine HCl 
 
Antibacterials 
Isoniazid 
 
Antidiabetics 
Glibenclamide 
 
Antiepileptics 
Clobazam, clonazepam, oxcarbazepine, 
phenobarbital, phenytoin, sodium 
valproate, topiramate, vigabatrin 
 
Antifungals 
Miconazole 
 
Antihistamines 
Hydroxyzine HCl 
 
Antineoplastics 
Flutamide, mercaptopurine, methotrexate, 
tioguanine 
 
Antiprotozoals 
Metronidazole 
 
Anxiolytic, sedatives, hypnotics and 
antipsychotics 
Midazolam, nitrazepam 
 
Cardiovascular drugs 
Amiodarone, captopril, carvedilol, 
defibrotide, diazoxide, dipyridamole, 
enalapril, flecainide acetate, furosemide, 
hydrochlorothiazide, mannitol, metoprolol, 
nifedipine, nimodipine, 
phenoxybenzamine HCl, propranolol HCl, 
sotalol HCl, spironolactone, warfarin 
sodium 
 
Chelators, antidotes and antagonists 
Sodium polystyrene sulfonate 
 
Contrast media 
Barium sulfate 
 
Corticosteroids 
Dexamethasone, hydrocortisone, 
prednisolone 
 
Dermatological drugs and sunscreens 
Urea 
 
Disinfectants and preservatives 
Sodium benzoate, sodium hypochlorite 
 
Electrolytes 
Dibasic sodium phosphate, monobasic 
sodium phosphate, sodium chloride, 
sodium citrate 
 
GI drugs 
Aluminium hydroxide, calcium carbonate, 
magnesium hydroxide, simeticone 
 
Hypothalamic and pituitary hormones 
Desmopressin 
 
Local anaesthetics 
Cocaine, lidocaine 
 
Muscle relaxants 
Baclofen 
 
Nutritional agents and vitamins 
Ascorbic acid, ergocalciferol, glucose, 
lactose, phytomenadione, pyridoxine HCl, 
selenium, sodium fluoride, tocopherol, 
vitamin A 
 
Stabilising and suspending agents 
Ceratonia, methylcellulose 
 
Supplementary drugs and other 
substances 
Phosphoric acid, sodium phenylbutyrate, 
thalidomide, ursodeoxycholic acid 
 
Thyroid and antithyroid drugs 
Carbimazole, iodine, potassium iodide, 
potassium perchlorate 
 
Urological drugs 
Sildenafil citrate
 
 
The active substances dispensed by most hospitals were: hydrocortisone 
and spironolactone (all participant hospitals, n=7); hydrochlorothiazide, 
morphine and propranolol HCl (n=6). 
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Almost all compounded medicines included just 1 active substance (single-
drug) in their composition. In fact, only 6 compounded medicines included 
more than 1 active substance (multi-drug), in combinations of up to 4 
different active substances, as follows:  
• 2 active substances (n=4): ergocalciferol and vitamin A; iodine and 
potassium iodide (Lugol’s Solution, Appendix 16); mannitol and ceratonia 
(Appendix 14); miconazole and lidocaine. 
• 3 active substances (n=1): dibasic sodium phosphate, monobasic sodium 
phosphate and sodium fluoride. 
• 4 active substances (n=1): lidocaine, hydroxyzine HCl, aluminium 
hydroxide and magnesium hydroxide. 
Multi-drugs were dispensed as oral liquids and oromucosal preparations (all 
oral solids included 1 active substance only), by a total of 4 participant 
hospitals. 
In total, 13 proprietary medicines were reported by 2 hospitals, both as oral 
solids and oromucosal preparations, as follows:  
• Oral solids (n=2,649 individual units): Adursal (ursodeoxycholic acid); 
Cordarone (amiodarone HCl); Frisium (clobazam); Insomin (nitrazepam); 
Kalcipos (calcium carbonate); Nifangin (nifedipine); Orfiril (sodium valproate); 
Resonium (sodium polystyrene sulfonate); Rivatril (clonazepam); and 
Topimax (topiramate). 
• Oromucosal preparations (n=9 multidose units): Daktarin (miconazole); 
Jekovit (ergocalciferol); and Vitol (vitamin A and ergocalciferol). 
  
 Chapter 10: COMPOUNDING IN FINLAND | Results and discussion | 231 
 
10.4.2 Oral solids 
Oral solid dosage forms were reported by all participant hospitals and 
included oral powders (6 hospitals) and capsules (4 hospitals). In total, 6 
hospitals shared quantitative datasets, whereas 1 hospital disclosed only 
semi-quantitative data with regards to the oral powders dispensed, which 
was processed and analysed accordingly (Section 2.4). 
The quantities of oral solids were provided as the number of individual units 
and/or the number of packs dispensed, which are shown separately below 
(Figure 10.4). A total of 3 hospitals provided both figures whereas 3 hospitals 
provided the number of packs and 1 hospital provided the number of units 
only. The number of packs of oral solids dispensed varied from 25 to 1,423 
packs, whereas the number of units varied from 2,500 to 6,700 units. In total, 
2,363 packs and 18,605 units of oral solids were reported. 
 
Figure 10.4 Oral solids dispensed by number of units and number of packs, per hospital. 
The top 10 active substances dispensed as oral solids by number of units 
and by number of packs (and ranked by number of units) are listed in Figure 
10.5. A total of 16 active substances are shown; hydrocortisone, propranolol 
HCl, potassium perchlorate, hydrochlorothiazide, ursodeoxycholic acid and 
spironolactone are part of both top 10 active substances by number of units 
and by number of packs. 
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Figure 10.5 Top 10 active substances dispensed, by number of units and number of packs of 
oral solids (ranked by number of units). 
The top therapeutic groups, ranked by number of units of the corresponding 
oral solids, are listed in Figure 10.6. The most frequent therapeutic group 
was cardiovascular drugs, which comprised 12 different active substances 
that were dispensed in a total of 7,751 units and 1,201 packs of oral solids. 
Cardiovascular drugs represented 42% of the individual units dispensed and 
65% of the packs of oral solids dispensed. The active substances most 
frequently dispensed as cardiovascular drugs are displayed in Figure 10.7.  
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Figure 10.6 Dispensed oral solids classified by therapeutic groups, by number of units/packs. 
The next most frequent therapeutic groups were corticosteroids and 
antiepileptics (Figure 10.6). In total, oral solids corresponding to 20 
therapeutic groups (out of the 25 outlined in Table 10.1) were dispensed in 
Finland. The last category “others” included 14 therapeutic groups, as 
follows: analgesics, anti-inflammatory drugs and antipyretics; antibacterials; 
antihistamines; antineoplastics; antiprotozoals; chelators, antidotes and 
antagonists; dermatological drugs and sunscreens; disinfectants and 
preservatives; GI drugs; hypothalamic and pituitary hormones; local 
anaesthetics; muscle relaxants; nutritional agents and vitamins; and 
urological drugs. 
The majority of participant hospitals did not specify the strength of the oral 
solids dispensed. In fact, only 1 hospital provided detailed information, 
whereas all other hospitals provided either an interval of strengths (i.e. 
hydrochlorothiazide 1-10 mg) or no information at all. 
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Figure 10.7 Top 10 active substances dispensed as cardiovascular drugs (oral solids), by 
number of units/packs. 
In 2005, the number of patients discharged from all hospitals (including 
through death) in Finland was highest for diseases of the circulatory system 
(3,121 patients / 100,000 population) (Figure 10.8) (WHO Regional Office for 
Europe, 2008). It was to be expected then that cardiovascular drugs were the 
most frequent oral solids dispensed by the participant hospitals (Figure 10.6). 
Oral powders were dispensed in larger quantities than capsules, both by 
number of units and by number of packs dispensed (Figure 10.9). A total of 
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2,198 (93%) packs and 10,305 (55%) units of oral powders were reported, 
which is in accordance with Koskinen and Kela (2009) and Eronen et al. 
(2005), who stated that a large number of compounded medicines are 
prepared in Finland, particularly oral powders for paediatrics (Section 10). 
 
Figure 10.8 Number of patients per 100,000 population discharged from all hospitals 
(including through death) in Finland during 2005 (latest available year), categorised by 
principal diagnosis (adapted from WHO Regional Office for Europe, 2008). 
Oral powders were reported by 6 (86%) of hospitals (only 1 participant 
hospital did not report oral powders) and, considering the number of units 
dispensed, the top 5 active substances were: hydrocortisone, diazoxide, 
potassium perchlorate, amiodarone HCl and ursodeoxycholic acid; which 
were all included in the top 10 oral solids, dispensed by number of units and 
packs, displayed in Figure 10.5. Only 1 participant hospital classified the oral 
powders dispensed as sachets. 
 
Figure 10.9 Oral solids dispensed by number of units/packs, per dosage form. 
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Considering the capsules, a total of 8,300 (45%) units and 165 (7%) packs 
were reported. The top 5 active substances were also included in the top 10 
oral solids, dispensed by number of units and packs, displayed in Figure 
10.5, and corresponded to the following substances: hydrocortisone, 
ursodeoxycholic acid, propranolol HCl, nitrazepam and warfarin sodium. 
10.4.3 Oral liquids 
Oral liquid dosage forms were reported by all participant hospitals and 
included solutions and suspensions. The majority of oral liquids were 
reported as solutions (91.5%) but it is likely that the classification of some 
oral liquids was not accurate (Section 2.1.3). The volumes reported ranged 
from 0.4 mL to 1,000 mL, which corresponded to both multidose and unidose 
oral liquids. Only 1 hospital distinguished some oral liquids dispensed as 
(unidose) oral syringes but it was assumed that a total of 2 hospitals 
dispensed unidose oral liquids in Finland (Section 2.1.3). Only 5 active 
substances were dispensed as unidose (n=8,130 units), in limited strengths 
and in volumes of 0.4 mL to 32 mL, as displayed in Table 10.2. 
Table 10.2 Compounded medicines dispensed as unidose oral liquids. 
Active substances Strengths Volumes Number  of units 
Methadone HCl 5 mg/mL 8-32 mL 4,304 
Glucose 300 mg/mL 2 mL 2,300 
Hydrochlorothiazide 1-3 mg/mL 0.4-2 mL 790 
Spironolactone 2-10 mg/mL 0.5-2 mL 470 
Nimodipine 7.5 mg/mL 8 mL 266 
Total 8,130 
 
Multidose oral liquids were reported by all participant hospitals, in a total of 
16,948 units, from 171 to 8,336 units per hospital, as displayed in Figure 
10.10. Multidose oral liquids were dispensed in larger quantities than unidose 
oral liquids. Hospitals 1 to 4 are university hospitals, whereas hospitals 5 to 7 
are central hospitals. All unidose oral liquids and 90% of the multidose oral 
liquids were dispensed in university hospitals, whereas no unidose and only 
10% of the multidose liquids were dispensed in central hospitals. According 
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to Puumalainen (2009), university hospitals dispense the largest variety of 
compounded medicines in Finland. It is concluded that compounding 
practices vary within university and central hospitals, as previously 
anticipated (Section 10.3.2). 
 
Figure 10.10 Number of units of oral liquids (unidose and multidose) dispensed per hospital. 
The compounded medicines most frequently dispensed as multidose oral 
liquids are displayed in Table 10.3. Methadone HCl and glucose are also 
active substances which are most frequently dispensed as unidose oral 
liquids (Table 10.2). 
Table 10.3 Compounded medicines dispensed as multidose oral liquids. 
Active substances Strengths Volumes Number  of units 
Methadone HCl 5 and 10 mg/mL 20-500 mL 10,094 
Sodium citrate 0.3 M 30-500 mL 2,587 
Glucose 200-300 mg/mL 20-500 mL 1,666 
Morphine HCl 0.4-10 mg/mL 20-300 mL 1,328 
Others 1,273 
Total 16,948 
 
Methadone HCl was the active substance most frequently dispensed both as 
a unidose and multidose oral liquid. It was reported in the strengths of 5 
mg/mL and 10 mg/mL, and in the volumes of 8 mL to 500 mL. Methadone 
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HCl is an opioid analgesic commonly used in the treatment of severe pain 
and in the management of opioid dependence. For pain relief, usual doses 
range from 5 mg to 10 mg every 6-8 hours; for opioid withdrawal, daily doses 
range from 10 mg to 60 mg but there are reports of patients receiving 120 mg 
(or even more) daily (Martindale 35, 2007), which is in accordance with the 
strengths reported by Finnish hospitals. In 2009, it was estimated that 
approximately 1800 patients were receiving opioid substitution treatment in 
Finland, of whom 720 (40%) were on methadone (EMCDDA, 2012). 
Glucose was also frequently dispensed both as unidose and multidose oral 
liquids. It was reported in strengths of 200-300 mg/mL, and in volumes of 2 
mL to 500 mL. Glucose is a monosaccharide commonly used in the 
treatment of carbohydrate and fluid depletion, and also in the treatment of 
hypoglycaemia; the doses vary in accordance with the individual patient 
needs (Martindale 35, 2007). 
The top 5 therapeutic groups, ranked by number of units of the 
corresponding oral liquids, are listed in Figure 10.11. The most frequent 
therapeutic group was analgesics, anti-inflammatory drugs and antipyretics, 
which comprised the following active substances (in decreasing order): 
methadone HCl, morphine, morphine HCl and ethylmorphine HCl. 
 
Figure 10.11 Oral liquids classified by therapeutic groups and dispensed by number of units 
(unidose and multidose). 
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The last column “others” included the following therapeutic groups:  
• Multidose: antidiabetics; antiepileptics; antihistamines; antineoplastics; 
antiprotozoals; anxiolytic, sedatives, hypnotics and antipsychotics; 
cardiovascular drugs; contrast media; corticosteroids; local anaesthetics; 
supplementary drugs and other substances; thyroid and antithyroid drugs; 
and urological drugs; 
• Unidose: antineoplastics and cardiovascular drugs. 
 
The multidose oral liquids may be quantitatively compared to the oral solids 
dispensed (in packs). Considering that oral powders were dispensed in packs 
of 13 units (Section 2.1.3), the 10,305 individual units of oral powders 
corresponded approximately to 793 packs of oral powders (of 13 units each). 
Assuming that capsules were dispensed in packs of 50 units (Section 2.1.3), 
the 8,300 individual units of capsules corresponded approximately to 166 
packs of oral capsules (of 50 units each). Therefore, when the 16,948 units of 
multidose oral liquids are compared to the 2,363 packs of oral solids, and the 
estimation of 959 packs (793+166 packs of oral powders/capsules), it is 
concluded that oral liquids were dispensed in larger quantities than oral 
solids. This fact is not in accordance with Brion et al. (2003), who concluded 
that oral powders were the most frequently dispensed oral dosage forms in 
Finland but their findings related to only 1 Finnish hospital. 
When further comparing oral solids and oral liquids, the top 5 therapeutic 
groups (Figures 10.6 and 10.11) were all different, which suggests that active 
substances in Finland are preferably dispensed either as solid or liquid 
dosage forms; i.e. cardiovascular drugs are preferably dispensed as oral 
solids whereas analgesics, anti-inflammatory drugs and antipyretics are 
preferably dispensed as oral liquids. This is likely to be related with the 
physiochemical properties of the active substances. 
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10.4.4 Oromucosal preparations 
In Finland, oromucosal preparations were reported by 2 hospitals (29% of all 
participants) and, in total, 5 different compounded medicines were 
dispensed, in a sum of 835 multidose containers, namely: miconazole and 
lidocaine gel (20 g); sodium hypochlorite solutions 0.5% and 1% (100 mL); 
and 2 mouthwashes for CIOM: ergocalciferol solution (100 mL) and 
ergocalciferol and vitamin A solution (200 g) 
10.5 Summary 
• Compounded medicines are commonly prepared in community and hospital pharmacies 
in Finland. The university hospitals dispense the largest quantities and variety of 
compounded medicines. 
• Finnish pharmacies are allowed to prepare their own compounded medicines and also to 
dispense compounded medicines prepared in other pharmacies (contract manufacturing). 
• A purposive sample of 8 hospitals was included in the research and a response rate of 
88% was obtained. A total of 85 different active substances (including 4 NTI drugs) were 
reported corresponding to 25 different therapeutic groups. The top 3 therapeutic groups were 
cardiovascular drugs (n=19), nutritional agents and vitamins (n=10) and antiepileptics (n=8).  
• Oral solid dosage forms were reported by all participant hospitals and included oral 
powders and capsules. Oral powders were dispensed in a total sum of 10,305 (55%) units 
and the top 5 active substances were: hydrocortisone, diazoxide, potassium perchlorate, 
amiodarone HCl and ursodeoxycholic acid. Capsules were dispensed in a total sum of 8,300 
units (45%) and the top 5 active substances were: hydrocortisone, ursodeoxycholic acid, 
propranolol HCl, nitrazepam and warfarin sodium. 
• Oral liquid dosage forms were reported by all participant hospitals and included solutions 
and suspensions (multidose and unidose). Multidose oral liquids were dispensed in a total 
sum of 16,948 containers and the top 5 active substances were: methadone HCl, sodium 
citrate, glucose, morphine (HCl) and methylcellulose. Unidose oral liquids were dispensed in 
a total sum of 8,130 units and the top 5 active substances were: methadone HCl, glucose, 
hydrochlorothiazide, spironolactone and nimodipine. Multidose oral liquids were dispensed in 
larger quantities than unidose oral liquids. 
• Oral liquids were dispensed in larger numbers than oral solids. 
• Oromucosal preparations were reported in a total sum of 835 multidose containers and 
corresponded to the following: miconazole and lidocaine gel, sodium hypochlorite solutions 
and mouthwashes for CIOM. 
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11. Compounding in Spain 
Spain joined the EU in 1986 and its official language is Spanish (Europa, 
2009). The country is constituted by the mainland and 2 archipelagos - the 
Balearic Islands in the Mediterranean Sea and the Canary Islands in the 
Atlantic Ocean - plus the cities of Ceuta and Melilla, located on the coast of 
Africa. Spain is divided in 17 autonomous communities40: Andalucía, Aragón, 
Asturias, Islas Baleares, Islas Canarias, Cantabria, Castilla-La Mancha, 
Castilla y León, Cataluña, Comunidad Valenciana, Extremadura, Galicia, 
Comunidad Madrid, Murcia, Navarra, País Vasco and La Rioja (Turespaña, 
2011). Spain is the second largest EU country, having an area of 506,000 
Km2 and is the 5th most populated, with a population of 44.5 million in 2007 
(Figure 2.2) (Europa, 2008). 
In 2006, there were 746 hospitals in Spain (ratio of 1.72 hospitals per 
100,000 population) and a total of 146,202 hospital beds (ratio of 337.03 
hospital beds per 100,000 population) (WHO Regional Office for Europe, 
2010) (Appendix 3).  
In 2006, there were 39,900 pharmacists in Spain (ratio of 91.98 pharmacists 
per 100,000 population) (WHO Regional Office for Europe, 2010) (Appendix 
4). According to the EAHP survey, the average number of pharmacists in 
Spanish hospitals is 5.0, similar to the European average of 4.7 pharmacists 
per European hospital. In addition, Spanish hospitals have an average of 5.3 
qualified pharmacy technicians/assistants per hospital, similar to the 
European average of 6. Spain also has an average of 7.3 non-qualified 
pharmacy assistants per hospital (EAHP, 2005; Hartmann, 2010).  
Pharmaceutical compounding has a long tradition in Spain and is currently a 
common practice in both hospital and community pharmacies (CGCOF, 
2010). Sterile and non-sterile compounded medicines are prepared in both 
settings, although sterile compounding is more frequent in hospital 
pharmacies. 
                                            
40Spain is divided into 17 regional governments, which are designated by autonomous 
communities (regions) (European Countries, no date). 
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Of the 1,295 community pharmacies in the region of Madrid, certified by the 
respective board of pharmacy41 for the preparation of compounded 
medicines (Section 11.1), only 3 pharmacies (less than 0.5%) prepare sterile 
compounded medicines (COFM, 2011). On the other hand, non-sterile 
compounded medicines are prepared by the majority of the community 
pharmacies in Spain accounting, on average, for approximately 2% of all 
prescriptions dispensed (Baixauli, 2008a; Marro, 2008). 
In the hospital setting, pharmaceutical compounding is an important practice 
to meet patients’ therapeutic needs with customised medicines (CGCOF, 
2010). At Hospital Infantil Universitario Niño Jesús, a paediatric hospital 
located in Madrid, the compounded medicines dispensed from January to 
October 2007 were retrospectively analysed and it was concluded that 89 
active substances were dispensed, in a total of 142 different compounded 
medicines. The majority was prepared from proprietary medicines and only 
35% were prepared from raw materials. The most frequently dispensed 
dosage forms prepared from proprietary medicines were sachets (60%) and 
capsules (15%), whereas the most frequently dispensed dosage forms 
prepared from raw materials were sachets (52%) and solutions (27%). The 
majority of capsules and sachets were dispensed to neurology (43.66%), 
followed by the intensive care unit (15.47%), oncology (12.24%) and 
cardiology (9.56%) departments (Díaz et al., 2007). 
11.1 Legislation 
According to Spanish legislation, there are 4 types of legally recognised 
medicines, namely: medicines for human and veterinary use produced by 
industry; magistral formulae and officinal preparations (both compounded 
medicines); and special medicines foreseen by the legislation (Ministerio de 
Sanidad y Consumo, 2006a). 
Magistral formulae (formulas magistrales) correspond to medicines for a 
specific patient, prepared by the pharmacist, or under his/her supervision, to 
expressly comply with the detailed medical substances included in the 
doctor’s prescription, in accordance with the established “norms for the 
                                            
41In Spain, each autonomous community is represented by a board of pharmacy, which 
corresponds to a regional pharmaceutical society. 
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correct preparation and QC of compounded medicines”. They are dispensed 
in a community or hospital pharmacy together with the respective necessary 
information for the patient (Ministerio de Sanidad y Consumo, 2006a). 
Therefore, magistral formulae are prescription-only (compounded) medicines, 
prepared in accordance with a doctor’s prescription. These may be prepared 
in accordance with the Spanish official national formulary - Formulario 
Nacional - which includes a total of 21 standardised (“typified”) magistral 
formulae, corresponding to long-established formulae frequently prescribed 
in Spain (Section 11.2.2). According to Cortina et al. (2009a), the majority 
(81.74%) of compounded medicines dispensed in community pharmacies 
correspond to magistral formulae. 
Officinal preparations (preparados oficinales) are medicines prepared in 
accordance with the established “norms for the correct preparation and QC of 
compounded medicines” guaranteed by a pharmacist, or under his/her 
supervision, dispensed in a community or hospital pharmacy, numbered and 
described in the national formulary (Section 12.2.2), to be directly dispensed 
to the patients assisted by that pharmacy. Therefore, officinal preparations 
are compounded medicines described in the Spanish official national 
formulary and do not require a doctor’s prescription. It has been suggested 
(Marro, 2008), that the majority of these officinal preparations correspond to 
“old topical preparations of little interest in today’s therapeutic setting”. 
According to Cortina et al. (2009b), the most frequently dispensed officinal 
preparations in community pharmacies are for dermatological use, in 
particular “Water Paste” (Appendix 16) and “Salicylate Vaseline”. 
Community and hospital pharmacies that do not meet all necessary 
requirements may outsource the preparation and/or QC of compounded 
medicines from an entity authorised by the Spanish agency of medicines and 
sanitary products (AEMPS) (Ministerio de Sanidad y Consumo, 2006a). 
Pharmacies may lack facilities, equipment or even the skills to prepare a 
given compounded medicine, and third-party compounding allows patients to 
receive virtually all compounded medicines at their nearest local pharmacy 
(Marro, 2008). In practice, this authorised entity includes not only hospital 
and community pharmacies but also other organisations, for instance, the 
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Board of Pharmacy in Valencia and the Board of Pharmacy in Zaragoza. In 
these 2 autonomous communities, in particular, local community and hospital 
pharmacies have lost a considerable part of their compounding requests, 
since the regional Boards of Pharmacy represent a powerful and influential 
competitor. The ethics of having the regional Boards of Pharmacy as a 
competitor have been questioned in Spain (AEFF, 2012). 
In order to guarantee the quality of compounded medicines, the pharmacist 
must follow the “norms for the correct preparation and QC of compounded 
medicines” (Normas de correcta elaboración y control de calidad de fórmulas 
magistrales y preparados oficinales), established by law (Ministerio de 
Sanidad y Consumo, 2001). These norms corresponding to GCP comprise 6 
components, namely: personnel; facilities and equipment; documentation; 
raw materials and packaging materials; preparation; and dispensing; these 
norms are very similar to the Portuguese guidelines (Section 3.1). In Spain, 
QC must be performed on all compounded medicines prepared, and the 
minimum QC tests required depend on the type of compounded medicines, 
as follows:  
• Magistral formulae: verification of organoleptic characteristics. 
• Standardised “typified” magistral formulae and officinal preparations: all 
QC tests outlined in the Formulario Nacional (Ministerio de Sanidad y 
Consumo, 2001). 
According to Díaz et al. (2007), these norms have resulted in considerable 
change in the hospital compounding practices throughout Spain, in particular 
with regards to paediatric hospitals, which are nowadays characterised by 
rigour and quality with respect to pharmaceutical compounding. According to 
the latest EAHP survey, SOP (for compounding) are nowadays used in more 
than 90% of hospital pharmacies in Spain (EAHP, 2005). 
The raw materials included in the preparation of compounded medicines 
must be substances with legally recognised actions and indications in Spain 
(Ministerio de Sanidad y Consumo, 2001). Nevertheless, there are 
restrictions for the use of certain raw materials in pharmaceutical 
compounding, namely: human and animal organs or glands (and their 
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respective derivatives). Plus, raw materials with the following actions: 
anorexic, psychotropic, hormonal, laxative and diuretic, used in combination; 
2 of these raw materials may be exceptionally used in combination provided 
that the prescriber justifies the need, efficacy and safety of such combination 
(Ministerio de Sanidad y Consumo, 1997). These restrictions were introduced 
after the massive expansion of the market for slimming products in Spain, 
and the consequent misuse of such drugs by means of pharmaceutical 
compounding. 
In Spain, each autonomous community is responsible for the adaptation and 
enforcement of pharmaceutical legislation in the corresponding region, which 
results in different criteria with regards to the practice of pharmacy (and 
pharmaceutical compounding) within each community. For instance, the use 
of proprietary medicines in compounding is subject to varying restrictions. In 
some autonomous communities, the use of proprietary medicines is not 
allowed, though in others, Madrid, for example, a paediatric hospital reported 
that the majority of the compounded medicines dispensed were indeed 
prepared from proprietary medicines (Díaz et al., 2007). Furthermore, 
community pharmacies in the region of Madrid require specific certification 
from the respective Board of Pharmacy to prepare compounded medicines 
based on the criteria sterile/non-sterile and on the dosage forms prepared, 
whereas in other regions the same criteria may not apply. These differences 
in criteria within Spanish autonomous communities are bureaucratic (Marro, 
2006) and contribute to heterogeneous requirements and practices 
throughout the country (Rodríguez, 2005). 
11.2 Professional organisations and information sources 
11.2.1 Spanish professional organisations 
• Asociación Española de Farmacéuticos Formulistas (AEFF): is the 
Spanish association of compounding pharmacists, an organisation that 
promotes pharmaceutical compounding in Spain and helps pharmacists 
install and develop compounding laboratories in community pharmacies. The 
AEFF is steadily growing and has now over 400 members (AEFF, 2010). The 
AEFF organises a scientific congress every year and other compounding 
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events throughout the country. The International Society of Pharmaceutical 
Compounding (ISPhC) (Section 14.2.1) was officially constituted in Spain 
during the annual congress of the AEFF in 2004 (ISPhC, no date). 
• Asociación Profesional Independiente de Farmacéuticos Formuladores 
(Aprofarm): is the independent professional association of compounding 
pharmacists, an organisation created in 1996 in Barcelona that promotes 
individualised medicines; researches, develops and publicises 
pharmaceutical compounding; supports compounding pharmacists; 
establishes contacts and links between compounders; criticises, informs and 
collaborates with changes in legislation; and educates pharmacists and 
health professionals (Aprofarm, 2011). Aprofarm also organises 
compounding events in Spain. Aprofarm and AEFF are currently working 
together on “Formula 2015”, a 5-year project that aims to develop and 
promote pharmaceutical compounding in collaboration with doctors in 
hospitals and other health centres throughout Spain. A team of 35 
compounding experts is responsible for providing informative sessions to 
doctors, developing compounding formularies and undertaking research 
studies (Aprofarm and AEFF, 2010). 
• Asociación de Formulistas de Andalucía (AFA): is the association of 
compounding pharmacists from Andalucía (autonomous community), an 
association that includes 212 members (of which 40 members are from 
outside Andalucía), that promotes pharmaceutical compounding and 
represents the interests of compounding pharmacists in Spain (AFA, 2009). 
Since 2009, AFA organises an annual symposium - Rafael Alvarez Colunga - 
on compounding for paediatric patients (standardisation of criteria), where 
current compounding practices are discussed. 
• Instituto Tecnologico del Medicamento Individualizado (ITMI): is the 
technological institute of individualised medicine, an organisation promoted 
by AFA which collaborates with Spanish Universities (Granada, Seville and 
La Laguna) in the investigation and development of compounded medicines 
for paediatric patients. ITMI was constituted in 2009 and aims to promote 
pharmaceutical compounding in community and hospital pharmacies by 
providing consultancy on all technical aspects related to the practice of 
compounding (ITMI, no date). 
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• Sociedad Española de Farmacia Hospitalaria (SEFH): is the Spanish 
society of hospital pharmacy, a scientific, private, active and professional 
organisation dedicated to promoting knowledge about hospital pharmacy and 
whose actions aim to increase the appropriate and safe use of medicines 
(SEFH, no date). The SEFH has a working group dedicated specifically to 
pharmaceutical compounding - Farmacotecnia - which coordinates several 
compounding-related projects, for example, the development of a hospital 
pharmacy formulary, SOP and a manual with norms and procedures adapted 
to compounding legislation (Ministerio de Sanidad y Consumo, 2001; Vila 
and Martínez, 2009). 
• Sociedad Valenciana de Farmacia Hospitalaria (SVFH): is the hospital 
pharmacy society of the autonomous community of Valencia, a scientific non-
profit association that promotes and supports hospital pharmacy in the region 
of Valencia (SVFH, no date), including the practice of pharmaceutical 
compounding.  
• Consejo General de Colegios Oficiales de Farmacéuticos: is the general 
council of the official boards of pharmacy in Spain, an entity that brings all 
regional boards of pharmacy together. Although pharmaceutical 
compounding is relevant for all boards of pharmacy, their activities vary from 
region to region. For instance, some boards of pharmacy have a 
compounding laboratory and prepare compounded medicines for pharmacies 
within the region. Others offer only consultancy services and compounding 
courses to affiliated members. The Colegio Oficial de Farmacéuticos de 
Madrid (COFM), corresponding to the Board of Pharmacy from Madrid, has a 
department specifically dedicated to the practice of compounding and the 
COFM newsletter “practice of pharmacy” includes, in each publication, a 
revised monograph for a compounded medicine of interest (COFM, 2010). 
Other boards of pharmacy have also published compounding-specific 
formularies (Section 11.2.2). 
11.2.2 Spanish information sources 
• Formulario Nacional: is the Spanish national formulary, the official 
reference for pharmaceutical compounding in this country. It was initially 
published in 2003 (Ministerio de Sanidad y Consumo, 2003) and was first 
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updated in 2007 (Ministerio de Sanidad y Consumo, 2006b). This formulary 
is divided in 2 parts: Part I includes all relevant legislation for the practice of 
compounding in Spain. Part II includes 25 SOP (general; preparation of 
dosage forms; pharmaceutical operations and QC); 66 monographs for raw 
materials (active substances and excipients/vehicles); 63 monographs for 
long-established standardised (“typified”) magistral preparations and officinal 
preparations; and a separate chapter dedicated to phytotherapy (30 
monographs for active substances and officinal preparations). This formulary 
includes monographs for oral, oromucosal, topical and rectal compounded 
medicines; in liquid, semi-solid and solid dosage forms. According to Cristina 
Avendaño Solá42, the galenic and pharmacological information included in 
the national formulary is essential for the preparation (in community or 
hospital pharmacies) of medicines with appropriate quality, safety and 
efficacy (Comité del Formulario Nacional, 2007). Whilst this formulary is the 
official Spanish reference which compiles monographs for the long-
established standardised “typified” magistral preparations and officinal 
preparations, the Spanish Pharmacopoea (Real Farmacopea Española) is 
the official reference which contains monographs for medical substances and 
excipients for human and veterinary use, as well as the respective analytical 
control methods (Ministerio de Sanidad y Consumo, 1995).  
• Formularies established by the official boards of pharmacy: some boards 
of pharmacy have published compounding-specific formularies (Section 
11.2.1). For instance, the Formulario Regional (regional formulary) from the 
region of Murcia and the Guía de Calidad en Formulación Magistral 
(compounding quality guide) from the community of Valencia. 
• Formulario Básico de Medicamentos Magistrales: is a non-official Spanish 
formulary, published by Clavijo and Comes (2009), which includes complete 
monographs for vehicles/bases and raw materials (active substances and 
excipients) frequently used in pharmaceutical compounding in Spain. 
• Formulación en Farmacia Pediátrica: is another non-official Spanish 
formulary, published by Fernández et al. (2011), which includes detailed 
                                            
42Director of AEMPS in 2007. 
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procedures and patient information leaflets for more than 100 compounded 
medicines frequently used in paediatric patients in Spain. 
• Preparación de Medicamentos. Formulación Magistral: is a reference 
manual for pharmaceutical compounding in hospital pharmacy in Spain, 
published by Maria Eugenia Méndez Esteban43 in 2 large volumes as a result 
of her practice and expertise in pharmaceutical compounding at Hospital 
Universitario 12 de Octubre (Madrid) (Esteban, 2010). 
As shown in Table 11.1 (below), formularies for pharmaceutical compounding 
have been published, regularly in Spain, over the past years. 
Table 11.1 Formularies published in Spain from 1995-2008 (adapted from Baixauli, 2008b). 
Years Published formularies 
1995 5 
1997 5 
1998 4 
2002 1 
2003 3 
2004 1 
2007 1 
2008 1 
11.3 Methods 
The research project was initiated in 2006 by consulting representatives of 
the AEFF. In a second approach, the SEFH was contacted several times by 
email and telephone, and also the SVFH, but no response was provided. In a 
third approach, personal approaches were made by email and Diego 
Marro44, in particular, provided invaluable help by identifying and contacting 
directly José María Alonso Herreros45, who identified the purposive sample of 
hospitals based on his knowledge and expertise as a member of SEFH.  
                                            
43Pharmacist responsible for the compounding department at Hospital Universitario 12 de 
Octubre (Comunidad de Madrid). 
44Diego Marro is a pharmacist at Farmacia Marro in Huesca and director of the Master in 
Pharmaceutical Care and Pharmacotherapy at the University San Jorge in Zaragoza. 
45José Maria Alonso Herreros is a hospital pharmacist at Hospital Reina Sofía in Murcia and 
member of the working group on pharmaceutical compounding at SEFH (Section 11.2.1). 
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This list was further complemented by Manuela Atienza Fernández46, on the 
basis of her practice and expertise in paediatric hospital pharmacy in Spain. 
Vicente Baixauli Comes47 also contributed with the suggestion of 1 hospital. 
As a result, a purposive sample of 40 hospitals was established, including 
general hospitals, university hospitals and paediatric-specialist hospitals. 
No fieldwork was undertaken in Spain, nor it was necessary to request 
specific advice on the Spanish questionnaire, because of the expertise of MC 
in the field of pharmaceutical compounding in this country. 
11.3.1 Country-specific questionnaire 
The research instrument developed to collect information regarding oral 
compounded medicines most frequently dispensed in Spanish hospital 
pharmacies was a self-completion questionnaire (main heading in Figure 
11.1), based on the template established for Portugal (Section 3.3.1) and 
adapted to the practice of pharmaceutical compounding in Spain. This 
customised questionnaire comprised 1 table only and was developed in 
Spanish by MC. Data collection in Spain was undertaken in the year 2009 
and, therefore, the questionnaire addressed information relating to 2008.  
Compounded medicines were defined as “magistral formulae and/or officinal 
preparations prepared at the hospital pharmacy” because, although magistral 
formulae and officinal preparations are commonly distinguished in Spain 
(Section 11.1), both categories should be considered altogether when 
establishing the most frequently dispensed oral compounded medicines. 
 
 
                                            
46Manuela Atienza Fernández is a specialist in hospital pharmacy in Spain and author of the 
paediatrics formulary Formulación en Farmacia Pediátrica (Fernández et al., 2011) (Section 
11.2.2). 
47Vicente Baixauli Comes is a community pharmacist specialist in pharmaceutical 
compounding and author of the Spanish formulary Formulario Básico de Medicamentos 
Magistrales (Clavijo and Comes, 2009) (Section 11.2.2). 
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Chapter 11: COMPOUNDING IN SPAIN | Methods | 252 
 
11.3.2 Purposive sample of hospitals 
A purposive sample of 40 hospitals was selected across Spain, from the 
cities of: A Coruña, Alicante, Almería, Badajoz, Baracaldo, Barcelona, Cádiz, 
Córdoba, Donostia-San Sebastián, Getafe, Granada, Guadalajara, Huelva, 
Jaén, Las Palmas de Gran Canaria (not included in the map), Madrid 
(capital), Murcia, Oviedo, Palma de Mallorca, Salamanca, San Sebastián de 
los Reyes, Santander, Sevilla, Toledo, Valencia, Vigo and Zaragoza (Figure 
11.2). A total of 9 hospitals were from Madrid, 4 from Barcelona, 2 from 
Seville and 2 from Valencia. The 40 hospitals selected were identified by the 
stakeholders as the ones in which the largest quantities of compounded 
medicines were likely to be dispensed in Spain. 
 
Figure 11.2 Map of Spain (mainland) adapted from National Geographic Society (1998h); 
indicating the location of the purposive sample of hospitals (   ).  
11.3.3 Data collection 
Two hospitals were contacted directly by Manuela Atienza Fernández and all 
other 38 hospitals were contacted by MC by email (in Spanish) with the 
request to share data regarding the oral compounded medicines most 
frequently dispensed in 2008 (or the latest available year). A brief 
introductory email was then sent to the key contact person with the 
questionnaire attached as well as an electronic copy of the IJPC article 
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(Carvalho et al., 2008). Non-respondents were sent periodical email 
reminders (average of 3 emails per hospital pharmacy). All persistent non-
respondents were then contacted by MC by telephone (in Spanish), followed 
by a maximum of 4 additional email reminders. Data were collected by the 
hospital pharmacy’s staff and none of the Spanish hospitals were visited by 
MC. 
11.4 Results and discussion 
Of the 40 hospitals contacted, 31 hospital pharmacies responded to the 
request for collaboration and 9 were non-respondents, resulting in a 
response rate of 78%. From the 31 respondents, 30 contributed data 
regarding the oral compounded medicines most frequently dispensed by their 
pharmacies and 1 hospital pharmacy was a non-participant (Figure 11.3); the 
reason stated for not collaborating was that they did not dispense any 
compounded medicines.  
Of the 30 participant hospitals, 77% (n=23) shared quantitative and complete 
datasets. Other replies were distributed as follows: 1 hospital shared 
quantitative but incomplete data; another hospital provided semi-quantitative 
data; and 5 hospitals provided qualitative data only.  
 
 
 
 
 
 
 
 
 
 
Figure 11.3 Purposive sample distributed by respondent and participant hospitals. 
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The main reasons stated for not sharing quantitative and complete datasets 
were that data were not readily accessible and that no records were kept with 
regards to specific data. Only 1 hospital stated that they dispensed few oral 
compounded medicines. 
The majority of hospitals shared data in their own formats and only 43% used 
the questionnaire provided, which may result from the fact that the majority of 
hospital pharmacies in Spain have a software application for compounding. 
For instance, the SEFH collaborated with TECNO48 to develop the 
Formulario Magistral COPA, a Microsoft Access application for 
pharmaceutical compounding in Spanish hospital pharmacies (Vila and 
Martínez, 2009). One hospital provided the required data by telephone.  
The participant hospitals provided data mainly from 2008 and 2009; only 1 
hospital shared data from 2007 and 4 hospitals from 2 consecutive years. 
The research project undertaken in Spain was the second largest, after 
Portugal, and corresponded to a complex and time-consuming process. A 
total of 40 telephone calls were made to Spanish hospitals and a total of 152 
emails were sent with requests for collaboration. 
11.4.1 Active substances  
A complete list of the active substances most frequently dispensed as oral 
compounded medicines in Spain is shown in Table 11.2. Active substances 
were grouped according to their respective therapeutic classification 
(Martindale 35, 2007), giving a total of 35 therapeutic groups and 281 
different active substances, which is considerably more than the 89 active 
substances identified by Díaz et al. (2007) but this study related to only 1 
Spanish hospital (Section 11).  
Cardiovascular drugs was the group with the greatest number of different 
active substances (n=39), followed by nutritional agents and vitamins (n=34) 
and antibacterials (n=31).  
 
                                            
48TECNO is the acronym given to the committee within the SEFH that evaluates new 
technology relevant to hospital pharmacists (both software and hardware that is used in the 
care of patients at any phase of the medication process). 
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Table 11.2 Active substances most frequently dispensed as oral compounded medicines in 
Spain (NTI drugs underlined). 
Analgesics, anti-inflammatory drugs 
and antipyretics 
Aspirin, benzydamine HCl, celecoxib, 
codeine, dexketoprofen trometamol, 
dipyrone, ibuprofen, indometacin, 
ketorolac trometamol, meloxicam, 
methadone HCl, morphine, morphine HCl, 
paracetamol, tolmetin sodium, tramadol 
HCl 
 
Antihelmintics 
Levamisole, praziquantel 
 
Antibacterials 
Aminosalicylic acid, amoxicillin, ampicillin, 
cefaclor, cefalexin, chloramphenicol, 
ciprofloxacin, clindamycin, colistin sulfate, 
cycloserine, doxycycline, doxycycline 
hyclate, erythromycin, ethambutol HCl, 
gentamicin sulfate, isoniazid, levofloxacin, 
linezolid, neomycin, oxytetracycline, 
penicillin, pyrazinamide, rifabutin, 
rifampicin, sodium aminosalicylate, 
sulfadiazine, sulfamethoxazole, 
tobramycin, tobramycin sulfate, 
trimethoprim, vancomycin 
 
Antidementia drugs 
Idebenone 
 
Antidepressants 
Amitriptyline, doxepin HCl, duloxetine 
HCl, oxitriptan 
 
Antidiabetics 
Acarbose, metformin HCl 
 
Antiepileptics 
Carbamazepine, clobazam, ethosuximide, 
gabapentin, lamotrigine, levetiracetam, 
phenobarbital, phenytoin, phenytoin 
sodium, topiramate, vigabatrin, 
zonisamide 
 
Antifungals 
Amphotericin B, fluconazole, flucytosine, 
nystatin, terbinafine, voriconazole 
 
Antigout drugs 
Allopurinol, colchicine, probenecid 
 
Antimalarials 
Chloroquine, chloroquine phosphate, 
hydroxychloroquine sulfate, 
pyrimethamine, quinine, quinine HCl, 
quinine sulfate 
 
Antimyasthenics 
3,4-Diaminopyridine, fampridine, 
pyridostigmine bromide 
 
Antineoplastics 
Busulfan, cyclophosphamide, 
hydroxycarbamide, irinotecan HCl, 
lomustine, mercaptopurine, procarbazine 
HCl, sunitinib malate, temozolomide, 
tioguanine, topotecan HCl 
 
Antiparkinsonian drugs 
Carbidopa, entacapone, levodopa 
 
Antiprotozoals 
Benznidazole 
 
Antivirals 
Abacavir, abacavir sulfate, aciclovir, 
entecavir, lamivudine, nevirapine, 
oseltamivir phosphate, ribavirin, 
valaciclovir HCl, valganciclovir HCl, 
zidovudine 
 
Anxiolytic, sedatives, hypnotics and 
antipsychotics 
Alprazolam, chloral hydrate, clorazepate, 
diazepam, dipotassium clorazepate, 
levomepromazine, lorazepam, 
lormetazepam, midazolam, nitrazepam, 
zolpidem tartrate 
 
 
Bronchodilators and anti-asthma drugs 
Caffeine, caffeine citrate, sodium 
cromoglicate, theophylline 
 
 
Cardiovascular drugs 
Acenocoumarol, amiloride HCl, 
amiodarone, amlodipine besilate, atenolol, 
atropine sulfate, bisoprolol fumarate, 
bosentan, captopril, carvedilol, clonidine, 
clopidogrel bisulfate, colestipol 
hydrohloride, colestyramine, diazoxide, 
diltiazem HCl, dipyridamole, doxazosin 
mesilate, enalapril, enalapril maleate, 
flecainide acetate, furosemide, 
hydralazine HCl, hydrochlorothiazide, 
labetalol HCl, losartan potassium, 
mannitol, metoprolol, mexiletine HCl, 
minoxidil, nadolol, nifedipine, nimodipine, 
propafenone HCl, propranolol HCl, sotalol 
HCl, spironolactone, verapamil HCl, 
warfarin sodium 
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Chelators, antidotes and antagonists 
Calcium polystyrene sulfonate, 
methionine, sevelamer HCl, sodium 
polystyrene sulfonate, trientine 
dihydrochloride 
 
Contrast media 
Barium sulfate, meglumine amidotrizoate, 
sodium amidotrizoate 
 
Corticosteroids 
Beclometasone dipropionate, 
dexamethasone, dexamethasone 
phosphate, fludrocortisone acetate, 
hydrocortisone, methylprednisolone, 
prednisone, triamcinolone, triamcinolone 
acetonide 
 
Cough suppressants, expectorants, 
mucolytics and nasal decongestants 
Ephedrine, ipecacuanha 
 
Dermatological drugs and sunscreens 
Acitretin, tretinoin 
 
Disinfectants and preservatives 
Chlorhexidine, chlorhexidine gluconate, 
hexetidine, metabisulfite, sodium 
benzoate, sodium metabisulfite 
 
Electrolytes 
Bicarbonate, calcium, dibasic sodium 
phosphate, magnesium lactate, 
magnesium sulfate, monobasic sodium 
phosphate, potassium chloride, potassium 
citrate, sodium bicarbonate, sodium 
chloride, sodium citrate, sodium 
phosphate 
 
GI drugs 
Calcium carbonate, omeprazole, 
ondansetron, ranitidine, ranitidine HCl, 
sodium sulfate 
 
 
 
 
Immunosuppressants 
Azathioprine, mycophenolate mofetil, 
tacrolimus 
 
Local anaesthetics 
Lidocaine, lidocaine HCl, mepivacaine 
HCl 
 
Miotics, mydriatics and antiglaucoma 
drugs 
Acetazolamide 
 
Muscle relaxants 
Baclofen, tizanidine HCl 
 
Nutritional agents and vitamins 
Alanine, arginine, ascorbic acid, biotin, 
calcitriol, calcium folinate, citrulline, 
copper sulfate, folic acid, folinic acid, 
fructose, glucose, glutamine, isoleucine, 
lactose, maltodextrin, maltose, 
mecobalamin, nicotinamide, 
phenylalanine, pyridoxal phosphate, 
pyridoxine HCl, riboflavin, serine, sorbitol, 
sucrose, sucralose, thiamine, tocopherol, 
valine, vitamin E, zinc aspartate, zinc 
acetate, zinc sulfate 
 
Stabilising and suspending agents 
Methylcellulose, microcrystalline cellulose 
 
Supplementary drugs and other 
substances 
Belladonna, bethanechol chloride, borax, 
cellulase, citric acid, glycerol, melatonin, 
nitisinone, pancreatin, phosphoric acid, 
phosphorus, quercetin, sodium 
phenylbutyrate, taurine, thalidomide, 
ubidecarenone, ursodeoxycholic acid, 
xylose 
 
Thyroid and antithyroid drugs 
Iodine, levothyroxine sodium, potassium 
iodide, potassium perchlorate 
 
Urological drugs 
Finasteride, sildenafil citrate 
 
Although the active substances listed were reported as oral compounded 
medicines, the title of some therapeutic groups suggested non-oral 
(therapeutic) indications, namely: dermatological drugs and sunscreens 
(Appendix 11); disinfectants and preservatives (Appendix 12); stabilising and 
suspending agents (Appendix 14); and supplementary drugs and other 
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substances (Appendix 15). The active substances included in these groups 
are described in the respective appendixes.  
A total of 9 NTI drugs (ANVISA, 2007; Appendix 1), were dispensed as oral 
compounded medicines (underlined in Table 11.2). 
The active substances dispensed by most hospitals were: ranitidine (n=21); 
captopril, furosemide, hydrochlorothiazide, omeprazole, phenobarbital, 
spironolactone and ursodeoxycholic acid (n=16-20); chloral hydrate, 
dexamethasone, ipecacuanha, methadone HCl, midazolam, propranolol HCl, 
sildenafil citrate and tacrolimus (n=10-15). 
All active substances reported were included in Martindale 35 (2007) with the 
exception of 4 that were dispensed by 3 hospitals in a total of 21,969 units of 
capsules (Appendix 26), as follows: 
• Ambrisentan (5 mg): an orphan drug for the treatment of pulmonary 
arterial hypertension and chronic thromboembolic pulmonary hypertension 
(Committee for Orphan Medicinal Products, 2008). 
• Darunavir (150 mg): an oral HIV-1 (human immunodeficiency virus) 
protease inhibitor indicated in antiretroviral therapy (McKeage et al., 2009). 
• Detrothyronine (25 µg): the D-isomer of liothyronine that has been used as 
a lipid-regulating drug but is now part of the “Archive of deleted monographs” 
of Martindale 35 (2007), which includes substances that are no longer in use 
nor of general interest. 
• Maraviroc (150 mg): an oral HIV-1 drug (CCR5 receptor antagonist) 
indicated in multi-resistant antiretroviral therapy (SEFH, 2005). 
The majority of compounded medicines dispensed included 1 active 
substance only. Nevertheless, combinations of up to 4 different active 
substances were also dispensed both as solid and liquid dosage forms 
(Sections 11.4.1 and 11.4.2).  
Placebo was reported by 14 hospitals in a total of 27,703 units of capsules 
containing lactose or starch and dispensed in several sizes (0-3) and colours. 
Placebo capsules are indicated when a placebo effect is particularly 
beneficial for the therapeutic outcome and these are frequently used in 
different hospital services across the country. In Spain, placebo capsules 
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may also be indicated in protocols for the withdrawal of opioids and in clinical 
trials (Esteban, 2010). 
Compounded medicines were also reported by given titles, namely: Joulie’s 
Solution, Lugol’s Solution and Shohl’s Solution (Section 11.4.2).  
In addition, 9 proprietary medicines were reported as oral compounded 
medicines (solid and liquid dosage forms) by a total of 8 hospitals (Sections 
11.4.2 and 11.4.3). Finally, 2 hospitals reported nutritional supplements in a 
total of 4,314 units of capsules and sachets. 
11.4.2 Oral solids 
Oral solid dosage forms were reported by 93% (n=28) of all participant 
hospitals and included capsules (n=26), oral powders (n=17) and powders for 
oral liquids (n=2). In total, 20 hospitals shared complete (quantitative) data 
with regards to the oral solids dispensed; 4 hospitals disclosed qualitative 
data only; 3 hospitals disclosed semi-quantitative data; and 1 hospital 
reported partial data only. Qualitative, semi-quantitative and partial data were 
processed and analysed accordingly (Section 2.4). The quantities of oral 
solids were provided as the number of packs and/or the number of individual 
units dispensed, which are shown separately below (Figure 11.4). 
 
Figure 11.4 Oral solids dispensed per number of packs and number of individual units. 
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The top 20 active substances dispensed as oral solids and ranked by number 
of individual units are shown in Figure 11.5. Ribavirin, dexamethasone, 
clopidogrel bisulfate, 3,4-diaminopyridine, fampridine, chloramphenicol and 
potassium perchlorate are also part of the top 20 active substances ranked 
by number of packs. 
 
Figure 11.5 Top 20 active substances dispensed as oral solids (ranked by number of units). 
The top 5 therapeutic groups, ranked by the number of units of the 
corresponding oral solids, are shown in Table 11.3. The most frequent 
therapeutic group was antivirals, which comprised 8 different active 
substances that were dispensed in a total of 312,329 units of oral solids. All 5 
groups included active substances that were part of the top 20 shown in 
Figure 11.5. The therapeutic group containing the most active substances 
was nutritional agents and vitamins (n=26). 
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Table 11.3 Top 5 therapeutic groups ranked by number of units of oral solids dispensed. 
Therapeutic groups Number of  active substances 
Active substances 
included in top 20 
Number of  
units 
Antivirals 8 
Ribavirin 
Entecavir 
Aciclovir 
312,329 
Corticosteroids 6 Dexamethasone Fludrocortisone acetate 170,026 
Cardiovascular drugs 18 
Bosentan 
Clopidogrel bisulfate 
Atenolol 
Hydrochlorothiazide 
Spironolactone 
116,195 
Urological drugs 2 Sildenafil citrate 99,971 
Analgesics,  
anti-inflammatory 
drugs and antipyretics 
12 Ketorolac trometamol 41,539 
 
Capsules were dispensed in much larger quantities than oral powders and 
represented over 90% of all oral solids dispensed, both in number of packs 
and number of units dispensed (Figure 11.4). A total of 6,254 packs and 
1,033,665 units of capsules were reported but these figures are not directly 
comparable as 11 hospitals did not provide the number of packs and 1 
hospital did not provide the number of units of capsules dispensed. 
According to several participant hospitals, capsules were prepared in packs 
of 100 units and were dispensed individually, depending on the posology and 
duration of treatment. Capsules were reported by 87% of hospitals and, 
considering the number of units dispensed, the top 5 active substances are 
shown in Table 11.4, which corresponded to the top 5 active substances 
dispensed as oral solids (as shown in Figure 11.5).  
Table 11.4 Compounded medicines most frequently dispensed as capsules.  
Active substances Strengths Number of hospitals 
Number of 
units 
Ribavirin 300 mg 400 mg 3 288,924 
Dexamethasone 4-40 mg 13 130,956 
Sildenafil citrate 5-50 mg 3 98,581 
Bosentan 5-62.5 mg 5 40,385 
Fludrocortisone acetate 5-12.5 µg 2 34,220 
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None of these active substances have a monograph in the Spanish national 
formulary, which confirms the proposition that this formulary does not include 
monographs of interest in today’s therapeutic setting (Marro, 2008). 
Ribavirin is commercially available both as capsules and tablets of 200 mg 
and also as an oral solution of 40 mg/mL (AEMPS, 2011). Nevertheless, it 
was reported as capsules including higher strengths but these are still within 
the recommended dose for adults of 400 mg twice a day (Martindale 35, 
2007). 
Bosentan is commercially available as tablets of 62.5 mg and 125 mg 
(AEMPS, 2011) and was reported as capsules of variable strengths from 5 
mg up to 62.5 mg. The most frequently dispensed strength was 62.5 mg, 
which corresponded to 70% of all strengths dispensed. Bosentan is 
recommended in pulmonary hypertension and is given orally in an initial dose 
of 62.5 mg twice a day (Martindale 35, 2007). The fact that bosentan was 
dispensed as a compounded medicine in the same strength of the 
commercially available tablets may be explained by one of the following 
reasons: the patient was unable to swallow solid dosage forms and the 
capsules were meant to be opened prior administration; the patient was 
intolerant to one or more excipients included in the tablets; or the proprietary 
tablets were commercially unavailable.  
The top 5 active substances described were reported as capsules only, with 
the exception of sildenafil citrate and bosentan which were also reported as 
oral powders, but in much smaller quantities. 
Capsules including more than one active substance were dispensed by 4 
hospitals in a total of 5,693 units, which corresponded to only 0.6% of all 
capsules dispensed. In decreasing order, the combinations of 2 active 
substances dispensed as capsules were: carbidopa and levodopa; 
gentamicin sulfate and nystatin; abacavir and lamivudine; zidovudine and 
lamivudine. Likewise, the combinations of 3 active substances were the 
following: abacavir, lamivudine and zidovudine; methionine, ascorbic acid 
and tocopherol (named as “antioxidant capsules”); rifampicin, isoniazid and 
pyrazinamide; levodopa, carbidopa and entacapone. All these combinations 
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are therapeutically coherent as the active substances combined are part of 
the same therapeutic group or, alternatively, are included in therapeutic 
groups likely to be combined (i.e. antibacterials and antifungals). 
Placebo was also reported as capsules (Section 11.4.1). 
Resincalcio (calcium polystyrene sulfonate) was the only proprietary 
medicine reported quantitatively as capsules. A total of 243 units were 
dispensed by 1 hospital. Furthermore, a total of 48 proprietary medicines 
were reported qualitatively by another hospital as capsules and oral powders 
(sachets). 
Oral powders represented less than 5% of all oral solids dispensed, both in 
number of packs and number of units dispensed (Figure 11.4). A total of 222 
packs and 16,275 units of oral powders were reported but these figures are 
not directly comparable as 9 hospitals did not provide the number of packs 
and 1 hospital did not provide the number of units of oral powders dispensed. 
The majority of oral powders were reported as sachets (94%) (Figure 3.6) 
and only 6% were dispensed in flasks, which are usually reserved for larger 
quantities of powders. Oral powders were dispensed by 57% of hospitals 
and, considering the number of units dispensed, the top 5 active substances 
are shown below (Table 11.5).  
Table 11.5 Compounded medicines most frequently dispensed as oral powders. 
Active substances Strengths Number of hospitals 
Number of 
units dispensed 
Hydrochlorothiazide 1-5 mg 1 1,342 
Calcium polystyrene 
sulfonate 4 mg - 15 g 3 1,195 
Aspirin 5-450 mg 3 1,090 
Sucrose 1.2-2.4 g 2 909 
Monobasic sodium 
phosphate 0.5-3 g 2 855 
 
Hydrochlorothiazide, although reported by only 1 hospital, was the active 
substance most frequently dispensed as oral powders and the only active 
substance included in the top 20 active substances dispensed as oral solids. 
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Calcium polystyrene sulfonate is a cation-exchange resin used in the 
treatment of hyperkalaemia. The usual doses are 15 g, 3 to 4 times a day 
and, in children, the maintenance dose is 500 mg/kg a day in divided doses 
(Martindale 35, 2007), which explains the wide range of strengths 
encountered. 
Aspirin was reported by 3 hospitals in the strengths of 5 mg up to 450 mg. 
Since aspirin tablets are commercially available in the strengths of 100 mg 
and 500 mg (AEMPS, 2011), the evidence base for prescribing aspirin 450 
mg oral powders may be questionable. The most frequently dispensed 
strengths were 5 mg and 10 mg. Although aspirin is not licensed for use in 
children under 16 years, low doses of aspirin (1-5 mg/kg) are indicated in 
neonates and child (1 month - 12 years) as an antiplatelet agent in the 
prevention of thrombus formation after cardiac surgery (Paediatric Formulary 
Committee, 2008). 
A total of 4 proprietary medicines were reported as oral powders: Ammonaps 
(sodium phenylbutyrate); Lamisil (terbinafine); Resincalcio (calcium 
polystyrene sulfonate) and Resincolestiramina (colestyramine) in a total of 
962 units dispensed by 4 hospitals. Only 1 combination of 2 different active 
substances was dispensed as oral powders, namely maltodextrin and 
sucralose (sweetening agent), which was dispensed by 1 hospital in a total of 
35 units of sachets (correspondent to 0.2% of all oral powders dispensed). 
Powders for oral liquids represented less than 2% of all oral solids 
dispensed, both in number of packs and number of units dispensed (Figure 
11.4), and were reported by only 2 hospitals. A total of 120 packs and 2,578 
units were reported but these figures are not directly comparable as 1 
hospital did not provide the number of packs dispensed. Powders for oral 
liquids including more than 1 active substance were dispensed by only 1 
hospital, in a total of 393 units, and corresponded to the following 
combinations: codeine, aspirin and dipotassium clorazepate; codeine, 
aspirin, dipotassium clorazepate and levomepromazine. Both compounded 
medicines included the combination of “analgesics, anti-inflammatory drugs 
and antipyretics” with “anxiolytic, sedatives, hypnotics and antipsychotics” 
and were indicated in emergency withdrawal syndrome protocols. 
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11.4.3 Oral liquids 
Oral liquid dosage forms were reported by 90% (n=27) of all participant 
hospitals and included both multidose and unidose containers, as follows: 
• Multidose: solutions and suspensions (n=26), syrups (n=19), elixirs49 
(n=2), oral drops (n=1) and tinctures50 (n=1). 
• Unidose: oral syringes (n=4). 
In total, 24 hospitals shared complete (quantitative) data with regards to the 
oral liquids dispensed; 1 hospital reported partial data; 1 hospital disclosed 
semi-quantitative data; and another hospital disclosed qualitative data only. 
Partial, semi-quantitative and qualitative data were processed and analysed 
accordingly (Section 2.4). The majority of hospitals reported the volumes 
dispensed per container and only 4 hospitals reported total volumes. The 
volumes dispensed ranged from 1 mL up to 4,000 mL, which corresponded 
to both multidose and unidose oral liquids. Although not all hospitals 
distinguished multidose from unidose, it was assumed that quantities <10 mL 
corresponded to unidose, whereas quantities >10 mL corresponded to 
multidose containers. For quantities of 10 mL, each data entry was 
considered individually regarding the strengths reported (Section 2.1.3). As a 
result, it was concluded that 9 hospitals dispensed unidose oral liquids in 
Spain.  
Multidose oral liquids were dispensed in a total of 60,117 containers and the 
most frequently reported dosage forms were solutions and suspensions 
(80.4%), followed by syrups (7.2%), tinctures, elixirs and oral drops (0.2%). 
Over 12% of oral liquids were not classified with regards to the specific 
dosage form, as shown in Figure 11.6.  
The top 20 active substances dispensed as multidose oral liquids are 
displayed in Figure 11.7. Dexamethasone and sildenafil citrate are also part 
of the top 20 active substances dispensed as oral solids. 
                                            
49Although elixirs are not an official PhEur dosage form, these are subject of an individual 
monograph in the BP (Oral Liquids of the BP) and correspond to clear and flavoured oral 
liquids containing 1 or more active substances dissolved in a vehicle that usually contains a 
high proportion of sucrose, or a suitable polyhydric alcohol or alcohols, and may also contain 
ethanol (96% or diluted) (BP Commission, 2008a). 
50Tinctures are extracts of liquid consistency, usually obtained using 1 part of herbal drug / 
animal matter and either 10 or 5 parts of extraction solvent (EDQM, 2007). 
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Figure 11.6 Multidose oral liquid dosage forms dispensed per number of containers. 
 
Figure 11.7 Top 20 active substances dispensed as multidose oral liquids and ranked by 
number of containers dispensed. 
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The top 5 active substances (Table 11.6) represented 42% of the active 
substances dispensed as multidose oral liquids. Of these, only methadone 
HCl is included in the Spanish national formulary. 
Table 11.6 Compounded medicines most frequently dispensed as multidose oral liquids.  
Active substances Strengths Number of hospitals 
Number of 
containers 
Omeprazole 2 mg/mL 10 mg/mL  19 10,856 
Methadone HCl 0.1-10 mg/mL 11 3,670 
Colistin sulfate not specified 3 3,553 
Amphotericin B not specified 1 3,550 
Ranitidine 5-20 mg/mL 19 3,529 
 
Omeprazole is not commercially available in Spain as an oral liquid dosage 
form (AEMPS, 2011) and was reported as solutions, suspensions and syrups 
by 63% of hospitals (n=19). Omeprazole is indicated mainly in dyspepsia, 
gastro-oesophageal reflux disease and peptic ulcer disease, in daily doses of 
10 mg or 20 mg (Martindale 35, 2007). The most frequently dispensed 
strength was 2 mg/mL, which corresponds to a daily dose of 5 mL or 10 mL. 
Methadone HCl is commonly prepared in Spanish hospital (and community) 
pharmacies as oral solutions of variable strengths for the managed 
withdrawal of narcotics and treatment of acute pain. It was reported by 11 
hospitals as solutions and syrups of 10 mL to 4,000 mL; the preparation of 
large volumes suggests that methadone HCl is not always dispensed to 
individual patients. According to 1 participant, the hospital pharmacy 
established a protocol with several care centres for drug addicts and, 
therefore, they prepared methadone solution in large batches (Herreros, 
2010). The strengths reported varied from 0.1 mg/mL to 10 mg/mL; the most 
frequently dispensed strength was 3 mg/mL. The Spanish national formulary 
includes a monograph for an oral solution of methadone HCl 1% and 
suggests doses are adapted to the clinical outcome with a maximum of 200 
mg (20 mL) (or more) per day (Comité del Formulario Nacional, 2007). At 
Hospital Universitario 12 de Octubre (Madrid), methadone HCl is prepared as 
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an oral solution of 1 mg/mL (100 mL), which corresponds to the necessary 
quantity for a 4-day treatment (Esteban, 2010). 
Colistin sulfate and amphotericin B were both reported as solutions but the 
respective strength(s) were not specified. 
Ranitidine is not commercially available in Spain as an oral liquid dosage 
form (AEMPS, 2011) and it was reported as solutions, suspensions and 
syrups by 63% of hospitals. Ranitidine is indicated mainly in gastric and 
duodenal ulceration and also in gastro-oesophageal reflux disease, in a usual 
dose of 150 mg twice a day (Martindale 35, 2007). The most frequently 
dispensed strengths were 5 mg/mL and 15 mg/mL, which would correspond 
to dose volumes 30 mL and 10 mL respectively. This fact suggests that lower 
doses than 150 mg twice a day were administered, probably to paediatric 
patients, since volumes >10 mL are too large for a single dose. 
Iodine and potassium iodide were dispensed as Lugol’s Solution in a total of 
1,531 multidose containers (Figure 11.7) of 10 mL to 100 mL, by 13 
hospitals. The Spanish national formulary includes 2 monographs for Lugol’s 
Solution: Lugol’s Solution Weak (0.015%) and Lugol’s Solution Strong (5%) 
(Comité del Formulario Nacional, 2007), which are shown in Appendix 16. 
The Lugol’s Solution Strong is indicated, in combination with other antithyroid 
medicines, in the pre-operative treatment of hyperthyroidism (2-6 drops, 3 
times daily, for 7-14 days); thyrotoxic crisis; neonatal thyrotoxicosis; and in 
thyroids protection during nuclear emergencies (15 drops daily) (Comité del 
Formulario Nacional, 2007). The Lugol’s Solution Weak is indicated in the 
prophylaxis and treatment of disorders caused by lack of iodine (Comité del 
Formulario Nacional, 2007). The majority of the Lugol’s Solutions dispensed 
were not classified (76%) whereas 20% corresponded to Lugol’s Solution 
Strong and 4% were classified as Lugol’s Solution Weak. Apart from the 
Lugol’s Solution, 2 more compounded medicines were reported by given title: 
Shohl’s Solution (n=594; 2 hospitals); and Joulie’s Solution (n=4; 1 hospital). 
A formulary for the compounded medicines reported by given title is shown in 
Appendix 16. 
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Oral liquids including more than 1 active substance were dispensed by 6 
hospitals in a total of 2,979 multidose containers, which corresponded to only 
5% of all oral liquids. In decreasing order, the active substances dispensed in 
combination were: meglumine amidotrizoate and sodium amidotrizoate 
(Gastrografin, see below); levodopa and carbidopa; hydrochlorothiazide and 
spironolactone; amiloride HCl and hydrochlorothiazide; isoniazid and 
pyridoxine HCl; and colistin sulfate, tobramycin and nystatin. 
A total of 5 proprietary medicines, in a sum of 2,444 multidose containers, 
were reported by 4 hospitals as part of the multidose oral liquids dispensed, 
as follows: CellCept (mycophenolate mofetil); Colimicina (colistin sulfate); 
Gastrografin (meglumine amidotrizoate and sodium amidotrizoate); Kreon 
(pancreatin) and Vibracina (doxycycline hyclate). 
The top 5 therapeutic groups are listed in Table 11.7. The most frequent 
therapeutic group was GI drugs, which was constituted by 4 different active 
substances, dispensed in a total of 14,749 multidose containers. All 5 groups 
included active substances that were part of the top 20 shown above (Figure 
11.7). The group represented by most active substances was cardiovascular 
drugs which included 31 active substances dispensed as multidose oral 
liquids. Cardiovascular drugs and “analgesics, anti-inflammatory drugs and 
antipyretics” were also part of the top 5 therapeutic groups in oral solids 
(Table 11.3). The top 5 therapeutic groups represented almost 60% of all 
multidose oral liquids dispensed, which suggests that there is a demand for 
compounded medicines in Spain particularly for these 5 groups. 
Table 11.7 Top 5 therapeutic groups ranked by number of multidose oral liquids dispensed. 
Therapeutic groups Number of  active substances 
Active substances 
included in top 20 
Number of  
containers 
GI drugs 4 Omeprazole Ranitidine 14,749 
Cardiovascular 
drugs 31 
Captopril 
Propranolol HCl 7,427 
Antibacterials 12 Colistin sulfate Vancomycin 5,387 
Analgesics, anti-
inflammatory drugs 
and antipyretics 
6 Methadone HCl 4,339 
Antifungals 2 Amphotericin B 3,557 
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GI drugs and cardiovascular drugs were the most frequent therapeutic 
groups, which is consistent with the fact that diseases of the circulatory 
system and digestive system corresponded to the major causes of discharge 
from all Spanish hospitals, as shown in Figure 11.8. 
 
Figure 11.8 Number of patients per 100,000 population discharged from all hospitals 
(including through death) in Spain during 2005 (latest available year), categorised by 
principal diagnosis (WHO Regional Office for Europe, 2008). 
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represented only 7.24% of all oral liquids (Figure 11.6), though there may 
have been classification errors (Section 2.1.3). The top 5 active substances 
accounted for 70% of all syrups dispensed and corresponded to (in 
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dispensed as multidose oral liquids (Figure 11.7). Unidose syrups were 
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reported by 1 hospital, in a total sum of 3,263 oral syringes (5 mL) of 
propranolol HCl 1 mg/mL. 
Tinctures (Belladonna Tincture) were reported by 1 hospital, in a sum of 106 
containers of 10 mL each. Considering that therapeutic doses of Belladonna 
Tincture range from 0.5 mL to 2 mL (Marriott et al., 2010), the 10 mL 
containers dispensed were assumed multidose. Elixirs (cyclophosphamide 
10 mg/mL and 20 mg/mL) were reported by 2 hospitals, in a total of 12 
multidose containers. Finally, oral drops were reported by 1 hospital and only 
1 container of atropine sulfate (20 mL) was dispensed. However, oral drops 
may have been classified as solutions or suspensions instead (Section 
2.1.3). The tinctures, elixirs and oral drops accounted for only 0.2% of all 
multidose oral liquids (Figure 11.6). 
Multidose oral liquids may be quantitatively compared to the oral solids 
dispensed (in packs). Assuming all oral solids were dispensed in packs of 
100 units (Section 11.4.1), the 1,052,518 individual units of oral solids 
corresponded approximately to 10,525 packs of oral solids. Therefore, when 
the 60,117 units of multidose oral liquids are compared to the 10,525 packs 
of oral solids, it is concluded that oral liquids were dispensed in larger 
quantities than oral solids. This finding clarifies the conclusion of Brion et al. 
(2003) that, in Spain, a “non-well defined combination of liquids, powders and 
capsules is dispensed”. However, it disagrees with Díaz et al. (2007), who 
concluded in 2007 that the most frequently dispensed dosage form at their 
hospital was sachets. 
Unidose oral liquids were dispensed in a total of 59,142 units (from 1 mL to 
30 mL) by 9 hospitals. In fact, only 4 hospitals reported oral syringes but, 
considering the quantities dispensed for selected compounded medicines, it 
was assumed that 9 hospitals dispensed unidose oral liquids. In total, 20 
active substances from 12 therapeutic groups were reported. The top 5 
active substances (shown in Table 11.8) represented 74% of the active 
substances dispensed as unidose oral liquids. Of these, only barium sulfate 
and nystatin were not included in the top 5 active substances dispensed as 
multidose oral liquids. Therefore, it is concluded that methadone HCl, 
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omeprazole and ranitidine were the active substances most frequently 
dispensed as oral liquids (both unidose and multidose). 
Table 11.8 Compounded medicines most frequently dispensed as unidose oral liquids.  
Active substances Strengths Number of hospitals 
Number of 
units 
Barium sulfate not specified 1 11,448 
Nystatin 1,000,000 IU/mL 1 10,448 
Ranitidine 5 mg/mL 3 8,856 
Methadone HCl 1-20 mg/mL 2 8,400 
Omeprazole 2 mg/mL 20 mg/mL 2 4,793 
 
The multidose oral liquids dispensed may be quantitatively compared to the 
unidose oral liquids (in packs). Considering that the unidose (oral syringes) 
were dispensed in packs of 12 units (Section 2.3.1), the 59,142 individual 
units corresponded approximately to 4,929 packs of oral liquids (of 12 units 
each). Therefore, when the 60,117 multidose containers are compared to the 
4,929 packs of unidose oral liquids, it is concluded that multidose containers 
were clearly dispensed in larger quantities than the unidose/oral syringes. 
11.4.4 Oromucosal preparations 
In Spain, oromucosal preparations were reported by 8 hospitals (27% of all 
participants) and these were reported as solutions, suspensions, gels, 
ointments and gargles, in a total of 4,531 multidose containers. The most 
frequently dispensed oromucosal preparations are shown in Table 11.9, 
which corresponded to 88% of all oromucosal preparations reported. 
Table 11.9 Oromucosal preparations most frequently dispensed in Spain. 
Oromucosal preparations Number of hospitals 
Number of 
containers 
Anaesthetic solution 1 1,453 
Oral decontamination preparation 1 1,015 
Mouthwash for CIOM 6 984 
Gargle solution 2 539 
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• The anaesthetic solution was reported by only 1 hospital and included 
nystatin, mepivacaine HCl, sodium bicarbonate and hexetidine, in 500 mL 
containers. 
• The oral decontamination preparation was reported by another hospital 
and included tobramycin sulfate, amphotericin B and colistin sulfate. It was 
dispensed both as suspensions (2-6 L) and ointments (100-500 g); the large 
quantities reported suggest that these were not prepared for individual 
patients but to the hospitals’ wards instead. 
• The mouthwash for CIOM was reported by 6 hospitals and was also 
prepared in large scale to be dispensed to the wards. The composition of this 
mouthwash varied slightly within hospitals and corresponded to a sodium 
bicarbonate solution (in most cases) including 1 or more of the following 
active substances: gentamicin sulfate (antibacterials); nystatin (antifungals); 
hydrocortisone and methylprednisolone (corticosteroids); chlorhexidine 
(disinfectants and preservatives); and lidocaine and mepivacaine HCl (local 
anaesthetics). 
These 3 oromucosal preparations are very similar in their composition and 
are mainly constituted by a combination of antibacterials, antifungals, 
disinfectants and preservatives and/or local anaesthetics. In total, these were 
dispensed in a sum of 3,452 multidose containers, which represented 76% of 
all oromucosal preparations. 
• The gargle solution51 was reported by 2 hospitals in a sum of 539 
multidose containers and was prepared on large scale to be dispensed to the 
wards. This solution is included in the Spanish national formulary and it is 
indicated as a mouth antiseptic for aphthous ulcers and stomatitis (Comité 
del Formulario Nacional, 2007). The composition of this officinal preparation 
includes borax in glycerol (Appendix 16), which was formerly used as paints 
for the throat, tongue and mouth but should no longer be used because of 
toxicity risks (Martindale 35, 2007). Since the Spanish national formulary is 
the official reference for pharmaceutical compounding in this country (Section 
12.2.2), this formula in particular should be revised. 
                                            
51Gargles are aqueous solutions intended for gargling to obtain local effect and are not 
meant to be swallowed (EDQM, 2007). 
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11.5 Summary 
• Compounded medicines (both sterile and non-sterile) are commonly prepared in hospital 
and community pharmacies in Spain. Apart from these, compounded medicines may also be 
prepared by other “entities previously authorised” which, so far, correspond to the regional 
boards of pharmacy of selected autonomous communities. 
• Legislation on pharmaceutical compounding is detailed and includes GCP. Professional 
organisations are common across the country and numerous compounding courses and 
events are organised throughout the year. Information sources, including an official national 
formulary, are frequent in Spain.  
• A purposive sample of 40 hospitals was included in the research and a response rate of 
78% was obtained. A total of 281 different active substances (including 9 NTI drugs) was 
reported, corresponding to 35 different therapeutic groups. The top 3 therapeutic groups 
were cardiovascular drugs (n=39), nutritional agents and vitamins (n=34) and antibacterials 
(n=31). Placebo was dispensed in a total sum of 27,703 units of capsules (n=14). 
• Oral solid dosage forms were reported by 93% of all participant hospitals and included 
capsules, oral powders and powders for oral liquids. Capsules were dispensed in a total of 
1,033,665 units (over 90% of all oral solids) and the top 5 active substances were: ribavirin, 
dexamethasone, sildenafil citrate, bosentan and fludrocortisone acetate. Oral powders 
(mainly sachets) were dispensed in a total of 16,275 units (less than 5% of all oral solids) 
and the top 5 active substances were: hydrochlorothiazide, calcium polystyrene sulfonate, 
aspirin, sucrose and monobasic sodium phosphate. Powders for oral liquids were dispensed 
in a total sum of 2,578 units (less than 2% of all oral solids). 
• Oral liquid dosage forms were reported by 90% of all participant hospitals and included 
solutions and suspensions, syrups, tinctures, oral drops and elixirs (multidose); oral syringes 
(unidose). Multidose oral liquids were dispensed in a total sum of 60,117 containers and the 
top 5 active substances were: omeprazole, methadone HCl, colistin sulfate, amphotericin B 
and ranitidine. 
• Solutions and suspensions were dispensed in a total of 48,321 multidose containers 
(over 80% of all multidose oral liquids) and the top 5 active substances corresponded to the 
top 5 of multidose oral liquids. Syrups were dispensed in 4,343 multidose containers (over 
7% of all multidose oral liquids) and the top 5 active substances were: midazolam, ranitidine, 
chloral hydrate, dexamethasone and potassium iodide. Tinctures, elixirs and oral drops 
accounted for only 0.2% of all multidose oral liquids dispensed. Unidose oral liquids were 
dispensed in a total of 59,142 units and the top 5 active substances correspond to the top 5 
of multidose oral liquids, with the exception of nystatin and barium sulfate. Oral liquids were 
dispensed in larger quantities than oral solids. 
• Oromucosal preparations were reported in a total of 4,531 multidose containers and the 
most frequently dispensed preparations included a combination of antibacterials, antifungals, 
disinfectants and preservatives and/or local anaesthetics.  
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12. Compounding in France 
France is one of the 6 founding member states of the EU and its official 
language is French (Europa, 2009). France is the largest EU country, with a 
surface area of 544,000 Km2, and is the second most populated EU country, 
with a population of 63.4 million in 2007 (Figure 2.2) (Europa, 2008).  
In 2005, there were 2,856 hospitals in France (ratio of 4.68 hospitals per 
100,000 population) and, in 2006, there were a total of 439,765 hospital beds 
(ratio of 716.78 hospital beds per 100,000 population) (WHO Regional Office 
for Europe, 2010) (Appendix 3). 
In 2007, there were 70,498 pharmacists in France (ratio of 113.82 
pharmacists per 100,000 population) (WHO Regional Office for Europe, 
2010) (Appendix 4). According to the EAHP survey, the average number of 
pharmacists in French hospitals is 3.3 pharmacists per hospital, which is 
lower than the European average of 4.7. According to Cornette and Jolivet 
(2007), although the number of hospital pharmacists in France has greatly 
increased over the past decade, this number is still insufficient considering 
the responsibilities and duties of hospital pharmacists. French hospitals have 
an average of 7.7 qualified pharmacy technicians/assistants per hospital, 
which is higher than the European average of 6. Regarding non-qualified 
pharmacy assistants, France has an average of 0.7 (EAHP, 2005; Hartmann, 
2010). Qualified pharmacy technicians/assistants must have at least a 
bachelor's degree and 2 years of training, plus a 3rd year of hospital 
specialisation for a permanent job in a French hospital pharmacy (Cornette 
and Jolivet, 2007). 
Prot-Labarthe et al. (2007) compared pharmacy practices at the French 
maternal and children’s teaching hospital in Paris - Hôpital Robert Debré - 
with a similar institution in Canada. According to their findings, the practice in 
France seems to be more product-oriented whereas in Canada it seems 
more patient-oriented. The French hospital prepared annually a total of 
approximately 95,000 compounded medicines: 3.5% oral preparations; 
78.8% other non-sterile preparations; 3.9% sterile preparations; 10.9% TPN 
infusion bags; and 2.9% sterile cytotoxic preparations. A test for uniformity of 
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content is performed for each batch of capsules in this hospital; and both 
sterile and non-sterile compounded medicines are identified with patient-
specific labels (Prot-Labarthe et al., 2007). 
Fontan et al. (2000) identified the compounded medicines prepared and 
dispensed for paediatric patients in 53 French hospital pharmacies in 1997. 
According to their findings, oral dosage forms were more frequently 
dispensed than sterile dosage forms. Capsules were the most frequently 
dispensed oral dosage form (97%) and were dispensed by 96% of the 
participant hospitals. A total of 220 active substances were dispensed as 
capsules and the top 10 (and the respective number of strengths) were as 
follows: diphemanil (n=38), captopril (n=36), fludrocortisone (n=21), 
hydrocortisone (n=25), ranitidine (n=36), spironolactone (n=46), 
ursodeoxycholic acid (n=19), capsules for decontamination (n=1), caloreen 
(dextrin; n=2) and phenytoin (n=26). Oral liquids, on the other hand, were 
dispensed by 62% of the participant hospitals and represented only 3% of all 
oral compounded medicines dispensed. This study demonstrated the need 
and importance of oral compounded medicines, in particular capsules, for 
paediatric patients in France (Fontan et al., 2000). Storme (2010) also stated 
that capsules were the most frequently compounded medicines in France. 
When administered to children, capsules are opened just before 
administration and their contents added to liquids or food. Although this 
administration is complicated, capsules are very popular in France because 
of their likely stability and easy preparation (Storme, 2010). 
12.1 Legislation 
According to the French legislation, compounded medicines may be 
classified into 4 categories, as follows: 
1. Préparation Magistrale (magistral preparation): any medicine prepared 
according to a medical prescription intended for a specific disease and 
prepared extemporaneously in a pharmacy (Legifrance, 2010a). Magistral 
preparations are prepared individually. 
2. Préparation Hospitalière (hospital preparation): any medicine prepared 
according to the indications of the French Pharmacopoeia and in conformity 
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with GCP. Hospital preparations are dispensed by the hospital pharmacy to 
one or more patients according to a medical prescription, and these 
preparations must be declared to the AFSSAPS (Section 12.2.1) (Legifrance, 
2010a). Hospital preparations are usually prepared in batches. 
3. Préparation Officinale (officinal preparation): any medicine prepared in a 
pharmacy that is included in the French Pharmacopoeia or in the national 
formulary and is intended to be directly dispensed to patients assisted by that 
pharmacy (Legifrance, 2010a). 
4. Produit Officinal Divisé (POD) (divided officinal product): any chemical 
product or medicine included in the French Pharmacopoeia that is prepared 
and packaged in advance by a pharmaceutical institution, the community 
pharmacy that sells it, or a hospital pharmacy (Legifrance, 2010a).  
In France, hospital pharmacies are named “pharmacies à usage intérieur” 
and hospitals may have one or more pharmacies (Legifrance, 2010b). The 
duties of these pharmacies are divided into compulsory duties and optional 
duties (performed if needed, but only after a special authorisation). Part of 
the compulsory duties is to compound magistral preparations (from bulk raw 
materials or proprietary medicines) and PODs (Legifrance, 2010c). Optional 
duties may only be authorised if the hospital pharmacy meets the necessary 
requirements in terms of facilities, personnel, equipment and information 
systems. If hospital pharmacies do not have the necessary resources, 
another institution may be subcontracted to perform the optional duties. Part 
of the list of optional duties is to compound hospital preparations (Legifrance, 
2010d). Since 2004, all hospital pharmacies that are authorised to compound 
hospital preparations must report electronically the medicines prepared to 
AFSSAPS (Section 12.2.1). The aim of this declaration is to gather complete 
information regarding compounded medicines prepared in large quantities so 
that essential and non-essential medicines are identified. Essential hospital 
preparations could then be developed commercially, if pharmaceutical 
companies are interested; otherwise, AFSSAPS would standardise their 
preparation and QC through the PUI-DLC department (Section 12.2.1) 
(Cornette and Jolivet, 2007; Crauste-Manciet, 2007; Storme, 2010). French 
legislation states that the preparation of compounded medicines must be in 
accordance with the GCP - “bonnes pratiques de préparation” - established 
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by the AFSSAPS (Section 12.2.1) (Legifrance, 2010e). The GCP (published 
in December 2007) is a legally binding document for the preparation of 
compounded medicines; it is based on industrial GMP (Storme, 2010) and 
aims to guarantee the quality of the medicines prepared in hospital and 
community pharmacies (Chauvé, 2007). This reference document is divided 
into 4 parts: part 1 is composed of 5 general chapters (including preparation, 
QC and documentation); part 2 is composed of specific guidelines common 
to community and hospital pharmacies (e.g. preparation of sterile 
compounded medicines); part 3 is composed of specific guidelines for 
hospital pharmacies only (e.g. preparation of radiopharmaceuticals); and part 
4 comprises annexes (Crauste-Manciet, 2007; AFSSAPS, 2010b). Adverse 
compounding incidents have happened in France, which raise the awareness 
for good quality compounding, such as the intoxication of 48 patients with 
capsules containing an overdose of thyroid extracts prepared at a community 
pharmacy (Perez, 2007). In the opinion of Chauvé (2007), GCP is a 
complete, precise and realistic document that does not represent an obstacle 
to compounding but, instead, represents a means to guarantee health safety.  
12.2 Professional organisations and information sources 
12.2.1 French professional organisations 
• Agence Française de Sécurité Sanitaire des Produits de Santé 
(AFSSAPS): is the French Medicines Agency, a public institution guided by 
the Ministry of Health that was created in 1999 with the mission to guaranty 
the quality and safe use of health products, including medicines and raw 
materials. This institution performs activities of evaluation, control and 
inspection; it employs nearly 1,000 professionals and is an important 
component of the public health system (AFSSAPS, 2010a).  
• Pharmacies à Usage Intérieur - Département des Laboratoires de 
Contrôles (PUI-DLC): is the department of AFSSAPS responsible for 
laboratory control of batch preparations. It was founded in 2008 with the main 
goal to improve the quality of batch preparations and to standardise their 
preparation and QC throughout France. Monographs for batch preparations 
may be submitted to this department and, once approved, are published in 
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the French national formulary (Section 12.2.2), setting the standards for 
future preparations (Storme, 2010).  
• Societe des Officinaux sous-Traitants en Preparations (SOTP): is a 
society of community pharmacists that prepare compounded medicines for 
other pharmacies (third-party) (SOTP, no date). According to Fabien Bruno52, 
the SOTP is constituted by approximately 40 community pharmacists and 
aims to promote and support pharmaceutical compounding in France (Bruno, 
2011).  
12.2.2 French information sources  
• Pharmacopée Française: is the French Pharmacopoeia, an official 
publication for health professionals that includes the texts of the PhEur and 
also nation-specific texts (Legifrance, 2010f). It was first published in 1983 
and is now in its 10th edition The French Pharmacopoeia currently contains 
part XI - Formulaire National - that aims to replace the national formulary 
published in 1974 (now obsolete) (AFSSAPS, 2010e). 
• Formulaire National: is the French national formulary, established by the 
national commission of the French Pharmacopoeia, which corresponds to a 
collection of the standardised formulae from the pharmacopoeia. This 
formulary comprises 50 complete monographs that not only include the 
pharmaceutical product’s formula and preparation method but also the QC 
method, storage conditions and labelling. Potential new formulae for the 
national formulary include formulae with demonstrated clinical effect; 
formulae currently prepared in community pharmacies; and formulae 
reported to AFSSAPS by hospital pharmacies. When a preparation is 
included in the national formulary, the pharmacist must comply with the 
monograph as described (Chaumeil, 2007; AFSSAPS, 2010b; 2010c). 
• Défense de la Préparation Officinale: is a report that was developed by 
French compounding stakeholders, working in different professional 
activities, and aimed to promote and support pharmaceutical compounding in 
France. Fabien Bruno was part of this working group (Bruno, 2011; Laurent 
et al., 2011). 
                                            
52Fabien Bruno is the vice-president of the SOTP and responsible pharmacist for Pharmacie 
/ Laboratoire Delpeche, in Paris. 
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12.3 Methods 
France was the first European country, to be included in the research, whose 
data on pharmaceutical compounding had already being collected by another 
institution. Hospital preparations must be reported periodically to AFSSAPS 
by all hospital pharmacies that are authorised to compound hospital 
preparations. Since magistral preparations are prepared individually and 
hospital preparations are usually prepared in larger quantities, data on the 
hospital preparations most frequently dispensed by the French hospitals was 
precisely the relevant data envisaged for this study. Consequently, and to 
avoid duplication of data collection, it was decided not to develop a 
customised questionnaire but, instead, to request the relevant data from 
AFSSAPS. Therefore, AFSSAPS was first contacted by email in August 2007 
and by telephone in January 2008, with the request for them to supply the list 
of oral hospital preparations most frequently dispensed by the French 
hospital pharmacies, in the latest available year.  
In May 2008, AFSSAPS agreed to share the requested data for analysis and 
inclusion in the Europe-wide study. In France, the research project consisted 
then in analysing the data received electronically by AFSSAPS and not, as in 
all previous European countries, in collecting comparable data by means of a 
country-specific questionnaire. 
12.4 Results and discussion 
The “List of oral hospital preparations declared electronically to AFSSAPS by 
the hospital pharmacies between 23 November 2004 and 7 May 2008” was 
received by post in June 2008, and soon after by email, from the AFSSAPS: 
Direction de l’Evaluation des Médicaments et des Produits Biologiques, 
Département de l’Evaluation des Essais Cliniques et des Médicaments à 
Statut Particulier and Cellule Préparations Hospitalières. The complete list 
included the oral hospital preparations reported to AFSSAPS by 60 French 
hospital pharmacies, in a total of 3,704 data entries. According to Dichou 
(2008), there were 2,700 hospital pharmacies in France but only 200 were in 
fact authorised to compound hospital preparations. However, only 140 
declared the hospital preparations to AFSSAPS and, of these, only 60 
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agreed with AFSSAPS to share their data. As a result, the purposive sample 
in France was constituted by 60 hospital pharmacies.  
For each European country, the objective was to identify the purposive 
sample of hospitals that dispensed the largest quantities of compounded 
medicines throughout the country. In France, however, it was not possible to 
conclude that the 60 hospitals were the ones that dispensed the most. In 
addition, the names and location of the hospitals were not disclosed and, 
hence, it was not possible to identify their distribution across the country.  
The participant hospitals shared their data in different periods of time as, for 
example, 25 July 2005 - 24 January 2006 (hospital X); 10 August 2006 - 9 
February 2007 (hospital Y); 25 July 2007 - 24 January 2008 (hospital Z). For 
this reason, it was not possible to extract the data relative to one complete 
year only. Consequently, the list provided was analysed as a whole, from the 
23 November 2004 to the 7 May 2008, as opposed to the one-year studies 
undertaken in the previous EU countries.  
AFSSAPS acknowledges that the electronic input of hospital preparations by 
the pharmacies is subject to error (Belorgey-Bismut, 2008). In fact, when the 
list provided was processed and analysed, it was found that some data 
entries were indeed incomplete or inaccurate as, for example, capsules of 
ursodeoxycholic acid being reported as 50 mg and 51 mg, in the same data 
entry (hospital X); capsules of 3,4-diaminopyridine 10 mg being reported as a 
gel, also in the same data entry (hospital Y); potassium chloride 0.7 mg oral 
solution (hospital Z). Since the identification of the hospital pharmacies was 
not disclosed by AFSSAPS, it was not possible to check the data entries with 
the pharmacies that dispensed the respective compounded medicines. 
However, the complete list of hospital preparations provided was thoroughly 
and carefully processed and analysed, taking into account the exclusion 
criteria in Section 2.4.1. 
12.4.1 Active substances  
A list of the active substances dispensed as oral hospital preparations is 
presented in Table 12.1. Active substances were grouped by therapeutic 
classification (Martindale 35, 2007), giving a total of 34 therapeutic groups 
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and 197 different active substances, similar to the 220 active substances 
identified by Fontan et al. (2000) in a study of 53 hospitals (Section 12). 
Cardiovascular drugs was the group with the greatest number of different 
active substances (n=39), followed by antibacterials (n=22) and nutritional 
agents and vitamins (n=18). Although these active substances were all 
reported as oral hospital preparations, the title of some therapeutic groups 
suggested non-oral (therapeutic) indications, namely: colouring agents 
(Appendix 25); disinfectants and preservatives (Appendix 12); and 
supplementary drugs and other substances (Appendix 15). The active 
substances included in these groups are described in the respective 
appendixes.  
The group “general anaesthetics” included ketamine HCl, which is commonly 
given by IV injection, infusion or intramuscular injection (Martindale 35, 
2007). However, it was reported as syrup by 1 hospital and, therefore, it was 
exceptionally included as for oral use. 
A total of 7 NTI drugs (ANVISA, 2007; Appendix 1), were dispensed as oral 
hospital preparations (underlined in Table 12.1). 
The active substances dispensed by most hospitals were: sodium 
bicarbonate (n=24); captopril, carmine, dexamethasone and spironolactone 
(n=16-20); 3,4-diaminopyridine, amiodarone, hydrocortisone and sodium 
chloride (n=10-15).  
All active substances reported were included in Martindale 35 (2007) with the 
exception of the following: 
• Nickel sulfate: reported as capsules (2.5 mg and 11.2 mg) by 2 hospitals 
(Appendix 26) (Section 4.4.1).  
• Potassium dichromate: reported as capsules (7.1 mg) by 1 hospital 
(Appendix 26). Since chromate is a common cause of contact allergy, it is 
likely that it was indicated for oral hyposensitization therapy or allergy testing 
(Rui et al., 2010). 
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Table 12.1 Active substances dispensed as oral hospital preparations in France (NTI drugs 
underlined). 
Analgesics, anti-inflammatory drugs 
and antipyretics  
Aspirin, codeine, codeine phosphate, 
ethylmorphine HCl, indometacin, 
morphine, morphine HCl, morphine 
sulfate, paracetamol, sulindac 
 
Anthelmintics  
Levamisole HCl 
 
Antibacterials  
Amoxicillin, cefuroxime, clavulanic acid, 
clindamycin, colistin sulfate, 
demeclocycline HCl, erythromycin, 
ethambutol HCl, framycetin sulfate, 
gentamicin sulfate, isoniazid, norfloxacin, 
ofloxacin, phenoxymethylpenicillin, 
pristinamycin, pyrazinamide, rifampicin, 
roxithromycin, sulfadiazine, telithromycin, 
vancomycin HCl 
 
Antidementia drugs 
Donepezil HCl 
 
Antidepressants 
Mianserin HCl, paroxetine HCl, paroxetine 
mesilate, tianeptine sodium,  venlafaxine 
HCl, viloxazine HCl 
 
Antidiabetics 
Metformin HCl 
 
Antiepileptics  
Clobazam, levetiracetam, phenobarbital, 
phenytoin, topiramate, vigabatrin 
 
Antigout drugs 
Allopurinol 
 
Antihistamines  
Alimemazine tartrate 
 
Antimalarials  
Pyrimethamine, quinine 
 
Antimyasthenics  
3,4-diaminopyridine, fampridine, 
pyridostigmine bromide 
 
Antineoplastics 
Busulfan, hydroxycarbamide, 
mercaptopurine, methotrexate, tioguanine 
 
Antiparkinsonian drugs  
Benserazide, bromocriptine mesilate, 
levodopa 
 
Antivirals 
Valganciclovir HCl 
 
Anxiolytic, sedatives, hypnotics and 
antipsychotics 
Alprazolam, chloral hydrate, lorazepam, 
meprobamate, midazolam, oxazepam, 
pentobarbital, tiapride HCl, zolpidem 
tartrate, zopiclone 
 
Bronchodilators and anti-asthma drugs 
Bambuterol HCl, caffeine, caffeine citrate 
 
Cardiovascular drugs 
Acenocoumarol, altizide, amiodarone HCl, 
amlodipine besilate, atenolol, betaxolol 
HCl, bisoprolol fumarate, buflomedil HCl,  
captopril, carvedilol, celiprolol HCl, 
clonidine, clopidogrel bisulfate, diazoxide, 
disopyramide, enalapril maleate, 
flecainide acetate, fluindione, furosemide, 
hydrochlorothiazide, irbesartan, labetalol 
HCl, lercanidipine HCl, lisinopril, losartan 
potassium, mannitol, metoprolol, nadolol, 
nicardipine HCl, nifedipine, perindopril 
erbumine, pravastatin sodium, propranolol 
HCl, quinidine, ramipril, sotalol HCl, 
spironolactone, verapamil HCl, warfarin 
sodium 
 
Chelators, antidotes and antagonists 
Activated charcoal, calcium polystyrene 
sulfonate, methionine, methylthioninium 
chloride, sodium polystyrene sulfonate 
 
Colouring agents 
Carmine, carmoisine, erythrosine, 
ponceau 4R, sunset yellow FCF, 
tartrazine 
 
Contrast media 
Barium sulfate 
 
Corticosteroids 
Dexamethasone, dexamethasone 
acetate, fludrocortisone acetate, 
hydrocortisone 
 
Cough suppressants, expectorants, 
mucolytics and nasal decongestants 
Ipecacuanha 
 
Disinfectants and preservatives 
Alcohol, butylated hydroxyanisole, 
butylated hydroxytoluene, potassium 
metabisulfite, sodium metabisulfite 
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Electrolytes 
Bicarbonate, potassium bicarbonate, 
potassium chloride, sodium bicarbonate, 
sodium chloride, sodium citrate 
 
GI drugs 
Calcium carbonate, kaolin, lactilol, 
lactulose, magnesium hydroxide, 
omeprazole, ranitidine HCl 
 
General anaesthetics 
Ketamine HCl 
 
Immunosuppressants 
Azathioprine, tacrolimus 
 
Miotics, mydriatics and antiglaucoma 
drugs 
Acetazolamide, pilocarpine 
 
 
Muscle relaxants 
Baclofen, dantrolene sodium 
 
 
 
 
Nutritional agents and vitamins 
Ascorbic acid, dextrin, ferrous fumarate, 
ferrous sulfate, folic acid, folinic acid, 
fructose, glucose, glutamine, iron, lactose, 
maltodextrin, maltose, menadione, 
nicotinamide, sucrose, vitamin B, vitamin 
E 
 
Prostaglandins 
Misoprostol 
 
Supplementary drugs and other 
substances 
Bethanechol chloride, calcium hydroxide, 
cinchona bark, cobalt chloride, diphemanil 
metilsulfate, glycerol, indigo carmine, 
melatonin, menthol, papain, patent blue V, 
phosphoric acid, riluzole, tolonium 
chloride, ursodeoxycholic acid, xylose 
 
Thyroid and antithyroid drugs 
Carbimazole, iodine, potassium iodide, 
potassium perchlorate 
 
Urological drugs 
Alfuzosin HCl, sildenafil citrate
 
The majority of oral hospital preparations included 1 active substance only. 
Multi-drugs were thus uncommon and these included the combination of 2 
(mainly) or 3 active substances, as follows:  
• 2 active substances (n=12): alcohol and menthol (Appendixes 12 and 15); 
altizide and spironolactone; amoxicillin and clavulanic acid; butylated 
hydroxyanisole and butylated hydroxytoluene (Appendix 12); calcium 
hydroxide and barium sulfate; codeine and ethylmorphine HCl; folic acid and 
vitamin E; iodine and potassium iodide (Lugol’s Solution, Appendix 16); iron 
and vitamin C; lactilol and mannitol; lactulose and mannitol; and 
pyrimethamine and sulfadoxine. 
• 3 active substances (n=1): quinine, quinidine and cinchona bark (Appendix 
15). 
Placebo was reported by 8 hospitals, exclusively capsules, in a total of 
53,460 units. The French national formulary (Section 12.2.2) comprises a 
monograph for placebo capsules - Capsules of Placebo for Therapeutic Use -
comprising microcrystalline cellulose (diluent) and silica colloidal anhydrous 
(lubricant) (AFSSAPS, 2010c). According to the French GCP, when a 
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preparation is included in the national formulary, the pharmacist must comply 
with formula described (AFSSAPS, 2010b) and, therefore, the placebo 
capsules reported should have complied with the corresponding monograph 
in the national formulary. 
Oral hospital preparations were also reported by the respective given titles 
but, since the identification of the hospital pharmacies was not disclosed by 
AFSSAPS, it was not possible to check their composition. Each given title 
was reported by only 1 hospital, as follows:  
• Capsules: Decontamination Capsules named “Kachouga”; Trimetallic 
Capsules; Capsules 89 CGV3; and Capsules 555. 
• Powders for oral liquids: Powder for Syrup “Kachouga”. 
• Oral liquids: Composed Oil; Mixture of Three Oils; Potion “Charrier”; 
Potion Paregoric; Solute Pectoral for Diabetics; Syrup of “Docteur Blayac” 
and Treatment of Adult Growth Hormone Deficiency. 
• Oral drops: Tincture of “Jaborandi” Solution diluted to ¼ and Tincture of 
“Laudanum de Sydenham” diluted to ¼. 
Capsules for the selective decontamination of the digestive tract (SDD) were 
also reported (Section 12.4.2).  
In addition, 16 hospitals reported proprietary medicines as part of the oral 
hospital preparations dispensed (both solid and liquid dosage forms). In total, 
almost 80 different proprietary medicines were reported but, since hospital 
preparations are usually prepared in large scale (as opposed to magistral 
preparations that are prepared individually), these should preferably include 
raw materials in bulk instead (Section 1.1.2.2).  
12.4.2 Oral solids 
Oral solid dosage forms were dispensed by 58 (97%) of the participant 
hospitals and included capsules, oral powders, powders for oral liquids and 
tablets. Capsules were the most frequently dispensed dosage form (total of 
3,873,453 units) and represented 99.1% of all oral solid hospital 
preparations. These figures are in accordance with the study undertaken by 
Fontan et al. (2000), in which capsules were dispensed by 96% of the 
hospitals studied and were also the most frequently dispensed dosage form. 
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The top 5 hospital preparations dispensed as oral solids are shown in Table 
12.2 and corresponded to capsules only. Capsules for SDD, captopril and 
hydrocortisone were also included in the top 10 identified by Fontan et al. 
(2000). In general, the number of strengths encountered is considerably 
lower than in their study (e.g. captopril 15 vs 36 strengths; hydrocortisone 12 
vs 25 strengths), which may be due to improved standardisation of hospital 
preparations from 1997 (Fontan et al., 2000) to 2004/2008 (AFSSAPS). 
Table 12.2 Top 5 hospital preparations dispensed as oral solids (capsules). 
Active substances Strengths (number of strengths) 
Number of 
hospitals 
Number of 
units 
3,4-Diaminopyridine 5-50 mg (5) 15 558,209 
Capsules for SDD n/a 5 473,902 
Sodium bicarbonate 125-1,000 mg (4) 24 219,978 
Captopril 0.5-25 mg (15) 16 199,862 
Hydrocortisone 0.5-9 mg (12) 10 184,817 
 
Capsules for SDD were reported for both adult and paediatric patients by a 
total of 5 hospitals. The selective decontamination of the digestive tract is an 
infection-prevention regimen used in critically ill patients that aims to 
eradicate aerobic (potentially pathogenic) microorganisms from the 
oropharynx, stomach and gut. The SDD regimen includes the oral 
administration of antibiotics such as polymyxin E, tobramycin and 
amphotericin B (Jonge et al., 2003).  
Sodium bicarbonate (capsules) is included in the French national formulary 
(Section 12.2.2) and the monograph states the same 4 strengths reported 
here: 125 mg, 250 mg, 500 mg and 1,000 mg. The excipient (diluent) stated 
in the monograph is microcrystalline cellulose (AFSSAPS, 2010c). Because 
these capsules are included in the French national formulary, the hospital 
preparations reported should have complied with corresponding monograph 
(AFSSAPS, 2010b). 
In France, conditions of the digestive and circulatory systems were the major 
causes of discharge from all hospitals (including through death) during 2005 
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(Figure 12.1), which is consistent with the fact that capsules for SDD and 
captopril are part of the top 5 hospital preparations. 
 
Figure 12.1 Number of patients per 100,000 population discharged from all hospitals 
(including through death) in France during 2005 (latest available year), categorised by 
principal diagnosis (WHO Regional Office for Europe, 2008). 
Tablets were the next most frequently dispensed oral solids (total of 23,996 
units; 0.6%) and these were reported by 6 (10%) participant hospitals. The 
top 5 active substances dispensed were, in decreasing order: sodium 
chloride (500 mg), calcium carbonate (500 mg), celiprolol HCl (100 mg), 
spironolactone (1 mg, 2.5 mg and 5 mg) and amiodarone HCl (5 mg). 
Spironolactone was also part of the top 10 identified by Fontan et al. (2000) 
but in fewer strengths compared to their study. The French national formulary 
includes monographs for tablets of both sodium chloride and calcium 
carbonate (AFSSAPS, 2010d). 
Powders for oral liquids were reported by 5 (8%) hospitals, in a sum of 8,688 
units (0.2%). In total, only 5 different hospital preparations were reported and 
these corresponded (in decreasing order) to the following: sodium 
polystyrene sulfonate (15 g), Powder for Syrup “Kachouga”, pentobarbital 
(100 mg), sucrose (3.75 g) and sodium metabisulfite (25 mg; Appendix 12). 
Oral powders were reported by 5 (8%) of participant hospitals, in a sum of 
4,484 units (0.1%). The top 5 active substances dispensed were, in 
decreasing order: caffeine (150 mg), glucose (50 g and 75 g), lactose (50 g), 
erythromycin (500 mg and 1,000 mg) and xylose (25 g; Appendix 15). 
The oral solids dispensed were reported by number of individual units only, in 
a total of 3,910,621 units. The number of packs of oral solids was not 
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provided and, therefore, it was not possible to conclude the number of times 
each hospital preparation was dispensed (as a pack). Nevertheless, since 
capsules corresponded to 99.1% of all oral solids dispensed, it is possible to 
estimate that each oral solid hospital preparation was dispensed, on average, 
as packs of 50 individual units (Section 2.1.3). Consequently, it is possible to 
estimate that oral solids were dispensed in a total of 78,212 packs (of 50 
individual units). 
12.4.3 Oral liquids  
Oral liquid dosage forms were reported by 34 (54%) hospitals, which is 
similar to the results by Fontan et al. (2000), in which oral liquids were 
dispensed by 62% participant hospitals. The oral liquids dispensed included 
multidose and unidose dosage forms, as follows: solutions, suspensions, 
syrups and oral drops (multidose) and oral syringes (unidose). The most 
frequently dispensed dosage forms were solutions and suspensions (total of 
29,475 units), which represented 62% of all multidose oral liquids dispensed 
(Figure 12.2). The top 5 hospital preparations dispensed as solutions and 
suspensions were, in decreasing order: sucrose (4 hospitals), mannitol and 
lactulose (1 hospital), vitamin E (1 hospital), folinic acid (1 hospital) and 
Potion “Charrier” (1 hospital). As previously stated, many data entries were 
incomplete or inaccurate (Section 12.4) and, therefore, the individual 
strengths and pack sizes of oral liquids will not be addressed in detail. 
 
Figure 12.2 Oral liquid dosage forms dispensed per number of units. 
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14,592 units), which represented 31% of all multidose oral liquids dispensed 
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4 different hospital preparations were reported, namely (in decreasing order): 
Tincture of “Laudanum de Sydenham” diluted to ¼ (1 hospital); Tincture of 
“Jaborandi” Solution diluted to ¼ (1 hospital); iodine and potassium iodide (3 
hospitals); and codeine and ethylmorphine HCl (1 hospital). It was not 
possible to check the composition of the oral hospital preparations reported 
by given titles since the identification of the hospital pharmacies was not 
disclosed by AFSSAPS (Section 12.4.1). 
Syrups were reported by 15 participant hospitals, in a total of 3,407 multidose 
units, which represented 7% of all multidose oral liquids dispensed (Figure 
12.2). The top 5 hospital preparations dispensed as syrups were (in 
decreasing order): sodium citrate (1 hospital); chloral hydrate (5 hospitals); 
ketamine HCl (1 hospital); ipecacuanha (6 hospitals); and Syrup of “Docteur 
Blayac” (1 hospital). The French national formulary includes a monograph for 
“Syrup of Ipecacuanha” (AFSSAPS, 2010d). As mentioned in Section 2.1.3, 
classification of some oral liquids by the hospital pharmacies may not have 
been accurate. 
Oral syringes were reported as unidose oral liquids, in a total of 19,519 
individual units (Figure 12.2), by 2 hospital pharmacies. Only 2 active 
substances were dispensed as oral syringes, namely (in decreasing order): 
alimemazine tartrate (30-100 mg/5 mL, 5 strengths) and sucrose (1 strength).  
In total, hospital pharmacies dispensed 47,474 multidose oral liquids and 
19,519 unidose oral liquids. The quantities of multidose and unidose oral 
liquids cannot be directly compared as 1 syringe (unidose) is equivalent only 
to one dose of the multidose oral liquids. Nevertheless, when both figures are 
compared to the estimation of 78,212 oral solids (packs of 50 units) (Section 
12.4.2), it is possible to conclude that oral solids (capsules) were more 
frequently dispensed than oral liquid dosage forms (Figure 12.3). This fact is 
in accordance with Brion et al. (2003), who also concluded that capsules 
were the most frequently dispensed oral dosage forms in France. 
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Figure 12.3 Number of units of oral solid and oral liquid dosage forms (unidose and 
multidose) dispensed by the participant hospitals. 
12.4.4 Oromucosal preparations 
In France, the “List of oral hospital preparations” shared by AFSSAPS 
included only 2 hospital preparations classified as oromucosal, namely: 
methylthioninium chloride solution 1% and Lugol’s Solution 2%. Since the 
French database included inaccurate entries (Section 12.4), it was assumed 
that these 2 oromucosal preparations corresponded, instead, to oral hospital 
preparations (as shared by AFSSAPS). Therefore, no oromucosal 
preparations were considered in France. 
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12.5 Summary 
• Compounded medicines in France may be classified into 4 categories: magistral 
preparations, hospital preparations, officinal preparations and divided officinal products. 
Hospital preparations must be declared to AFSSAPS and are usually prepared in batches. 
The preparation of compounded medicines must be in accordance with French GCP. 
• PUI-DLC (AFSSAPS), SOTP and Défense de la Préparation Officinale represent 3 
professional organisations that support pharmaceutical compounding in France. The national 
formulary is part of the French Pharmacopoeia and includes 50 standardised formulae. 
• Data collection was not undertaken in France. Instead, the “List of oral hospital 
preparations declared electronically to AFSSAPS by the hospital pharmacies between 23 
November 2004 and 7 May 2008” was shared by AFSSAPS for analysis. A total of 60 
French hospitals were included in the research. 
• According to the data shared, a total of 197 active substances (including 7 NTI drugs) 
were dispensed as oral hospital preparations, corresponding to 34 therapeutic groups. 
• The therapeutic groups with the greatest number of different active substances were: 
cardiovascular drugs (n=39), antibacterials (n=22) and nutritional agents and vitamins 
(n=18). Placebo was dispensed in a total sum of 53,460 units of capsules (n=8). 
• Oral solid dosage forms were dispensed in 97% of hospitals and included capsules, 
tablets, powders for oral liquids and oral powders. Capsules were dispensed in a total of 
3,873,453 units (99.1% of oral solids) and the top 5 active substances were: 3,4-
diaminopyridine, capsules for SDD, sodium bicarbonate, captopril and hydrocortisone. 
Tablets were dispensed in a total of 23,996 units (0.6% of oral solids) and the top 5 active 
substances were: sodium chloride, calcium carbonate, celiprolol HCl, spironolactone and 
amiodarone HCl. Powders for oral liquids were dispensed in a total of 8,688 units (0.2%) and 
oral powders in a total of 4,484 units (0.1% of oral solids). 
• Oral liquid dosage forms were dispensed in 54% of hospitals and included solutions and 
suspensions, oral drops and syrups (multidose) and oral syringes (unidose). 
• Solutions and suspensions were dispensed in a total of 29,475 containers (62% of 
multidose oral liquids) and the top 5 active substances were: sucrose, mannitol and 
lactulose, vitamin E, folinic acid and Potion “Charrier”. Oral drops were dispensed in a total 
of 14,592 containers (31% of multidose oral liquids) and the top 3 hospital preparations 
were: Tincture of “Laudanum de Sydenham” diluted to ¼; Tincture of “Jaborandi” Solution 
diluted to ¼; iodine and potassium iodide. Syrups were dispensed in a total of 3,407 
containers (7% of multidose oral liquids) and the top 5 active substances were: sodium 
citrate, chloral hydrate, ketamine HCl, ipecacuanha and Syrup of “Docteur Blayac”. Oral 
syringes (alimemazine tartrate and sucrose) were dispensed in a total of 19,519 unidose oral 
liquids. 
• Oral solids were dispensed in larger quantities than oral liquids.  
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13. Compounding in Germany 
Germany is one of the 6 founding member states of the EU and its official 
language is German (the most widely spoken first language in the EU). 
Germany is the most populated country in the EU, with a population of 82.4 
million in 2007 (Figure 2.2), and is physically the 4th largest EU country, 
occupying a surface area of 357,000 Km2 from the North Sea and the Baltic 
in the North, to the alps in the South (Europa, 2008; 2009).  
In 2006, there were 3,359 hospitals in Germany (ratio of 4.07 hospitals per 
100,000 population) and a total of 683,484 hospital beds (ratio of 829.09 
hospital beds per 100,000 population) (WHO Regional Office for Europe, 
2010) (Appendix 3). 
In 2007, there were 49,528 pharmacists in Germany (ratio of 59.87 
pharmacists per 100,000 population) (WHO Regional Office for Europe, 
2010) (Appendix 4). In total, only 3.2% of German pharmacists work in 
hospital pharmacy (ABDA, 2010). According to the EAHP survey, the 
average number of pharmacists per German hospital is 4.0, which is lower 
than the European average of 4.7. Moreover, German hospitals have an 
average of 5.0 qualified pharmacy technicians/assistants per hospital, which 
is also lower than the European average of 6. Regarding non-qualified 
pharmacy assistants per hospital, Germany has an average of 4.3 (EAHP, 
2005; Hartmann, 2010). 
In Germany, pharmaceutical compounding is part of pharmacists’ activity in 
both community (Zueck, 2008) and hospital pharmacies (Ohem, 2007) and is 
considered an indispensable part of therapy (Kinget, 2009). Upon a 
compounding prescription, pharmacists have to prepare the respective 
compounded medicine(s) and all 21,500 community pharmacies in Germany 
are capable of performing, at least, basic compounding for their patients. It 
has been estimated that around 25 million compounded medicines are 
prepared in the community setting every year (around 1,100 compounded 
medicines per pharmacy per year) (Zueck, 2008; Kinget, 2009). The quality 
of the compounded medicines prepared is of major concern in Germany and 
community pharmacies regularly participate in quality testing by submitting 
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selected compounded medicines, on a voluntary basis, to the “Central 
Laboratory of German Pharmacists” (Zentrallaboratorium Deutscher 
Apotheker e.V.). Quality testing in Germany is recommended at least once a 
year so that pharmacists assess and optimise their compounding practices 
(Zueck, 2008; Kinget, 2009). 
Hospitals in Germany are not obliged to have their own hospital pharmacy as 
medicines may be supplied by the hospital pharmacy of another hospital or 
even by a community pharmacy (EAHP and HOPE, 2002; Amann and 
Hoppe-Tichy, 2007). In fact, 78% of German hospitals do not have a 
pharmacy of their own (61% are supplied by other hospitals and 39% by 
community pharmacies). Considering the German hospitals that do have a 
pharmacy on their own, 71% of the hospital pharmacies supply not only their 
own hospital but also other hospitals (Amann and Hoppe-Tichy, 2007). The 
total number of German hospitals has been decreasing and more and more 
hospitals are being supplied by other hospital pharmacies; the larger 
hospitals in Germany are the ones most likely to have a pharmacy on their 
own (EAHP and HOPE, 2002; Krämer, 2007). 
Hospital pharmacy in Germany is traditionally a manufacturing and supply-
based activity and pharmaceutical compounding is still one of the core areas 
of hospital pharmacists’ activities and responsibilities; together with 
pharmaceutical logistics, pharmacoeconomics and clinical pharmacy 
(Gessel, 2006; Krämer, 2007). 
13.1 Legislation 
In accordance with the German Medicinal Products Act (Gesetz über den 
Verkehr mit Arzneimitteln), medicinal products prepared according to a 
prescription for an individual patient are exempt from needing a marketing 
authorisation (Bundesministerium der Justiz, 2009). These medicines may be 
considered in 3 different categories, as follows:  compounded medicines 
prepared extemporaneously for an individual patient (rezeptur); compounded 
medicines prepared in advance as batches up to a maximum of 100 packs 
(of the same compounded medicine) per day (defektur); and compounded 
medicines prepared in larger quantities (more than 100 packs per day) 
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(großherstellung). For each category, different requirements apply with 
regards to compounding records and testing (among others) (EAHP and 
HOPE, 2002; Ohem, 2007; Bundesministerium der Justiz, 2008). 
Guidelines for the practice of pharmaceutical compounding have been 
developed (and updated) by ABDA (Section 13.2.1) and, although not legally 
binding, these guidelines are the foundation for GCP in Germany. A total of 
23 guidelines have been developed, covering all relevant steps of the 
practice of compounding, from checking the prescription and testing the raw 
materials to the QC of the final compounded medicines (Kinget, 2009; ABDA, 
2011a). 
13.2 Professional organisations and information sources 
13.2.1 German professional organisations 
• Bundesverband Deutscher Krankenhausapotheker e.V. (ADKA): is the 
German Society of Hospital Pharmacists, the only organisation in Germany 
that represents hospital pharmacy and supports pharmacists working in 
German hospitals. This nation-wide society is constituted by 8 special 
interest groups, from drug production to QA, which comprise its scientific and 
professional foundation (Amann, 2007; 2011; ADKA, no date). According to 
the president of ADKA: “Drug manufacturing is to be performed in the 
hospital pharmacy department considering state-of-the-art processes. 
Facilities and equipment should correspond with the type and amount of 
products manufactured” (Krämer, 2011). 
• Bundesvereinigung Deutscher Apothekerverbände (ABDA): is the Federal 
Union of German Associations of Pharmacists, the main organisation of 
German pharmacists, which aims to join together and bring forward the 
common interests of its 34 member organisations, namely: 17 State level 
councils of pharmacists (confederated to the National Council of 
Pharmacists) and 17 State level associations of pharmacists (confederated to 
the German Pharmacists’ Association (DAV) - Deutscher Apotheker Verlag) 
(ABDA, 2011b). ABDA is the editor organisation of the German national 
formulary (Section 13.2.2). 
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13.2.2 German information sources 
• Deutscher Arzneimittel-Codex - Neues Rezeptur-Formularium (DAC-
NRF): is the German drug-codex, which includes the national formulary - 
know in short as NRF (New Recipe-Formulary) - a loose-leaf reference 
source comprising 3 volumes and divided into 5 parts, as follows: (I) General 
notices; (II) Individualised processing pattern; (III) References for starting 
material; (IV) 239 standardised formulae; (V) 23 stock preparation 
monographs (ABDA, 2008). Standardised Recipes (Standardisierte 
Rezepturen) is the corresponding reference for doctors, known as the 
doctor’s NRF (Reimann, 2007). The formulae in the NRF are based on real 
prescriptions and were designed for the preparation of standardised 
individual compounded medicines. The development of NRF formulae is 
undertaken in collaboration with several German pharmaceutical institutions 
and also with the LNA in the Netherlands (Section 7.2.1) (Kinget, 2009). 
There is cooperation between the Dutch formulary (FNA, Section 7.2.2) and 
the German formulary in relation to “formulations, procedures and 
guidelines”, which is gradually developing into harmonisation of both 
(Bouwman, 2007). The DAC-NRF is available online (for subscribers only) at 
the Pharmazeutische Zeitung (2011), together with additional compounding 
information and technological support (Reimann, 2007). 
• Herstellungsvorschriften aus Krankenhausapotheken: is a formulary for 
hospital compounding, edited by the DAV (Section 13.2.1), also in a loose-
leaf format and comprising monographs for the preparation of compounded 
medicines specially needed in the hospital setting (Kinget, 2009; DAV, no 
date). 
13.3 Methods 
Germany was the second European country to be included in the research 
whose data on hospital pharmaceutical compounding was previously 
collected by another institution. Barnscheid (2008) at the “Institute of 
Pharmaceutics and Biopharmaceutics (IPB)” (Institut für Pharmazeutische 
Technologie und Biopharmazie) from the Heinrich Heine University in 
Düsseldorf (Heinrich Heine Universität Düsseldorf, 2011), undertook PhD 
research on “Child-appropriate drug formulations including diuretic drugs” 
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(Kindgerechte Arzneizubereitungen mit diuretischen Wirkstoffen), supervised 
by Jörg Breitkreutz and supported by the Hexal-Initiative Kinderarzneimittel. 
For this reason, and so that data collection would not be duplicated, it was 
decided not to develop a customised questionnaire for German hospitals but, 
instead, to request the relevant data from the IPB. Therefore, Jörg Breitkreutz 
was contacted by email in May 2009 with the request for the list of oral 
compounded medicines most frequently dispensed by the German hospitals 
included in their research. In July 2009, the required data was shared during 
a 2-day visit to Düsseldorf. 
During his PhD research, Barnscheid (2008) contacted all German hospitals 
that had a paediatric department (including all paediatric hospitals) with the 
request to participate in his study. A total of 234 hospitals were initially 
contacted and the hospitals willing to participate were sent an introductory 
letter, a collection box and a few prescription notebooks, as illustrated in 
Figure 13.1. 
The prescription notebooks were to be distributed to all hospital 
paediatricians53 to record all their prescriptions for compounded medicines 
(only) during a 6-month period (2005/2006). Each prescription notebook was 
made up of prescription sheets (in white) and the respective carbon copies 
(in yellow). The carbon copies included all the information from the 
prescription sheets, with the exception of the patient name and respective 
location, the date and the doctor’s signature; this information was omitted for 
blinding purposes (Figure 13.1) (Breitkreutz, 2006; 2009; Hermes et al., 
2010). The prescription sheets were to be used in the hospital and the 
respective carbon copies were to be put inside the collection box, which was 
to be sent back to the IPB at the end of the study period (Breitkreutz, 2006; 
2009). Once received, the carbon copies (inside the collection box) were 
analysed and all relevant data inserted in an Excel database.  
 
 
                                            
53If more prescription notebooks were required these would be sent by post (as many as 
necessary) at anytime and free of charge (Breitkreutz, 2009). 
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Figure 13.1 Collection box (left), prescription notebook and inside contents (right). 
The complete Excel database was shared including data regarding all oral 
and non-oral compounded medicines prescribed to paediatric patients during 
the study period but, for comparative purposes, data regarding non-oral 
compounded medicines was excluded from the database. Furthermore, the 
database was not formatted and some data entries were missing key 
information such as the dosage form and the quantities prescribed. Other 
data entries were not clearly identified in terms of the respective active 
substances. Since the identification of the hospital pharmacies was not 
disclosed, all data entries that were missing key information and also those 
not clearly identified were excluded from the database for this study.  
13.4 Results and discussion 
A total of 40 hospitals participated in the research study and these were 
distributed throughout Germany, as shown in Figure 13.2 (Breitkreutz, 2006; 
2009; Hermes et al., 2010). A total of 4,895 carbon copies of the 
prescriptions for paediatric patients were received and analysed. The 
majority of the compounded medicines were for oral administration (87%), 
followed by parenteral (5%) and rectal administration (4%) (Barnscheid, 
2008). Unfortunately, only a few prescriptions sheets were fully completed by 
paediatricians (Breitkreutz, 2009). The Excel database shared included data 
regarding 37 German hospitals and, since 1 hospital did not provide any 
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quantities of the medicines prescribed, only 36 German hospitals were 
considered for analysis.  
 
Figure 13.2 Map of Germany adapted from National Geographic Society (1998i); indicating 
the location of the 40 participant hospitals (   ). 
13.4.1 Active substances  
A complete list of the active substances prescribed as oral (and oromucosal) 
compounded medicines in Germany (for paediatric patients) is shown in 
Table 13.1. All active substances were included in Martindale 35 (2007) and 
these were grouped according to the respective therapeutic classification, 
giving a total of 147 different active substances and 32 therapeutic groups. 
Cardiovascular drugs was the group with the greatest number of different 
active substances (n=26), followed by supplementary drugs and other 
substances (n=14) and antiepileptics / nutritional agents and vitamins (n=11).  
Although these active substances were all prescribed as oral (and 
oromucosal) compounded medicines, the title of some therapeutic groups 
suggested non-oral (therapeutic) indications, namely: colouring agents 
(Appendix 25); disinfectants and preservatives (Appendix 12); nonionic 
surfactants (Appendix 25); and supplementary drugs and other substances 
(Appendix 15). The active substances included in these groups were 
described in the respective appendixes. 
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Table 13.1 Active substances prescribed as oral (and oromucosal) compounded medicines 
in Germany (for paediatric patients) (NTI drugs underlined). 
Analgesics, anti-inflammatory drugs 
and antipyretics 
Aspirin, celecoxib, flupirtine maleate, 
indometacin, morphine, morphine HCl, 
morphine sulfate, naproxen, opium 
 
Antibacterials 
Cefuroxime, colistin sulfate, nitrofurantoin, 
protionamide, pyrazinamide, 
roxithromycin, sultamicillin, trimethoprim, 
vancomycin 
 
Antiepileptics 
Clobazam, lamotrigine, levetiracetam, 
mesuximide, phenobarbital, phenytoin, 
sodium valproate, sultiame, topiramate, 
vigabatrin, zonisamide 
 
Antifungals 
Ciclopirox, fluconazole, itraconazole, 
miconazole, nystatin 
 
Antigout drugs 
Allopurinol, probenecid 
 
Antihistamines 
Flunarizine HCl, pheniramine maleate 
 
Antimalarials 
Hydroxychloroquine sulfate 
 
Antiparkinsonian drugs 
Bromocriptine mesilate 
 
Antiprotozoals 
Emetine HCl, metronidazole 
 
Antivirals 
Aciclovir, ganciclovir, oseltamivir 
phosphate, valganciclovir HCl 
 
Anxiolytic, sedatives, hypnotics and 
antipsychotics 
Chloral hydrate, midazolam, midazolam 
HCl, tetrazepam 
 
Bronchodilators and anti-asthma drugs 
Caffeine, caffeine citrate, ipratropium 
bromide, orciprenaline sulfate, 
theophylline 
 
Cardiovascular drugs 
Amiodarone, atenolol, bosentan, captopril, 
carvedilol, clonidine, clonidine HCl, 
diazoxide, dihydralazine sulfate, enalapril, 
enalapril maleate, furosemide, 
hydrochlorothiazide, irbesartan, 
metoprolol, mexiletine HCl, nifedipine, 
phenprocoumon, potassium canrenoate, 
propafenone HCl, propranolol HCl, 
ramipril, sotalol HCl, spironolactone, 
verapamil HCl, warfarin sodium 
 
Chelators, antidotes and antagonists 
Sevelamer HCl 
 
Colouring agents 
Carmine 
 
Corticosteroids 
Betamethasone, budenoside, 
dexamethasone, fludrocortisone acetate, 
hydrocortisone 
 
Cough suppressants, expectorants, 
mucolytics and nasal decongestants 
Ipecacuanha 
 
Disinfectants and preservatives 
Acriflavinium chloride 
 
Electrolytes 
Calcium, calcium gluconate, calcium 
glycerophosphate, calcium hydrogen 
phosphate, calcium lactate, calcium 
phosphate, dibasic sodium phosphate, 
sodium chloride, sodium citrate, sodium 
phosphate 
 
GI drugs 
Aluminium hydroxide, dronabinol, 
esomeprazole magnesium, mesalazine, 
omeprazole, ranitidine, sulfasalazine, 
tegaserod maleate 
 
General anaesthetics 
Ketamine HCl 
 
Hypothalamic and pituitary hormones 
Desmopressin acetate 
 
Immunosuppressants 
Azathioprine 
 
Local anaesthetics 
Procaine HCl 
 
Miotics, mydriatics and antiglaucoma 
drugs 
Acetazolamide, pilocarpine HCl 
 
Muscle relaxants 
Baclofen 
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Nonionic surfactants 
Polysorbate 80 
 
 
Nutritional agents and vitamins 
Calcitriol, calcium folinate, ferrous sulfate, 
folic acid, fructose, glucose, iron, lactose, 
maltodextrin, pyridoxine HCl, sucrose 
 
 
Sex hormones 
Estradiol valerate 
 
 
 
Supplementary drugs and other 
substances 
Dexpanthenol, macrogols, macrogol 
4000, melatonin, orotic acid, pancreatin, 
phosphorus, potassium bromide, taurine, 
thyme, tormentil, ursodeoxycholic acid, 
vanillin, xylose 
 
Thyroid and antithyroid drugs 
Levothyroxine sodium, propylthiouracil 
 
Urological drugs 
Oxybutynin HCl, sildenafil citrate, 
tamsulosin HCl
 
With reference to the official list provided by ANVISA (2007) (Appendix 1), a 
total of 6 NTI drugs were prescribed as oral compounded medicines 
(underlined in Table 13.1). 
The active substances prescribed in most hospitals were: spironolactone 
(n=30); hydrochlorothiazide (n=28); caffeine citrate (n=18); chloral hydrate 
(n=16) and theophylline (n=15). 
Almost all medicines prescribed included just 1 active substance and only 4 
compounded medicines contained up to 3 different active substances, which 
were dispensed both as oral solid and liquid dosage forms, and also as 
oromucosal preparations (described below). 
13.4.1 Oral solids 
Oral solid dosage forms were prescribed in 97% of the hospitals (only 1 
hospital did not report oral solids) and included capsules (n=33), oral 
powders (n=13), tablets (n=3) and pellets (n=2). The quantities of oral solids 
were provided as the number of individual units prescribed, which may not 
correspond to the exact number of units dispensed by the hospital pharmacy; 
compounding records identify the compounded medicines dispensed more 
accurately than the respective prescriptions (Giam and McLachlan, 2008). 
Therefore, in accordance with the data shared, the most frequent dosage 
forms were capsules (92.36%), followed by oral powders (7.39%) and, in a 
minority, pellets and tablets (Figure 13.3). Since all compounded medicines 
prescribed were for the paediatric population, it is likely that part of the 
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capsules prescribed were opened before administration and given to 
paediatric patients with liquids or food. 
 
Figure 13.3 Number of units of oral solids prescribed per dosage form. 
The top 20 active substances prescribed as oral solids and ranked by 
number of units are listed in Figure 13.4. Hydrochlorothiazide was the most 
frequently prescribed active substance (10.5%), followed by calcium 
gluconate (10.1%) and spironolactone (9.5%). Hydrochlorothiazide and 
spironolactone were also the active substances prescribed by most hospitals.  
 
Figure 13.4 Top 20 active substances prescribed as oral solids and ranked by units. 
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The top 10 active substances represented over 60% of all active substances 
prescribed as oral solids, which indicates that these are the active 
substances most highly demanded as compounded medicines for paediatric 
patients in Germany. 
The top 5 therapeutic groups, ranked by number of units prescribed of the 
corresponding oral solids, are listed below in Table 13.2. All 5 groups 
included active substances that were part of the top 20 (Figure 13.4). 
Table 13.2 Top 5 therapeutic groups ranked by number of units of oral solids prescribed. 
Therapeutic groups Number of  active substances 
Active substances 
included in top 20 
Number of  
units prescribed 
Cardiovascular drugs 26 7 26,361 
Electrolytes 9 4 10,793 
Corticosteroids 3 2 7,855 
Antibacterials 9 1 5,795 
Antiepileptics 11 3 5,018 
 
The most frequent therapeutic group was cardiovascular drugs, which is 
consistent with the fact that conditions of the circulatory system are the major 
cause of discharge from all German hospitals (including through death) 
(Figure 13.5). Cardiovascular drugs was also the therapeutic group 
constituted by most active substances dispensed as oral solids and included 
all active substances shown in Table 13.1. 
 
Figure 13.5 Number of patients per 100,000 population discharged from all hospitals 
(including through death) in Germany during 2005 (latest available year), categorised by 
principal diagnosis (WHO Regional Office for Europe, 2008). 
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Capsules were prescribed in 92.4% of the hospitals and the top 20 active 
substances corresponded to the top 20 prescribed as oral solids, with the 
exception of calcium hydrogen phosphate and dibasic sodium phosphate 
(Figure 13.4), which is consistent with the fact that capsules were the most 
frequently prescribed oral solid dosage forms. Capsules including more than 
1 active substance were prescribed by 3 hospitals, in a total of 3,990 units, 
as follows: calcium and phosphorous; calcium hydrogen phosphate and 
dibasic sodium phosphate; and spironolactone and hydrochlorothiazide.  
Because only a few prescriptions were fully completed by paediatricians 
(Breitkreutz, 2009), the majority of the data entries were incomplete and, 
therefore, the individual strengths and pack sizes of oral solids will not be 
addressed in detail. 
Oral powders were prescribed by only 36% of the hospitals and the top 5 
active substances (spironolactone, caffeine citrate, hydrochlorothiazide, 
topiramate and furosemide) were part of the top 20 prescribed as oral solids, 
with the exception of caffeine citrate. These top 5 active substances 
accounted for almost 60% of all active substances prescribed as oral 
powders. Oral powders were prescribed comprising 1 active substance only. 
Pellets represented less than 0.2% of all oral solids and were prescribed in 
only 2 hospitals, as follows: theophylline (75 mg and 100 mg) and topiramate 
(30 mg). Tablets, on the other hand, represented only 0.1% of all oral solids 
and were prescribed in 3 hospitals, as follows: nitrofurantoin (20 mg); 
hydrochlorothiazide and spironolactone (1.8 mg and 1 mg); and 
metronidazole (50 mg). 
13.4.2 Oral liquids 
Oral liquid dosage forms were prescribed in 89% of the hospitals and 
included solutions and suspensions (n=31), oral drops (n=14), syrups (n=7), 
tinctures (n=2) and mixtures (n=2). Oral syringes were not prescribed in 
Germany and it was assumed that all oral liquids were multidose. 
Nevertheless, it is possible that part of the oral liquids prescribed were 
actually unidose but, since the majority of data entries were incomplete, this 
information could not be accurately retrieved from the database. In addition, it 
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is possible that the dosage forms and quantities prescribed did not always 
correspond to that actually dispensed by the hospital pharmacy. Some 
interchange might have occurred, particularly between solutions, 
suspensions, syrups and mixtures since the distinction between these 
dosage forms is not always clear to all health care professionals (Section 
2.1.3). 
The most frequent dosage forms were solutions and suspensions (87.8%), 
followed by oral drops (10.9%), syrups (1%) and, in a minority, tinctures and 
mixtures (Figure 13.6). 
 
Figure 13.6 Number of multidose containers of oral liquids prescribed per dosage form. 
The top 10 active substances dispensed as oral liquids and ranked by 
number of multidose containers are listed below (Figure 13.7). Caffeine 
citrate was the most frequently prescribed active substance (39.7%), followed 
by midazolam (19.1%) and the combination of calcium hydrogen phosphate 
with dibasic sodium phosphate (11.2%), which was the only oral liquid 
prescribed including more than 1 active substance. 
Caffeine citrate (bronchodilators and anti-asthma drugs) is commonly used in 
the short-term treatment of neonatal apnoea54 as it has been found to reduce 
the number and severity of apnoeic episodes (Martindale 35, 2007). Caffeine 
citrate was also part of the top 5 active substances prescribed as oral 
                                            
54Neonatal apnoea corresponds to the cessation of breathing either lasting 20 seconds or 
more or associated with bradycardia, cyanosis, pallor and hypotonia, for which no specific 
cause can be identified (Martindale 35, 2007). 
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powders (Section 13.4.2). Hydrochlorothiazide, spironolactone and 
furosemide were also included in the top 20 active substances prescribed as 
oral solids (Figure 13.4). The active substances prescribed by most hospitals 
(spironolactone, hydrochlorothiazide, caffeine citrate, chloral hydrate and 
theophylline) are all included in the top 10 oral liquids. 
 
Figure 13.7 Top 10 active substances prescribed as oral liquids and ranked by number of 
multidose containers. 
The top 3 active substances represented almost 70% of all active substances 
prescribed as oral liquids, which indicates that these are also part of the 
active substances most highly demanded as compounded medicines for 
paediatric use in Germany.  
The top 5 therapeutic groups, ranked by number of multidose containers of 
the corresponding oral liquids, are listed below in Table 13.3. The most 
frequent therapeutic group was bronchodilators and anti-asthma drugs, which 
represented 50% of all active substances prescribed as oral liquids. All 5 
groups included active substances that were part of the top 10 shown above 
(Figure 13.7).  
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Electrolytes and cardiovascular drugs were the only therapeutic groups 
common to the corresponding top 5 of oral solids (Table 13.2). In 
comparison, the top 5 therapeutic groups of oral solids included a larger 
number of active substances per group, which indicates that the prescription 
of oral liquids is likely to be reserved for a limited number of active 
substances, as opposed to oral solids that potentially permit more prescribing 
flexibility.  
Table 13.3 Top 5 therapeutic groups ranked by number of multidose containers of oral 
liquids prescribed. 
Therapeutic groups Number of  active substances 
Active substances 
included in top 10 
Number of  
containers 
Bronchodilators and 
anti-asthma drugs 5 3 1,791 
Anxiolytic, sedatives, 
hypnotics and 
antipsychotics 
3 2 958 
Electrolytes 3 1 401 
Cardiovascular 
drugs 7 3 236 
Nutritional agents 
and vitamins 5 1 91 
 
The multidose oral liquids prescribed may be quantitatively compared to the 
oral solids prescribed in packs (and not in individual units). Considering that 
capsules corresponded to 92.4% of all oral solids prescribed, it is possible to 
estimate that oral solids were prescribed in packs of 50 units (Section 2.1.3) 
and, therefore, the 69,161 individual units of oral solids corresponded to 
1,383 packs (of 50 units each). Consequently, when the 3,586 multidose oral 
liquids are compared to the 1,383 packs of oral solids, it is concluded that 
oral liquids were prescribed to paediatric patients in larger quantities than 
oral solid dosage forms. This finding clarifies the conclusion of Brion et al. 
(2003) that, in Germany, a “non-well defined combination of liquids, powders 
and capsules is dispensed”. Oral liquids allow dosing flexibility and are easy 
to administer (in particular to paediatric patients) (Section 2.1.3) and, hence, 
it was not surprising that these were the most frequently prescribed dosage 
forms to paediatric patients in Germany. 
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Solutions and suspensions were prescribed in 86% of the hospitals and the 
top 10 active substances corresponded to the top 10 prescribed as oral 
liquids, with the exception of glucose (Figure 13.7), which is consistent with 
the fact that solutions and suspensions were the most frequently prescribed 
oral liquid dosage forms. As previously stated, because only a few 
prescriptions were fully completed by paediatricians (Breitkreutz, 2009), the 
majority of data entries were incomplete and, therefore, the individual 
strengths and pack sizes of oral liquids will not be addressed in detail. 
Oral drops were prescribed in 39% of the hospitals, in a total of 392 
containers corresponding to just 12 different active substances. The top 3 
active substances were theophylline, glucose and caffeine citrate, which are 
part of the top 10 active substances prescribed as oral liquids (Figure 13.7) 
and accounted for over 70% of all oral drops. 
Syrups, on the other hand, were prescribed in only 19% of the hospitals, in a 
total of 37 containers corresponding to just 8 different active substances. The 
top 3 active substances were ketamine HCl, chloral hydrate and nystatin, 
which accounted for 70% of the syrups prescribed. Tinctures represented just 
0.2% of all oral liquids and corresponded to opium tincture only, which was 
prescribed in 2 hospitals in a total of 7 multidose containers. Mixtures were 
the least prescribed oral liquids (less than 0.1%) and only 1 mixture of 
ipecacuanha and another mixture of thyme were prescribed in 1 hospital 
each. 
13.4.3 Oromucosal preparations 
Oromucosal preparations were prescribed in just 4 hospitals (11% of all 
participant hospitals), in a total of only 24 multidose containers. The active 
substances prescribed as oromucosal preparations were: acriflavinium 
chloride (5 mg/g, 10 g); miconazole (20 mg/g, 20 g); aluminium hydroxide 
(300 g); and procaine HCl (10 mg/g, 20 g). A combination of 3 active 
substances was also prescribed as an oromucosal preparation, namely: 
betamethasone, pheniramine maleate and nystatin (225 mL). 
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13.5 Summary 
• Compounded medicines are commonly prepared in hospital and community pharmacies 
and the quality of compounded medicines is of major concern in Germany. 
• The NRF is the German national formulary, a reference for the practice of pharmaceutical 
compounding developed in collaboration with several pharmaceutical institutions. 
• Data collection was not undertaken in Germany since the prescriptions for paediatric 
compounded medicines in 40 German hospitals had been recently collected by the IPB 
(Heinrich Heine University in Düsseldorf). The appropriate data were shared for analysis and 
a total of 36 German hospitals were included in the research. 
• According to the data shared, a total of 147 active substances (including 6 NTI drugs) 
were prescribed for oral (and oromucosal) paediatric compounded medicines, corresponding 
to 32 therapeutic groups. 
• The therapeutic groups with the greatest number of different active substances were: 
cardiovascular drugs (n=26), supplementary drugs and other substances (n=14) and 
antiepileptics (n=11) / nutritional agents and vitamins (n=11). 
• Oral solid dosage forms were prescribed in 97% of hospitals and included capsules, oral 
powders, pellets and tablets. 
• Capsules were prescribed in a total of 63,878 units (92.4% of oral solids) and the top 5 
active substances were: calcium gluconate, hydrochlorothiazide, spironolactone, colistin 
sulfate and hydrocortisone. Oral powders were prescribed in a total of 5,110 units (7.4% of 
oral solids) and the top 5 active substances were: spironolactone, caffeine citrate, 
hydrochlorothiazide, topiramate and furosemide. Pellets were prescribed in a total of 101 
units (<0.2%) and tablets in a total of 72 units (0.1% of oral solids). 
• Oral liquid dosage forms were prescribed in 89% of hospitals and included solutions and 
suspensions, oral drops, syrups, tinctures and mixtures (multidose). 
• Solutions and suspensions were prescribed in a total of 3,148 multidose containers 
(87.8% of oral liquids) and the top 5 active substances were: caffeine citrate, midazolam, 
calcium hydrogen phosphate and dibasic sodium phosphate, theophylline and chloral 
hydrate. Oral drops were prescribed in a total of 392 multidose containers (10.9% of oral 
liquids) and the top 3 active substances were: theophylline, glucose and caffeine citrate. 
Syrups represented only 1% of oral liquids; the least prescribed were tinctures (0.2%) and 
mixtures (<0.1%). 
• Oral liquids were prescribed in larger quantities than oral solids. 
• Oromucosal preparations were prescribed in 0.1% of hospitals and included 7 different 
active substances, in a total of only 32 multidose containers.  
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14. Compounding in Europe: overview and discussion 
Europe is a large and heterogeneous continent, with a population of over 800 
million distributed in 49 (EU and non-EU) countries (Lanzieri, 2008; Europa, 
2009). A total of 11 European countries were included in this research, 
corresponding to 10 EU countries (Portugal, UK, Poland, Netherlands, 
Denmark, Slovenia, Finland, Spain, France and Germany) and 1 non-EU 
country (Switzerland). These 11 countries have a total population of 293.7 
million, more than half of the EU’s population, and 10 official languages. 
When ranked by population, the top 3 countries included in the research 
were Germany, France and UK (Table 14.1), which are also the most 
populated countries in the EU (Figure 2.2). 
The European countries included in the research with most hospitals per 
100,000 population were Finland, France and Switzerland, all with more 
hospitals per 100,000 population than the European average of 3.73. The 
countries with most hospital beds per 100,000 population were Germany, 
France and Finland (Appendix 3), all exceeding the European average of 
665.8. The European countries with most pharmacists per 100,000 
population were Finland, France and Portugal (Appendix 4), also all over the 
European average of 52.27. Finland, although the second least populated 
country (after Slovenia), was the European country with the most hospitals 
(and also most pharmacists) per 100,000 population. Germany, the most 
populated country included in the research, was the European country with 
the most hospital beds per 100,000 population, as highlighted in Table 14.1 
(WHO Regional Office for Europe, 2010). 
According to the EAHP survey, the average number of pharmacists in 
European hospitals is 4.7 pharmacists per hospital (EAHP, 2005). Spain, 
Netherlands and Denmark were the only European countries included in the 
research with more pharmacists per hospital than the European average. 
Denmark was, by far, the European country with the highest proportion of 
pharmacists: 10.3 pharmacists per hospital (more than twice the European 
average) (Table 14.1).  
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Table 14.1 D
em
ographics of the E
uropean countries included in the research (ranked by population and top 3 underlined; data sources in individual chapters). 
European  
countries 
Population 
(in m
illions) 
N
um
ber of hospitals 
per 100,000 
population 
N
um
ber of hospital 
beds per 100,000 
population 
N
um
ber of 
pharm
acists per 
100,000 population 
A
verage num
ber of 
pharm
acists per 
hospital 
G
erm
any 
82.1 
4.07 
829.09 
59.87 
4.0 
France 
64.4 
4.68 
716.78 
113.82 
3.3 
U
K
 
61.6 
3.79 
370.00 
78.66 
4.4 
Spain 
45.8 
1.72 
337.03 
91.98 
5.0 
Poland 
38.1 
2.08 
516.17 
58.85 
3.4 
N
etherlands 
16.5 
1.16 
480.8 
17.53 
5.2 
Portugal 
10.6 
1.93 
345.44 
97.83 
3.7 
Sw
itzerland 
7.6 
4.53 
553.92 
57.04 
4.1 
D
enm
ark 
5.5 
1.09 
349.48 
68.51 
10.3 
Finland 
5.3 
6.45 
682.49 
155.11 
3.1 
Slovenia 
2.0 
1.44 
466.18 
47 
2.7 
Europe 
822.4 
3.73 
665.8 
52.27 
4.7 
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14.1 Legislation 
EU pharmaceutical legislation is compiled in 10 volumes, which constitute 
“The Rules Governing Medicinal Products in the EU”. Volume 1 corresponds 
to the “EU pharmaceutical legislation for medicinal products for human use” 
and volume 4 corresponds to the “Guidelines for GMP for Medicinal Products 
for Human and Veterinary use” (European Commission, 2011). 
In volume 1, the EU Directive 2004/27/EC (amending Directive 2001/83/EC 
on the Community code relating to medicinal products for human use) 
excludes pharmaceutical compounding from the provisions of this directive 
and allows member states to supply compounded medicines in accordance 
with the legislation in force and to fulfil special needs. These medicines are to 
be supplied “in response to a bona fide unsolicited order, formulated in 
accordance with the specifications of an authorised health care professional 
and for use by an individual patient under his direct personal responsibility” 
(European Parliament and the Council, 2004). 
Compounded medicines are officially classified as either magistral formula or 
officinal formula. A magistral formula is “any medicinal product prepared in a 
pharmacy in accordance with a medical prescription for an individual patient” 
(European Parliament and the Council, 2001). An officinal formula is “any 
medicinal product which is prepared in a pharmacy in accordance with the 
prescriptions of a pharmacopoeia and is intended to be supplied directly to 
patients served by the pharmacy in question” (European Parliament and the 
Council, 2004). 
Member states have transposed the EU directive into their national legal 
frameworks and adapted the concept of compounded medicines to their 
compounding practices. As a result, the terminology and meaning of 
compounded medicines, which are addressed individually in the respective 
preceding chapters, may vary considerably within the EU countries. For 
instance, Portugal has adopted the EU directive without major adaptations, 
and compounded medicines in this country correspond to the magistral and 
officinal formulae outlined above. In the UK, on the other hand, compounded 
medicines correspond to unlicensed medicines, and those prepared in GMP 
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facilities are distinguished and classified as specials, whereas all others are 
classified as extemporaneous preparations. For some health care 
professionals, “unlicensed medicines” correlates with medicines that are not 
regulated, which is not the case for the “UK unlicensed medicines”. Further 
concepts for compounded medicines were acknowledged as, for example, 
standardised (batch) preparations and non-standardised (individual) 
preparations (e.g. Netherlands and Germany).  
The variations in terminology and meaning of compounded medicines in the 
EU may contribute to a lack of understanding between health care 
professionals. For instance, the concept of specials is not applicable to the 
majority of the EU countries; extemporaneous preparations are not 
necessarily prepared extemporaneously; and batch preparation is not always 
allowed in the EU. Although compounding practices vary within EU countries, 
the terminology and concept of compounded medicines should ideally be 
harmonised so that consensus is achieved and practices become more 
standardised across Europe.  
The inclusion of an official definition for compounded medicines in the PhEur 
is under discussion (Keitel, 2011) and this will be an important step towards 
the harmonisation of terminology and standardisation of compounding 
practices in Europe. 
a. PIC/S PE 010-3 
In 2008, the Pharmaceutical Inspection Convention (PIC) published a 
guidance document for the preparation of compounded medicines, namely: 
Pharmaceutical Inspection Co-operation Scheme (PIC/S) Guide to Good 
Practices for the Preparation of Medicinal Products in Healthcare 
Establishments (PE 010-3) (PIC, 2008). This guidance document was based 
on the PIC/S GMP Guide (PE 009-9) for industry (PIC, 2009), which is 
equivalent to the EU GMP guidelines (Volume 4) (European Commission, 
2011). The PIC/S is an informal co-operative arrangement (with no legal 
status) between health authorities in the field of GMP and aims to harmonise 
the inspection procedures worldwide by developing common GMP standards 
(PIC, 2010). Whilst the guidance document PIC/S PE 009-9 was developed 
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for the preparation of proprietary medicines, the PIC/S PE 010-3 was 
developed for the preparation of compounded medicines.  
However, PIC/S PE 010-3 did not take into account country-specific 
compounding practices across Europe and, therefore, its application is not 
straightforward Europe-wide. For instance, this guidance document states 
that: “for products prepared extemporaneously on a frequent basis, a product 
file should be kept including specifications, instructions and records (based 
on a pharmaceutical assessment of therapeutic rationale, safety data, 
toxicity, biopharmaceutical aspects, stability and product design); and also a 
product review (QC testing data and validation data)” (PIC, 2008). For those 
countries with limited resources, such a wide requirement is not practicable 
without highly specific guidance and support. For instance, in Poland, it is not 
currently required to keep detailed documentation of the compounded 
medicines prepared and Polish legislation does not specify any QA/QC 
requirements for pharmaceutical compounding. As a result, the development 
of product files in this country would not be straightforward.  
The PIC/S PE 010-3 also includes statements that are too general to add any 
value to the practice of pharmaceutical compounding. For instance: 
“Personnel should be qualified and trained in accordance with their function”; 
“Premises and equipment should be suitable for their intended purpose”; “All 
areas should be clean, orderly and well lit” (PIC, 2008). According to 
Torniainen (2007), this guidance document responds to a need for 
authoritative European level guidance in pharmaceutical compounding, but 
more attention should be paid to terminology as English expressions vary 
throughout the document.  
In conclusion, this guidance document is not immediately applicable in all EU 
countries and does not constitute a valuable reference for those engaged in 
pharmaceutical compounding across Europe. Nevertheless, in an EDQM 
expert workshop on “Promoting standards for the quality and safety 
assurance of pharmacy-prepared medicinal products for the needs of 
patients”, held in September 2009, it was suggested that the PIC/S PE 010-3 
would become the enforceable EU guidelines for pharmaceutical 
compounding. However, it is important to realise that the aim of enforceable 
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EU guidelines is to improve the quality of patient care and not to prohibit care 
at all (Kirchdorfer, 2011) and the PIC/S PE 010-3, because of its inadequacy, 
should not be regarded as standard setting for the practice of compounding 
Europe-wide. 
b. Resolution CM/ResAP(2011)1 
In January 2011, the Council of Europe recognised the need for European 
guidelines on pharmaceutical compounding with the publication of the 
“Resolution CM/ResAP(2011)1 on Quality and Safety Assurance 
Requirements for Medicinal Products Prepared in Pharmacies for the Special 
Needs of Patients”. This resolution acknowledges the importance and need 
for compounded medicines and aims to ensure patient safety in Europe by 
harmonising compounding practices within the countries that are signatories 
to the Convention on the Elaboration of a PhEur55 (Council of Europe, 2011), 
which include all the countries in the present research.  
This resolution was adopted considering both the EDQM expert workshop 
and the PIC/S PE 010-3 document and consists of 11 principles, including 
the preparation process, product dossier and labeling of compounded 
medicines. In order to implement this resolution, European countries have to 
adopt additional guidance considering their national compounding 
frameworks (Council of Europe, 2011). For instance, a product dossier is 
required for stock preparations, but not all countries permit the preparation of 
compounded medicines as stock preparations (e.g. Portugal and Poland). 
Furthermore, it is suggested that a special authorisation for the practice of 
compounding should be required which, again, is not applicable to all 
European countries under their current legislations (e.g. Portugal and 
Poland).  
The implementation of this resolution will not be straightforward as it lacks a 
clear definition of pharmaceutical compounding and compounded medicines 
(to be adopted Europe-wide). Consequently, the principles set in this 
                                            
55The member states concerned are: Austria, Belgium, Bosnia and Herzegovina, Bulgaria, 
Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France Germany, Greece, 
Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Montenegro, 
Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovak Republic, Slovenia, Spain, 
Sweden, Switzerland, “the former Yugoslav Republic of Macedonia”, Turkey and UK. 
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resolution may be regarded as ambiguous, and even confusing, considering 
the different terminology, concepts and compounding practices across 
Europe. According to Bouwman-Boer (2011), this resolution appeared “out of 
the blue” and was not well received by European pharmacists who fear 
inappropriate interference in their practices. The principles set out should 
have considered the expertise of compounding pharmacists Europe-wide in 
order to avoid the “splashdown” of inadequate standards. One of the 
important deficiencies highlighted by Bouwman-Boer (2011) was the fact that 
this resolution facilitates the preparation of compounded medicines on a 
large scale by the pharmaceutical industry, which may reduce the drive for 
licensing and, consequently, the drive to produce licensed proprietary 
medicines instead of preparing compounded medicines. According to Vulto 
(2011), this resolution looks like “a remedy that is far worse than the disease” 
and it may have far-reaching effects on the compounding activities in Europe 
(Clark, 2011). 
c. Compounding settings 
For the majority of European countries, compounded medicines are mostly 
prepared in community and hospital pharmacies. In the UK, however, 
compounded medicines are mainly prepared by specials manufacturers 
which guarantee that these medicines are manufactured under GMP certified 
facilities and, for this reason, specials (compounded medicines manufactured 
under GMP) are regarded as a quality assured alternative to 
extemporaneous preparations (compounded medicines not manufactured 
under GMP). Nevertheless, “industrial” GMP was originally developed for the 
manufacture of licensed medicines and, therefore, it does not consider 
important aspects of the preparation of compounded medicines as, for 
instance, the development of a customised formula and the small scale 
method of preparation. Therefore, it is not just because specials are 
manufactured under GMP-certified facilities that these should be regarded as 
a quality assured alternative to extemporaneous preparations. Actually, 
extemporaneous preparations may be a better alternative if the respective 
formula and method of preparation were properly assessed, as opposed to 
the corresponding specials. 
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The concept of specials is unique to the UK but, in Portugal and Spain, 
although compounded medicines are mainly prepared in the community and 
hospital settings, these medicines may also be prepared by other entities 
previously authorised by the respective regulatory authorities. In Spain, in 
particular, selected regional boards of pharmacy have been given this 
authorisation and are currently competing with local pharmacies in relation to 
the preparation of compounded medicines. The ethics of having the regional 
boards of pharmacy as a competitor has been questioned in this country 
(Section 11.1).  
In all other European countries included in the research, compounded 
medicines may only be prepared in community and hospital pharmacies, 
which is in accordance with the triad relationship doctor-patient-pharmacist 
that has traditionally characterised pharmaceutical compounding.  
d. Third-party compounding 
When compounded medicines are prepared and dispensed at the same 
place, the triad relationship is kept. However, for the benefit of patients, if 
community and hospital pharmacies are not able to provide quality assured 
compounded medicines, their preparation should be allowed outside those 2 
settings. 
Third-party compounding within community and hospital pharmacies is 
allowed for the majority of European countries but, once again, this practice 
varies throughout Europe. For instance, third-party compounding is not 
permitted in Poland, and Polish pharmacies have to prepare all compounded 
medicines dispensed. Third-party compounding is allowed in Portugal, and all 
Portuguese pharmacies may dispense compounded medicines prepared by 
others. Third-party compounding is also allowed in Spain (for most 
autonomous communities) and France, but pharmacies have to be previously 
authorised by the respective regulatory authorities in order to compound for 
other pharmacies. It is important that in the future the same criteria apply to 
all European countries so that third-party compounding outside community 
and hospital pharmacies is harmonised in Europe and patients have the 
same access to compounded medicines Europe-wide. 
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14.2 Professional organisations and information sources 
14.2.1 International professional organisations 
• The European Association of Hospital Pharmacists (EAHP): is a working 
community of national associations of hospital pharmacists that represents 
the interests of over 21,000 hospital pharmacists in 31 European countries. 
The mission of the EAHP is to support European hospital pharmacists in 
improving health care through science, practice and collaborative actions. 
The goals of the EAHP are: “to develop hospital pharmacy and to establish a 
common pharmaceutical policy in Europe; to work for the advancement of the 
position and role of pharmacists in hospitals; to uphold the interests of 
hospital pharmacists in EU member states with the corresponding authorities; 
and to promote cooperation with other professional bodies” (EAHP, 2010b). 
The EAHP is responsible for publishing two official journals (6 times per year) 
that contain peer-reviewed articles. These are the European Journal of 
Hospital Pharmacy Practice (EJHP Practice) and the European Journal of 
Hospital Pharmacy Science (EJHP Science). Among other topics, 
pharmaceutical compounding is currently discussed in both journals (EAHP, 
2010c). Moreover, the EAHP holds an annual congress in a different 
European country each year. In 2010, the EAHP congress was held in Nice 
(France) and pharmaceutical compounding was one of the topics addressed 
(Seminar 11 / Paediatrics: handling of drugs in paediatric patients), as in 
most EAHP annual congresses (EAHP, 2010d). Every 5 years, the EAHP 
undertakes a survey on the current state and development of hospital 
pharmacy in Europe. In 2005 (latest available year), 22 European countries 
participated in this survey and data from 825 hospitals were collected (24% 
response rate), including information on sterile and non-sterile compounding 
practices (EAHP, 2005; 2010a).  
Professional organisations specifically focused on pharmaceutical 
compounding Europe-wide are yet to develop. Nevertheless, there are 2 
specialist international organisations that are available to European 
pharmacists, namely:  
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• International Society of Pharmaceutical Compounding (ISPhC): is a 
professional and scientific organisation that aims to promote pharmaceutical 
compounding worldwide. It was officially constituted in 2004 during the IX 
Scientific Congress of the Spanish Association of Compounding Pharmacists 
(AEFF), and the simultaneous 1st International Congress on Pharmaceutical 
Compounding, in Ciudad Real, Spain (ISPhC, no date). The ISPhC 
constitutes an open forum for pharmacists worldwide to collaborate and 
discuss the practice of pharmaceutical compounding (Marro, 2008). 
• International Academy of Compounding Pharmacists (IACP): is an 
international association that focuses on the specialty practice of pharmacy 
compounding, mainly in the USA. The IACP is constituted by pharmacists, 
technicians, prescribers and patients interested in compounded medicines; 
and aims to promote and advance personalised medical solutions (IACP, 
2010). European health care professionals may be part of IACP. 
The European country included in the research with the greatest number of 
professional organisations specifically focused on pharmaceutical 
compounding is Spain. In this country, there are a total of 3 independent 
nation-wide organisations (AEFF, Aprofarm and AFA) and many more 
compounding departments in other institutions. Consequently, Spain is the 
country that has held more annual congresses and other compounding 
events within Europe. 
14.2.2 International information sources 
Pharmacopoeias 
• The European Pharmacopoeia (PhEur): is the official reference that sets 
the standards for the quality of medicines in Europe by means of general and 
specific monographs legally enforceable in the countries which are 
signatories to the Convention on the Elaboration of a PhEur (EDQM, 2007). 
Pharmaceutical compounding is not specifically addressed in the PhEur but 
the inclusion of an official definition for compounded medicines is currently 
under discussion (Keitel, 2011).  
National pharmacopoeias may complement the PhEur with additional 
standards, which allows a rapid and flexible inclusion of nation-specific 
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quality requirements (Swissmedic, 2009). The BP is an example of a national 
pharmacopoeia that complements the PhEur with a dedicated chapter and 
specific monographs for compounded medicines. According to 
Breckenridge56, the BP works closely with the PhEur and plays a significant 
role in influencing the decisions of the PhEur Commission and in the 
standard setting process in Europe (BP Commission, 2008b). If the PhEur 
follows the example of the BP by including a dedicated chapter and specific 
monographs for compounded medicines, it would be a very important step 
towards the harmonisation of pharmaceutical compounding in Europe.  
• USP Pharmacists’ Pharmacopeia: is the official reference that sets the 
standards for the quality of compounded medicines in the USA (US 
Pharmacopeial Convention, 2005). The 2008-2009 edition includes 129 
official USP-NF (United States Pharmacopeia - National Formulary) 
monographs for compounded medicines and 73 USP general chapters 
covering compounding, packaging, labelling and storage of compounded 
medicines (CompoundingToday, 2011b). Although not enforceable in 
Europe, the USP Pharmacists’ Pharmacopeia includes monographs and 
standards that are a valuable reference for the practice of compounding in 
Europe.  
Formularies  
• European formulary: an officially recognised European formulary for 
pharmaceutical compounding has not yet been published. There are official 
national formularies for pharmaceutical compounding (e.g. Netherlands and 
Germany) but no work has been done so far in terms of translating to English 
and adapting any of these formularies to the current compounding practices 
in Europe. Likewise, there are only non-official national formularies (e.g. the 
Spanish Formulario Básico de Medicamentos Magistrales and Formulación 
en Farmacia Pediátrica).  
• European hospital formulary: it is common practice for European hospitals 
to have their own compounding formularies including monographs for the 
most frequently dispensed compounded medicines in their pharmacies. 
                                            
56Sir Alasdair Breckenridge was the chairman of MHRA in 2008. 
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If these formularies were combined, monographs would no longer be 
available as “local-only” and, as a consequence, duplication of studies would 
be avoided across Europe.  
• European paediatric formulary: the development of an officially recognised 
European formulary is currently under discussion by the EDQM and the 
respective European representatives. In November 2011, the “Workshop on 
the Elaboration of a European Formulary for Paediatric Formulations” was 
the first step of this EDQM initiative. Although not legally binding, the purpose 
of this compounding formulary is to become the Europe-wide reference for 
the preparation of compounded medicines for paediatric patients (Keitel, 
2011).  
An official or non-official European formulary, a European hospital formulary 
or a European paediatric formulary would be a very important step towards 
the harmonisation of pharmaceutical compounding in Europe. 
Apart from pharmacopoeias and formularies, European pharmacists also use 
other international information sources as a reference for the practice of 
pharmaceutical compounding, namely: 
• International textbooks, such as the “The Art and Science of 
Pharmaceutical Compounding” (Allen, 2008) and the “Trissel’s Stability of 
Compounded Formulations” (Trissel, 2009). 
• International journals and databases, such as the International Journal of 
Pharmaceutical Compounding (IJPC) and the Compounding Today 
interactive website (CompoundingToday, 2011c). 
14.3 Methods 
To identify and characterise the oral compounded medicines most frequently 
dispensed in European hospital pharmacies, tailored methods were adopted 
across countries in order to gather comparable information. For the majority 
of European countries, a country-specific questionnaire was developed and 
data collection was undertaken by MC. For Switzerland and Poland, a 
country-specific questionnaire was also developed but an international 
collaboration was established and data collection was undertaken by local 
researchers. For France and Germany, data collection was not undertaken 
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but, rather, an international collaboration was established with local 
organisations which had recently collected the required data (Table 14.2). 
The first 2 countries included in the research were Portugal and the UK 
because of their proximity and easy access of MC to hospital pharmacies in 
both countries. When data collection was already in place in these countries, 
more European countries were included in the research, namely: 
Netherlands, Denmark, Slovenia, Finland and Spain, with at stages data 
collection undertaken simultaneously in several countries. The research 
period covered ranged from 2005 to 2009, depending on the year(s) of data 
collection and the year of the most recently available data at hospital 
pharmacies (Table 14.2).  
Table 14.2 Data collection and research period by European country. 
European 
countries 
Data  
collection by 
Research  
periods 
Portugal MC 2005-2008 
UK MC 2006 
Switzerland Bettina Gasser 2006 
Poland Aleksandra  Neubauer-Vasquez 2007 
Netherlands MC 2007-2008 
Denmark MC 2008 
Slovenia MC 2008-2009 
Finland MC 2008 
Spain MC 2007-2009 
France AFSSAPS 2004-2008 
Germany IPB 2006-2007 
 
Stakeholders for pharmaceutical compounding in each country were selected 
and contacted by MC in order to contribute their knowledge and experience 
to the research. For the majority of European countries, these stakeholders 
were particularly important in the initial stages of the research, for the design 
of the country-specific questionnaire (Section 14.3.1) and for identifying a 
purposive sample of hospitals (Section 14.3.2). 
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14.3.1 Country-specific questionnaires 
Tailored questionnaires were developed for Portugal, UK, Switzerland, 
Netherlands, Denmark, Slovenia, Finland and Spain (Table 14.3). The first 
questionnaire was developed for Portugal and was piloted in selected 
Portuguese hospital pharmacies. The final version of this questionnaire was 
used as template for the subsequent country-specific questionnaires. 
Although all questionnaires sought to collect equivalent data across Europe, 
the contents and layout of each questionnaire varied slightly between 
countries. For instance, the UK questionnaire included 1 table for oral 
extemporaneous preparations and another for oral specials, rather than a 
single table for oral compounded medicines. The Dutch and Finnish 
questionnaires included an extra column - Manufacturer - so that the 
compounded medicines prepared in other hospital/community pharmacies 
would be identified.  
Table 14.3 Country-specific questionnaires, languages and other data formats by country. 
European 
countries 
Country-specific 
questionnaires Languages 
Other 
data formats 
Portugal ! Portuguese 44% 
UK ! English 33% 
Switzerland ! English 20% 
Poland x x 100% 
Netherlands ! English 58% 
Denmark ! English 29% 
Slovenia ! Slovenian 11% 
Finland ! English 29% 
Spain ! Spanish 57% 
France x x x 
Germany x x x 
 
As the research progressed, layout and content improvements were also 
undertaken in order to simplify the request for information and to enhance 
response rates. A flow chart highlighting the systematic approach to the 
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research instrument is shown in Figure 14.1. Country-specific questionnaires 
were developed in the official national languages for Portugal, Spain, UK and 
Slovenia; and in English for Switzerland, Netherlands, Denmark and Finland 
(Table 14.3). Hospital pharmacies were invited to input data directly in the 
country-specific questionnaire provided or, alternatively, in any other 
convenient format (in order to encourage participation and enhance response 
rates). The majority of European hospitals provided data directly in the 
questionnaire provided. An average of 35% of hospitals provided data in their 
own formats, which varied from simple lists to complex and detailed tables. 
Hospital pharmacies in Europe keep records of the compounded medicines 
prepared and/or dispensed, although to very different extents and in differing 
formats. Information is documented in different ways as a result of nation-
specific legal requirements (e.g. in Poland, only 3 dates are required; Section 
6.1) as well as pharmacy organisation-specific requirements. In the 
Netherlands and Spain, more than 50% of the hospitals shared data in their 
own formats, particularly because the majority of these extracted data directly 
from their own software applications (Table 14.3). In general, data processing 
and analysis was more complicated and took much longer for those hospitals 
presenting data in their own formats. However, using data in this format was 
necessary in order to encourage participation and enhance response rates. 
Almost all hospitals provided the required data by email, as an attached 
document. In total, only 4 hospitals (Portugal and Spain) shared data with 
MC by telephone; 2 (Portugal and Denmark) by post; and 1 (Portugal) by fax. 
Furthermore, all hospitals provided data electronically, with the exception of 3 
(Portugal and Denmark) that provided handwritten data. A country-specific 
questionnaire was not developed for Poland because of the arduous and 
time-consuming process necessary for retrieving information from manual 
records. Therefore, Polish pharmacists were requested to provide data in the 
most convenient format. Country-specific questionnaires were not developed 
for France and Germany, as data collection was previously undertaken by 
other bodies (Table 14.3). 
 C
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14.3.2 Purposive sample of hospitals 
The purposive sample for each European country was chosen to include the 
hospital pharmacies that most frequently dispense oral compounded 
medicines in that country. Thus, the data are not representative of all hospital 
pharmacies in a particular country; but the sample was designed to capture 
the greatest compounding activity per country, and to identify the most 
frequently dispensed compounded medicines. This sample was established 
by consulting key experts in the area of pharmaceutical compounding in each 
country and this was later confirmed with selected participant hospitals during 
data collection. Sample sizes varied from 7 pharmacies (Denmark) to 60 
hospital pharmacies (Portugal and France), with an average of 31 hospitals 
per country (Table 14.4).  
Table 14.4 Purposive samples and respective remarks per European country. 
European 
countries 
Purposive  
samples Remarks 
Portugal 60 Included selected hospitals nation-wide 
UK 36 
Included licensed hospital 
manufacturing units and 
paediatric hospitals 
Switzerland 33 Included paediatric hospitals only 
Poland 13 Included northern and central hospitals only 
Netherlands 17 Included selected hospitals nation-wide 
Denmark 7 Included 2 additional community pharmacies 
Slovenia 29 Included all Slovenian hospitals 
Finland 8 Included all university hospitals 
Spain 40 Included selected hospitals nation-wide 
France 60 Included all hospitals surveyed by AFSSAPS 
Germany 36 Included all hospitals surveyed by IPB 
 
A total of 339 European hospitals were included in the research, plus 2 
additional community pharmacies from Denmark, which frequently prepared 
compounded medicines for Danish hospitals. The purposive samples for 
Portugal, Netherlands, Denmark, Finland and Spain included hospitals 
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nation-wide. For Slovenia, all hospitals were included in the project. For the 
UK, Switzerland and Poland, specific criteria determined the respective 
purposive samples. For France and Germany, the purposive samples 
corresponded to the hospitals whose data were provided by the AFSSAPS 
and the IPB, respectively (Table 14.4). 
14.3.3 Data collection 
For the majority of European countries, hospital pharmacies were contacted 
by email/telephone directly by MC. For Switzerland and Poland, none of the 
hospitals was contacted directly by MC but, instead, these were contacted by 
email/telephone by local researchers. For France and Germany, none of the 
hospitals was contacted directly by MC since the required data were provided 
by the AFSSAPS and the IPB, respectively. 
Because email is the most accessible and efficient means of contacting a 
large and widespread sample of European hospitals, the majority of 
pharmacies were initially contacted by email, with the exception of Portugal. 
All Portuguese hospitals were initially contacted by telephone because the 
email addresses of the chief pharmacists for each hospital pharmacy were 
not available, which considerably lengthened the stage of data collection. All 
European hospitals that did not respond to the initial email/telephone contact 
were sent email reminders. In total, over 500 personalised email requests for 
collaboration were sent by MC to hospital pharmacies across Europe. The 
majority of non-respondents were followed up by telephone in order to 
increase response rates. The number of hospitals contacted by telephone in 
each country varied from 1 hospital (Finland) to 60 hospitals (Portugal) 
(Table 14.5). A total of almost 300 telephone calls were made by MC to 
hospital pharmacies across Europe. For Portugal, UK and Spain, email and 
telephone contacts were established in the respective official national 
languages. For Slovenia, the initial email and telephone contacts were made 
in English and, for this language reason, the majority of the contacts 
established by MC with Slovenian hospitals were unsuccessful.  
In general, the disclosure of compounding information by the hospital 
pharmacies did not require authorisation from the management board of the 
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hospitals. Indeed, a few hospital pharmacies in Portugal and Spain 
mentioned the need for such authorisation, prior to sharing the required data. 
None of these hospital pharmacies though were refused authorisation. The 
fact that the required compounding data did not include any patients’ details 
may have contributed to the ready disclosure of information. 
Fieldwork was undertaken by MC in a total of 7 European countries. For each 
country, fieldwork was carefully planned with the respective stakeholders 
and, for most countries (with the exception of Germany), it included visits to 
key hospital pharmacies. The number of hospitals visited by MC in each 
country varied from 1 hospital (Switzerland) to 8 hospitals (Portugal), with an 
average of 4 hospital visits per country. Data were collected by MC during 
fieldwork in 6 hospital pharmacies (Portugal and Netherlands). For the 
Netherlands and Denmark, fieldwork also included visits to key community 
pharmacies. In total, 22 European hospitals and 4 community pharmacies 
were visited between 2006 and 2009 (Table 14.5). 
Table 14.5 Fieldwork, number of hospitals visited and contacted by telephone per country. 
European 
countries 
Hospitals 
contacted by 
telephone 
Fieldwork Hospitals  visited 
Portugal 60 ! 8 
UK 3 ! 5 
Switzerland x ! 1 
Poland x ! 2 + 1* 
Netherlands 13 ! 4 + 2* 
Denmark 3 ! 2 + 1* 
Slovenia 12 x x 
Finland 1 x x 
Spain 27 x x 
France x x x 
Germany x ! x 
*Community pharmacies visited 
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14.3.4 Limitations of the research 
The limitations that had the greatest potential impact on the research were 
acknowledged during the pilot study and were considered from the beginning 
to the end of the research. These limitations may be summarised as follows: 
• Incomplete purposive sample of hospitals 
It is possible that not all hospitals that most frequently dispense oral 
compounded medicines in each country were included in the research. 
• Incomplete records at the hospital pharmacy 
There is a chance that not all compounded medicines dispensed in the 
hospital were recorded at the hospital pharmacy. The limitation of a 
retrospective study is that it is restricted to existing data. 
• Inaccurate records at the hospital pharmacy 
It is possible that not all compounded medicines dispensed were accurately 
recorded at the hospital pharmacy. For instance, inaccuracy in relation to 
active substances and respective salts (morphine HCl reported as morphine 
or morphine sulfate); dosage strengths (e.g. grams reported as milligrams); 
dosage forms (e.g. solutions reported as suspensions); and quantities (packs 
reported as individual units). 
• Transcribing errors at the hospital pharmacy 
There is a chance that not all compounded medicines reported were 
accurately transcribed from the records at the hospital pharmacy. It is also 
possible that selected compounded medicines were mistakenly omitted from 
the records; mistakenly considered as “for oral administration”; or mistakenly 
considered as “compounded medicines”.  
• Transcribing errors at data processing and analysis 
It is possible that not all compounded medicines processed and analysed 
were accurately transcribed from the data reported; different languages are 
often a strong limitation to clear and effective communication. There is also a 
chance that selected compounded medicines were mistakenly omitted from 
the data reported; or mistakenly considered as “for non-oral administration”. 
Despite the acknowledged limitations, this research offers the most 
comprehensive study to date that identifies and characterises the oral 
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compounded medicines most frequently dispensed in European hospital 
pharmacies. 
14.4 Results and discussion 
The overall response rate of the international (European) survey was 76%, 
which is much higher than the 24% achieved by EAHP (2005). The highest 
response rates were achieved in Denmark (100%) and Portugal (93%). 
Response rates were greater than 50% in all countries, with the exception of 
Switzerland, as shown in Table 14.6. In total, 242 European hospitals 
participated in the research. The majority of hospitals provided complete 
datasets and only a few hospital pharmacies, in 5 European countries, 
provided partial data, as follows: Portugal and Spain (quantitative but 
incomplete; semi-quantitative and qualitative data); Poland (semi-quantitative 
and qualitative data); Slovenia (qualitative data) and Finland (semi-
quantitative data).  
Table 14.6 Purposive samples, hospitals (participant, non-participant and non-respondent) 
and response rates per European country. 
European  
countries 
Purposive  
samples 
Participant 
hospitals 
Non-
participant 
hospitals 
Non-
respondent 
hospitals 
Response  
rates 
Portugal 60 39 17 4 93% 
UK 36 15 5 16 56% 
Switzerland 33 15 18 18 45% 
Poland 13 12 0 1 92% 
Netherlands 17 12 1 4 76% 
Denmark 7 7 0 0 100% 
Slovenia 29 9 8 12 59% 
Finland 8 7 0 1 88% 
Spain 40 30 1 9 78% 
France 60 60 ____ 
Germany 36 36 ____ 
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Hospital pharmacies in all European countries provided datasets including 
non-oral compounded medicines, mainly for cutaneous application but also 
ear, nasal, rectal and vaginal preparations; as well as parenteral and eye 
preparations, which were excluded from the datasets (Section 2.4.1). 
There were non-participant hospitals in all European countries, with the 
exception of Poland, Denmark and Finland (Table 14.6). The highest 
percentage of non-participants was in Portugal and Slovenia (28%), in which 
the majority of the reasons given by hospital pharmacies for not collaborating 
with data provision was that they had not dispensed any oral compounded 
medicines (only non-orals, in most cases) during the times indicated. 
The most common reason stated for non-participation across Europe was 
that data were not readily accessible and, in most cases, the pharmacy staff 
was not able to commit the necessary time and effort to collecting the 
requested data. This reason was anticipated from the beginning of the 
research, in particular for those hospital pharmacies that kept manual records 
of the compounded medicines dispensed per day. For these hospitals, listing 
the most frequently dispensed compounded medicines for one year would be 
highly time-consuming.  
The fact that compounding data was considered confidential was a reason 
stated by non-participant hospitals exclusively in Portugal and the UK. 
14.4.1 Active substances  
The active substances most frequently dispensed as oral compounded 
medicines in the European participant hospitals were all included in 
Martindale 35 (2007), with the exception of only 13 active substances that 
were dispensed, mainly as capsules, in a total of 7 countries (Appendix 26). 
Since Martindale is based on published information (Section 2.4), this fact 
indicates that the majority of active substances used in pharmaceutical 
compounding are well known and referenced in the literature. Martindale was 
the reference of choice to determine the therapeutic category of the 
corresponding compounded medicines because it includes active 
substances, currently in use throughout the world, in one therapeutic group 
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(only) that reflects the uses of the substances being described (Martindale 
35, 2007). 
For each individual country, the active substances included in Martindale 
were grouped according to their therapeutic classification and NTI drugs 
were identified. The top 5 European countries ranked by number of active 
substances were: Spain, Netherlands, France, Portugal and UK. These were 
also the top 5 countries in relation to the number of NTI drugs and the 
number of therapeutic groups (Table 14.7). 
Table 14.7 Number of active substances, NTI drugs and therapeutic groups per country. 
European  
countries 
Participant 
hospitals 
Active  
substances 
NTI  
drugs 
Therapeutic 
groups 
Spain 30 281 9 35 
Netherlands 12 226 9 38 
France 60 197 7 34 
Portugal 39 175 8 33 
UK 15 159 7 36 
Germany 36 147 6 32 
Poland 12 149 6 31 
Switzerland 15 142 3 31 
Denmark 7 87 3 23 
Finland 7 85 4 25 
Slovenia 9 68 3 19 
 
For these countries, the number of active substances reported varied from 
159 to 281; the number of NTI drugs ranged from 7 to 10; and the number of 
therapeutic groups from 33 to 38. These findings show that Spain, 
Netherlands, France, Portugal and UK are the European countries in which 
the highest diversity of oral compounded medicines was dispensed. 
Consequently, it may be concluded that there is a higher lack of active 
substances commercially available in appropriate forms in these countries in 
particular. The purposive samples included more hospitals than the majority 
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of other countries, which may have impacted the diversity of oral 
compounded medicines dispensed.  
The top 5 countries dispensed active substances included in over 70% of all 
therapeutic groups (Appendix 27), which shows the diversity of 
pharmaceutical compounding in Europe and reinforces the importance of this 
practice in current therapeutics. 
The top 3 active substances dispensed by most European hospitals were:  
1. Spironolactone: reported in all European countries, by a total of 123 
hospital pharmacies (51%), in both solid and liquid dosage forms. It was 
reported alone and also in combination with the following active substances: 
hydrochlorothiazide (most of the time) and altizide. 
2. Captopril: reported in all European countries, by a total of 97 hospital 
pharmacies (40%), in both solid and liquid dosage forms. It was not reported 
in combination with any other active substances. 
3. Hydrochlorothiazide: reported in all European countries with the exception 
of UK, Denmark and Slovenia, by a total of 96 hospital pharmacies (40%), in 
both solid and liquid dosage forms. It was reported alone and in combination 
with: spironolactone (most of the time), amiloride HCl and triamterene. 
Hydrochlorothiazide was not frequently dispensed as an oral compounded 
medicine in UK, Denmark and Slovenia, suggesting that it is commercially 
available in appropriate forms in these countries in particular. 
The top 3 active substances were reported by 40 to 51% of all participant 
hospitals, indicating that there is a Europe-wide need for compounded 
medicines including spironolactone, captopril and hydrochlorothiazide.  
Although these active substances were not exclusively dispensed to 
paediatric patients, this population has a special need for compounded 
medicines and, therefore, age-appropriate formulations including 
spironolactone, captopril and hydrochlorothiazide should be prioritised for 
studies. However, only spironolactone is currently considered in the EMA 
(2012b) “Revised priority list for studies into off-patent paediatric medicinal 
products”, regarding data on pharmacokinetics, efficacy and safety; and also 
age-appropriate formulations. It is recommended that captopril and 
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hydrochlorothiazide should be added to the EMA (2012b) priority list for 
studies. 
Monographs for compounded medicines including spironolactone, captopril 
and hydrochlorothiazide may be found in national information sources across 
Europe but the respective formulas and methods of preparation are usually 
country-specific. Therefore, oral compounded medicines including these 3 
active substances should be considered for licensing or prioritised for 
standardisation in official (European) monographs. 
a. NTI drugs 
NTI drugs were dispensed in all European countries, from 3 to 9 per country 
(Table 14.7). The top 5 ranked by number of NTI drugs were: Netherlands 
and Spain (n=9); Portugal (n=8); UK and France (n=7). These countries 
correspond to the top 5 ranked by number of active substances (Table 14.7), 
i.e. the countries that dispensed more active substances also dispensed 
more NTI drugs. In relation to the number of active substances, an average 
of 4% of NTI drugs were dispensed per country, ranging from 2.1% 
(Switzerland) to 4.7% (Finland). 
A total of 19 different NTI drugs were dispensed by the participant hospitals, 
which represent 86% of all active substances included in the official list 
provided by ANVISA (2007) (Appendix 1). Only 3 NTI drugs from this list 
were not reported, namely: digitoxin, procainamide (both cardiovascular 
drugs) and ciclosporin (immunosuppressants). Thus, the participant hospitals 
dispensed the majority of the NTI drugs currently available. However, there is 
a chance that hospitals were not aware of this fact since an official list of NTI 
drugs has not yet been published in Europe and there are no official 
guidelines for compounding these potentially toxic active substances. These 
findings reinforce the need for official Europe-wide guidance on NTI drugs.  
The most common NTI drugs were phenytoin, clonidine, warfarin sodium and 
clindamycin, which were reported by 9, 8, 7 and 6 European countries, 
respectively. Consequently, these are the NTI drugs that would best be 
prioritised for Europe-wide guidance regarding pharmaceutical compounding. 
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All 4 active substances were dispensed in variable dosage forms and 
strengths, as follows:  
• Phenytoin was reported as cachets (Poland), oral powders (Portugal, 
Finland and Spain), capsules (Portugal, Switzerland, Netherlands, Spain, 
France and Germany), tablets (France) and oral liquids (Netherlands, 
Denmark and Spain). It was the most common NTI drug dispensed in 
Europe, which may be explained by the fact that, in order to control epilepsy, 
the dose of phenytoin should be adjusted to the individual needs of patients 
(Martindale 35, 2007). The solid dosage forms were reported in the strengths 
of 1-100 mg and the liquid dosage forms in the strengths of 5-15 mg/mL. The 
suggested initial dose of phenytoin in epilepsy is 3 to 4 mg/kg per day (in 
single or divided doses), up to a maximum of 300 mg daily in children 
(Martindale 35, 2007), which is in accordance with the strengths reported. 
• Clonidine was reported as oral powders (Portugal) and capsules 
(Switzerland, France and Germany) in strengths of 2-100 µg; and also in 
Germany (1 hospital) in the strength of 50 mg (likely to be 50 µg). Clonidine 
was also reported as oral drops (Germany) and oral liquids (UK, Netherlands, 
Slovenia, Spain and Germany) in strengths of 5-100 µg/mL; and also in the 
UK (2 hospitals) in strengths of 12.5 mg/5mL and 50 mg/5mL, which are 
considerably higher than the usual maintenance dose of clonidine in 
hypertension (300 to 1200 µg per day up to a maximum of 1800 µg) 
(Martindale 35, 2007). Therefore, there is a good chance that µg/mcg were 
mistakenly reported as mg in the German and UK hospitals. A very similar 
compounding error was reported in the literature - 50 mg of clonidine being 
administered to a child instead of 50 µg - and represented, at that time, the 
largest reported ingestion of clonidine on a mg per kg basis (Romano and 
Dinh, 2001). Compounding errors with NTI drugs are potentially very 
dangerous and consequently close attention should be given to the use of 
these particular active substances in pharmaceutical compounding. 
• Warfarin sodium was reported as oral solids (Portugal, Netherlands, 
Finland, Spain, France and Germany) in strengths of 0.1-3.8 mg; and as an 
oral liquid (UK) in the strength of 1 mg/mL. Warfarin sodium is an 
anticoagulant that should be adjusted to the individual needs of patients and 
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the strengths reported are in accordance with the doses of less than 5 mg 
per day used in elderly patients and those at increased risk of bleeding 
(Martindale 35, 2007). 
• Clindamycin was reported as cachets (Poland), oral powders (Portugal), 
capsules (Netherlands, Spain and France) and oral liquids (UK) from 20 mg 
to 300 mg per dose, which is less than the maximum recommended dose of 
450 mg in severe infections (Martindale 35, 2007). 
Of these 4 most common NTI drugs, clonidine and clindamycin are currently 
considered in the EMA (2012b) “Revised priority list for studies into off-patent 
paediatric medicinal products”. Therefore, it is recommended that phenytoin 
and warfarin sodium be added to this list as well, considering the potential 
toxicity of NTI drugs, in particular in paediatrics that have an increased 
sensibility to medicines (Section 1.1.5.1). 
 
b. Placebo 
Compounded placebo medicines were reported by a total of 5 European 
countries (Table 14.8), which correspond to the top 5 ranked by number of 
active substances (Table 14.7). Switzerland, Poland, Denmark, Slovenia and 
Finland did not report placebos as part of their most frequently dispensed 
oral compounded medicines; placebo was not part of the German database 
either, though it could have been prescribed but excluded from the research 
as a non-active substance. Thus, only the countries that dispensed the 
largest quantities of compounded medicines also dispensed compounded 
placebos. Placebos are indicated when a placebo effect is particularly 
beneficial for the therapeutic outcome as, for instance, in protocols for the 
withdrawal of opioids and in clinical trials. 
Placebo compounded medicines were reported as solid dosage forms only, 
namely: capsules (all 5 countries), tablets (Netherlands) and oral powders 
(UK). The largest quantities of placebo were dispensed in the Netherlands (3 
hospitals only), followed by France (8 hospitals) and Spain (14 hospitals). 
This finding suggests that placebo is prepared and dispensed on a large 
scale in the Netherlands by just a few hospitals, which is likely to include 
outsourcing since the majority of Dutch hospitals prepare compounded 
medicines for other hospitals and community pharmacies. In France and 
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Spain, placebo is dispensed on a smaller scale by a large number of 
hospitals, possibly for individual patients only. A monograph for placebo 
capsules is included in both the French National Formulary and the Spanish 
Reference Manual for Compounding in Hospital Pharmacy (Esteban, 2010), 
which may contribute for the wider use of placebo compounded medicines in 
these two countries. 
Table 14.8 Placebo compounded medicines reported by the European countries and ranked 
by number of units. 
European  
countries 
Dosage  
forms 
Number of hospitals 
(participant hospitals) 
Number of 
units 
Netherlands Capsules Tablets 3 (12) 130,652 
France Capsules 8 (60) 53,460 
Spain Capsules 14 (30) 27,703 
Portugal Capsules 1 (39) 1,400 
UK Capsules Oral powders 2 (15) 392 
 
c. Combinations (of more than one active substance) 
The compounded medicines dispensed by the European hospitals were 
reported either by the active substance(s), their given titles or by the 
proprietary medicines used in their preparation. The majority of compounded 
medicines dispensed included just 1 active substance (single-drug). 
Nevertheless, combinations of more than 1 active substance per 
compounded medicine (multi-drug preparations) were also reported. These 
combinations varied from 2 up to 6 different active substances, in either solid 
or liquid dosage forms. The majority of combinations included just 2 active 
substances (all European countries); others included 3 active substances 
(Netherlands, France and Germany); 4 active substances (Switzerland, 
Finland and Spain); and 6 active substances (Poland). The rationale for 
combining more than 1 active substance per compounded medicine is 
usually either to achieve synergistic effects (e.g. spironolactone and 
hydrochlorothiazide) or to reduce dosing frequency (e.g. polypharmacy; 
Appendix 2). In any case, the combination of multiple active substances 
should be therapeutically coherent so that the safety and efficacy of the 
 Chapter 14: COMPOUNDING IN EUROPE | Results and discussion | 336 
 
compounded medicines can be assured. In addition, there is usually limited 
data regarding the stability and ADME of compounded medicines with 
multiple active substances and, therefore, these combinations should be 
avoided unless supported by adequate literature. 
d. Given titles 
The majority of compounded medicines were reported by the respective 
active substance(s). Some, however, were reported by the given titles that 
they are commonly known for. Given titles are designations attributed to 
specific formulae, which may be either official (e.g. included in the national 
pharmacopoeia or formulary) or non-official (e.g. included in hospital 
formularies). Given titles were reported by hospital pharmacies in all 
European countries, particularly in France and the UK. The given title 
reported by most countries was Lugol’s Solution, dispensed by hospital 
pharmacies in all European countries, with the exception of UK, Denmark, 
Slovenia and Germany. A formulary for selected compounded medicines 
reported by given title is shown in Appendix 16. The prescription of 
compounded medicines by their given title is a common practice Europe-
wide. Nevertheless, this practice might represent a problem when 
compounded medicines are prescribed in one country and prepared in 
another country.  
For well-established given titles (e.g. Lugol’s Solution and Shohl’s Solution), 
the preparation of compounded medicines across Europe should be 
straightforward provided that pharmacists know the appropriate reference 
source for the formulae. Nevertheless, in order to avoid ambiguity, doctors 
should be recommended to provide the reference source (or the complete 
formula) of the compounded medicines prescribed since the same given title 
might correspond to different formulae depending on the reference source 
used. For instance, Joulie’s Solution is described in the literature including 
dibasic sodium phosphate 13.6 g in the anhydrous, dihydrate and 
heptahydrate forms. A case report of the adverse effects resulting from 
different intake of phosphorous by a 4 year-old with Dent Disease has been 
discussed in Spain (Fernández and Rivas, 2011). 
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For well-established given titles that are country-specific (e.g. Hoestdrank in 
the Netherlands and Mixture nervinae in Poland), the preparation of the 
respective compounded medicines across Europe might be challenging since 
the corresponding formula may not be readily accessible across borders. 
Currently, there is a need for a Europe-wide compounding database for 
doctors and pharmacists including a complete description of the compounded 
medicines commonly prescribed by well-established given titles. 
For non-official given titles, the preparation of the respective compounded 
medicines may be challenging not only across Europe but also within the 
same country. Hospital pharmacies in all countries prepare compounded 
medicines in accordance with local formulae as, for instance, cough syrup; 
electrolytes solution; and mouthwash for radiation therapy. These given titles 
should always be accompanied by the respective formulae so that patients 
and health care professionals know, at all times, the exact composition of the 
respective compounded medicines. 
e. Proprietary medicines 
Hospital pharmacies in all European countries reported proprietary medicines 
as part of the compounded medicines dispensed. The top 3 countries were: 
France (almost 80 proprietary medicines reported by a total of 16 hospitals); 
Spain (56 proprietary medicines reported by 9 hospitals); and Switzerland (41 
proprietary medicines reported by 8 hospitals). In France, the electronic 
declaration of compounded medicines to the national authority included a 
specific section for the indication of the use of proprietary medicines. For this 
reason, it is likely that the majority of hospitals completed the respective 
section and, therefore, France is the European country where more 
proprietary medicines were reported as part of the compounded medicines 
dispensed. The country-specific questionnaires, on the other hand, did not 
include a dedicated section for reporting the use of proprietary medicines. 
Therefore, all proprietary medicines reported were indicated either as active 
substances or as supplementary information. In addition, hospital pharmacies 
do not systematically record the use of proprietary medicines in 
pharmaceutical compounding and, consequently, this information is not 
complete for most hospitals. For these reasons, it is likely that more 
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proprietary medicines were used in the preparation of the compounded 
medicines reported but detailed information was not shared. 
The proprietary medicines used included solid and liquid dosage forms, but 
proprietary tablets were most frequently used, mainly to provide appropriate 
strengths and/or obtain an easy to swallow dosage form. Proprietary 
medicines are used in pharmaceutical compounding either because it is 
common practice at the hospital pharmacy or when the individual raw 
materials are not available. The availability of raw materials depends on the 
compounding suppliers, who do not always have the required raw materials 
and/or in reasonably small quantities. Compounding suppliers vary 
considerably throughout Europe and, therefore, the availability of raw 
materials is, most of the time, country-specific. Although the use of 
proprietary medicines in pharmaceutical compounding may be common 
practice for certain hospitals, in general, this practice is usually discouraged 
and it is actually forbidden in certain Spanish autonomous communities. In 
these regions, when the individual raw materials are not available, Spanish 
pharmacists are not allowed to prepare the compounded medicine. The 
variable practices and criteria throughout Europe suggest that there is a need 
for Europe-wide guidance on the use of proprietary medicines in 
pharmaceutical compounding. 
The majority of professional information sources include formulae that imply 
the use of raw materials in bulk and, only rarely, the use of proprietary 
medicines is suggested. In fact, proprietary medicines not only include the 
required active substance(s) but also a miriad of excipients that may 
compromise the resulting compounded medicines. Actually, depending on 
the brand of the proprietary medicines used, the resulting compounded 
medicines may be considerably different. Therefore, if raw materials in bulk 
are available, pharmacists should not use proprietary medicines for the 
preparation of the respective compounded medicines, in particular if these 
are prepared on a large scale. For instance, the proprietary medicines 
reported in the UK were used in specials, which are usually prepared on a 
large scale and, therefore, should preferably include raw materials in bulk; 
likewise, in France, proprietary medicines were used in the preparation of 
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hospital preparations, which are also (usually) prepared on a large scale and, 
therefore, should preferably include raw materials in bulk as well. Europe-
wide guidance on the use of proprietary medicines in pharmaceutical 
compounding should separately consider the individual and batch 
preparation of compounded medicines. 
f. Therapeutic groups 
A total of 46 therapeutic groups were identified from the research (Appendix 
27), which represents 85% of all groups in Martindale 35 (2007) and 
indicates that compounded medicines from the majority of current therapeutic 
areas were dispensed by European hospitals. This illustrated the diversity of 
pharmaceutical compounding in Europe and reinforces the importance of this 
practice in current therapeutics. Of these 46 therapeutic groups, 11 were 
common to all European countries (Table 14.9), which indicates that there is 
a Europe-wide need for compounded medicines from 20% of all current 
therapeutic areas. Although active substances were all reported as oral (and 
oromucosal) compounded medicines, the designation of 8 therapeutic groups 
suggested non-oral indications (Table 14.10) (Appendix 11-15 and 26).  
Table 14.9 Therapeutic groups common to all European countries. 
1. Analgesics, anti-inflammatory drugs and antipyretics 
2. Antibacterials 
3. Antiepileptics 
4. Anxiolytic, sedatives, hypnotics and antipsychotics 
5. Cardiovascular drugs 
6. Electrolytes 
7. GI drugs 
8. Nutritional agents and vitamins 
9. Supplementary drugs and other substances 
10. Thyroid and antithyroid drugs 
11. Urological drugs 
 
Martindale classifies active substances according to their main therapeutic 
use and brings together active substances that have similar uses or actions. 
Nevertheless, active substances may be indicated in other additional 
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therapeutic uses. For this reason, the 8 groups that suggest non-oral 
therapeutic indications include active substances that were dispensed as oral 
compounded medicines in Europe. 
Table 14.10 Therapeutic groups that suggest non-oral (therapeutic) indications. 
1. Colouring agents 
2. Dermatological drugs and sunscreens 
3. Disinfectants and preservatives 
4. Non-ionic surfactants 
5. Organic solvents 
6. Paraffins and similar bases 
7. Stabilising and suspending agents 
8. Supplementary drugs and other substances 
The least common groups indicate the country-specific therapeutic areas and 
corresponded to the following: 
• Exclusive to 1 country: non-ionic surfactants (Germany) and organic 
solvents (Netherlands) (Appendix 25). 
• Exclusive to 2 countries: colouring agents (France and Germany) 
(Appendix 25). 
• Exclusive to 3 countries: antidementia drugs (Poland, Spain and France); 
paraffins and similar bases (Portugal, UK and Switzerland) (Appendix 13); 
and stimulants and anorectics (UK, Netherlands and Denmark). 
 
The top 3 therapeutic groups, per country, with the greatest number of 
different active substances were:  
• Cardiovascular drugs (n=10-39): all countries but Denmark. 
• Antibacterials (n=9-31): all countries but Finland and Germany. 
• Nutritional agents and vitamins (n=9-34): all countries but UK, Switzerland 
and Slovenia.  
• Electrolytes (n=7-14): UK, Switzerland, Denmark and Slovenia. 
• Antiepileptics (n=8,11): Finland and Germany.  
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In conclusion, the greatest number of different active substances is 
associated with just 5 therapeutic groups, which represent only 11% of all 
therapeutic groups included in the research. The diversity of pharmaceutical 
compounding in Europe was shown before with the fact that the top 5 
European countries dispensed active substances included in over 70% of all 
therapeutic groups. Therefore, the fact that the greatest number of different 
active substances is associated with just 11% of all therapeutic groups 
indicates that the largest diversity of pharmaceutical compounding in Europe 
is restricted to a few therapeutic groups only. Consequently, these 5 groups 
represent the therapeutic areas where there is a higher lack of active 
substances commercially available (i.e. proprietary medicines) in appropriate 
forms and, consequently, these are the therapeutic areas where more active 
substances are dispensed as compounded medicines. 
Compounded medicines were reported as oral solid and oral liquid dosage 
forms, and also as oromucosal preparations, which are discussed separately 
below. 
14.4.2 Oral solids 
Oral solid dosage forms were dispensed in all European countries, as 
follows: cachets (Poland), oral powders (all countries but Poland), powders 
for oral liquids (Netherlands, Slovenia, Spain and France), capsules (all 
countries) and tablets (Switzerland, Netherlands, Denmark, France and 
Germany). The most frequently dispensed dosage forms varied within the 
countries, from traditional cachets to complex tablets. The top oral solids (the 
most frequently dispensed solid dosage forms by number of packs and/or by 
number of individual units) are shown in Table 14.11.  
The Netherlands and France dispensed the highest variety of oral solid 
dosage forms, which suggests that these two countries are the ones that 
offer more flexibility in terms of meeting the individual patient needs. 
 
 
 
 Chapter 14: COMPOUNDING IN EUROPE | Results and discussion | 342 
 
Table 14.11 Oral solid dosage forms dispensed per country. 
European  
countries 
Most frequent  
oral solid dosage forms 
Other  
solid dosage forms 
Portugal Oral powders Capsules 
UK Oral powders Capsules 
Switzerland Capsules Oral powders Tablets 
Poland Cachets Capsules 
Netherlands Tablets 
Oral powders 
Powders for oral liquids 
Capsules 
Denmark Tablets Oral powders Capsules 
Slovenia Capsules Oral powders Powders for oral liquids 
Finland Oral powders Capsules 
Spain Capsules Oral powders Powders for oral liquids 
France Capsules 
Oral powders 
Powders for oral liquids 
Tablets 
Germany Capsules Oral powders Tablets 
 
a. Dosage forms 
Capsules were the only dosage form common to all countries, which shows 
that these are part of the current compounding practices Europe-wide. 
Gelatin capsules are an elegant, stable and flexible dosage form that may be 
rapidly prepared extemporaneously by means of inexpensive manual (or 
semi-automatic) capsule machines (usually in standardised quantities of 50, 
100 or 300 units, depending on the equipment) and, therefore, these are 
widely dispensed in European hospitals. However, capsule calculations are 
not always straightforward as the active substance(s) determine the size of 
capsules, choice of excipients and the respective amounts (calculated per 
density). It is important that hospital pharmacies are fully familiar with these 
calculations so that the uniformity of capsules can be guaranteed. In most 
countries, uniformity of weight is not undertaken for capsules prepared 
extemporaneously, as required in Portugal (Section 3.1), but it would be 
recommended that a non-destructive quality control test be considered 
Europe-wide. When indicated for paediatrics patients, capsules are 
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commonly opened before administration and their contents added to liquids 
or food. Capsules were the most frequently dispensed oral solids in 
Switzerland (85%), Slovenia (76%), Spain (98%), France (99%) and 
Germany (92%). 
Oral powders were also common to all countries, with the exception of 
Poland, and these were mainly dispensed as sachets (single-dose, 
individually weighed) (Figure 3.6). Oral powders are a traditional dosage 
form, stable and flexible, that may be prepared extemporaneously by means 
of basic compounding equipment. However, these are very time-consuming 
to prepare and, therefore, are only appropriate for the preparation of non-
standardised (small) quantities. Oral powders are usually administered in or 
with water, or another suitable liquid, and may also by swallowed directly. 
Oral powders were the most frequently dispensed oral solids in Portugal 
(73%), UK (94%) and Finland (55%), which suggests that these have not 
been largely replaced by capsules and tablets, at least in all countries 
(Section 2.1.3). In these countries, capsules are less common probably due 
to the lack of capsule machines in the hospital setting and also the need for 
the preparation of non-standardised quantities of oral solids. In Poland, 
instead of oral powders, cachets were the most frequently dispensed oral 
solids. Cachets, one of the oldest dosage forms encountered in Europe, were 
the only dosage form exclusive to a single country, which shows that these 
have been substituted by other less traditional dosage forms across Europe. 
Powders for oral liquids were only reported in the Netherlands, Slovenia, 
Spain and France but it is likely that other countries also dispensed this 
dosage form but classified it as oral powders. In fact, powders for oral liquids 
generally conform to the definition of oral powders (Section 2.1.3) (EDQM, 
2007) and, therefore, their distinction is not always clear. Likewise, it is 
possible that some of the powders for oral liquids reported corresponded to 
oral powders (in particular those to be administered in or with water, or 
another suitable liquid). For these reasons, this dosage form was considered 
as part of the oral solids category. Examples of powders for oral liquids 
dispensed are glucose (nutritional agents and vitamins) and magnesium 
sulfate (electrolytes). A distinct difference between oral powders and 
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powders for oral liquids is most likely to be recorded in hospital pharmacies 
that have complete and detailed records of the compounded medicines 
dispensed. The Netherlands and Spain were the European countries that 
shared the most comprehensive records. In France, hospital pharmacies 
have to report the compounded medicines dispensed to the national authority 
and, consequently, it is expected that the exact dosage forms are reported. 
For these reasons, it is clear that the Netherlands, Spain and France 
specifically reported powders for oral liquids. In Slovenia, only one hospital 
reported one compounded medicine as a powder for oral liquid. 
Tablets were the most frequently dispensed oral solids in the Netherlands 
(80%) and Denmark (84%) but these were also dispensed in Switzerland, 
France and Germany. Tablets are an elegant and stable dosage form but, 
unlike capsules, these are more complex to formulate and produce, plus they 
require expensive equipment for their preparation. Consequently, tablets are 
not usually prepared extemporaneously but instead, are produced in large 
quantities for stock preparation. Out of all European countries included in the 
research, UK, Netherlands and Denmark were the only ones in which 
compounded medicines were frequently prepared in large quantities for stock 
preparation. In the UK, special manufacturers do not commonly produce 
tablets and, hence, it is not surprising that tablets were not reported in this 
country. Therefore, the Netherlands and Denmark were the only European 
countries in which tablets corresponded to the top oral solids dispensed. 
Pellets were also reported by hospital pharmacies in the UK and Germany 
and, although not considered an official dosage form in the PhEur (EDQM, 
2007), these correspond to small cylinders (about 3.2 mm in diameter by 8 
mm in length) of an active substance (Rudnic and Schwartz, 2005). In 
pharmaceutical compounding, pellets of an active substance are usually 
combined with “non-active” pellets, to obtain the required strength of the 
active substance, and are then divided in solid dosage forms (e.g. capsules). 
In the UK, pellets were dispensed as capsules and, in Germany, it is likely 
that the theophylline and topiramate pellets reported by hospital pharmacies 
were also dispensed as capsules. Because pellets are not an official PhEur 
dosage form, and may actually be considered as an “intermediate” product 
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(Nuez, 2009), this terminology should be discouraged so that there is no 
ambiguity in the classification of medicines Europe-wide. 
b. Quantities 
Oral solids were reported by all participant hospitals in Poland, Slovenia and 
Finland; and by over 90% of the hospitals in Switzerland, Netherlands, Spain, 
France and Germany, which indicates that the majority of European hospitals 
dispensed solid dosage forms as oral compounded medicines. 
The quantities of oral solids were provided as the number of individual units 
dispensed and/or the number of packs dispensed. For selected European 
countries, data have been displayed in both formats so that all compounded 
medicines reported were included in the data analysis. Considering the 
number of individual units dispensed, the top 5 European countries that 
reported the largest quantities of oral solids were, in decreasing order: 
France, Denmark, Netherlands, Spain and Poland. However, the number of 
participant hospitals varied within countries and, therefore, the European 
countries that reported the largest quantities of oral solids per hospital were 
as follows: Denmark (522,588 units), Netherlands, France, Spain and 
Poland, as shown in Table 14.12. 
In Denmark and the Netherlands, hospital pharmacies frequently prepare 
compounded medicines for their own patients, both extemporaneously and 
for stock, and also for other hospital and community pharmacies. Therefore, 
it is not unexpected that the largest quantities of oral solids (tablets), per 
hospital, were reported by these 2 countries. 
France and Spain dispensed the largest quantities of capsules. In both 
countries, there was no evidence of capsules being prepared for stock, which 
suggests that the largest extemporaneous preparation of oral solids took 
place in France and Spain. Cachets correspond to a dosage form prepared 
extemporaneously and, therefore, Poland was the European country in which 
the next largest extemporaneous preparation of oral solids, (as cachets) took 
place. 
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Table 14.12 Top 5 European countries ranked by the total number of individual units of oral 
solids dispensed and the respective mean of individual units per hospital. 
European 
countries 
Oral solids 
(total units) 
Participant  
hospitals 
Oral solids 
(mean units  
per hospital) 
Ranking 
France 3,910,621 60 65,177 3 
Denmark 3,658,118 7 522,588 1 
Netherlands 3,281,601 12 273,467 2 
Spain 1,052,518 30 35,084 4 
Poland 213,021 12 17,752 5 
 
c. Active substances 
When the top 10 active substances (per solid dosage form) are considered 
for each European country, there is evidence of common active substances 
being frequently dispensed in hospital pharmacies across Europe. Table 
14.13 displays the active substances common to most European countries. 
Glucose (oral powders and capsules) and hydrocortisone (oral powders, 
capsules and tablets) were part of the top 10 active substances in a total of 6 
countries and, therefore, these were the active substances most frequently 
dispensed as oral solids Europe-wide. The next most frequently dispensed 
active substances were calcium carbonate (oral powders, cachets and 
tablets), captopril (cachets and capsules), lactose and sodium bicarbonate 
(oral powders and capsules), which were part of the top 10 active substances 
dispensed in a total of 5 countries. Phenobarbital was the only NTI drug 
included in the top oral solids and was frequently dispensed, both as oral 
powders and capsules, in a total of 4 countries. 
The majority of active substances were dispensed as 2 or 3 different dosage 
forms. These results show that although the same active substances are 
frequently dispensed, the solid dosage forms and the resulting oral 
compounded medicines may vary widely depending on the European country 
and the particular hospital pharmacy. Therefore, these top oral solids should 
be the ones considered for licensing or prioritised for standardisation in 
official (European) monographs.  
 
C
hapter 14: C
O
M
P
O
U
N
D
IN
G
 IN
 E
U
R
O
P
E
 | R
esults and discussion | 347  
Table 14.13 A
ctive substances (per solid dosage form
) dispensed by m
ost E
uropean countries. 
 
G
lucose 
H
ydrocortisone 
C
alcium
 
carbonate 
C
aptopril 
Lactose 
Sodium
 
bicarbonate 
Phenobarbital 
Sodium
 
chloride 
Spironolactone 
Total 
Portugal 
______ 
O
ral pow
ders 
O
ral 
pow
ders 
______ 
______ 
C
apsules 
O
ral pow
ders 
O
ral 
pow
ders 
C
apsules 
______ 
5 
U
K
 
O
ral 
pow
ders 
______ 
______ 
______ 
O
ral 
pow
ders 
O
ral 
pow
ders 
______ 
______ 
______ 
3 
Sw
itzerland 
O
ral 
pow
ders 
______ 
O
ral 
pow
ders 
C
apsules 
______ 
O
ral 
pow
ders 
______ 
O
ral 
pow
ders 
C
apsules 
______ 
5 
Poland 
______ 
______ 
C
achets 
C
achets 
______ 
______ 
______ 
______ 
______ 
2 
N
etherlands 
______ 
C
apsules 
______ 
C
apsules 
______ 
______ 
______ 
______ 
O
ral pow
ders 
C
apsules 
3 
D
enm
ark 
O
ral 
pow
ders 
Tablets 
______ 
______ 
O
ral 
pow
ders 
______ 
______ 
______ 
______ 
3 
Slovenia 
C
apsules 
______ 
______ 
______ 
C
apsules 
O
ral 
pow
ders 
C
apsules 
C
apsules 
O
ral 
pow
ders 
C
apsules 
6 
Finland 
______ 
O
ral pow
ders 
C
apsules 
O
ral 
pow
ders 
______ 
______ 
______ 
O
ral pow
ders 
______ 
______ 
3 
Spain 
O
ral 
pow
ders 
______ 
______ 
______ 
O
ral 
pow
ders 
______ 
______ 
______ 
______ 
2 
France 
O
ral 
pow
ders 
C
apsules 
Tablets 
C
apsules 
O
ral 
pow
ders 
C
apsules 
______ 
C
apsules 
Tablets 
C
apsules 
Tablets 
8 
G
erm
any 
______ 
C
apsules 
______ 
C
apsules 
______ 
______ 
O
ral pow
ders 
______ 
O
ral pow
ders 
C
apsules 
Tablets 
4 
Total 
6 
6 
5 
5 
5 
5 
4 
4 
4 
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Although these active substances were not exclusively dispensed to 
paediatric patients, this population has a special need for compounded 
medicines and, therefore, age-appropriate formulations including these top 
active substances (dispensed by most European countries) should be 
considered for studies. However, only spironolactone is currently considered 
in the EMA (2012b) “Revised priority list for studies into off-patent paediatric 
medicinal products” and, therefore, it is recommended that all other top active 
substances be added to this list. 
The countries that shared most active substances were France (8 active 
substances) and Slovenia (6 active substances). The Netherlands and 
Germany were the European countries with more similarities in terms of 
active substances and the respective oral solid dosage forms dispensed. The 
fact that there is cooperation between the Dutch and German formularies in 
relation to formulations, procedures and guidelines is likely to contribute to 
the harmonisation of some compounding practices in both countries. This 
finding highlights the importance of international information sources and 
reinforces the desirability for a Europe-wide compounding formulary. 
In comparison with the study by Brion et al. (2003), only 5 active substances 
were common to their top 20 of capsules and top 20 of oral powders, as 
follows (in decreasing order): spironolactone, captopril, phenobarbital, 
hydrocortisone and glucose. The few similarities between both studies may 
be explained with the fact that Brion et al. (2003) included only 21 hospitals 
(convenience sample; children's hospitals only) whereas the present study 
included 242 hospitals (purposive sample). 
d. Strengths 
The strengths of oral solids were not always provided by hospital pharmacies 
and, when provided, these were occasionally reported as an interval (e.g. 
aspirin 15-320 mg). Therefore, it was not always possible to determine the 
range and the exact number of strengths dispensed. Table 14.14 displays the 
range and number (approximate) of strengths for the top 5 active substances 
common to most European countries. 
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The active substances associated with the highest number of strengths 
(highlighted in bold) were hydrocortisone (up to 12 strengths) and captopril 
(up to 23 strengths). Very similar strengths were encountered: hydrocortisone 
1 mg, 1.25 mg, 1.35 mg, 1.5 mg, 1.6 mg; and captopril 0.1 mg, 0.2 mg, 0.3 
mg, 0.4 mg, 0.5 mg. On the other hand, a wide range of strengths was also 
encountered: hydrocortisone 0.1-80 mg and captopril 0.01-25 mg. The high 
number and wide range of strengths encountered reinforce the fact that 
individualised dosage strengths is one of the main reasons for 
pharmaceutical compounding, in particular for the paediatric population 
(Section 1.1.4).  
Table 14.14 Top 5 active substances (per dosage form) dispensed by most European 
countries and indication of the respective range and number (approximate) of strengths 
(highest number of strengths highlighted in bold). 
 Glucose Hydrocortisone Calcium carbonate Captopril 
Sodium 
bicarbonate 
Portugal ______ 1-80 mg  10 strengths 
100-250 mg 
4 strengths ______ 
30 mg  
500 mg 
2 strengths 
UK 14.6 g, 75 g 2 strengths ______ ______ ______ 
100 g 
1 strength 
Switzerland 68 g, 91 g 2 strengths ______ n/a 
0.01-7.5 mg 
19 strengths 
100 g 
1 strength 
Poland ______ ______ 50-2,000 mg 9 strengths 
0.05-25 mg 
23 strengths ______ 
Netherlands ______ 0.25-5 mg  6 strengths ______ 
0.5-6.25 mg 
7 strengths ______ 
Denmark 75 g, 82.5 g 2 strengths 
1 mg, 5 mg 
2 strengths ______ ______ ______ 
Slovenia 15-100 g  5 strengths ______ ______ ______ 
500-
2,000mg 
5 strengths 
Finland ______ 0.1-2.5 mg  10 strengths 
50-500 mg 
3 strengths ______ ______ 
Spain 5-100 g  5 strengths ______ ______ ______ ______ 
France 50 g, 75 g 2 strengths 
0.5-9 mg  
12 strengths 
500 mg 
1 strength 
0.5-25 mg 
15 strengths 
125-
1,000mg 
4 strengths 
Germany ______ 0.1-7.5 mg  12 strengths ______ 
0.1-8 mg 
13 strengths ______ 
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Brion et al. (2003) also concluded that a large number of strengths, for the 
same active substance, were dispensed in European hospitals. In practice, 
the evidence-base for distinguishing certain dosage strengths might be 
arguable as, for instance, captopril 3.125 mg and captopril 3.2 mg. 
Nevertheless, if the dosage strengths are within the therapeutic window of 
the respective active substances, it is the pharmacists’ duty to prepare the 
compounded medicines prescribed. 
For compounded medicines prepared extemporaneously, it takes the same 
amount of time and effort to prepare, for instance, captopril 3.125 mg and 
captopril 3.2 mg. Provided that the pharmacy has a QA/QC system for the 
practice of compounding, the preparation of compounded medicines in 
variable strengths should not be more risky than the preparation of 
standardised strengths. 
14.4.3 Oral liquids 
Oral liquid dosage forms were dispensed in all European countries, as 
follows: solutions and suspensions (all countries), syrups (all countries but 
Denmark and Finland), mixtures (UK, Poland, Denmark and Germany), oral 
drops (Switzerland, Netherlands, Denmark, Spain, France and Germany), 
oral syringes (Netherlands, Finland, Spain and France) and others 
(Switzerland, Spain and Germany). Others included tinctures and elixirs. The 
dosage forms reported included both multidose and unidose oral liquids. 
Multidose oral liquids were dispensed in all European countries whereas 
unidose oral liquids were dispensed only in the UK, Switzerland, 
Netherlands, Finland, Spain and France. 
Oral liquids may be rapidly prepared by pharmacists, both extemporaneously 
in small quantities and in advance for stock, by means of basic compounding 
equipment. They allow the administration of 1 or more active substances in 
flexible strengths (by variable volumes). In addition, oral liquids may be easily 
taken by patients (including paediatric and geriatric patients) and allow the 
adaptation of the vehicle to individual patient needs (e.g. sugar free) and 
preferences (e.g. flavour). Oral liquid dosage forms offer a myriad of 
advantages to both pharmacists and patients and, therefore, it was not 
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unexpected that these were dispensed in all European countries. However, 
the formulation and stability of oral liquids are usually complex (Section 2.1.3) 
and not all hospital pharmacies have sufficient resources to assure optimal 
formulations, in terms of choice of excipients (e.g. suspending agents, buffers 
and preservatives) and method of preparation. This reinforces the need for a 
Europe-wide compounding formulary including, in particular, monographs for 
oral liquid dosage forms. A national formulary based exclusively on oral 
liquids (for paediatrics) is already available in Portugal (LEF, 2007) but it is 
published in Portuguese only and, therefore, has limited use across Europe. 
Such locally developed professional information sources should be 
considered when compiling a Europe-wide compounding formulary in order 
to avoid duplication of potentially expensive and time-consuming studies. 
a. Dosage forms 
Solutions and suspensions were specifically reported in all countries and 
corresponded to the most frequently dispensed liquid dosage forms, which 
shows that these are part of the current compounding practices Europe-wide. 
In fact, solutions and suspensions corresponded to over 90% of all multidose 
oral liquids dispensed in the UK, Switzerland, Netherlands, Slovenia and 
Finland; and over 80% in all other European countries, with the exception of 
France (62%). The distinction between solutions and suspensions is not 
always straightforward as it is not always clear at hospital pharmacies if 
active substances are actually dissolved or suspended in a given vehicle. 
Therefore, it is likely that some interchange in terminology will have occurred 
and, for this reason, solutions and suspensions were considered altogether 
for the purposes of overall data comparison. However, it is important that 
hospital pharmacies acknowledge the differences between solutions and 
suspensions and label the compounded medicines accordingly. For instance, 
all suspensions should have the indication “Mix well before use”, in order to 
assure uniformity of dosage. In addition, it is likely that some interchange will 
have also occurred in relation to syrups, mixtures, oral drops, elixirs and 
tinctures reported and, therefore, some of these oral liquids may have 
corresponded to solutions/suspensions (and vice-versa). Despite the 
complexity of oral liquids, the formulation and stability of suspensions, in 
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particular, has been made easy by compounding suppliers that offer 
proprietary suspending vehicles and publish corresponding peer-reviewed 
stability studies. For instance, metronidazole benzoate in SyrSpend SF, a 
starch-based, sugar-free suspension system with low osmolality, which is 
considered a one-step suspension system (Vu et al., 2008). In addition, there 
are non-proprietary suspending vehicles that have also been studied and are 
described in professional information sources. For instance, the “B.9. Vehicle 
for the preparation of oral suspensions, sugar-free”, described in the 
Portuguese galenic formulary (CETMED, 2005). These proprietary and non-
proprietary suspending vehicles are a valuable source for compounding 
settings that do not have sufficient resources to assure optimal formulations 
for oral liquids. 
Unidose oral liquids were dispensed by 22 hospitals in 6 European countries, 
corresponding to only 0.1% of all participant hospitals, but not all hospital 
pharmacies distinguished unidose from multidose oral liquids. For the 
purposes of overall data comparison, quantities <10 mL have been 
considered to correspond to unidose; whereas quantities ≥10 mL have been 
taken as corresponding to multidose containers (unless otherwise indicated). 
As a result, the top 3 European countries were: Switzerland (228,689 units, 2 
hospitals), Spain (59,147 units, 9 hospitals) and France (19,519 units, 2 
hospitals). Only 3 active substances were frequently dispensed as unidose 
oral liquids in more than 1 European country, namely: midazolam, nystatin 
and methadone HCl (2 countries). Unidose oral liquids offer advantages 
when compared to multidose oral liquids, as follows: no administration errors 
in terms of volumes measured by patients or caregivers (unidoses are pre-
packed at the pharmacy) and no contamination of subsequent doses 
(unidoses are individually packed). In the hospital setting, unidoses are 
particularly convenient as nurses are provided the exact dose for a patient. 
Unidose oral liquids are accurately measured and usually administered by 
means of oral syringes (Paediatric Formulary Committee, 2008), but these 
were specifically reported in 4 European countries only. However, it is likely 
that almost all unidose oral liquids were dispensed by means of oral syringes 
since these are the most popular unidose devices. Nevertheless, oral 
 Chapter 14: COMPOUNDING IN EUROPE | Results and discussion | 353 
 
syringes are not always well accepted by the paediatric population because 
of their resemblance to painful injectable products. An innovative alternative 
to oral syringes is blister packs constituted by small containers for unidose 
oral liquids. 
Syrups were specifically reported in all European countries, with the 
exception of Denmark and Finland. However, as indicated, the distinction 
between solutions, suspensions and syrups is not always straightforward and 
it is likely that some interchange in terminology may have occurred. Hence, it 
is likely that syrups were also dispensed in Denmark and Finland but were 
reported as solutions/suspensions. Syrups are aqueous preparations 
characterised by a sweet taste and high viscosity and usually contain 
sucrose at a concentration of at least 45% (w/w). Therefore, syrups are 
generally regarded as a pleasant tasting dosage form, in particular, for the 
paediatric population. However, syrups containing sucrose should be avoided 
when compounded medicines are intended, for instance, to be used by 
diabetic patients or for long periods of treatment. For this reason, it is 
important that hospital pharmacies acknowledge the difference between 
syrups and other oral liquid dosage forms, and label the compounded 
medicines accordingly (e.g. contains sucrose). Syrups corresponded to less 
than 10% of oral liquids in all countries, from 0.2% in the UK to 9.3% in 
Portugal, and were dispensed both as multidose and unidose containers; 
unidose syrups were reported by only 1 Spanish hospital, whereas multidose 
syrups were reported by 81 European hospitals. A total of 10 active 
substances were frequently dispensed as syrups in more than 1 European 
country, as follows: chloral hydrate (5 countries); ipecacuanha and 
midazolam (4 countries); codeine, furosemide, ketamine HCl, phenobarbital, 
ranitidine, spironolactone and zinc acetate (2 countries). These active 
substances are described in professional information sources across Europe, 
which is likely to contribute to their widespread use in pharmaceutical 
compounding. However, there is ambiguity in the classification of the 
respective dosage forms. For instance, chloral hydrate is described as a 
mixture and as an elixir, both containing syrup, and also as an oral solution 
and as an oral liquid (Section 4.4.3). This reinforces the importance of 
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prioritising these top 10 syrups for standardisation in official (European) 
monographs. 
Oral drops were specifically reported in 6 European countries, by a total of 30 
hospital pharmacies, though the distinction between solutions, suspensions 
and oral drops is not always straightforward as it depends on the 
characteristics of the container/additional devices (i.e. dropper). However, it 
is important that hospital pharmacies acknowledge this distinction and 
dispense the compounded medicines accordingly. Oral drops are commonly 
prescribed taking into account the following:  
1. The administration of the compounded medicine is facilitated by drops.  
In this situation, if the dosage of the compounded medicine is per mL, the 
dropper should include a scale for measuring the required volume. 
2. The dosage of the compounded medicine is indicated by number of drops. 
In this situation, the dropper does not have to include a scale but attention 
should be paid at the hospital pharmacy in order to assure the dose per drop. 
Oral drops were most frequently dispensed in France (31%), Germany (11%) 
and Denmark (10%); and least frequently dispensed in the Netherlands (6%), 
Switzerland and Spain (<0.1%). In France, hospital pharmacies have to 
report the compounded medicines dispensed to the national authority 
(AFSSAPS) and, consequently, it is expected that the exact dosage forms 
are reported. This fact is likely to have contributed to the highest % of oral 
drops being reported in France. Only 3 active substances were frequently 
dispensed as oral drops in more than 1 European country, as follows: 
morphine (2 countries); iodine and potassium iodide (2 countries), commonly 
dispensed as Lugol’s Solution (Appendix 16).  
Mixtures were specifically reported in 4 European countries, by a total of 11 
hospital pharmacies. Mixtures are not an official PhEur dosage form but are 
subject of an individual monograph in the BP (Oral Liquids of the BP) and 
correspond to an oral liquid containing 1 or more active substances 
dissolved, suspended or dispersed in a suitable vehicle (BP Commission, 
2008a). This definition also applies to the “liquid preparations for oral use” 
described in the PhEur, which adds ambiguity to the classification of oral 
liquids. Therefore, the need for mixtures as an additional BP official dosage 
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form should be questioned in the UK. Hence, it is likely that “mixtures” were 
also dispensed in other European countries but were reported as oral liquids. 
It is recommended that the countries which are signatories to the Convention 
on the Elaboration of a PhEur be consistent with the terminology used in the 
PhEur, so that there is no ambiguity in the classification of medicines Europe-
wide. Mixtures were most frequently dispensed in Poland (10.6%) and 
corresponded to a minority dosage form in the UK (0.3%), Denmark (0.2%) 
and Germany (<0.1%). It is likely that these 4 European countries were the 
only ones that actually recognise mixtures as an additional official dosage 
form. Sodium benzoate was the only active substance frequently dispensed 
as mixtures in more than 1 European country (i.e. UK and Poland). 
Tinctures were specifically reported in Spain and Germany, by a total of 3 
hospitals; 1 additional Swiss hospital is likely to have dispensed a tincture 
(opium), but it was classified as an oral solution. Tinctures are extracts of 
liquid consistency, usually obtained using 1 part of herbal drug / animal 
matter and either 10 or 5 parts of extraction solvent. The extraction process 
can be time consuming and it is not always straightforward for hospital 
pharmacies. Therefore, it was not unexpected that tinctures corresponded to 
a minority dosage form in all countries (<0.5%) and only 2 active substances 
were dispensed, namely: belladonna and opium. Although these 2 tinctures 
are described in international information sources, which is expected to 
contribute to their widespread use in pharmaceutical compounding, it is likely 
that tinctures have been substituted by alternative oral liquid dosage forms in 
most countries. 
Elixirs were only reported by 2 Spanish hospitals and represented <0.1% of 
all oral liquids; the only active substance reported was cyclophosphamide. 
Elixirs are not an official PhEur dosage form and, therefore, the use of this 
terminology should be discouraged so that there is no ambiguity in the 
classification of medicines Europe-wide. 
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b. Quantities 
Oral liquids were reported by all participant hospitals in Portugal, UK, 
Netherlands, Denmark and Finland; and by 90% (or more) of hospitals in 
Switzerland, Poland and Spain, which suggests that almost all European 
hospitals dispensed liquid dosage forms as oral compounded medicines. 
The quantities of oral liquids were provided as the number of multidose and 
unidose units dispensed. Considering the number of multidose units, the 5 
European countries that reported the largest quantities of oral liquids were, in 
decreasing order: Netherlands, Spain, UK, France and Denmark. However, 
the number of participant hospitals varied within countries and, therefore, the 
European countries that reported the largest quantities of oral liquids per 
hospital were: Netherlands (6,842 units), Denmark, UK, Spain and France 
(Table 14.15). 
In the Netherlands and Denmark, hospital pharmacies frequently prepare 
compounded medicines for their own patients, both extemporaneously and 
for stock, and also for other hospital and community pharmacies. Therefore, 
it is not unexpected that the largest quantities of oral liquids (per hospital) 
were reported by these 2 countries. 
Table 14.15 Top 5 European countries ranked by the total number of multidose units of oral 
liquids dispensed and the respective mean of multidose units per hospital. 
European 
countries 
Oral liquids 
Total  
(multidose units) 
Participant  
hospitals 
Oral liquids 
Mean 
(multidose units per hospital) 
Ranking 
Netherlands 82,104 12 6,842 1 
Spain 60,117 30 2,004 4 
UK 50,200 15 3,347 3 
France 47,474 60 791 5 
Denmark 26,870 7 3,839 2 
 
In the UK, hospital pharmacies with a manufacturing specials licence 
commonly prepare specials on a large scale, for their own patients and also 
for other hospital and community pharmacies. Therefore, it is not unexpected 
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either that the UK was the European country in which the next largest 
quantities of oral liquids were reported (per hospital). 
c. Active substances 
When the top 10 active substances (per liquid dosage form) are considered 
for each European country, there is evidence of common active substances 
being frequently dispensed in hospital pharmacies across Europe. Table 
14.16 displays the top active substances common to most European 
countries. 
Morphine (solutions/suspensions, syrups and oral drops) and phenobarbital 
(solutions/suspensions, syrups, mixtures and oral drops) were included in the 
top 10 active substances in a total of 7 countries, being the active substances 
most frequently dispensed as oral liquids Europe-wide. Phenobarbital was 
the only NTI drug included in the top oral liquids.  
The next most frequently dispensed active substances were chloral hydrate 
(solutions/suspensions, syrups and mixtures), midazolam (solutions/ 
suspensions, syrups and oral drops) and spironolactone (solutions/ 
suspensions and syrups), which were part of the top 10 active substances 
dispensed in a total of 6 countries.  
Although these active substances were not exclusively dispensed to 
paediatric patients, as mentioned above, this population has a special need 
for compounded medicines and, therefore, age-appropriate formulations 
including these top active substances (dispensed by most European 
countries) should be considered for studies. However, again, only 
spironolactone is currently considered in the EMA (2012b) “Revised priority 
list for studies into off-patent paediatric medicinal products” and, therefore, it 
is recommended that all other top active substances be added to this list. 
The countries that shared most active substances were Switzerland and 
Germany (6 active substances). These 2 countries were the only ones 
included in the research in which data collection referred exclusively to 
paediatrics.  
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Therefore, the similarities encountered suggest that the need for oral liquid 
compounded medicines in the paediatric population is likely to be the same 
Europe-wide. This reinforces the importance of including these oral liquids in 
the EMA priority list for studies and also in European Paediatric Formulary 
(Section 14.2.2) in the format of standardised (official) monographs. 
Considering the study by Brion et al. (2003), the top 4 active substances 
(morphine, phenobarbital, chloral hydrate and midazolam) were included in 
their top 20 oral liquids. More similarities between both studies were unlikely 
since Brion et al. (2003) included only 21 hospitals (convenience sample) 
whereas the present study included 242 hospitals (purposive sample). 
d. Oral solids vs oral liquids 
Oral solids and oral liquids were dispensed in all European countries but the 
specific dosage forms varied within the countries. Capsules and 
solutions/suspensions were the only dosage forms dispensed in all countries, 
which indicates that these are the most common dosage forms in 
pharmaceutical compounding Europe-wide. However, capsule calculations 
and the formulation/stability of solutions and suspensions are not always 
straightforward. It is important that hospital pharmacies become fully familiar 
with the preparation of these dosage forms so that the quality and safety of 
compounded medicines can be guaranteed. This finding reinforces the 
importance of European guidelines on pharmaceutical compounding, 
particularly in relation to methods of preparation for the most frequently 
dispensed dosage forms. In addition, there is a continued need for 
compounding education in schools of pharmacy adapted to current practices. 
For instance, not all European schools of pharmacy have manual capsule 
machines and, therefore, not all pharmacy graduates actually know how to 
prepare such compounded medicines. Considering that capsules are 
extemporaneously prepared in all European countries, it is crucial that the 
academic curriculum is adapted to current compounding practices.  
The multidose oral liquids were quantitatively compared to the oral solids 
dispensed (in packs), per European country. In conclusion, a total of 6 
countries (55%) dispensed more oral liquids whereas 4 countries (36%) 
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dispensed more oral solids. In 1 country (Slovenia), oral liquids and oral 
solids were dispensed in comparable quantities, as displayed in Table 14.17. 
Table 14.17 Top oral dosage forms (solid or liquid) per European country. 
European  
countries 
Oral solid  
dosage forms 
Oral liquid 
dosage forms 
Portugal ! _____ 
UK _____ ! 
Switzerland _____ ! 
Poland ! _____ 
Netherlands _____ ! 
Denmark ! _____ 
Slovenia ! ! 
Finland _____ ! 
Spain _____ ! 
France ! _____ 
Germany _____ ! 
 
As stated, oral liquid dosage forms offer a myriad of advantages to both 
pharmacists and patients and, therefore, it was not unexpected that these 
were more frequently dispensed than oral solids across Europe. However, 
the formulation and stability of oral liquids can be complex and not all hospital 
pharmacies have sufficient resources to assure optimal formulations. 
In Portugal and Poland, compounding practices may be considered 
“traditional” as sachets and cachets, respectively, are still popular dosage 
forms. In these 2 countries, it is not unexpected that oral liquids did not 
correspond to the most frequently dispensed dosage forms. In Denmark, 
practices are not traditional as pharmaceutical compounding is centralised in 
a few hospital and community pharmacies, which prepare compounded 
medicines in large quantities for stock. Tablets, an elegant and stable dosage 
form, may be rapidly prepared in large quantities provided that the pharmacy 
has the necessary equipment. Therefore, it is not unexpected that, in 
Denmark, oral liquids were not the most frequently dispensed dosage forms 
either. In France, considering the large quantities of capsules dispensed, it is 
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suggested that these are culturally preferable to other dosage forms. Hence, 
oral liquids were not more frequently dispensed than oral solids in this 
country. 
Phenobarbital, spironolactone and glucose were the active substances 
common to both top oral solids and oral liquids dispensed by most countries. 
The fact that phenobarbital, an NTI drug, is included in both reinforces the 
need for Europe-wide guidance on NTI drugs. These active substances were 
part of the top 10 active substances (per solid or liquid dosage forms) in all 
countries, with exception of 3 countries for phenobarbital and spironolactone, 
and only 2 countries for glucose. Therefore, oral compounded medicines 
including these 3 active substances, in particular, should be the considered 
for licensing or prioritised for standardisation in official (European) 
monographs. This finding suggests that although there are active substances 
common to most European countries, dosage forms may vary remarkably 
between countries. As a result, the compounded medicines dispensed are 
deemed to be country-specific and, therefore, there is a high need for 
harmonisation of compounding practices across Europe. 
14.4.4 Oromucosal preparations 
Although the aim of the research was to identify and characterise the most 
frequently dispensed oral compounded medicines, some hospital pharmacies 
also shared data regarding oromucosal preparations. These medicines were 
either specifically classified by hospital pharmacies as oromucosal or, 
alternatively, the additional comments to their use clearly suggested that 
these were not oral compounded medicines, but rather oromucosal 
preparations. This finding suggests that the classification of oral liquids and 
oromucosal preparations is not always clear in hospital pharmacies and, 
therefore, it highlights the need for a better understanding of the 
compounded medicines dispensed to patients. The safety of raw materials in 
oral liquids and oromucosal preparations is not the same because different 
routes of administration are implied, and these issues have to be 
acknowledged when preparing compounded medicines.  
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Oromucosal preparations were reported in all European countries, with the 
exception of Poland, Slovenia and France (Table 14.18). The number of 
participant hospitals that reported oromucosal preparations varied from 7% 
(Switzerland) to 40% (UK). The European countries that reported the largest 
quantities of multidose units were: Portugal (>16,000 units), Spain and 
Denmark. The oromucosal preparations varied considerably within the 
European countries and only a few were reported in more than 1 country as, 
for instance, the mouthwash for CIOM (Portugal, Spain and Finland). The 
dosage forms reported included mouthwashes (mainly), oromucosal liquids 
(solutions and suspensions), semi-solid oromucosal preparations (gels, 
ointments and pastes) and gargles. There is evidence of oromucosal 
preparations being dispensed in large quantities (e.g. oral decontamination 
suspension; 2-6 L), which suggests that not all oromucosal preparations were 
prepared for individual patients but instead for the hospital wards. Since the 
request for data specifically referred to oral compounded medicines, the list 
included in Table 14.18 is not comprehensive as more European hospitals 
might have dispensed additional oromucosal preparations but excluded this 
information from the dataset. 
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Table 14.18 Oromucosal preparations dispensed per European country and the respective 
participant hospitals and quantities dispensed. 
European 
countries 
Participant 
hospitals Oromucosal preparations 
Quantities 
dispensed 
Portugal 28% 
1. Mouthwash for CIOM (50-560 mL) 
2. Sodium fluoride gel (20 g) 
3. Artificial saliva (100-1,000 mL) 
> 16,000 
units 
UK 40% 
1. Tranexamic acid 50 mg/mL (100-500 mL) 
2. Knox Mouthwash (100-300 mL) 
3. Folinic acid 3mg/10 mL (200 mL) 
4. Tetracycline 5% (200 mL) 
189 units 
Switzerland 7% 1. Chlorhexidine 0.05% (250 mL) 80 units 
Poland 0% n/a n/a 
Netherlands 33% 
1. Amphotericin B 2% paste (5 g) 
2. Cetrimide 0.1% mouthwash (300 mL) 
3. Chlorhexidine HCl 2% ointment 
4. Colistin sulfate 1 mg/mL mouthwash (100 mL) 
5. Povidone-iodine 1% mouthwash (100 mL) 
6. Sodium fluoride 1% mouthwash and gel  
    (100 mL) 
7. Tacrolimus 1 mg/g paste (30 g) 
1,838 units 
Denmark 14% 1. Chlorhexidine mouthwash 0.12% (300 mL) 2. Lidocaine gel 20% (100 mL) 3,000 units 
Slovenia 0% n/a n/a 
Finland 29% 
1. Miconazole and lidocaine gel (20 g) 
2. Sodium hypochlorite solution 0.5%, 1%  
    (100 mL) 
    Mouthwashes for CIOM 
3. Ergocalciferol solution (100 mL) 
4. Ergocalciferol and vitamin A solution (200 g) 
835 units 
Spain 27% 
1. Anaesthetic solution (500 mL) 
2. Oral decontamination preparation  
    (suspensions 2-6L and ointments 100-500 g) 
3. Mouthwash for CIOM 
4. Gargle solution 
5. Others (12%) 
4,531 units 
France 0% n/a n/a 
Germany 11% 
1. Acriflavinium chloride 5 mg/g (10 g) 
2. Miconazole 20 mg/g (20 g) 
3. Aluminium hydroxide (300 g) 
4. Procaine HCl 10 mg/g (20 g) 
5. Betamethasone, pheniramine maleate and 
    nystatin (225 mL) 
24 units 
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14.5 Conclusions and recommendations 
Pharmaceutical compounding, the preparation of customised medicines in 
order to meet the specific needs of patients, represents the origins of the 
pharmacy profession and, throughout the centuries, it has remained an 
integral part of this profession. Despite the changes in pharmacy practice, in 
particular the advent of industrialised medicine, compounding remains a 
relatively common practice worldwide. In Europe, compounded medicines 
are prepared and dispensed in all countries, but this study has shown that 
the practice varies considerably with regards to legislation, professional 
organisations, information sources and, ultimately, with regards to the oral 
compounded medicines dispensed to patients. 
Legislation regarding pharmaceutical compounding is country-specific in 
relation to terminology and the concept of compounded medicines, which 
potentially contributes to a lack of understanding between health care 
professionals. The requirements for the preparation and QC of compounded 
medicines are also country-specific, which results in variable expectations 
depending on the European country considered. Third-party compounding 
and batch preparation (in advance) are not permitted in all European 
countries. Compounded medicines are mainly prepared in community and 
hospital pharmacies but, in a few countries, these may also be prepared in 
other authorised entities. The same criteria should ideally apply to all 
European countries so that the practice of compounding is harmonised in 
Europe. The PIC/S PE 010-3 and the Resolution CM/ResAP(2011)1 are 
European guidance on pharmaceutical compounding but there is still need 
for adequate (official) Europe-wide standards of practice. 
Professional organisations for pharmaceutical compounding in Europe do not 
yet exist and even national organisations are very limited. Spain is the 
European country (sampled in this research) with the greatest number of 
professional organisations specifically focused on pharmaceutical 
compounding. The only two specialist international organisations available to 
European pharmacists are the ISPhC and the IACP. 
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Information sources on pharmaceutical compounding in Europe are also yet 
to be developed. There are official (and non-official) national formularies but 
no work has been done so far in terms of translating to English and adapting 
any of these formularies to current compounding practices in Europe. There 
are also national pharmacopoeias that address pharmaceutical 
compounding, but the PhEur does not yet consider this practice. There is a 
need for an officially recognised European formulary on pharmaceutical 
compounding and/or a dedicated chapter and specific monographs for 
compounded medicines in the PhEur.  
The oral compounded medicines most frequently dispensed in hospital 
pharmacy varied considerably throughout Europe, from traditional cachets in 
Poland to complex tablets in the Netherlands and Denmark. Oral liquid 
dosage forms were more frequently dispensed than oral solids, which was 
not unexpected considering that oral liquids offer a myriad of advantages to 
both pharmacists and patients. The compounded medicines dispensed were 
reported either by the respective active substance(s), their given titles or by 
the proprietary medicines used in their preparation; placebo compounded 
medicines were also reported. Compounded medicines were prepared 
individually and also in batches of variable sizes, depending on the hospitals 
and the European countries considered. A wide range of active substances, 
including NTI drugs, and dosage strengths were dispensed, which showed 
the diversity of pharmaceutical compounding in Europe and reinforced the 
importance of this practice in current therapeutics. The active substances 
dispensed by most hospitals were spironolactone, captopril and 
hydrochlorothiazide. The active substances most frequently dispensed as 
oral solids and oral liquids Europe-wide were phenobarbital, spironolactone 
and glucose. Therefore, it was recommended that these oral compounded 
medicines, in particular, should be the ones considered for licensing or 
prioritised for standardisation in official (European) monographs. 
This project corresponds to the largest and most complex research in 
pharmaceutical compounding across Europe and aims to contribute to the 
harmonisation of quality and safety of compounded medicines in Europe. 
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14.5.1 Recommendations for further research 
Pharmaceutical compounding in Europe is a research subject that has rarely 
been addressed in the scientific literature. However, there has been an 
increasing interest in this subject by European health care professionals and 
authorities, which stimulated the 2 recent initiatives of EDQM (Sections 14.1 
and 14.2.2).  
This research project constitutes the first extensive and structured analysis of 
pharmaceutical compounding in Europe and it represents a major 
contribution to a better understanding of the current practices within the 
European countries.  Further research is necessary to build on this project so 
that more Europe-wide initiatives are initiated and pharmaceutical 
compounding in Europe progresses, for the benefit of all.  
The aim of this project was to identify and characterise the extemporaneously 
compounded oral medicines most frequently dispensed in European hospital 
pharmacies. A total of 11 European countries were included in the research, 
namely 10 members of the EU and 1 non-member of the EU. There is still 
need to identify and characterise the extemporaneously compounded oral 
medicines most frequently dispensed in hospital pharmacies in all 17 EU 
countries57 and 21 non-EU countries58. 
The research project focused only on oral compounded medicines and there 
is still lack of knowledge regarding non-oral (both sterile and non-sterile) 
compounded medicines dispensed in European hospital pharmacies. 
Considering oral compounded medicines, further research is necessary to 
identify the formulae, source of raw materials (i.e. proprietary medicines or 
bulk), method of preparation, QC and beyond-use-dates for the most 
frequently dispensed oral compounded medicines, per country and across 
Europe. A risk assessment should be undertaken and the oral compounded 
medicines identified at a higher risk (e.g. NTI drugs), should also be 
considered for further research. 
                                            
57Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Estonia, Greece, Hungary, Ireland, 
Italy, Latvia, Lithuania, Luxembourg, Malta, Romania, Slovakia and Sweden. 
58Albania, Andorra, Armenia, Azerbaijan, Belarus, Bosnia-Herzegovina, Croatia, Former 
Yugoslav Republic of Macedonia, Georgia, Iceland, Liechtenstein, Moldova, Monaco, 
Montenegro, Norway, Russia, San Marino, Serbia, Turkey, Ukraine and Vatican City State. 
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The present research project consisted of a retrospective analysis of the 
compounding records and, almost always, no information was found 
regarding the patient and the evidence-base for the compounded medicines 
dispensed. There is a need for prospective studies on pharmaceutical 
compounding in Europe including data on patient information, clinical need 
and evidence-based analysis. 
Compounded medicines are not always prepared extemporaneously as one-
off preparations but, instead, these medicines are frequently prepared in 
advance in “small” batches: studies should be undertaken to clearly 
distinguish these 2 practices. Moreover, the facilities and equipment used in 
the preparation of compounded medicines vary within hospital pharmacies 
and also between countries. Country-specific compounding practices and 
issues should be explored in-depth by means of interviews with pharmacy 
staff.  
Not all compounded medicines dispensed in the hospital setting are actually 
prepared at the respective hospital pharmacies and there is currently a lack 
of knowledge regarding the source of the medicines dispensed. For instance, 
further research is necessary to identify and characterise the specials 
prepared at specials manufacturers in the UK. 
The research project did not include an analysis of the staff at hospital 
pharmacies and no information was collected regarding the size and level of 
education of the staff involved in pharmaceutical compounding. This 
information is important as it contributes to a better understanding of current 
compounding practices per country. In addition, pharmacists and pharmacy 
technicians are taught pharmaceutical compounding during graduate and/or 
at post-graduate courses. The information taught strongly influences current 
practices per country. Research should also be undertaken to distinguish 
teaching of pharmaceutical compounding throughout Europe. 
Very little research has been undertaken regarding the community setting 
and there is a need to identify and characterise the oral and non-oral (both 
sterile and non-sterile) compounded medicines most frequently dispensed in 
European community pharmacies. 
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14.5.2 Recommendations for further initiatives 
• Establishment of an official concept of compounded medicines, including types and 
definitions, common to all European countries. A clear distinguish should be made in relation 
to standardised (small and large scale) and non-standardised compounded medicines.  
• Development of Europe-wide official and enforceable compounding legislation, based on 
standard operating procedures and not on industrial GMP (certified facilities). A clear 
distinguish should be made between SOP and individualised medicines: the way forward is 
the standardisation of practices and not the standardisation of medicines, which is 
incompatible with individualised therapy. Europe-wide legislation should include allowance of 
third-party compounding, batch preparation, use of all authorised active substances (no 
negative lists) and exceptional use of commercial medicines in compounding across Europe.  
• Establishment of mandatory quality control tests (for all types of compounded medicines) 
and development of standardised legal requirements for labelling compounded medicines.  
• Development of a Europe-wide professional organisation specifically focused on 
pharmaceutical compounding. Organisation of compounding educational events and courses 
for pharmacists, doctors and all health care professionals involved in this practice throughout 
Europe. 
• Inclusion of a compounding dedicated chapter on the PhEur, addressing not only the 
official concept of compounded medicines Europe-wide but also reference formulas and 
SOP. Development of an official (or non-official) European formulary for pharmaceutical 
compounding, including the extensive work previously published in national formularies so 
that there is no duplication of time and efforts. Likewise, development of a Europe-wide 
textbook on pharmaceutical compounding based on national textbooks of reference. 
• Development of an official list of NTI drugs and official guidelines for compounding these 
potentially toxic active substances. Development of an international reference list of 
compounded medicines commonly known by given titles (non-proprietary names). 
• Licensing, or prioritised for standardisation in official (European) monographs, of the most 
frequently dispensed oral compounded medicines in hospital pharmacies across Europe. 
• Development of an official register of compounding pharmacies (hospital, community and 
other settings), per European country, including the contact details of the responsible 
pharmacists. Development of an official template for registering all compounded medicines 
dispensed, preferably in a digital format to easy traceability. Establishment of mandatory 
periodical reports of large scale compounded medicines to national authorities (following the 
example of France). 
• Teaching of modern pharmaceutical compounding at the university level by updating the 
academic curriculum to current Europe-wide practices. Establishment of mandatory 
compounding continuing education across Europe. 
• Establishment of governmental or private compounding consulting companies to support 
and reinforce quality compounding Europe-wide. 
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Appendix 1 
NTI drugs 
List of active substances with a narrow therapeutic index (NTI drugs) 
classified by therapeutic groups (adapted from ANVISA, 2007) 
 
Therapeutic groups Active substances 
Antibacterials Clindamycin 
Antidepressants Lithium 
Antiepileptics 
Carbamazepine 
Oxcarbazepine 
Phenytoin 
Primidone 
Valproic acid 
Antigout drugs Colchicine 
Anxiolytic, sedatives, hypnotics and antipsychotics Clozapine 
Bronchodilators and anti-asthma drugs 
Aminophylline 
Theophylline 
Cardiovascular drugs 
Clonidine 
Digitoxin 
Digoxin 
Disopyramide 
Minoxidil 
Prazosin 
Procainamide 
Quinidine 
Verapamil HCl 
Warfarin 
Immunosuppressants Ciclosporin 
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Appendix 2 
Compounding formulary 
 
Compounded medicines Formulas 
Chloral hydrate 50 mg/mL oral liquid 
(Allen, 2006c) 
Chloral hydrate           5 g 
Purified water           10 mL 
Syrup                  to 100 mL 
Chloral Elixir, Paediatric BPC 
(Council of the Pharmaceutical Society of Great Britain, 1973) 
Chloral hydrate                40 g 
Water                               20 mL 
Black currant syrup        200 mL 
Syrup                       to 1,000 mL 
Chloral Mixture BPC 
(Chloral Hydrate Mixture) 
(Council of the Pharmaceutical Society of Great Britain, 1973) 
Chloral hydrate             100 g 
Syrup                            200 mL 
Water                     to 1,000 mL 
Golytely 
(powders for oral liquids) 
(Braintree Laboratories, 2001) 
Macrogol 3350                         236 g 
Sodium bicarbonate                6.74 g 
Sodium chloride                      5.86 g 
Potassium chloride                 2.97 g 
Sodium sulfate (anhydrous)  22.74 g 
(Purified water                   to 4,000 mL) 
Methadone HCl 10 mg/mL Oral Solution 
(Swissmedic, 2006a) 
Methadone HCl                        5 g 
Methylparaben                  0.335 g 
Propylparaben                  0.144 g 
Propylene glycol                 9.52 g 
Purified water                   to 500 mL 
Polypharmacy (example) 
(Section 6.4.2) 
Paracetamol               300 mg 
Diazepam                       2 mg 
Codeine                        15 mg 
Prednisone                     5 mg 
Dipyrone                     300 mg 
Syrup BP 
(BP Commission, 2008a) 
Sucrose                         667 g 
Purified water          to 1,000 g 
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Appendix 3 
Number of hospitals and hospital beds 
(adapted from WHO Regional Office for Europe, 2010) 
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Appendix 4 
Number of pharmacists 
(adapted from WHO Regional Office for Europe, 2010; 2011) 
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Appendix 5 
Phenobarbital 1% Oral Suspension (FGP 2005) 
(adapted from CETMED, 2001) 
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Appendix 11 
Dermatological drugs and sunscreens 
Active substances included in this therapeutic group were reported by only 4 
European countries (Portugal, UK, Finland and Spain), as follows: 
• Acitretin: is a retinoid that is given orally for the treatment of severe psoriasis resistant to 
other forms of therapy (Martindale 35, 2007). Acitretin was reported as an oral suspension (1 
mg/mL) / special by 1 UK hospital and as capsules (8 mg) by 1 Spanish hospital. 
• Salicylic acid: is applied topically for its keratolytic and caustic properties, depending on 
the concentrations used (Martindale 35, 2007). It was reported as 15 mg sachets by only 1 
Portuguese hospital but, because of the similarities between salicylic acid and acetylsalicylic 
acid (aspirin), a frequently dispensed active substance in Portugal, it is likely that the hospital 
pharmacy dispensed aspirin instead. 
• Tretinoin: is a retinoid (acid form of vitamin A) that is mainly applied topically for the 
treatment of acne vulgaris but it is also given orally (Martindale 35, 2007). Tretinoin was 
reported as capsules of variable strengths by only 1 hospital in Spain. 
• Urea: is mainly applied topically in the treatment of ichthyosis and hyperkeratotic skin 
disorders. Nevertheless, urea has other therapeutic indications and may also be given 
intravenously and orally (Martindale 35, 2007). For instance, oral urea has been successfully 
used in the management of children with chronic syndrome of inappropriate antidiuretic 
hormone secretion (SIAD) (Huang et al., 2006). Oral urea was reported in Finland as 
capsules (75 mg) by only 1 hospital and in Portugal as sachets (20-30 g) by another hospital. 
 
  
 Appendix 12 | 415 
 
Appendix 12 
Disinfectants and preservatives 
Active substances included in this therapeutic group were reported by all 
European countries, with the exception of Slovenia, as follows: 
• Acriflavinium chloride: is an acridine derivative, a slow-acting antiseptic, which has been 
used in the treatment of oropharyngeal infections (Martindale 35, 2007). It was reported in 
Germany as an oromucosal preparation. 
• Alcohol: was reported by 1 French hospital as an oral solution of alcohol and menthol, 
which is mainly used to relieve symptoms of bronchitis, sinusitis and other similar conditions 
(Martindale 35, 2007). 
• Butylated hydroxyanisole and butylated hydroxytoluene: are antioxidants frequently used 
in combination (Martindale 35, 2007) and were reported as capsules of 5 mg and 25 mg (of 
each) by 1 French hospital. 
• Cetrimide: is a quaternary ammonium antiseptic that is used as an aqueous solution in 
concentrations of 0.1 to 1% for cleansing skin, wounds and burns (Martindale 35, 2007). It 
was reported as an oromucosal preparation 0.1% (300 mL) by 1 Dutch hospital. 
• Chlorhexidine: is an antiseptic and disinfectant that is used as oral gels, sprays and 
mouthwashes for the treatment of mouth infections and to reduce dental plaque 
accumulation (Martindale 35, 2007). It was reported as oral and oromucosal preparations in 
5 European countries, namely: Portugal (alone and in combination), Switzerland, 
Netherlands (chlorhexidine HCl), Denmark and Spain (chlorhexidine and also chlorhexidine 
gluconate in combination), by a total of 8 European hospitals. Chlorhexidine was reported as 
oral and oromucosal solutions (0.05-1%, 4 strengths; 50-500 mL) and ointments (2%). 
• Hexetidine: is a bactericidal and fungicidal antiseptic frequently used as a mouthwash 
0.1% in the treatment of local infections and oral hygiene (Martindale 35, 2007). It was 
reported in Spain (1 hospital) as an oromucosal preparation (anaesthetic solution) including 
nystatin, mepivacaine HCl, sodium bicarbonate and hexetidine. 
• Hydrogen peroxide: is an oxidising agent used as an antiseptic for the disinfection of 
mucous membranes (Martindale 35, 2007). It was used as a solution in mouthwashes for 
CIOM in Spain (2 hospitals).  
• Potassium/sodium metabisulfite: sulphites are strong reducing agents and are used as 
antioxidants (Martindale 35, 2007). Metabisulfite was reported in Spain as capsules of 5 and 
100 mg (1 hospital). Potassium metabisulfite, in particular, was reported as capsules of 10 
and 20 mg by 1 French hospital. Sodium metabisulfite, on the other hand, was reported in 
the UK, Netherlands, France and Spain, both as capsules (1-200 mg; 7 strengths) and 
powders for oral liquids (25 mg), by a total of 5 European hospitals. 
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• Povidone-iodine: is an iodophore that is used as a disinfectant and antiseptic; it has been 
used as a 1% mouthwash for oral infections, including candidiasis (Martindale 35, 2007). It 
was reported by only 1 Dutch hospital as a 1% mouthwash (100 mL). 
• Sodium benzoate: is used in the treatment of hyperammonaemia and in nonketotic 
hyperglycinaemia; it is also a common ingredient in cough preparations (Martindale 35, 
2007). It was reported in 7 European countries, namely: Portugal, UK (both as specials and 
extemporaneous preparations), Switzerland, Poland (in combination with multiple active 
substances), Netherlands, Finland and Spain, by a total of 19 European hospitals. Sodium 
benzoate was reported as oral liquids (2-250 mg/mL, 5 strengths; 100-1,000 mL), capsules 
(100 and 500 mg), oral powders (0.85-3 g) and cachets. 
• Sodium hypochlorite: is a disinfectant and antiseptic (with the brief and rapid actions of 
chlorine) that is used in dentistry as 0.5-5.25% solutions (Martindale 35, 2007). It was 
reported only in Finland (1 hospital) as 0.5 and 1% oromucosal preparations (dental 
solutions). 
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Appendix 13 
Paraffins and similar bases 
Active substances included in this therapeutic group were reported by only 3 
European countries (Portugal, UK and Switzerland), as follows: 
• Cholesterol: Oral cholesterol is included in compounding formularies as, for instance, 150 
mg/mL suspension (Nationwide Children’s Hospital, 2010) and 200 mg/mL suspension (IWK 
Health Centre, 2009). Cholesterol was reported as oral solids in Portugal (300 mg oral 
powders) and Switzerland (200 mg capsules), by a total of 2 hospitals; and also as an oral 
liquid (100 mg/mL solution) in the UK, by only 1 hospital.  
• Liquid paraffin: oral liquid paraffin has been used as a lubricant and in the symptomatic 
treatment of constipation, in volumes up to 45 mL daily (Martindale 35, 2007). It was 
reported by 2 Swiss hospitals as an oral liquid of 200 mL and 500 mL, respectively. 
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Appendix 14 
Stabilising and suspending agents 
Active substances included in this therapeutic group were reported by only 4 
European countries (Portugal, Netherlands, Finland and Spain), as follows: 
• Carmellose: has a variety of uses in pharmaceutical manufacturing but it is also given 
orally in the treatment of constipation and management of obesity (Martindale 35, 2007). 
Carmellose was reported by 1 Portuguese hospital as an oral liquid (solution) 1%. 
• Cellulose: although primarily used in pharmaceutical manufacturing, various forms of 
cellulose have been used in constipation and obesity (Martindale 35, 2007). Cellulose was 
reported as capsules in the Netherlands and also in Spain (capsules of microcrystalline 
cellulose 200 g), by a total of 2 hospitals. 
• Ceratonia: is commonly used in combination with an osmotic carbohydrate sugar alcohol 
for small bowel distension for magnetic resonance imaging (Ajaj et al., 2004). Ceratonia was 
reported in Portugal (1 hospital) as an oral suspension (2,000 mL) in combination with 
sorbitol and in Finland (1 hospital) as an oral solution (750 mL) in combination with mannitol. 
• Methylcellulose: is widely used in pharmaceutical manufacturing as an emulsifying, 
suspending and thickening agent. However, oral methylcellulose is also used clinically as, for 
example, a bulk laxative in the treatment of constipation and the control of faecal consistency 
in ostomies (Martindale 35, 2007). Methylcellulose was reported in Portugal as an oral liquid 
(solution) 0.5% and 1% (2 hospitals); in the Netherlands as an oral liquid (300 mL - 1L) 
0.5%, 1% and 2% (3 hospitals); in Finland as an oral liquid (solution) 1% (2 hospitals); and, 
finally, in Spain as an oral liquid (both solutions and suspensions) 1% and oral powders 
(sachets) 7.5 g, by a total of 3 hospitals. In Finland, it was reported that the methylcellulose 
solution was indicated for enterography. Nevertheless, because methylcellulose solutions (of 
variable strengths) are commonly used as vehicles in pharmaceutical compounding, it is 
likely that some of the oral liquids reported by the European hospitals corresponded, instead, 
to vehicles for the preparation of oral compounded medicines. 
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Appendix 15 
Supplementary drugs and other substances 
This therapeutic group includes monographs for drugs which are not easily 
classified, new drugs whose place in therapy is not yet clear and drugs no 
longer used clinically but still of interest; it also includes herbal medicines 
(Martindale 35, 2007). Active substances included in this group were reported 
by all European countries, as follows:  
• Ammonia: oral solutions of ammonia (diluted) have been administered as reflex 
stimulants (Martindale 35, 2007). Ammonia aniseed (oral solution) was reported by 1 
hospital in Switzerland and ammonia spirit aniseed (as part of an anti-cough preparation) 
was reported by 2 Dutch hospitals. 
• Amylase: is commonly included in preparations of digestive enzymes and is given orally 
to reduce the respiratory-tract inflammation, local swelling and oedema (Martindale 35, 
2007). It was reported as oral powders, in combination with protease and amylase (digestive 
enzymes, Appendix 26), by 1 Slovenian hospital. 
• Belladonna: has been used for its antimuscarinic actions but is now considered an 
obsolete therapeutic option (Martindale 35, 2007). It was reported as belladonna tincture by 
1 Spanish hospital. 
• Betaine: is given orally in the treatment of patients with homocystinuria in usual doses of 
3 g twice daily (Martindale 35, 2007). It was reported in Portugal (1 hospital) as oral powders 
(3 g). 
• Bethanechol chloride: is a muscarinic parasympathomimetic that is used for its activity on 
the bladder and GI tract (Martindale 35, 2007). It was reported as capsules (0.3-20 mg) in 
Spain and France and as an oral solution (1 mg/mL) in France, by a total of 4 hospitals. 
• Borax and boric acid: have similar uses and should not be used internally. Preparations 
of borax in glycerol or honey were formerly used as paints for the throat, tongue and mouth 
but should no longer be used because of toxicity risks (Martindale 35, 2007). Borax was 
reported by 1 Portuguese hospital as oral powders (30 g) and by 2 Spanish hospitals as a 
gargle solution (in combination with other substances). Boric acid was reported by 2 
Portuguese hospital as oral powders (100 g). 
• Bromides (ammonium, sodium and potassium): bromides depress the CNS; potassium 
and sodium bromide have been used as sedatives and anticonvulsants but are considered 
toxic and have been replaced by more effective and less toxic drugs (Martindale 35, 2007). 
Bromides were reported in Poland and mainly as part of the oral solutions: sol. sal. 
erlenmayeri and mixture nervinae (Appendix 16). Potassium bromide was also reported in 
Denmark (1 pharmacy) as an oral solution 6.5% (500 mL); and in Germany (1 hospital) as 
capsules (425, 848 and 850 mg). 
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• Calcium hydroxide: is a weak alkali frequently indicated for external use (Martindale 35, 
2007) but was reported, in combination with barium sulfate, as (oral) capsules (14.6-176 mg) 
by 1 French hospital. Since the identification of the French hospitals was not disclosed by 
AFSSAPS (Section 12.3), it was not possible to check the (oral) therapeutic use of these 
compounded medicines. 
• Cannabis: the major psychoactive constituent of cannabis is dronabinol, which is used as 
an antiemetic in patients receiving chemotherapy; it is also reported to have analgesic, 
muscle relaxant and appetite stimulant effects (Martindale 35, 2007). It was reported only in 
the Netherlands (4 hospitals) as oral powders (125 g), powders for oral liquids (0.5 and 1 g) 
and oral solutions (1 mg/mL, 100 mL). 
• Cellulase: is used orally in minor digestive disorders, as dyspepsia and flatulence 
(Martindale 35, 2007) and was reported in Spain (1 hospital) as capsules (10 mg). 
• Cinchona bark: is constituted by several alkaloids, including quinine and quinidine, and is 
indicated for malaria (Martindale 35, 2007). It was reported as capsules in France (1 
hospital), as part of the proprietary medicine Quinimax (quinine, quinidine and cinchona 
bark).  
• Citric acid: is used to dissolve renal calculi, alkalinise the urine and prevent encrustation 
of urinary catheters. It is also used for the management of dry mouth, treatment of coughs, 
GI disturbances and metabolic acidosis (Martindale 35, 2007). It was reported in 5 European 
countries, namely: UK (in combination with citrate salts and named tricitrates oral solution, 
specials only), Poland, Netherlands (in combination with glycerol), Denmark (in combination 
with glycerol and as monohydrate) and Slovenia (in combination with multiple active 
substances and named laxative salts) and by a total of 6 European hospitals. Citric acid was 
reported as oral solutions (5 and 10%), capsules, oral powders (100 g) and cachets (0.5 g). 
Citric acid is also part of the Shohl’s Solution (Appendix 16), which was reported in Portugal 
and Spain, by a total of 4 hospitals. 
• Cobalt chloride: although not commonly used in therapy because of safety concerns, it 
may be indicated in the treatment of certain types of anaemia as it produces reticulocytosis 
and a rise in the erythrocyte count (Martindale 35, 2007). It was reported only in France (1 
hospital) as capsules of 4.75 mg. 
• Crataegus: has flavonoid glycosides with cardiotonic properties (Martindale 35, 2007) and 
was reported in Poland (1 hospital) as an oral solution (in combination with multiple active 
substances). 
• Creatine: is an endogenous substance used in cardiac and metabolic disorders, as well 
as a dietary supplement (Martindale 35, 2007). It was reported by 1 Portuguese hospital as 
oral powders of 3 g. 
• Diphemanil metilsulfate: is usually indicated for external use but has been investigated 
orally for the treatment of symptomatic bradycardia in infants (Martindale 35, 2007). It was 
reported in France as capsules (1-50 mg; 9 strengths) and oral solutions (10 mg/mL), by a 
total of 5 hospitals. 
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• Disulfiram: inhibits aldehyde dehydrogenase, the enzyme responsible for the oxidation of 
acetaldehyde (a metabolite of alcohol), resulting in increased blood levels of acetaldehyde, 
which is responsible for unpleasant symptoms and, therefore, is used as an adjunct in the 
treatment of chronic alcoholism. Disulfiram was reported as an oral suspension (40 mg/mL, 
500 mL) by only 1 Danish pharmacy. 
• Drotaverine: is an antispasmodic used in the management of biliary and urinary-tract 
spasm and also GI spasm (Martindale 35, 2007). It was reported as cachets (10 mg) by 1 
Polish hospital only. 
• Fluorescein: the sodium salt has been given orally for angiography and the dilaurate salt 
for the assessment of exocrine pancreatic function (Martindale 35, 2007). It was reported in 
Portugal only (1 hospital) as oral powders of 5 g. 
• Glycerol: is an osmotic dehydrating agent that is given orally for the short-term reduction 
of vitreous volume and intra-ocular pressure and as an adjunct in the management of acute 
glaucoma; it is also used to reduce intracranial pressure and as a demulcent in cough 
preparations (Martindale 35, 2007). Glycerol was reported in 5 European countries, namely: 
Portugal, UK, Netherlands (in combination with citric acid), Denmark and Spain, and by a 
total of 10 European hospitals. It was reported as oral solutions (50, 60 and 62.8%), syrups 
(20%) and as a gargle solution (in combination with other substances). 
• Glycopyrronium bromide: is a quaternary ammonium antimuscarinic used orally as an 
adjunct in the treatment of peptic ulcer disease (Martindale 35, 2007). It was reported in the 
UK and the Netherlands as an oral liquid (0.5, 1 and 5 mg/5mL; 50-300 mL) by a total of 2 
hospitals. 
• Hydrochloric acid: is used diluted as an escharotic in the treatment of achlorhydria and in 
other GI disorders (Martindale 35, 2007). It was reported only in the Netherlands (1 hospital) 
as a syrup 1.1 mg/mL (300 mL). 
• Indigo carmine: is usually administered by IV or intramuscular injection (Martindale 35, 
2007) but it is also used orally in routine chromoendoscopy for GI diseases (Kida et al., 
2003). It was reported in Portugal and France as an oral liquid (0.3, 0.8 and 1%) and as 
capsules (300 mg), by a total of 4 hospitals.  
• Lipase (see amylase and Appendix 26). 
• Macrogols: are a group of substances that have different activities according to their 
molecular weight. These may be administered with electrolytes in bowel preparation before 
colonoscopy, radiological procedures and surgery; and may also be used in chronic 
constipation and faecal impaction (Martindale 35, 2007). Macrogols (and Macrogols 3000 
and 4000, in particular) were reported in 5 European countries, namely: UK, Switzerland, 
Netherlands (in combination with electrolytes and indicated as a laxative), Slovenia 
(indicated for pre-colonoscopy bowel emptying; also in combination with other substances) 
and Germany, by a total of 7 European hospitals. Macrogols were reported as oral solutions 
(300-3,000 mL) and oral powders (0.5 g, 15 g, 100 g and 300 g). 
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• Manuka: has antimicrobial properties (Martindale 35, 2007) and it was dispensed as oral 
powders (80 g) by only 1 UK hospital (as a special). 
• Melatonin: has been tried in several disorders and may be beneficial in malignant 
neoplasms, hyperlipidaemias, cluster headaches, tinnitus, alopecia in women and irritable 
bowel syndrome associated with sleep disturbances (Martindale 35, 2007). Melatonin was 
reported in 6 European countries, namely: Switzerland, Netherlands, Denmark, Spain, 
France and Germany, by a total of 22 European hospitals. It was reported as tablets (3 mg) 
and capsules (0.5-10 mg; 12 strengths). 
• Menthol (see alcohol in Appendix 12). 
• Methacholine chloride: is a quaternary ammonium parasympathomimetic with the 
muscarinic actions of acetylcholine (Martindale 35, 2007). It was reported in Portugal (1 
hospital) as oral powders (75 mg). 
• Miglustat: is an inhibitor of the glucosylceramide synthase and is indicated in the type 1 
Gaucher disease and in the type C Niemann-Pick disease (Martindale 35, 2007). It was 
reported in Portugal (1 hospital) as oral powders (35 mg). 
• Monosodium glutamate: is a sodium salt of the amino acid glutamic acid that is commonly 
used as a flavour enhancer agent (Martindale 35, 2007). Clinically, there is some preliminary 
evidence of the benefits of monosodium glutamate as, for example, in improving nutritional 
status and well being in elderly individuals (Yamamoto et al., 2009). Monosodium glutamate 
was reported in the UK and the Netherlands as capsules (200 mg) and oral powders (100, 
250, 500 and 1,000 mg), by a total of 2 hospitals. 
• Nitisinone: is used in hereditary metabolic disorders, as the tyrosinaemia type 1 and 
alkaptonuria (Martindale 35, 2007). It was reported only in Spain (1 hospital) as oral powders 
1.5 mg. 
• Pancreatic enzymes (such as pancreatin or pancrelipase): are responsible for the 
hydrolyse of fats, break down of proteins and conversion of starch; these enzymes are given 
orally in conditions of pancreatic exocrine deficiency and the dose is usually adjusted 
according to the individual needs of patients (Martindale 35, 2007). Pancreatin was reported 
in 5 European countries, namely: Portugal, Poland, Netherlands, Spain and Germany, by a 
total of 10 hospitals. It was reported as oral solids (capsules, oral powders and cachets; 100-
15,000 IU; 50-275 mg) and oral liquids (2,000 IU/mL). 
• Papain: is used orally for its anti-inflammatory activity or to aid digestion (Martindale 35, 
2007). It was reported as a syrup by only 1 French hospital. 
• Patent blue V: is usually administered intravenously to colour the lymph vessels 
(Martindale 35, 2007) but was reported as (oral) capsules (2.5 mg) by 1 French hospital. 
Since the identification of the French hospitals was not disclosed by AFSSAPS (Section 
12.3), it was not possible to check the (oral) therapeutic use of this compounded medicine. 
• Phosphoric acid: is used well diluted in medicines intended for the management of 
nausea and vomiting (Martindale 35, 2007). It was reported as an oral solution in Finland 
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(500 mL) and France (10%); and as part of Joulie’s Solution (Appendix 16) in Spain, by a 
total of 3 hospitals. 
• Phosphorus: elemental phosphorus is no longer used in medicine but the inorganic 
phosphates have several oral indications (Martindale 35, 2007). Phosphorus was reported 
by 3 Spanish hospitals - as an oral solution (10 mg/mL) and capsules (25 and 50 mg) - but it 
is likely that the respective inorganic phosphates were used instead. 
• Potassium bromide (see bromides). 
• Protease (see amylase and Appendix 26). 
• Quercetin: is a flavonoid and, therefore, may be used to relieve capillary impairment, 
venous insufficiency and haemorrhoids (Martindale 35, 2007). It was reported in Spain only 
(1 hospital) as capsules of 50 mg. 
• Riluzole: is indicated in a motor neuron disease (amyotrophic lateral sclerosis) and the 
usual oral dose is 50 mg twice a day (Martindale 35, 2007). It was reported in France only (1 
hospital) as capsules of 50 mg. 
• Sodium carbonate: is used in antacid preparations (Martindale 35, 2007) and was 
reported as capsules (50 and 200 mg) in the Netherlands only (1 hospital). 
• Sodium phenylbutyrate: is a prodrug for sodium phenylacetate and is used in patients 
with urea cycle disorders as an adjuvant treatment for hyperammonaemia (Martindale 35, 
2007). It was reported as oral liquids (200, 250 mg/mL and 250 mg/5 mL; 100 mL) in the UK 
(specials only), Netherlands and Spain; and also as capsules (100 mg) in Finland and 
sachets in Spain, by a total of 6 European hospitals. 
• Strychnine nitrate: has a central stimulant effect and has been used in multi-ingredient 
preparations for the treatment of ophthalmic and urinary-tract disorders; and also in the 
treatment of nonketotic hyperglycinaemia (Martindale 35, 2007). It was reported as oral 
solutions (1 and 4 mg/mL) in Portugal and Switzerland; and also as oral powders in Portugal, 
by a total of 2 hospitals. 
• Taurine: is an aminoacid used as an essential nutrient; it is also included in preparations 
for cardiovascular and metabolic disorders (Martindale 35, 2007). It was reported only in 
Spain and Germany as capsules (30, 200 and 300 mg) by a total of 3 hospitals. 
• Tetrabenazine: is used in the management of movement disorders (such as chorea, 
ballism, dystonias, tardive dyskinesia) and other similar symptoms of CNS dysfunction 
(Martindale 35, 2007). It was reported in the UK as an oral suspension (25 mg/5mL; 150, 
200 and 300 mL) and in the Netherlands as capsules (1 mg), by a total of 3 hospitals. 
• Thalidomide: is used for the treatment and prevention of type 2 lepra reactions; multiple 
myeloma refractory to standard therapies; primary brain malignancies; and several other 
conditions whose aetiology may involve the immune system (Martindale 35, 2007). It was 
reported as capsules (10, 50 and 100 mg) in Switzerland, Finland and Spain, by a total of 7 
hospitals. 
• Thyme: is mainly used in preparations for respiratory-tract disorders for its carminative, 
antiseptic, antitussive and expectorant activities (Martindale 35, 2007). It was reported in 
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Poland (1 hospital) as thyme syrup (in combination with multiple active substances) and 1 
Germany (1 hospital) as a mixture (100 mL). 
• Tolonium chloride: may be used to stain oral and gastric neoplasms or to treat menstrual 
disorders and methaemoglobinaemia (Martindale 35, 2007). It was reported as an oral 
solution 1% by only 1 French hospital. 
• Tormentil: is used for its astringent properties in preparations for diarrhoea and other 
indications (Martindale 35, 2007). It was reported only in Germany (1 hospital) as capsules 
of 5 and 10 mg. 
• Trypsin: is a proteolytic enzyme that has been used orally, frequently associated with 
other substances, in the relief of oedema, inflammation and several GI disorders (Martindale 
35, 2007). It was reported only in the Netherlands as powders for oral liquids (100 mL). 
• Ubidecarenone: is given orally in conditions associated with coenzyme deficiency, as an 
adjunct in cardiovascular disorders and as dietary supplement (Martindale 35, 2007). It was 
reported in Portugal (1 hospital) as oral powders (7 mg) and in Spain (2 hospitals) as 
capsules (30, 50 and 150 mg). 
• Ursodeoxycholic acid: is a naturally occurring bile acid that is used for dissolution of 
cholesterol-rich gallstones (in patients with functioning gallbladders) and in primary biliary 
cirrhosis (Martindale 35, 2007). Ursodeoxycholic acid was reported in 8 European countries, 
namely: Portugal, Switzerland, Poland, Netherlands, Finland, Spain, France and Germany, 
by a total of 67 European hospitals. It was reported as oral solids (capsules, oral powders 
and cachets; 5-1,600 mg; 41 strengths) and oral liquids (solutions, suspensions and syrups, 
both unidose and multidose; 15-60 mg/mL; 5 strengths; 1-300 mL). 
• Valerian: has been used as a sedative and also as a carminative (Martindale 35, 2007) 
and was reported in Poland (2 hospitals) as oral liquids (in combination with multiple active 
substances). 
• Vanillin: is used as a flavour (Martindale 35, 2007) but was as reported as an oral solution 
(10 mg/mL) by 1 German hospital. Since the identification of the German hospitals was not 
disclosed (Section 13.3), it was not possible to check the (oral) therapeutic use of this 
compounded medicine. 
• Xylose: is given orally to test absorption from the GI tract, usually in a dose of 5 or 25 g 
with up to 700 mL of water (Martindale 35, 2007). It was reported as oral powders in Portugal 
(25 g), UK (5 g), Spain (25 g), France (25 g) and Germany (4.5-22g; 10 strengths), by a total 
of 7 hospitals. 
• Zinc orotate: is a salt of orotic acid and has been used as a mineral source (Martindale 
35, 2007). It was reported only in Germany (1 hospital) as capsules of 6.25 mg. 
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Appendix 16 
Given titles59 formulary 
 
Compounded medicines 
Given titles Formulas 
Albright's Solution 
(Shohl’s Solution, modified) 
(Allen, 2005g) 
Citric acid              6.68 g 
Sodium citrate          10 g 
Purified water     to 100 mL 
Gargle Solution 
(Comité del Formulario Nacional, 2007) 
Glycerol                        10 g 
Sodium bicarbonate       1 g 
Borax                              1 g 
Spearmint oil             0.05 mL 
Purified water         to 100 mL 
Hoestdrank FNA 
(WINAp, 2004) 
Ammonium chloride                  2 g 
Liquorice                                   2 g 
Ammonia spirit aniseed            1 g 
Methyl hydroxybenzoate      150 mg 
Purified water                    95.85 g 
Joulie's Solution 
(Allen, 2005h) 
Dibasic sodium phosphate,  
heptahydrate                        13.6 g 
Phosphoric acid                     3.5 mL 
Methylparaben                      100 mg 
Propylparaben                         50 mg 
Purified water                    to 100 mL 
Knox Mouthwash* 
(Jackson and Lowey, 2010) 
Triamcinolone acetonide         500  µg/mL 
Erythromycin ethyl succinate  47.5 mg/mL 
*Preferred formula 
Lugol's Solution (5%) 
(Aqueous Iodine Oral Solution BP) 
(BP Commission, 2008a) 
Iodine                                   50 g 
Potassium iodide               100 g 
Purified water*            to 1,000 mL 
*freshly boiled and cooled 
Lugol's Solution (Weak) (0.015%) 
 (Comité del Formulario Nacional, 2007) 
Iodine                         0.15 g 
Potassium iodide       0.30 g 
Purified water       to 1,000 mL 
Mixture Nervinae 
(Janicki et al., 2003) 
Ammonium bromide       4 g 
Potassium bromide         8 g 
Sodium bromide              4 g 
Purified water          to 200 g 
                                            
59 For the purposes of this research, given titles are non-proprietary names attributed to 
specific compounded medicines. 
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Concentrated Peppermint Emulsion BP*/BPC 
(BP Commission, 2008a) 
*replaced Concentrated Peppermint Water BP  
(Marriot et al., 2010) 
 
 
 
(Council of the Pharmaceutical Society of Great Britain, 1973) 
Peppermint oil                              20 mL 
Polysorbate 20                               1 mL 
Double-strength  
chloroform water                        500 mL 
Purified water*                     to 1,000 mL 
*freshly boiled and cooled 
When diluted with 39 times its volume of 
freshly boiled and cooled purified water, a 
preparation equivalent in strength to 
Peppermint Water BP is produced 
Poção de Todd 
(Potio Cinnamomi spirituosa) 
(Farmacopeia Portuguesa IV, 1946) 
Cinnamon tincture        5 g 
Alcohol 65º                 30 g 
Simple syrup              20 g 
Purified water             45 g 
Shohl's Solution 
(Allen, 2005g) 
Sodium citrate            9 g 
Citric acid                 14 g 
Purified water     to 100 mL 
Simple Linctus, Paediatric BPC/BP 
(Council of the Pharmaceutical Society of Great Britain, 1973) 
 
 
(BP Commission, 2008a) 
Simple Linctus          250 mL 
Syrup                 to 1,000 mL 
Paediatric Simple Linctus is an oral 
solution containing 0.625% w/v of citric 
acid monohydrate in a suitable vehicle 
with an anise flavour 
Sol. Sal. Erlenmayeri  
(Janicki et al., 2003) 
Ammonium bromide        2 g 
Potassium bromide         4 g 
Sodium bromide              4 g 
Purified water          to 200 g 
St Mark’s Powders 
(Jackson and Lowey, 2010) 
Glucose                20 g 
Sodium citrate      2.5 g 
Sodium chloride   3.5 g 
Water Paste 
 (Comité del Formulario Nacional, 2007) 
Zinc oxide             25 g 
Talc                       25 g 
Glycerol                 25 g 
Purified water        25 g 
WHO ORS (hypo-osmolar) 
(245 mOsm/L; 20.5 g) 
(WHO and UNICEF, 2006) 
Sodium chloride                      2.6 g 
Glucose, anhydrous              13.5 g 
Potassium chloride                  1.5 g 
Trisodium citrate, dihydrate    2.9 g 
WHO ORS (standard) 
(311 mOsm/L; 27.9 g) 
(Dutta et al., 2001) 
Sodium chloride                     3.5 g 
Glucose                                  20 g 
Potassium chloride                1.5 g 
Trisodium citrate, dihydrate   2.9 g 
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Appendix 17 
Top 20 active substances dispensed in 7 English paediatric hospitals 
(adapted from Yeung et al., 2004) 
 
 
 
1. Potassium chloride (n=435 units) 
2. Midazolam (n=168) 
3. Vancomycin (n=158) 
4. Clonidine HCl (n=132) 
5. Isoleucine (n=111) 
6. Valine (n=106) 
7. Potassium dihydrogen phosphate (n=101) 
8. Mercaptopurine (n=101) 
9. Co-careldopa (n=101) 
10. Dichloroacetate sodium (n=93) 
11. Cholesterol (n=89) 
12. Sodium chloride (n=84) 
13. Aspirin (n=75) 
14. Didanosine (n=62) 
15. Acetylcysteine (n=61) 
16. Diazoxide (n=60) 
17. Clobazam (n=59) 
18. Sucralfate (n=57) 
19. Cysteamine (n=57) 
20. Warfarin (n=53) 
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Appendix 18 
Top 50 extemporaneous preparations dispensed in selected UK NHS Trusts 
(adapted from Lowey and Jackson, 2008) 
 
 
 
1. Levothyroxine (n=880 units) 
2. Clobazam (n=743) 
3. Clozapine (n=693) 
4. Sodium chloride (n=621) 
5. Morphine sulfate (n=475) 
6. Ethambutol  (n=371) 
7. Lorazepam  (n=353) 
8. Pyrazinamide (n=330) 
9. Vancomycin (n=320) 
10. Knox Mouthwash (n=281) 
11. Amiodarone (n=277) 
12. Azathioprine (n=277) 
13. Hydrocortisone (n=274) 
14. Clonidine (n=266) 
15. Sodium bicarbonate (n=261) 
16. Captopril (n=246) 
17. Acetazolamide (n=198) 
18. Midazolam (n=185) 
19. Tranexamic acid (mouthwash) (n=182) 
20. Magnesium glycerophosphate (n=173) 
21. Tacrolimus mouthwash (n=173) 
22. Allopurinol (n=149) 
23. Clonazepam (n=146) 
24. Quinine sulfate (n=131) 
25. Warfarin (n=131) 
 
26. Pyridoxine (n=128) 
27. Metformin (n=120) 
28. Dinoprostone (n=113) 
29. Sodium phenylbutyrate (n=112) 
30. Ergocalciferol (n=110) 
31. Omeprazole (n=108) 
32. Dexamethasone (n=107) 
33. Phenoxybenzamine (n=107) 
34. Diazoxide (n=99) 
35. Menadiol (n=95) 
36. Ubiquinone (n=90) 
37. Thiamine (n=84) 
38. Potassium phosphate (n=77) 
39. Indometacin (n=76) 
40. Joulie’s Solution (n=69) 
41. Gliclazide (n=69) 
42. Primidone (n=69) 
43. Phenobarbital (n=64) 
44. Isosorbide mononitrate (n=64) 
45. Gabapentin (n=64) 
46. Arginine (n=60) 
47. St Mark’s Solution (n=60) 
48. Sildenafil (n=57) 
49. Co-careldopa (n=53) 
50. Bendroflumethiazide (n=53) 
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Appendix 19 
Unlicensed formulations (BP 2008-2011)  
 
 
BP 2008  
(adapted from BP Commission, 2008b) 
1. Caffeine citrate injection 
2. Caffeine citrate oral solution 
3. Dantrolene oral suspension 
4. Levomenthol cream 
5. Mercaptopurine oral suspension 
6. Paediatric phenobarbital oral solution 
7. Potassium chloride oral solution 
8. Sodium bicarbonate oral solution 
9. Sodium fluoride oral solution 
 
BP 2009  
(adapted from Lee, 2010) 
1. Adrenaline and cocaine intranasal 
injection 
2. Captopril oral solution 
3. Cocaine paste 
4. Compound glucose, sodium chloride 
and sodium citrate oral solution 
5. Hydrocortisone sodium phosphate 
oral solution 
6. Potassium dihydrogen phosphate oral 
solution 
7. Vancomycin oral solution 
 
 
 
 
BP 2010  
(adapted from Lee, 2010) 
1. Allopurinol oral suspension 
2. Bupivacaine and fentanyl injection 
3. Chloral hydrate oral solution 
4. Magnesium glycerophosphate oral 
solution 
5. Midazolam oral solution 
6. Phosphate oral solution 
7. Propylene glycol solution 
8. Warfarin oral suspension 
 
BP 2011  
(adapted from Lee, 2010) 
1. Bupivacaine and diamorphine 
injection 
2. Clozapine oral suspension 
3. Dinoprostone oral solution 
4. Coal tar paste 
5. Coal tar and salicylic acid ointment 
6. Salicylic acid cream 
7. Salicylic acid ointment 
8. Silver nitrate solution 
9. Sodium chloride nebulizer solution 
10. Sodium carbonate oral solution 
11. Cefuroxime eye drops 
12. Disodium edetate eye drops 
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Appendix 20 
Paediatric Phenobarbital Oral Solution (BP 2008) 
(adapted from BP Commission, 2008b) 
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Appendix 23 
List of special-order manufacturers / hospital manufacturing units 
(adapted from Joint Formulary Committee, 2006; Paediatric Formulary 
Committee, 2007) 
 
England 
1. Ipswich Hospital NHS Trust 
2. Barts and the London NHS Trust, St. Bartholomew’s Hospital 
3. Guy’s and St. Thomas’ NHS Foundation Trust, St. Thomas’ Hospital 
4. St. George’s Hospital 
5. Moorfields Pharmaceuticals 
6. Stockport Pharmaceuticals, Stepping Hill Hospital 
7. Royal Victoria Infirmary 
8. St. Peter’s Hospital 
9. Queen Alexandra Hospital 
10. Torbay PMU, South Devon Healthcare 
11. Royal Hallamshire Hospital 
12. Queen Elizabeth Medical Centre 
13. Queens Hospital, Burton Hospitals NHS Trust 
14. Huddersfield Royal Infirmary 
15. Northwick Park and St Mark’s Hospital 
16. Royal Free Hospital 
17. Queens Medical Centre, Nottingham University Hospitals NHS Trust 
18. University Hospital of North Staffordshire NHS Trust 
19. Colchester General Hospital, Colchester Hospital University NHS Foundation Trust 
20. Royal Preston Hospital 
21. Eastbourne District General Hospital, East Sussex Hospitals NHS Trust 
 
Northern Ireland 
22. Victoria Pharmaceuticals, Royal Group of Hospitals 
Scotland 
23. Tayside Pharmaceuticals, Ninewells Hospital 
24. Western Infirmary 
Wales 
25. Cardiff and Vale NHS Trust 
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Appendix 24 
List of paediatric hospitals in England 
(adapted from Yeung et al., 2004) 
 
 
1. Alder Hey Hospital (Liverpool) 
2. Birmingham Children’s Hospital (Birmingham) 
3. Royal Alexandra Children’s Hospital (Brighton) 
4. Derbyshire Children’s Hospital (Derby) 
5. Great Ormond Street Hospital for Children (London) 
6. Royal Manchester Children’s Hospital (Manchester) 
7. Sheffield Children’s Hospital (Sheffield) 
 
 
  
 Appendix 25 | 435 
 
 
Appendix 25 
Organic solvents, Colouring agents and Nonionic surfactants 
Organic solvents 
This therapeutic group was exclusive of the Netherlands and only 1 active substance was 
reported, namely: 
• Dimethyl sulfoxide: a highly polar substance that has been administered orally for a wide 
range of indications. Nevertheless, according to Martindale 35 (2007), the evidence of 
beneficial effects from the use of dimethyl sulfoxide is limited. This substance was reported 
as an oral liquid (100 mL) and by only 1 Dutch hospital pharmacy. 
 
Colouring agents 
This therapeutic group was exclusive of France and Germany (only) and almost all active 
substances reported are described in Martindale 35 (2007) only as colouring agents in 
medicines, cosmetics and foodstuffs.  
This is the case for carmoisine, erythrosine, ponceau 4R, sunset yellow FCF and tartrazine, 
which were all reported as capsules and in France only.  
Carmine was the only colouring agent that is used in other indications, namely as a faecal 
marker since it passes through the GI tract unchanged (Martindale 35, 2007). Carmine was 
reported in France as capsules and oral powders of variable strengths (2.5-500 mg) and also 
in Germany as capsules 50 mg. 
 
Nonionic surfactants 
This therapeutic group was exclusive of Germany and only 1 active substance was reported, 
namely: 
• Polysorbate 80: Polysorbates are hydrophilic nonionic surfactants and may be used in the 
management of upper respiratory-tract conditions (Martindale 35, 2007). Polysorbate 80 was 
reported as an oral liquid 1 mg/mL (100 mL) and by only 1 German hospital.  
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Appendix 26 
Active substances not included in Martindale 35 (2007)  
dispensed by the participant European hospitals 
 
Active substances European countries Dosage forms 
Ambrisentan Spain Capsules 
Ammonia  
spirit aniseed Netherlands Oral liquid 
Cystamine dihydrochloride Switzerland Capsules 
Darunavir Spain Capsules 
Detrothyronine Spain Capsules 
Heptobarbital Netherlands Capsules 
Lipase Slovenia Oral powders 
Lithium Netherlands Oral liquid 
Maraviroc Spain Capsules 
Nickel  
sulfate 
UK Capsules 
France Capsules 
Potassium  
dichromate France Capsules 
Protease Slovenia Oral powders 
Uracil Denmark Capsules 
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Appendix 27 
Therapeutic groups (Martindale 35, 2007) included in the research  
 
1. Analgesics, anti-inflammatory drugs and antipyretics 
2. Anthelmintics 
3. Antibacterials 
4. Antidementia drugs 
5. Antidepressants 
6. Antidiabetics 
7. Antiepileptics 
8. Antifungals 
9. Antigout drugs 
10. Antihistamines 
11. Antimalarials 
12. Antimyasthenics 
13. Antineoplastics 
14. Antiparkinsonian drugs 
15. Antiprotozoals  
16. Antivirals 
17. Anxiolytic, sedatives, hypnotics and antipsychotics 
18. Blood products, plasma expanders and haemostatics 
19. Bronchodilators and anti-asthma drugs 
20. Cardiovascular drugs 
21. Chelators, antidotes and antagonists 
22. Colouring agents 
23. Contrast media 
24. Corticosteroids 
25. Cough suppressants, expectorants, mucolytics and nasal decongestants 
26. Dermatological drugs and sunscreens 
27. Disinfectants and preservatives 
28. Electrolytes 
29. GI drugs 
30. General anaesthetics 
31. Hypothalamic and pituitary hormones 
32. Immunosuppressants 
33. Local anaesthetics 
34. Miotics, mydriatics and antiglaucoma drugs 
35. Muscle relaxants 
36. Non-ionic surfactants 
37. Nutritional agents and vitamins 
38. Organic solvents 
39. Paraffins and similar bases 
40. Prostaglandins 
41. Sex hormones 
42. Stabilising and suspending agents 
43. Stimulants and anorectics 
44. Supplementary drugs and other substances 
45. Thyroid and antithyroid drugs 
46. Urological drugs  
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